


**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 12
December 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	ix
1.5 Availability of the Edition	xi
1.6 Report of Counts for the Prescription Drug Product List.....	xii
1.7 Cumulative Supplement Legend	xiii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 12
DECEMBER 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been

discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AMNEAL PHARMACEUTICALS CO GMBH
(AMNEAL PHARMS CO)

AMNEAL EU LTD
(AMNEAL EU)

ANDA REPOSITORY LLC
(ANDA REPOSITORY)

PHARMACEUTICS INTERNATIONAL INC
(PII)

ANDA REPOSITORY LLC (ANDA REPOSITORY)	RISING PHARMA HOLDINGS INC (RISING)
G AND W LABORATORIES INC (G AND W LABS)	ACP NIMBLE BUYER INC (ACP NIMBLE)
G AND W LABORATORIES INC (G AND W LABS INC)	ACP NIMBLE BUYER INC (ACP NIMBLE)
HOUSTON CYCLOTRON PARTNERS LP (HOUSTON CYCLOTRON)	SOFIE CO DBA SOFIE (SOFIE)
INVATECH PHARMA SOLUTION INC (INVATECH)	ATHEM HOLDINGS LLC (ATHEM)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
MIKART LLC (MIKART)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
PD PARTNERS IV LLC (PD PARTNERS)	PHARMACEUTICAL ASSOCIATES INC (PHARM ASSOC)
PFIZER CONSUMER HEALTHCARE (PFIZER CONS HLTHCARE)	GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC (GLAXOSMITHKLINE)
PFIZER INC (PFIZER)	GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC (GLAXOSMITHKLINE)
RISING HOLDINGS INC (RISING)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
RISING PHARMACEUTICALS INC (RISING PHARMS)	RISING PHARMA HOLDINGS INC (RISING)
SUN PHARMA GLOBAL FZE (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL INC (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)

TEVA PHARMACEUTICALS USA (TEVA PHARMS USA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA INC (TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WATSON LABORATORIES INC (WATSON LABS)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS INC)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS INC)	DR REDDYS LABORATORIES INC (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS INC)	HERITAGE PHARMA LABS INC (WATSON LABS INC)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT)	HIKMA PHARMACEUTICALS USA INC (HIKMA)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), Levo-T (Cediprof Inc NDA 021342), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Stevens J NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), Unithroid (Stevens J NDA 021210), Thyro-tabs (Alvogen NDA 021116), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Stevens J NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Thyro-tabs (Alvogen NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB1	209713	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
THYRO-TABS	ALVOGEN	0.025MG	AB2	021116	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE	MYLAN	0.025MG	AB3	076187	001

SODIUM					
LEVOTHYROXINE	LUPIN	0.025MG	AB3	209713	001
SODIUM	ATLANTIS				
THYRO-TABS	ALVOGEN	0.025MG	AB4	021116	001
LEVOTHYROXINE	MYLAN	0.025MG	AB4	076187	001
SODIUM					

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580	20693	20688	20567
LISTED SINGLE	2724	2713	2729	2713	2743
SOURCE	(13.4%)	(13.2%)	(13.2%)	(13.1%)	(13.3%)
MULTISOURCE	17571	17867	17964	17975	17824
	(86.6%)	(86.8%)	(86.8%)	(86.9%)	(86.7%)
THERAPEUTICALLY	17483	17777	17964	17892	17740
EQUIVALENT	(86.1%)	(86.4%)	(86.8%)	(86.5%)	(86.3%)
NOT THERAPEUTICALLY	88	90	85	83	84
EQUIVALENT	(0.4%)	(0.4%)	(0.4%)	(0.4%)	(0.4%)
EXCEPTIONS ¹	58	58	58	54	54
	(0.3%)	(0.3%)	(0.3%)	(0.3%)	(0.3%)
NEW MOLECULAR	25	3	16	21	17
ENTITIES APPROVED					

NUMBER OF
APPLICANTS

1133

1129

1132

1140

1162

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS EQ 600MG BASE;300MG

A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB GLENMARK PHARMS 250MG

A209227 001 Oct 16, 2019 Sep NEWA

AB MSN 250MG

A210686 001 Jul 10, 2019 Jun NEWA

AB QILU 250MG

A212462 001 Sep 27, 2019 Sep NEWA

AB WOCKHARDT BIO AG 250MG

A208380 001 Feb 27, 2019 Feb NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

@ BARR LABS DIV TEVA 333MG

A200143 001 Nov 18, 2013 Nov DISC

ACARBOSE

TABLET;ORAL

ACARBOSE

@ MYLAN 25MG

A091053 001 Jan 06, 2011 Jun DISC

@ 50MG

A091053 002 Jan 06, 2011 Jun DISC

@ 100MG

A091053 003 Jan 06, 2011 Jun DISC

AB ! STRIDES PHARMA 25MG

A090912 001 Jul 27, 2011 Oct CHRS

PRECOSE

+ @ BAYER HLTHCARE 25MG

N020482 004 May 29, 1997 Oct DISC

+ @ 50MG

N020482 001 Sep 06, 1995 Oct DISC

+ @ 100MG

N020482 002 Sep 06, 1995 Oct DISC

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

@ ANI PHARMS INC EQ 200MG BASE

A074007 001 Oct 18, 1995 Jul CAHN

@ EQ 400MG BASE

A074007 002 Oct 18, 1995 Jul CAHN

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ KEMPHARM 325MG;EQ 4.08MG BASE

N208653 002 Jan 04, 2019 Jan NEWA

+ 325MG;EQ 8.16MG BASE

N208653 003 Jan 04, 2019 Jan NEWA

+ KVK TECH INC 325MG;EQ 4.08MG BASE

N208653 002 Jan 04, 2019 Feb CAHN

+ 325MG;EQ 6.12MG BASE

N208653 001 Feb 23, 2018 Feb CAHN

+! 325MG;EQ 8.16MG BASE

N208653 003 Jan 04, 2019 Aug CHRS

+ 325MG;EQ 8.16MG BASE

N208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA GRANULES PHARMS 300MG;50MG

A213115 001 Nov 22, 2019 Nov NFTG

AA ! MAYNE PHARMA INC 300MG;50MG

A207313 001 Dec 27, 2017 Nov CFTG

TABLET;ORAL

ALLZITAL

! LARKEN LABS INC 325MG;25MG

A203484 001 Dec 04, 2015 Sep CHRS

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A> AA LANNETT CO INC 300MG;50MG;40MG

A212082 001 Dec 17, 2019 Dec NEWA

>A> AA 325MG;50MG;40MG

A212083 001 Dec 17, 2019 Dec NEWA

>A> AA MAYNE PHARMA INC 300MG;50MG;40MG

A210817 001 Dec 17, 2019 Dec NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC 120MG/5ML;12MG/5ML

A091238 001 Nov 10, 2011 Jan DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA ELITE LABS INC 300MG;15MG

A212418 001 Sep 10, 2019 Aug NEWA

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		300MG;30MG	A212418	002	Sep 10, 2019	Aug NEWA
AA		300MG;60MG	A212418	003	Sep 10, 2019	Aug NEWA
AA	EYWA	300MG;15MG	A211610	001	Jun 27, 2019	Sep CAHN
AA		300MG;30MG	A211610	002	Jun 27, 2019	Sep CAHN
AA		300MG;60MG	A211610	003	Jun 27, 2019	Sep CAHN
AA	WES PHARMA INC	300MG;15MG	A211610	001	Jun 27, 2019	Jun NEWA
AA		300MG;30MG	A211610	002	Jun 27, 2019	Jun NEWA
AA		300MG;60MG	A211610	003	Jun 27, 2019	Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb NEWA
----	----------------	-----------------------	---------	-----	--------------	----------

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ ALVOGEN PINE BROOK	300MG;5MG	A208540	001	Nov 08, 2018	Apr DISC
	@	300MG;7.5MG	A208540	002	Nov 08, 2018	Apr DISC
	@	300MG;10MG	A208540	003	Nov 08, 2018	Apr DISC
	@	325MG;2.5MG	A209958	001	Oct 24, 2018	Apr DISC
	@	325MG;5MG	A209958	002	Oct 24, 2018	Apr DISC
	@	325MG;7.5MG	A209958	003	Oct 24, 2018	Apr DISC
	@	325MG;10MG	A209958	004	Oct 24, 2018	Apr DISC
>D>	@ ELITE LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018	Dec CAHN
	@	325MG;2.5MG	A209924	001	Nov 16, 2018	May DISC
>D>	@	325MG;5MG	A209924	002	Nov 16, 2018	Dec CAHN
	@	325MG;5MG	A209924	002	Nov 16, 2018	May DISC
>D>	@	325MG;7.5MG	A209924	003	Nov 16, 2018	Dec CAHN
	@	325MG;7.5MG	A209924	003	Nov 16, 2018	May DISC
>D>	@	325MG;10MG	A209924	004	Nov 16, 2018	Dec CAHN
	@	325MG;10MG	A209924	004	Nov 16, 2018	May DISC
>A> AA	GRANULES PHARMS	325MG;5MG	A211729	001	Jan 03, 2020	Dec NEWA
>A> AA		325MG;7.5MG	A211729	002	Jan 03, 2020	Dec NEWA
>A> AA		325MG;10MG	A211729	003	Jan 03, 2020	Dec NEWA
	@ LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017	Sep DISC
	@	300MG;7.5MG	A207171	002	Jun 20, 2017	Sep DISC
	@	300MG;10MG	A207171	003	Jun 20, 2017	Sep DISC
	@	325MG;5MG	A207172	001	Jun 22, 2017	Sep DISC
	@	325MG;7.5MG	A207172	002	Jun 22, 2017	Sep DISC
	@	325MG;10MG	A207172	003	Jun 22, 2017	Sep DISC
>A>	@ NOSTRUM LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018	Dec CAHN
>A>	@	325MG;5MG	A209924	002	Nov 16, 2018	Dec CAHN
>A>	@	325MG;7.5MG	A209924	003	Nov 16, 2018	Dec CAHN
>A>	@	325MG;10MG	A209924	004	Nov 16, 2018	Dec CAHN
	@ UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017	Jan DISC
	@	325MG;7.5MG	A206484	002	Mar 24, 2017	Jan DISC
	@	325MG;10MG	A206484	003	Mar 24, 2017	Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

@ MIKART INC 300MG/5ML;10MG/5ML

A202142 001 Nov 27, 2018 May DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ANDA REPOSITORY	325MG;5MG	A207834	001	Aug 15, 2019	Sep CAHN
AA		325MG;7.5MG	A207834	002	Aug 15, 2019	Sep CAHN
AA		325MG;10MG	A207834	003	Aug 15, 2019	Sep CAHN
>D> AA	ELITE LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Dec CAHN
>D> AA		325MG;7.5MG	A209385	002	Jul 02, 2018	Dec CAHN
>D> AA		325MG;10MG	A209385	003	Jul 02, 2018	Dec CAHN
AA	GRANULES PHARMS	325MG;2.5MG	A211708	001	Oct 31, 2019	Oct NEWA
AA		325MG;5MG	A211708	002	Oct 31, 2019	Oct NEWA
AA		325MG;7.5MG	A211708	003	Oct 31, 2019	Oct NEWA
AA		325MG;10MG	A211708	004	Oct 31, 2019	Oct NEWA
AA	HALO PHARM CANADA	325MG;5MG	A207834	001	Aug 15, 2019	Aug NEWA
AA		325MG;7.5MG	A207834	002	Aug 15, 2019	Aug NEWA
AA		325MG;10MG	A207834	003	Aug 15, 2019	Aug NEWA
>A> AA	NOSTRUM LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Dec CAHN
>A> AA		325MG;7.5MG	A209385	002	Jul 02, 2018	Dec CAHN
>A> AA		325MG;10MG	A209385	003	Jul 02, 2018	Dec CAHN
AA	XIROMED	325MG;5MG	A207574	001	Dec 13, 2016	Aug CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@ PAR PHARM

325MG; 37.5MG

A076475 001 Apr 21, 2005 Nov DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

@ ACCORD HLTHCARE

500MG

A207659 001 Oct 18, 2018 Apr DISC

AB ALEMBIC PHARMS LTD

500MG

A210423 001 Feb 19, 2019 Feb NEWA

AB CADILA

500MG

A205301 001 Jan 16, 2019 Mar CAHN

AB HERITAGE PHARMA

500MG

A040904 001 Dec 10, 2008 Jul CAHN

AB ! HERITAGE PHARMS INC

500MG

A090779 001 Jul 14, 2011 Jul CHRS

@ MYLAN

500MG

A203917 001 Jun 18, 2019 Jul DISC

AB

500MG

A203917 001 Jun 18, 2019 Jun NEWA

DIAMOX

+ @ TEVA BRANDED PHARM

500MG

N012945 001 Jul DISC

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP ZYDUS PHARMS

EQ 500MG BASE/VIAL

A206533 001 Apr 15, 2019 Apr NEWA

TABLET; ORAL

ACETAZOLAMIDE

AB EYWA PHARMA

125MG

A211556 001 Oct 18, 2019 Oct NEWA

AB

250MG

A211556 002 Oct 18, 2019 Oct NEWA

AB NOVITIUM PHARMA

125MG

A210588 001 Oct 17, 2019 Oct NEWA

AB

250MG

A210588 002 Oct 17, 2019 Oct NEWA

@ SUN PHARM INDUSTRIES

125MG

A089753 002 Jun 22, 1988 Oct DISC

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

@ EMCURE PHARMS LTD

EQ 500MG BASE/VIAL

A202693 001 Dec 19, 2014 Nov DISC

@ PAR STERILE PRODUCTS

EQ 500MG BASE/VIAL

A205358 001 Jun 20, 2017 Apr DISC

AP ZYDUS PHARMS

EQ 500MG BASE/VIAL

A206533 001 Apr 15, 2019 Jun CAIN

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

AT MLV

2%

A040607 001 Feb 24, 2005 Sep CAHN

AT SAPTALIS PHARMS

2%

A040607 001 Feb 24, 2005 May CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

@ ACTAVIS MID ATLANTIC

2%; 1%

A087143 001 Jan 13, 1982 Jun DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

@ MYLAN INSTITUTIONAL

6GM/30ML (200MG/ML)

A203624 001 Jun 19, 2015 Mar DISC

TABLET, EFFERVESCENT; ORAL

CETYLEV

+ @ ARBOR PHARMS LLC

500MG

N207916 001 Jan 29, 2016 Mar DISC

+ @

2.5GM

N207916 002 Jan 29, 2016 Mar DISC

ACITRETIN

CAPSULE; ORAL

SORIATANE

+ @ STIEFEL LABS INC

17.5MG

N019821 003 Aug 06, 2009 Jan DISC

+ @

22.5MG

N019821 004 Aug 06, 2009 Jan DISC

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+! CIRCASSIA

0.4MG/INH

N202450 001 Jul 23, 2012 Jun CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATEPOWDER, METERED; INHALATION
DUAKLIR PRESSAIRASTRAZENECA PHARMS 0.4MG/INH; 0.012MG/INH
CIRCASSIA 0.4MG/INH; 0.012MG/INHN210595 001 Mar 29, 2019 Mar NEWA
N210595 001 Mar 29, 2019 Apr CAHNACYCLOVIRCAPSULE; ORAL
ACYCLOVIRAB CADILA 200MG A204313 001 Mar 25, 2016 Aug CAHN
AB KENTON 200MG A075090 001 Jan 26, 1999 Mar CAHN

ZOVIRAX

+ @ MYLAN 200MG

N018828 001 Jan 25, 1985 Nov DISC

CREAM; TOPICAL

ACYCLOVIR

AB PERRIGO UK FINCO 5% A208702 001 Feb 04, 2019 Jan NFTG

ZOVIRAX

AB +! BAUSCH 5% N021478 001 Dec 30, 2002 Feb CAHN

AB +! VIB 5% N021478 001 Dec 30, 2002 Jan CFTG

OINTMENT; OPHTHALMIC

AVACLYR

+ @ FERA PHARMS LLC 3%

N202408 001 Mar 29, 2019 Aug DISC

+! 3%

N202408 001 Mar 29, 2019 Mar NEWA

OINTMENT; TOPICAL

ACYCLOVIR

AB APOTEX 5% A210774 001 Sep 06, 2019 Aug NEWA

AB CADILA 5% A205974 001 Mar 15, 2019 Oct CAHN

AB CIPLA 5% A211794 001 Jan 18, 2019 Jan NEWA

AB GLENMARK PHARMS SA 5% A205510 001 Jul 31, 2017 Jun CAHN

@ PERRIGO UK FINCO 5%

A205659 001 Feb 20, 2019 Aug DISC

AB 5% A205659 001 Feb 20, 2019 Feb NEWA

AB ZYDUS PHARMS 5% A205974 001 Mar 15, 2019 Mar NEWA

ZOVIRAX

AB +! BAUSCH 5% N018604 001 Mar 29, 1982 Feb CAHN

TABLET; ORAL

ACYCLOVIR

AB SQUARE PHARMS LTD 400MG A209366 001 Oct 07, 2019 Sep NEWA

AB 800MG A209366 002 Oct 07, 2019 Sep NEWA

ACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUM

! ZYDUS PHARMS EQ 500MG BASE/VIAL

A206535 001 Aug 31, 2018 Jan CHRS

! EQ 1GM BASE/VIAL

A206535 002 Aug 31, 2018 Jan CHRS

ACYCLOVIR; HYDROCORTISONECREAM; TOPICAL
XERESE

+! BAUSCH 5%; 1%

N022436 001 Jul 31, 2009 Feb CAHN

ADAPALENEGEL; TOPICAL
ADAPALENE

AB P AND L 0.1% A090962 001 Jun 02, 2010 Jul CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB GLENMARK PHARMS LTD 0.1%; 2.5% A208108 001 Nov 08, 2019 Oct NEWA

AB PERRIGO UK FINCO 0.1%; 2.5% A205033 001 Jan 23, 2018 May CAHN

@ TARO 0.3%; 2.5%

A209148 001 Oct 17, 2018 May DISC

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

@ LUITPOLD 3MG/ML

A090010 001 Apr 28, 2009 Mar DISC

SOLUTION; INTRAVENOUS

ADENOSINE

@ EMCURE PHARMS LTD 60MG/20ML (3MG/ML)

A202313 001 Sep 15, 2014 Nov DISC

@ 90MG/30ML (3MG/ML)

A202313 002 Sep 15, 2014 Nov DISC

AFAMELANOTIDEIMPLANT; SUBCUTANEOUS
SCENESSE

+! CLIVUNEL INC 16MG N210797 001 Oct 08, 2019 Oct NEWA

AIR POLYMER-TYPE AFOAM; INTRAUTERINE
EXEM FOAM KIT

+! GISKIT 10ML N212279 001 Nov 07, 2019 Nov NEWA

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB	ACTAVIS ELIZABETH	200MG	A208094	001	May 20, 2019	May NEWA
AB	EDENBRIDGE PHARMS	200MG	A211117	001	May 14, 2019	Apr NEWA
AB	STRIDES PHARMA	200MG	A210011	001	Dec 07, 2018	Aug CAHN

ALBUTEROL SULFATEPOWDER, METERED; INHALATION
PROAIR DIGIHALER

+ TEVA BRANDED PHARM EQ 0.09MG BASE/INH N205636 002 Dec 21, 2018 Jan NEWA

PROAIR RESPICLICK

+! TEVA BRANDED PHARM EQ 0.09MG BASE/INH N205636 001 Mar 31, 2015 Jan CPOT

SYRUP; ORAL

ALBUTEROL SULFATE

AA	COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Nov CAHN
AA	QUAGEN	EQ 2MG BASE/5ML	A212197	001	Sep 06, 2019	Aug NEWA

TABLET; ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Mar NEWA
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Mar NEWA
AB	APPCO	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb CAHN
AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb CAHN
AB	ARISE	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep CAHN
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

@ MYLAN EQ 5MG BASE

A076584 001 Aug 04, 2008 Jul DISC

@ EQ 10MG BASE

A076584 002 Aug 04, 2008 Jul DISC

TABLET, EFFERVESCENT; ORAL
BINOSTO

+! ASCEND THERAPS US EQ 70MG BASE N202344 001 Mar 12, 2012 Sep CAHN

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

AB	@ HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011	Sep DISC
		10MG	A079056	001	Jul 18, 2011	May CAHN
	@ MYLAN	10MG	A079014	001	Jul 18, 2011	Oct DISC

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

AB	ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar NFTG
AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar NFTG

TEKTURNIA

AB	+ NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar CFTG
AB	+!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar CFTG

ALITRETINOINGEL; TOPICAL
PANRETIN

+! CONCORDIA EQ 0.1% BASE N020886 001 Feb 02, 1999 Jul CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

	@ SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007	Oct	DISC
	@	300MG	A078390	002	Aug 30, 2007	Oct	DISC
AB	UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb	NEWA
AB		300MG	A211820	002	Mar 12, 2019	Feb	NEWA

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

	+ @ IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Apr	DISC
	+ @	300MG; 200MG	N209203	002	Aug 18, 2017	Apr	DISC

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	! AJANTA PHARMA LTD	EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Sep	CHRS
	AXERT						
	+ @ JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Sep	DISC
	+ @	EQ 12.5MG BASE	N021001	002	May 07, 2001	Sep	DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	NEWA
AB		EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	NEWA

ALPELISIB

TABLET; ORAL

PIQRAY

	+ NOVARTIS	50MG	N212526	001	May 24, 2019	May	NEWA
	+	150MG	N212526	002	May 24, 2019	May	NEWA
	+!	200MG	N212526	003	May 24, 2019	May	NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

	+! SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	Jul	CAHN
	+!	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021163	002	Jun 16, 2003	Sep	CMS1

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>D>	AB	ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Dec	DISC
>A>		@	0.5MG	A077725	001	Jul 31, 2006	Dec	DISC
>D>	AB		1MG	A077725	002	Jul 31, 2006	Dec	DISC
>A>		@	1MG	A077725	002	Jul 31, 2006	Dec	DISC
>D>	AB		2MG	A077725	004	Jul 31, 2006	Dec	DISC
>A>		@	2MG	A077725	004	Jul 31, 2006	Dec	DISC
>D>	AB		3MG	A077725	003	Jul 31, 2006	Dec	DISC
>A>		@	3MG	A077725	003	Jul 31, 2006	Dec	DISC
>D>	AB	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008	Dec	DISC
>A>		@	0.5MG	A078489	001	Oct 17, 2008	Dec	DISC
>D>	AB		1MG	A078489	002	Oct 17, 2008	Dec	DISC
>A>		@	1MG	A078489	002	Oct 17, 2008	Dec	DISC
>D>	AB		2MG	A078489	003	Oct 17, 2008	Dec	DISC
>A>		@	2MG	A078489	003	Oct 17, 2008	Dec	DISC
>D>	AB		3MG	A078489	004	Oct 17, 2008	Dec	DISC
>A>		@	3MG	A078489	004	Oct 17, 2008	Dec	DISC

ALTRETAMINECAPSULE;ORAL
HEXALEN

+ @ EISAI INC

50MG

N019926 001 Dec 26, 1990 Feb DISC

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

>A>

>A> AB

WATSON LABS TEVA

12MG

A208295 001 Dec 19, 2019 Dec NFTG

ENTEREG

>D>

+! CUBIST PHARMS

12MG

N021775 001 May 20, 2008 Dec CFTG

>A> AB

+!

12MG

N021775 001 May 20, 2008 Dec CFTG

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB

INVAGEN PHARMS

100MG

A207570 001 Sep 30, 2016 Sep CAHN

AB

UPSHER SMITH LABS

100MG

A070589 001 Aug 05, 1986 Jul CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB

INVAGEN PHARMS

100MG

A207571 001 Jan 31, 2017 Sep CAHN

AB

!

UPSHER SMITH LABS

100MG

A076186 001 Dec 16, 2002 Jul CAHN

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

AB

CIPLA

5MG

A210715 001 Apr 26, 2019 Apr NEWA

AB

10MG

A210715 002 Apr 26, 2019 Apr NEWA

AB

MYLAN

5MG

A208441 001 Mar 28, 2019 Mar NFTG

AB

10MG

A208441 002 Mar 28, 2019 Mar NFTG

AB

PAR PHARM INC

5MG

A209509 001 Apr 10, 2019 Mar NEWA

AB

10MG

A209509 002 Apr 10, 2019 Mar NEWA

AB

SIGMAPHARM LABS LLC

5MG

A208354 001 Apr 10, 2019 Mar NEWA

AB

10MG

A208354 002 Apr 10, 2019 Mar NEWA

AB

SUN PHARM

5MG

A210784 001 Mar 28, 2019 Mar NFTG

AB

10MG

A210784 002 Mar 28, 2019 Mar NFTG

AB

WATSON LABS INC

5MG

A208252 001 Mar 28, 2019 Mar NFTG

AB

10MG

A208252 002 Mar 28, 2019 Mar NFTG

AB

ZYDUS PHARMS

5MG

A210058 001 Mar 28, 2019 Mar NFTG

AB

10MG

A210058 002 Mar 28, 2019 Mar NFTG

LETAIRIS

AB

+

GILEAD

5MG

N022081 001 Jun 15, 2007 Mar CFTG

AB

+!

10MG

N022081 002 Jun 15, 2007 Mar CFTG

AMIFAMPRIDINE

TABLET;ORAL

RUZURGI

+! JACOBUS PHARM CO INC

10MG

N209321 001 May 06, 2019 May NEWA

AMIFOSTINE

INJECTABLE;INJECTION

ETHYOL

>A>

@ CLINIGEN

375MG/VIAL

N020221 002 Sep 10, 1999 Dec CAHN

>A> AP

+!

500MG/VIAL

N020221 001 Dec 08, 1995 Dec CAHN

>D>

@ CLINIGEN HLTHCARE

375MG/VIAL

N020221 002 Sep 10, 1999 Dec CAHN

>D> AP

+!

500MG/VIAL

N020221 001 Dec 08, 1995 Dec CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

@ TEVA PHARMS USA

EQ 250MG BASE/ML

A064045 002 Sep 28, 1993 Sep DISC

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB

WINDLAS HLTHCARE

5MG

A204180 001 Aug 07, 2015 Feb CAHN

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN 10%

@ ICU MEDICAL INC

10% (10GM/100ML)

N017673 003

Jul DISC

AMINOSYN 8.5%

@ ICU MEDICAL INC

8.5% (8.5GM/100ML)

N017673 004

Jul DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

@ ICU MEDICAL INC

3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML

N017789 003

Jul DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

@ ICU MEDICAL INC

8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML

N017673 009

Oct 25, 2002

Jul DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMICAR

AA +! CLOVER PHARMS

1.25GM/5ML

N015230 002

Aug CTEC

AMINOCAPROIC ACID

AA AMNEAL PHARMS LLC

1.25GM/5ML

A212780 001

Aug 23, 2019

Aug NEWA

TABLET;ORAL

AMICAR

AB + CLOVER PHARMS

1GM

N015197 002

Jun 24, 2004

Feb CHRS

AMINOCAPROIC ACID

>A> AB AMNEAL

500MG

A212492 001

Nov 26, 2019

Dec CAHN

>D> AB AMNEAL PHARMS CO

500MG

A212492 001

Nov 26, 2019

Dec CAHN

AB

500MG

A212492 001

Nov 26, 2019

Nov NEWA

AB ! SUNNY PHARMTECH INC

1GM

A209060 002

Nov 27, 2018

Feb CHRS

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

! HOSPIRA

25MG/ML

A087242 001

Oct 26, 1983

Feb CTEC

@ LUITPOLD

25MG/ML

A087600 001

Feb DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

@ DR REDDYS

50MG/ML

A076163 001

Sep 05, 2003

May CAHN

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB RUBICON

200MG

A078578 001

Nov 06, 2008

Jul CAHN

AMLODIPINE BENZOATE

SOLUTION;ORAL

KATERZIA

+! SILVERGATE PHARMS

EQ 1MG BASE/ML

N211340 001

Jul 08, 2019

Jul NEWA

SUSPENSION;ORAL

KATERZIA

+! SILVERGATE PHARMS

EQ 1MG BASE/ML

N211340 001

Jul 08, 2019

Nov CDFR

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB STRIDES PHARMA

EQ 2.5MG BASE

A077516 001

Jul 11, 2007

Apr CAHN

AB

EQ 5MG BASE

A077516 002

Jul 11, 2007

Apr CAHN

AB

EQ 10MG BASE

A077516 003

Jul 11, 2007

Apr CAHN

@ SUN PHARM INDS INC

EQ 2.5MG BASE

A078231 001

Nov 30, 2007

Oct DISC

@

EQ 5MG BASE

A078231 002

Nov 30, 2007

Oct DISC

@

EQ 10MG BASE

A078231 003

Nov 30, 2007

Oct DISC

@ TEVA

EQ 2.5MG BASE

A076846 001

Jun 28, 2007

Oct DISC

@

EQ 5MG BASE

A076846 002

Jun 28, 2007

Oct DISC

@

EQ 10MG BASE

A076846 003

Jun 28, 2007

Oct DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	APOTEX	EQ 5MG BASE;EQ 10MG BASE	A205199	001	Nov 18, 2019	Nov	NEWA
AB		EQ 5MG BASE;EQ 20MG BASE	A205199	002	Nov 18, 2019	Nov	NEWA
AB		EQ 5MG BASE;EQ 40MG BASE	A205199	003	Nov 18, 2019	Nov	NEWA
AB		EQ 5MG BASE;EQ 80MG BASE	A205199	004	Nov 18, 2019	Nov	NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A205199	005	Nov 18, 2019	Nov	NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A205199	006	Nov 18, 2019	Nov	NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A205199	007	Nov 18, 2019	Nov	NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A205199	008	Nov 18, 2019	Nov	NEWA
	@ ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Jun	DISC
	@	EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Jun	DISC
	@	EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Jun	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	May	DISC
@		EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	May	DISC
@		EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	May	DISC
@		EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	May	DISC
@	MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Feb	DISC
@		EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Feb	DISC
@		EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Feb	DISC
@		EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Feb	DISC
@		EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Feb	DISC
@		EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Feb	DISC
@	TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007	Jun	DISC
@		EQ 5MG BASE;10MG	A077179	002	May 18, 2007	Jun	DISC
@		EQ 5MG BASE;20MG	A077179	003	May 18, 2007	Jun	DISC
@		EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun	DISC
@		EQ 10MG BASE;20MG	A077179	004	May 18, 2007	Jun	DISC
@		EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun	DISC

AMLODIPINE BESYLATE; CELECOXIB

TABLET; ORAL

CONSENSI

+	COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Mar	CAHN
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Mar	CAHN
+	!	EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Mar	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul	DISC
@		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul	DISC
@		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul	DISC
@		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul	DISC
@		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul	DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Jul	DISC
@		5MG;25MG;160MG	A200435	002	Sep 25, 2012	Jul	DISC
@		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Jul	DISC
@		10MG;25MG;160MG	A200435	003	Sep 25, 2012	Jul	DISC
@		10MG;25MG;320MG	A200435	004	Sep 25, 2012	Jul	DISC
@	TORRENT	5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Nov	DISC
@		5MG;25MG;160MG	A201593	002	Jun 03, 2015	Nov	DISC
@		10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Nov	DISC
@		10MG;25MG;160MG	A201593	004	Jun 03, 2015	Nov	DISC
@		10MG;25MG;320MG	A201593	005	Jun 03, 2015	Nov	DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@ ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar DISC
@	EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar DISC
@	EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar DISC
@	EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar DISC
@ TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun DISC
@	EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun DISC
@	EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun DISC
@	EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

+ ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr CAHN
+	EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr CAHN
+	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

@ TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Jul DISC
@	EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Jul DISC
@	EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Jul DISC
@	EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Jul DISC
@ TORRENT	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Nov DISC
@	EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Nov DISC
@	EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Nov DISC
@	EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Nov DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr CAHN
AP UNIV TX SW MEDCTR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A209507	001	Nov 01, 2019	Oct NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB ! PERRIGO ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	May CAHN
---------------------	-------------	---------	-----	--------------	----------

LOTION; TOPICAL

AMMONIUM LACTATE

AB ! PERRIGO ISRAEL	EQ 12% BASE	A075570	001	Jun 23, 2004	May CAHN
---------------------	-------------	---------	-----	--------------	----------

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ TEVA	125MG/5ML	A061931	001		Jun DISC
--------	-----------	---------	-----	--	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB AUROBINDO PHARMA LTD	125MG/5ML;EQ 31.25MG BASE/5ML	A209371	001	Apr 19, 2019	Apr NFTG
AB	250MG/5ML;EQ 62.5MG BASE/5ML	A209371	002	Apr 19, 2019	Apr NEWA

AUGMENTIN '125'

AB + NEOPHARMA	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Apr CFTG
----------------	-------------------------------	---------	-----	--------------	----------

TABLET; ORAL

AUGMENTIN '875'

AB + NEOPHARMA	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb CAHN
----------------	---------------------	---------	-----	--------------	----------

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE; ORAL

TALICIA

+	REDHILL	250MG;EQ 10MG BASE;12.5MG	N213004	001	Nov 01, 2019	Nov NEWA
---	---------	---------------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan NEWA
AB		5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan NEWA
AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	Nov CTNA
AB		1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	Nov CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	Nov CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May NEWA
AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	Nov CTNA
AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	Nov CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	Nov CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May NEWA
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	May NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	May NEWA
AB		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	May NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	May NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	May NEWA
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Apr NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Apr NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Apr NEWA
AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Apr NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Apr NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Apr NEWA
AB	@ SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Nov DISC
AB		1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	May NEWA
AB	@	2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Nov DISC
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	May NEWA
AB	@	3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Nov DISC
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	May NEWA
AB	@	5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Nov DISC
AB		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	May NEWA
AB	@	6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Nov DISC
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	May NEWA
AB	@	7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Nov DISC
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	May NEWA
AB	SUNGEN PHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019	Nov NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019	Nov NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A212037	003	Dec 11, 2019	Nov NEWA
AB		5MG;5MG;5MG;5MG	A212037	004	Dec 11, 2019	Nov NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019	Nov NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019	Nov NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019	Apr NEWA
AA		10MG	A211639	002	Apr 17, 2019	Apr NEWA
AA	BIONPHARMA INC	5MG	A212919	001	Nov 22, 2019	Nov NEWA
AA		10MG	A212919	002	Nov 22, 2019	Nov NEWA
AA	GRANULES PHARMS	5MG	A212619	001	Aug 05, 2019	Jul NEWA
AA		10MG	A212619	002	Aug 05, 2019	Jul NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan NEWA
+		10MG	N209905	002	Jan 30, 2019	Jan NEWA
+		15MG	N209905	003	Jan 30, 2019	Jan NEWA
+		20MG	N209905	004	Jan 30, 2019	Jan NEWA

TABLET;ORAL
ARIPIPIRAZOLE

AB		10MG	A207105	003	Feb 21, 2019	Feb NEWA
AB		15MG	A207105	004	Feb 21, 2019	Feb NEWA
AB		20MG	A207105	005	Feb 21, 2019	Feb NEWA
AB		30MG	A207105	006	Feb 21, 2019	Feb NEWA
	@ TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Jun DISC
	@	5MG	A078607	002	Apr 28, 2015	Jun DISC
	@	10MG	A078608	001	Apr 28, 2015	May DISC
	@	15MG	A078708	001	Apr 28, 2015	May DISC
	@	20MG	A078708	002	Apr 28, 2015	May DISC
	@	30MG	A078708	003	Apr 28, 2015	May DISC
	@ ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019	Jun DISC
	@	5MG	A090472	002	Jan 07, 2019	Jun DISC
	@	10MG	A090472	003	Jan 07, 2019	Jun DISC
	@	15MG	A090472	004	Jan 07, 2019	Jun DISC
	@	20MG	A090472	005	Jan 07, 2019	Jun DISC
	@	30MG	A090472	006	Jan 07, 2019	Jun DISC

ARMODAFINIL

TABLET;ORAL
ARMODAFINIL

	@ APOTEX INC	50MG	A201514	001	Mar 25, 2019	Sep DISC
AB		50MG	A201514	001	Mar 25, 2019	Mar NEWA
	@	150MG	A201514	002	Mar 25, 2019	Sep DISC
AB		150MG	A201514	002	Mar 25, 2019	Mar NEWA
	@	250MG	A201514	003	Mar 25, 2019	Sep DISC
AB		250MG	A201514	003	Mar 25, 2019	Mar NEWA
AB	AUROBINDO PHARMA LTD	200MG	A206069	004	Dec 07, 2018	Mar NEWA
AB	MYLAN PHARMS INC	100MG	A200043	004	May 09, 2019	Apr NEWA
AB		200MG	A200043	005	May 09, 2019	Apr NEWA
AB	NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Apr CTEC

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
ARSENIC TRIOXIDE

AP	STI PHARMA LLC	1MG/ML	A209873	001	May 06, 2019	Apr NEWA
AP	ZYDUS PHARMS	2MG/ML	A206228	002	Aug 30, 2019	Aug NFTA
	TRISENOX					
AP	+! CEPHALON	2MG/ML	N021248	002	Oct 13, 2017	Aug CFTG

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS
INFUVITE PEDIATRIC

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	Jul CAHN
----	-------------------	--	---------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Sep CMS1
----	-------------------	--	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL
MOVIPREP

AA	+! SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	N021881	001	Aug 02, 2006	Nov CTEC
	PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID					
AA	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Nov CMFD

ASENAPINESYSTEM; TRANSDERMAL
SECUADO

+	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019	Oct	NEWA
+		5.7MG/24HR	N212268	002	Oct 11, 2019	Oct	NEWA
+	!	7.6MG/24HR	N212268	003	Oct 11, 2019	Oct	NEWA

ASENAPINE MALEATETABLET; SUBLINGUAL
SAPHRIS

+	ALLERGAN	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Oct	CAHN
+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Oct	CAHN
+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Oct	CAHN
+	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CTEC
+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CTEC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AA	BRECKENRIDGE	325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Dec	CAHN
	AA		325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Aug	CAHN
>A>	AA	PII	325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Dec	CAHN

>D> ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

>D> TABLET; ORAL

>D> ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

>D>		SANDOZ	385MG; 30MG; 25MG	A074654	001	Dec 31, 1996	Dec	DISC
>A>		@	385MG; 30MG; 25MG	A074654	001	Dec 31, 1996	Dec	DISC
>D>	AB	!	770MG; 60MG; 50MG	A074654	002	Dec 31, 1996	Dec	DISC
>A>		@	770MG; 60MG; 50MG	A074654	002	Dec 31, 1996	Dec	DISC
	AB	!	770MG; 60MG; 50MG	A074654	002	Dec 31, 1996	May	CTEC
>D>		ORPHENGESIC FORTE						
>D>	AB	GALT PHARMS	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Dec	DISC
>A>		@	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Dec	DISC
	AB		770MG; 60MG; 50MG	A075141	002	May 29, 1998	May	CMFD

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE

>D>	AB	ANI PHARMS INC	25MG; 200MG	A206964	001	Jan 18, 2017	Dec	DISC
>A>		@	25MG; 200MG	A206964	001	Jan 18, 2017	Dec	DISC
	AB	GLENMARK PHARMS LTD	25MG; 200MG	A210318	001	May 24, 2019	May	NEWA
	AB	GLENMARK PHARMS SA	25MG; 200MG	A210318	001	May 24, 2019	Jun	CAHN
	AB	LANNETT CO INC	25MG; 200MG	A204552	001	Mar 20, 2019	Mar	NEWA

ATENOLOL

TABLET; ORAL

ATENOLOL

	AB	HLTHCARE	25MG	A074052	001	May 01, 1992	Sep	CAHN
	AB		50MG	A073025	001	Sep 17, 1991	Sep	CAHN
	AB		100MG	A073026	001	Sep 17, 1991	Sep	CAHN
>A>		@ INVATECH	25MG	A074265	001	Feb 28, 1994	Dec	CAHN
>A>		@	50MG	A074265	002	Feb 28, 1994	Dec	CAHN
>A>		@	100MG	A074265	003	Feb 28, 1994	Dec	CAHN
>D>		@ SANDOZ	25MG	A074265	001	Feb 28, 1994	Dec	CAHN
>D>		@	50MG	A074265	002	Feb 28, 1994	Dec	CAHN
>D>		@	100MG	A074265	003	Feb 28, 1994	Dec	CAHN
		@ SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007	Oct	DISC
		@	50MG	A078210	002	Jul 10, 2007	Oct	DISC
		@	100MG	A078210	003	Jul 10, 2007	Oct	DISC
		@ SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997	Oct	DISC
		@	50MG	A073475	001	Mar 30, 1993	Oct	DISC
		@	100MG	A073476	001	Mar 30, 1993	Oct	DISC
	AB	UNICHEM LABS LTD	25MG	A213136	001	Nov 21, 2019	Nov	NEWA
	AB		50MG	A213136	002	Nov 21, 2019	Nov	NEWA
	AB		100MG	A213136	003	Nov 21, 2019	Nov	NEWA

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

	@ SUN PHARM INDUSTRIES	50MG;25MG	A073582	002	Apr 29, 1993	Oct DISC
	@	100MG;25MG	A073582	001	Apr 29, 1993	Oct DISC
AB	ZYDUS PHARMS	50MG;25MG	A210028	001	Mar 08, 2019	Feb NEWA
AB		100MG;25MG	A210028	002	Mar 08, 2019	Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Mar CMFD
AB		25MG	A079017	002	Sep 17, 2010	Mar CMFD
AB		40MG	A079017	003	Sep 17, 2010	Mar CMFD
AB		60MG	A079017	004	Sep 17, 2010	Mar CMFD
AB		80MG	A079017	005	Sep 17, 2010	Mar CMFD
AB		100MG	A079017	006	Sep 17, 2010	Mar CMFD

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	MICRO LABS LTD INDIA	EQ 10MG BASE	A205945	001	Nov 07, 2019	Oct NEWA
AB		EQ 20MG BASE	A205945	002	Nov 07, 2019	Oct NEWA
AB		EQ 40MG BASE	A205945	003	Nov 07, 2019	Oct NEWA
AB		EQ 80MG BASE	A205945	004	Nov 07, 2019	Oct NEWA
AB	MSN	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb NEWA
AB		EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb NEWA
AB		EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb NEWA
AB		EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb NEWA

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

AB	ABHAI LLC	750MG/5ML	A210510	001	May 31, 2019	May NEWA
----	-----------	-----------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb CAHN
AP	MEITHEAL	10MG/ML	A091489	001	Feb 17, 2012	Nov CAHN
	@ MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Sep DISC
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb CAHN
AP	MEITHEAL	10MG/ML	A091488	001	Feb 17, 2012	Nov CAHN
	@ MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Sep DISC

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar CPOT
+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar CPOT
+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar CPOT
+	!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar CPOT

ATROPINE

	@ ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar CDFR
--	----------	----------------------	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	May CDFR
---	---	--------------------	---------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

	@ LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Sep DISC
AP		100MG/VIAL	A210748	001	Feb 27, 2019	Feb NEWA

AZELAIC ACID

	CREAM; TOPICAL								
	AZELEX								
	+! ALMIRALL	20%		N020428	001	Sep 13, 1995	Apr	CAHN	
	GEL; TOPICAL								
	AZELAIC ACID								
AB	TARO	15%		A210549	001	Aug 23, 2019	Aug	NEWA	

AZELASTINE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC								
	AZELASTINE HYDROCHLORIDE								
AT	ALEMBIC PHARMS LTD	0.05%		A209620	001	Mar 20, 2019	Mar	NEWA	
AT	SOMERSET THERAPS LLC	0.05%		A207411	001	Mar 29, 2019	Mar	NEWA	
	SPRAY, METERED; NASAL								
	AZELASTINE HYDROCHLORIDE								
AB	HI TECH	EQ 0.125MG BASE/SPRAY		A207610	001	May 17, 2019	May	NEWA	
AB		EQ 0.1876MG BASE/SPRAY		A210032	001	Aug 23, 2019	Aug	NEWA	

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

	SPRAY, METERED; NASAL								
	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE								
>D>	@ APOTEX	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY		A207712	001	Apr 28, 2017	Dec	CMFD	
>A> AB		EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY		A207712	001	Apr 28, 2017	Dec	CMFD	
	DYMISTA								
>D>	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY		N202236	001	May 01, 2012	Dec	CTEC	
>A> AB	+!	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY		N202236	001	May 01, 2012	Dec	CTEC	

AZITHROMYCIN

	FOR SUSPENSION; ORAL								
	AZITHROMYCIN								
>D> AB	LUPIN LTD	EQ 100MG BASE/5ML		A065488	001	May 15, 2015	Dec	DISC	
>A>	@	EQ 100MG BASE/5ML		A065488	001	May 15, 2015	Dec	DISC	
>D> AB		EQ 200MG BASE/5ML		A065488	002	May 15, 2015	Dec	DISC	
>A>	@	EQ 200MG BASE/5ML		A065488	002	May 15, 2015	Dec	DISC	
AB	TARO	EQ 200MG BASE/5ML		A211521	001	Dec 11, 2019	Nov	NEWA	
	TABLET; ORAL								
	AZITHROMYCIN								
AB	BIONPHARMA INC	EQ 250MG BASE		A210000	001	Feb 26, 2019	Feb	NEWA	
AB		EQ 500MG BASE		A210001	001	Feb 26, 2019	Feb	NEWA	
AB	CSPC OUYI	EQ 250MG BASE		A208250	001	Apr 17, 2019	Apr	NEWA	
AB	! PLIVA	EQ 600MG BASE		A065218	001	Nov 14, 2005	Jul	CHRS	
	@ TEVA	EQ 250MG BASE		A065153	001	Nov 14, 2005	Jul	DISC	
	@	EQ 600MG BASE		A065150	001	Nov 14, 2005	Jul	DISC	

AZTREONAM

	INJECTABLE; INJECTION								
	AZACTAM IN PLASTIC CONTAINER								
	+ @ BRISTOL MYERS SQUIBB	20MG/ML		N050632	002	May 24, 1989	Jul	DISC	
	+ @	40MG/ML		N050632	001	May 24, 1989	Jul	DISC	

BACLOFEN

	INJECTABLE; INTRATHECAL								
	BACLOFEN								
AP	MAIA PHARMS INC	0.5MG/ML		A210048	001	Sep 11, 2019	Aug	NEWA	
AP		1MG/ML		A210315	001	Jul 30, 2019	Jul	NEWA	
AP		2MG/ML		A210048	002	Sep 11, 2019	Aug	NEWA	
	GABLOFEN								
AP	PIRAMAL CRITICAL	0.05MG/ML		N022462	001	Nov 19, 2010	Aug	CAHN	
AP		0.5MG/ML		N022462	002	Nov 19, 2010	Aug	CAHN	
AP	+!	1MG/ML		N022462	004	Jun 22, 2012	Aug	CAHN	
AP		2MG/ML		N022462	003	Nov 19, 2010	Aug	CAHN	
	SOLUTION; ORAL								
	OZOBAX								
	+! METACEL PHARMS LLC	5MG/5ML		N208193	001	Sep 18, 2019	Sep	NEWA	
	TABLET; ORAL								
	BACLOFEN								
AB	EYWA PHARMA	10MG		A211555	001	Feb 01, 2019	Jan	NEWA	
AB		20MG		A211555	002	Feb 01, 2019	Jan	NEWA	
	@ SUN PHARM INDS INC	10MG		A077862	001	Aug 14, 2006	Oct	DISC	
	@	20MG		A077862	002	Aug 14, 2006	Oct	DISC	
AB	UPSHER SMITH LABS	10MG		A074584	001	Aug 19, 1996	Jul	CAHN	

TABLET;ORAL									
BACLOFEN									
AB		20MG	A074584	002	Aug 19, 1996	Jul	CAHN		
<u>BALSALAZIDE DISODIUM</u>									
CAPSULE;ORAL									
BALSALAZIDE DISODIUM									
	@ MYLAN	750MG	A077807	001	Dec 28, 2007	Feb	DISC		
TABLET;ORAL									
BALSALAZIDE DISODIUM									
	@ PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Apr	DISC		
	GIAZO								
	+ @ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Apr	DISC		
<u>BARICITINIB</u>									
TABLET;ORAL									
OLUMIANT									
	+ ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Oct	NEWA		
<u>BARIUM SULFATE</u>									
FOR SUSPENSION;ORAL									
VARIBAR THIN LIQUID									
	+! BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019	May	NEWA		
SUSPENSION;ORAL									
READI-CAT 2 SMOOTHIE									
	+! BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Sep	CMS1		
<u>BELINOSTAT</u>									
POWDER;INTRAVENOUS									
BELEODAQ									
	+! ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014	Mar	CAHN		
<u>BENAZEPRIL HYDROCHLORIDE</u>									
TABLET;ORAL									
BENAZEPRIL HYDROCHLORIDE									
>D> AB	ANI PHARMS INC	5MG	A076333	001	Feb 11, 2004	Dec	DISC		
>A>	@	5MG	A076333	001	Feb 11, 2004	Dec	DISC		
>D> AB		10MG	A076333	002	Feb 11, 2004	Dec	DISC		
>A>	@	10MG	A076333	002	Feb 11, 2004	Dec	DISC		
>D> AB		20MG	A076333	003	Feb 11, 2004	Dec	DISC		
>A>	@	20MG	A076333	003	Feb 11, 2004	Dec	DISC		
>D> AB		40MG	A076333	004	Feb 11, 2004	Dec	DISC		
>A>	@	40MG	A076333	004	Feb 11, 2004	Dec	DISC		
	@ HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004	Feb	CAHN		
	@	10MG	A076267	002	Feb 11, 2004	Feb	CAHN		
	@	20MG	A076267	003	Feb 11, 2004	Feb	CAHN		
	@	40MG	A076267	004	Feb 11, 2004	Feb	CAHN		
<u>BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE</u>									
TABLET;ORAL									
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE									
	@ ANI PHARMS INC	5MG;6.25MG	A076342	001	Feb 11, 2004	May	CAHN		
	@	10MG;12.5MG	A076342	002	Feb 11, 2004	May	CAHN		
	@	20MG;12.5MG	A076342	003	Feb 11, 2004	May	CAHN		
	@	20MG;25MG	A076342	004	Feb 11, 2004	May	CAHN		
<u>BENDAMUSTINE HYDROCHLORIDE</u>									
POWDER;IV (INFUSION)									
TREANDA									
	+! CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Feb	CTEC		
	+!	100MG/VIAL	N022249	001	Mar 20, 2008	Feb	CTEC		
<u>BENZONATATE</u>									
CAPSULE;ORAL									
BENZONATATE									
AA	ASCENT PHARMS INC	100MG	A211518	001	Feb 22, 2019	Feb	NEWA		
AA		150MG	A211518	002	Feb 22, 2019	Feb	NEWA		
AA		200MG	A211518	003	Feb 22, 2019	Feb	NEWA		
AA	CSPC OUYI	100MG	A202765	002	Aug 25, 2017	Feb	CAHN		
AA		200MG	A202765	001	Jul 31, 2015	Feb	CAHN		
AA	QINGDAO BAHEAL PHARM	100MG	A210562	001	Nov 09, 2018	May	CAHN		
AA		150MG	A210562	002	Nov 09, 2018	May	CAHN		

CAPSULE;ORAL							
BENZONATATE							
AA		200MG	A210562	003	Nov 09, 2018	May	CAHN
	@ SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008	Oct	DISC
	@	200MG	A040587	002	Mar 19, 2008	Oct	DISC
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>							
GEL;TOPICAL							
ACANYA							
AB	+! BAUSCH	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Aug	CAHN
BENZACLIN							
AB	+! BAUSCH	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Aug	CAHN
	@	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Aug	CAHN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE							
	@ ANDA REPOSITORY	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Oct	DISC
AB		2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Aug	NEWA
AB	GLENMARK PHARMS	5%;EQ 1% BASE	A209252	001	Mar 14, 2019	Jun	CMS1
AB		5%;1% BASE	A209252	001	Mar 14, 2019	Mar	NEWA
AB	PERRIGO ISRAEL	2.5%;EQ 1.2% BASE	A205397	001	Sep 09, 2019	Aug	NEWA
AB	PERRIGO UK FINCO	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	May	CAHN
AB	TARO	2.5%;EQ 1.2% BASE	A206575	001	Aug 19, 2019	Aug	NEWA
	@	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May	DISC
ONEXTON							
	+! BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug	CAHN
	+! DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May	CTEC
<u>BENZOYL PEROXIDE; ERYTHROMYCIN</u>							
GEL;TOPICAL							
AKTIPAK							
	+ @ BIOFRONTERA	5%;3%	N050769	001	Nov 27, 2000	Aug	DISC
	+!	5%;3%	N050769	001	Nov 27, 2000	May	CAHN
<u>BENZTROPINE MESYLATE</u>							
INJECTABLE;INJECTION							
BENZTROPINE MESYLATE							
	@ LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	DISC
TABLET;ORAL							
BENZTROPINE MESYLATE							
AA	! ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Apr	CHRS
AA	!	1MG	A204713	002	Apr 14, 2015	Apr	CHRS
AA	!	2MG	A204713	003	Apr 14, 2015	Apr	CHRS
	@ OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	Mar	DISC
	@	1MG	A040706	003	Feb 14, 2008	Mar	DISC
	@ UPSHER SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Jul	CAHN
	@	1MG	A040103	002	Dec 12, 1996	Jul	CAHN
	@	2MG	A040103	003	Dec 12, 1996	Jul	CAHN
	@ USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Apr	DISC
	@	1MG	A040103	002	Dec 12, 1996	Apr	DISC
	@	2MG	A040103	003	Dec 12, 1996	Apr	DISC
<u>BENZYL ALCOHOL</u>							
LOTION;TOPICAL							
ULESFIA							
	+ @ SHIONOGI INC	5%	N022129	001	Apr 09, 2009	Sep	DISC
<u>BEPOTASTINE BESILATE</u>							
SOLUTION/DROPS;OPHTHALMIC							
BEPOTASTINE BESILATE							
	@ APOTEX	1.5%	A206066	001	Mar 05, 2019	Sep	DISC
AT	APOTEX INC	1.5%	A206066	001	Mar 05, 2019	Feb	NFTG
AT	MICRO LABS	1.5%	A206220	001	Mar 18, 2019	Mar	NEWA
AT	MYLAN	1.5%	A206220	001	Mar 18, 2019	Apr	CAHN
BEPREVE							
AT	+! BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb	CFTG
<u>BETAMETHASONE DIPROPIONATE</u>							
CREAM, AUGMENTED;TOPICAL							
BETAMETHASONE DIPROPIONATE							
AB	PERRIGO ISRAEL	EQ 0.05% BASE	A076592	001	Dec 09, 2003	May	CAHN

LOTION, AUGMENTED;TOPICAL					
BETAMETHASONE DIPROPIONATE					
AB	HI TECH	EQ 0.05% BASE	A208849	001	Oct 11, 2019 Sep NEWA
OINTMENT, AUGMENTED;TOPICAL					
BETAMETHASONE DIPROPIONATE					
>A> AB	LUPIN LTD	EQ 0.05% BASE	A209106	001	Dec 18, 2019 Dec NEWA
SPRAY;TOPICAL					
SERNIVO					
+	ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016 Mar CAHN
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE</u>					
OINTMENT;TOPICAL					
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE					
AB	PERRIGO ISRAEL	0.064%;0.005%	A200174	001	Dec 12, 2014 Mar CAIN
AB	PERRIGO UK FINCO	0.064%;0.005%	A200174	001	Dec 12, 2014 May CAHN
AB	TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013 Mar CAIN
TACLONEX					
AB	+	LEO PHARMA AS	0.064%;0.005%	N021852	001 Jan 09, 2006 Mar CAIN
SUSPENSION;TOPICAL					
TACLONEX					
+	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008 Mar CAIN
<u>BETAMETHASONE VALERATE</u>					
LOTION;TOPICAL					
BETAMETHASONE VALERATE					
AB	ANIMA	EQ 0.1% BASE	A070052	001	Jul 31, 1985 Sep CAHN
<u>BETHANECHOL CHLORIDE</u>					
TABLET;ORAL					
BETHANECHOL CHLORIDE					
>A> AA	ECI PHARMS LLC	5MG	A040728	002	Oct 26, 2007 Dec CMS1
>A> AA		10MG	A040728	003	Oct 26, 2007 Dec CMS1
>A> AA		25MG	A040728	004	Oct 26, 2007 Dec CMS1
DUVOID					
AA	CHARTWELL RX	10MG	A086262	001	Mar CAHN
AA		25MG	A086263	001	Mar CAHN
AA		50MG	A085882	003	Mar CAHN
<u>BEXAROTENE</u>					
GEL;TOPICAL					
TARGRETIN					
+	BAUSCH	1%	N021056	001	Jun 28, 2000 Jun CAHN
<u>BICALUTAMIDE</u>					
TABLET;ORAL					
BICALUTAMIDE					
	@ FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010 Oct DISC
AB		50MG	A079045	001	May 13, 2010 Feb CAHN
AB	KENTON	50MG	A091011	001	Jun 10, 2015 Jun CAHN
	@ TEVA	50MG	A076932	001	Jul 06, 2009 Sep DISC
<u>BIMATOPROST</u>					
SOLUTION/DROPS;OPHTHALMIC					
BIMATOPROST					
AT	ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019 Apr NEWA
AT	GLAND PHARMA LTD	0.03%	A210126	001	Mar 22, 2019 Mar NEWA
	@ HI-TECH PHARMA CO	0.03%	A203299	001	Nov 08, 2018 Jul DISC
AT	SOMERSET THERAPS LLC	0.03%	A207601	001	Jun 19, 2019 Jun NEWA
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE</u>					
CAPSULE;ORAL					
PYLERA					
+	ALLERGAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006 Nov CAIN
<u>BISOPROLOL FUMARATE</u>					
TABLET;ORAL					
BISOPROLOL FUMARATE					
AB	FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002 Jul CMFD
	@	5MG	A075474	001	Oct 25, 2002 Jan CAHN
AB		10MG	A075474	002	Oct 25, 2002 Jul CMFD
	@	10MG	A075474	002	Oct 25, 2002 Jan CAHN

TABLET;ORAL

BISOPROLOL FUMARATE

	@ MYLAN	5MG	A075831	001	Dec 14, 2005	Nov	DISC
	@	10MG	A075831	002	Dec 14, 2005	Nov	DISC
AB		10MG	A075831	002	Dec 14, 2005	Jul	CHRS
AB	! UNICHEM PHARMS (USA)	10MG	A078635	002	Aug 18, 2009	Jul	CHRS

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ MYLAN	2.5MG; 6.25MG	A075768	001	Sep 25, 2000	Jul	DISC
	@	5MG; 6.25MG	A075768	002	Sep 25, 2000	Jul	DISC
	@	10MG; 6.25MG	A075768	003	Sep 25, 2000	Jul	DISC

BIVALIRUDIN

SOLUTION;INTRAVENOUS

ANGIOMAX RTU

	+! MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019	Jul	NEWA
--	--------------------	---------------------	---------	-----	--------------	-----	------

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP	CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Feb	NEWA
AP	MEITHEAL	EQ 15 UNITS BASE/VIAL	A205030	001	Apr 20, 2018	Nov	CAHN
AP		EQ 30 UNITS BASE/VIAL	A205030	002	Apr 20, 2018	Nov	CAHN

BORTEZOMIB

POWDER;INTRAVENOUS

BORTEZOMIB

DR REDDYS LABS LTD 3.5MG/VIAL

N206927 001 Oct 04, 2019 Oct NEWA

POWDER;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	+ @ HOSPIRA INC	1MG/VIAL	N209191	002	Dec 28, 2018	Mar	DISC
--	-----------------	----------	---------	-----	--------------	-----	------

BOSENTAN

TABLET;ORAL

BOSENTAN

	@ ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019	Oct	DISC
AB		62.5MG	A206002	001	Apr 26, 2019	Apr	NFTG
	@	125MG	A206002	002	Apr 26, 2019	Oct	DISC
AB		125MG	A206002	002	Apr 26, 2019	Apr	NFTG
AB	AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A209742	002	Apr 26, 2019	Apr	NFTG
>A> AB	CIPLA	62.5MG	A210342	001	Jan 03, 2020	Dec	NEWA
>A> AB		125MG	A210342	002	Jan 03, 2020	Dec	NEWA
>A> AB	MYLAN	62.5MG	A205173	001	Jan 15, 2020	Dec	NEWA
>A> AB		125MG	A205173	002	Jan 15, 2020	Dec	NEWA
AB	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A206987	002	Apr 26, 2019	Apr	NFTG
AB	PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A205699	002	Apr 26, 2019	Apr	NFTG
AB	SUN PHARM	62.5MG	A209324	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A209324	002	Apr 26, 2019	Apr	NFTG
AB	WATSON LABS INC	62.5MG	A207110	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207110	002	Apr 26, 2019	Apr	NFTG
AB	ZYDUS PHARMS	62.5MG	A207760	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207760	002	Apr 26, 2019	Apr	NFTG
	TRACLEER						
AB	+ ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	Apr	CFTG
AB	+!	125MG	N021290	002	Nov 20, 2001	Apr	CFTG

BREMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

	+! AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jun	NEWA
--	--------------------	--	---------	-----	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

!	BAS ANDA	50MG/ML	A204386	001	Dec 21, 2018	Jun CAHN
!	BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Aug CAHN

BREXANOLONE

SOLUTION; INTRAVENOUS
ZULRESSO

+	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jun NEWA
---	-------------	---------------------	---------	-----	--------------	----------

>A> BRILLIANT BLUE G

>A> SOLUTION; OPHTHALMIC
>A> TISSUEBLUE

>A>	+	DUTCH OPHTHALMIC	0.025%	N209569	001	Dec 20, 2019	Dec NEWA
-----	---	------------------	--------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT		SOMERSET THERAPS LLC	0.2%	A208992	001	Mar 11, 2019	Feb NEWA
----	--	----------------------	------	---------	-----	--------------	----------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AT2		ALEMBIC PHARMS LTD	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun NEWA
AT2	!	HI TECH	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
AT2		INNOPHARMA LICENSING	EQ 0.09% ACID	A203368	001	Jun 03, 2019	May NEWA
AT2		MYLAN	EQ 0.09% ACID	A203368	001	Jun 03, 2019	Nov CAHN
	@	VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Nov CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@	VINTAGE PHARMS	2MG/5ML; 10MG/5ML; 30MG/5ML	A202940	001	Jul 21, 2014	Nov DISC
---	----------------	-----------------------------	---------	-----	--------------	----------

BUDESONIDE

CAPSULE; ORAL
BUDESONIDE

AB		APPCO	3MG	A207367	001	Apr 07, 2017	Feb CAHN
----	--	-------	-----	---------	-----	--------------	----------

CAPSULE, EXTENDED RELEASE; ORAL
ORTIKOS

+	SUN PHARMA GLOBAL	6MG	N211929	001	Jun 13, 2019	Jun NEWA
+	!	9MG	N211929	002	Jun 13, 2019	Jun NEWA

SUSPENSION; INHALATION
BUDESONIDE

AN		NEPHRON	0.25MG/2ML	A078202	001	Mar 30, 2009	Sep CAHN
AN			0.5MG/2ML	A078202	002	Mar 30, 2009	Sep CAHN

TABLET, EXTENDED RELEASE; ORAL
UCERIS

AB	+	SALIX	9MG	N203634	001	Jan 14, 2013	Mar CAHN
----	---	-------	-----	---------	-----	--------------	----------

BUMETANIDE

TABLET; ORAL
BUMETANIDE

>A>	AB		CEYONE	0.5MG	A212019	001	Dec 12, 2019	Dec NEWA
>A>	AB			1MG	A212019	002	Dec 12, 2019	Dec NEWA
>A>	AB			2MG	A212019	003	Dec 12, 2019	Dec NEWA
	AB		HERITAGE PHARMA	0.5MG	A074225	001	Apr 24, 1995	Feb CAHN
	AB			1MG	A074225	002	Apr 24, 1995	Feb CAHN
	AB			2MG	A074225	003	Apr 24, 1995	Feb CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

	@	MYLAN ASI	0.25%	A091503	001	Oct 18, 2011	Sep DISC
	@		0.5%	A091503	002	Oct 18, 2011	Sep DISC
	@	NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Jun DISC
AP			0.5%	A211096	001	Feb 19, 2019	Feb NEWA
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@	MYLAN ASI	0.25%	A091487	002	Oct 18, 2011	Sep DISC
	@		0.5%	A091487	001	Oct 18, 2011	Sep DISC

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

@ 0.75%

A091487 003 Oct 18, 2011 Sep DISC

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP B BRAUN MEDICAL INC 0.75%

A209087 001 Apr 02, 2019 Mar NEWA

>A> AP HUONS 0.75%

A212822 001 Dec 30, 2019 Dec NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

+ @ HOSPIRA 0.5%;0.0091MG/ML

N022046 001 Jul 13, 1983 Sep CMS1

! SEPTODONT 0.5%;0.0091MG/ML

A077250 001 Sep 27, 2006 Sep CHRS

0.5%;0.0091MG/ML

A077250 001 Sep 27, 2006 Sep CTEC

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

+ @ HOSPIRA 0.5%;0.0091MG/ML

N022046 001 Jul 13, 1983 Sep DISC

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@ BARR EQ 2MG BASE

A090360 001 May 07, 2010 Jul DISC

@ EQ 8MG BASE

A090360 002 May 07, 2010 Jul DISC

@ MYLAN EQ 2MG BASE

A201066 001 Mar 06, 2015 Sep DISC

@ EQ 8MG BASE

A201066 002 Mar 06, 2015 Sep DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB ALVOGEN PINE BROOK EQ 2MG BASE;EQ 0.5MG BASE

A205954 001 Jan 24, 2019 Jan NEWA

AB EQ 4MG BASE;EQ 1MG BASE

A205954 002 Jan 24, 2019 Jan NEWA

AB EQ 8MG BASE;EQ 2MG BASE

A205954 003 Jan 24, 2019 Jan NEWA

AB EQ 12MG BASE;EQ 3MG BASE

A205954 004 Jan 24, 2019 Jan NEWA

FILM;SUBLINGUAL

CASSIPA

+ @ TEVA PHARMS USA EQ 16MG BASE;EQ 4MG BASE

N208042 001 Sep 07, 2018 Mar DISC

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@ TEVA PHARMS USA EQ 2MG BASE;EQ 0.5MG BASE

A091149 001 Sep 08, 2014 Jan DISC

@ EQ 8MG BASE;EQ 2MG BASE

A091149 002 Sep 08, 2014 Jan DISC

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB APNAR PHARMA LP 75MG

A075584 001 Feb 07, 2000 Jun CAHN

AB 100MG

A075584 002 Feb 07, 2000 Jun CAHN

@ HERITAGE PHARMA 75MG

A075310 001 Nov 29, 1999 May CAHN

@ 100MG

A075310 002 Nov 29, 1999 May CAHN

>A> @ INVATECH 75MG

A075613 002 Oct 10, 2000 Dec CAHN

>A> @ 100MG

A075613 001 Oct 10, 2000 Dec CAHN

>D> @ SANDOZ 75MG

A075613 002 Oct 10, 2000 Dec CAHN

>D> @ 100MG

A075613 001 Oct 10, 2000 Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB2 ! ACTAVIS LABS FL INC 150MG

A079094 001 Mar 24, 2009 Jul CHRS

AB3 GRAVITI PHARMS 150MG

A211020 001 Jan 28, 2019 Jan NEWA

AB3 300MG

A211020 002 Jan 28, 2019 Jan NEWA

@ MYLAN 100MG

A090325 001 Apr 08, 2010 Nov DISC

@ 150MG

A090325 002 Apr 08, 2010 Nov DISC

@ 150MG

A090941 001 May 03, 2010 Nov DISC

@ 150MG

A090942 001 Jul 14, 2010 Jul DISC

@ 200MG

A090325 003 Apr 08, 2010 Nov DISC

@ 300MG

A090942 002 Jul 14, 2010 Oct DISC

@ SUN PHARM 150MG

A200695 001 Dec 18, 2014 Sep DISC

@ YICHANG HUMANWELL 100MG

A211347 001 Oct 16, 2018 Apr DISC

@ 150MG

A211347 002 Oct 16, 2018 Apr DISC

@ 200MG

A211347 003 Oct 16, 2018 Apr DISC

AB3 ZHEJIANG JUTAI PHARM 300MG

A211200 001 Sep 05, 2019 Aug NEWA

ZYBAN

+ @ GLAXOSMITHKLINE 150MG

N020711 003 May 14, 1997 Jul DISC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr	NEWA
AB		7.5MG	A208972	002	Apr 16, 2019	Apr	NEWA
AB		10MG	A208972	003	Apr 16, 2019	Apr	NEWA
AB		15MG	A208972	004	Apr 16, 2019	Apr	NEWA
AB		30MG	A208972	005	Apr 16, 2019	Apr	NEWA
	@ RUBICON	5MG	A075521	001	Apr 05, 2002	Aug	CAHN
	@	10MG	A075521	002	Apr 05, 2002	Aug	CAHN
	@	15MG	A075521	003	Apr 05, 2002	Aug	CAHN
AB	UNICHEM LABS LTD	5MG	A210907	001	Nov 14, 2019	Oct	NEWA
AB		10MG	A210907	002	Nov 14, 2019	Oct	NEWA
AB		15MG	A210907	003	Nov 14, 2019	Oct	NEWA
AB		30MG	A210907	004	Nov 14, 2019	Oct	NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb	NEWA
AP	APOTEX	6MG/ML	A210448	001	May 07, 2019	Apr	NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan	CAHN
AP	HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Sep	CMFD
	@	6MG/ML	A205672	001	Jul 31, 2018	Feb	DISC
AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr	NEWA
	MYLERAN						
AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jul	CAHN

CABERGOLINE

TABLET; ORAL

CABERGOLINE

	@ ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008	Aug	DISC
--	-----------------------	-------	---------	-----	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Aug	CAHN
	SOLUTION; ORAL						
	CAFCIT						
AA	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Aug	CAHN
	CAFFEINE CITRATE						
	@ LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009	Mar	DISC
>A> AA	MICRO LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213202	001	Dec 16, 2019	Dec	NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

!	COSETTE	100MG; 2MG	A086557	001	Oct 04, 1983	Jul	CAHN
---	---------	------------	---------	-----	--------------	-----	------

CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

+	@ MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug	CRLD
---	---------------------	-----------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

	@ SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Jul	DISC
AB		0.25MCG	A204556	001	Feb 21, 2019	Feb	NEWA
	@	0.5MCG	A204556	002	Feb 21, 2019	Jul	DISC
AB		0.5MCG	A204556	002	Feb 21, 2019	Feb	NEWA

SOLUTION; ORAL

CALCITRIOL

AA	ELYSIUM	1MCG/ML	A209798	001	Nov 21, 2018	Sep	CAHN
----	---------	---------	---------	-----	--------------	-----	------

CALCIUM ACETATE

TABLET; ORAL

CALCIUM ACETATE

AB	CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Jan	CAHN
----	---------------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDEINJECTABLE; INJECTION
CALCIUM CHLORIDE 10%

AP MEDEFIL INC 100MG/ML A211553 001 May 01, 2019 Apr NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

		DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	001	Dec 04, 1992	Jun	CRLD
		DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Aug	CTEC
	+		18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Jun	CRLD
		DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
	+ @	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992	Sep	DISC
	+		18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992	Jun	CRLD
		DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Aug	CTEC
	+		18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Jun	CRLD
		DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	012	Jan 10, 1989	Aug	NEWA
		DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	013	Jul 11, 1990	Aug	NEWA
		DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	014	Jul 11, 1990	Aug	NEWA
		DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	015	Jul 11, 1990	Aug	NEWA
		DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	004		Jun	CRLD
AT	+		25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	004		Aug	CPOT
AT	+		25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	001	Dec 04, 1992	Jun	CRLD
		DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	005		Jun	CRLD
AT	+		25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	002	Dec 04, 1992	Jun	CRLD
		DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
	+ @	BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985	Jun	CRLD
		DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	006		Jun	CRLD
AT	+		25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	003	Dec 04, 1992	Jun	CRLD

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP FRESENIUS KABI USA 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML A209338 001 Jan 28, 2019 Jan NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB		SUN PHARM	150MG	A204668	001	Jun 21, 2019	Jun	NEWA
AB			500MG	A204668	002	Jun 21, 2019	Jun	NEWA

CAPTOPRILTABLET; ORAL
CAPTOPRIL

>A>	AB	AJANTA PHARMA LTD	12.5MG	A212809	001	Dec 13, 2019	Dec	NEWA
>A>	AB		25MG	A212809	002	Dec 13, 2019	Dec	NEWA
>A>	AB		50MG	A212809	003	Dec 13, 2019	Dec	NEWA
>A>	AB		100MG	A212809	004	Dec 13, 2019	Dec	NEWA
	AB	BOSCOGEN	12.5MG	A074677	004	May 30, 1997	Jun	CMFD
	AB		25MG	A074677	002	May 30, 1997	Jun	CMFD
	AB		50MG	A074677	001	May 30, 1997	Jun	CMFD
	AB		100MG	A074677	003	May 30, 1997	Jun	CMFD
	AB	SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	Oct	NEWA
	AB		25MG	A212223	002	Oct 30, 2019	Oct	NEWA
	AB		50MG	A212223	003	Oct 30, 2019	Oct	NEWA
	AB		100MG	A212223	004	Oct 30, 2019	Oct	NEWA

CARBAMAZEPINECAPSULE, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

>D>	@	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Dec	CAHN
	@		100MG	A076697	001	May 20, 2011	Jul	DISC
>D>	@		200MG	A076697	002	May 20, 2011	Dec	CAHN
	@		200MG	A076697	002	May 20, 2011	Jul	DISC
>D>	@		300MG	A076697	003	May 20, 2011	Dec	CAHN
	@		300MG	A076697	003	May 20, 2011	Jul	DISC
>A>	@	NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011	Dec	CAHN
>A>	@		200MG	A076697	002	May 20, 2011	Dec	CAHN
>A>	@		300MG	A076697	003	May 20, 2011	Dec	CAHN

CARBATROL

AB	+	SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan	CAHN
AB	+		200MG	N020712	001	Sep 30, 1997	Jan	CAHN
AB	+	!	300MG	N020712	002	Sep 30, 1997	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

AB		ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan	NEWA
AB			200MG	A205571	002	Feb 07, 2019	Jan	NEWA
AB			400MG	A205571	003	Feb 07, 2019	Jan	NEWA

CARBIDOPATABLET; ORAL
CARBIDOPA

AB		AUROBINDO PHARMA LTD	25MG	A211055	001	Oct 21, 2019	Oct	NEWA
----	--	----------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

	@	WOCKHARDT LTD	18.75MG; 200MG; 75MG	A090833	001	Nov 20, 2012	Aug	DISC
	@		25MG; 200MG; 100MG	A090833	002	Nov 20, 2012	Aug	DISC
	@		31.25MG; 200MG; 125MG	A090833	003	Nov 20, 2012	Aug	DISC
	@		37.5MG; 200MG; 150MG	A090833	004	Nov 20, 2012	Aug	DISC
	@		50MG; 200MG; 200MG	A090833	005	Nov 20, 2012	Aug	DISC
		STALEVO 125						
+		ORION PHARMA	31.25MG; 200MG; 125MG	N021485	006	Aug 29, 2008	Aug	CTEC
		STALEVO 200						
+	!	ORION PHARMA	50MG; 200MG; 200MG	N021485	004	Aug 02, 2007	Aug	CTEC
		STALEVO 50						
+	!	ORION PHARMA	12.5MG; 200MG; 50MG	N021485	001	Jun 11, 2003	Aug	CTEC
		STALEVO 75						
+		ORION PHARMA	18.75MG; 200MG; 75MG	N021485	005	Aug 29, 2008	Aug	CTEC

CARBIDOPA; LEVODOPATABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB		ALEMBIC PHARMS LTD	25MG; 100MG	A210341	001	Jun 05, 2019	May	NEWA
AB			50MG; 200MG	A210341	002	Jun 05, 2019	May	NEWA
AB	!	SUN PHARM INDS	50MG; 200MG	A077828	002	Aug 23, 2007	Oct	CHRS
		SINEMET CR						
+	@	MERCK SHARP DOHME	50MG; 200MG	N019856	001	May 30, 1991	Oct	DISC

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

! MIKART 4MG/5ML

A 040458 001 Apr 25, 2003 Jun CTEC

@ VINTAGE PHARMS 4MG/5ML

A 040814 001 Feb 26, 2008 Jun DISC

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

>A> +! AYU 4MG/5ML

N 022556 001 Mar 28, 2013 Dec CAHN

>D> +! TRIS PHARMA INC 4MG/5ML

N 022556 001 Mar 28, 2013 Dec CAHN

TABLET;ORAL

CARBINOXAMINE MALEATE

! MIKART 6MG

A 207484 001 May 31, 2016 Mar CHRS

@ VINTAGE PHARMS 4MG

A 040639 002 May 30, 2008 Nov DISC

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP ACCORD HLTHCARE 50MG/5ML (10MG/ML)

A 206775 001 Feb 09, 2017 May CDFR

AP 150MG/15ML (10MG/ML)

A 206775 002 Feb 09, 2017 May CDFR

AP 450MG/45ML (10MG/ML)

A 206775 003 Feb 09, 2017 May CDFR

AP 600MG/60ML (10MG/ML)

A 206775 004 Feb 09, 2017 May CDFR

@ ACTAVIS TOTOWA 50MG/5ML (10MG/ML)

A 078732 001 Feb 06, 2012 Mar CDFR

@ 150MG/15ML (10MG/ML)

A 078732 002 Feb 06, 2012 Mar CDFR

@ 450MG/45ML (10MG/ML)

A 078732 003 Feb 06, 2012 Mar CDFR

@ 600MG/60ML (10MG/ML)

A 078732 004 Feb 06, 2012 Mar CDFR

AP AKORN 50MG/5ML (10MG/ML)

A 090475 001 Jul 29, 2009 May CDFR

AP 150MG/15ML (10MG/ML)

A 090475 002 Jul 29, 2009 May CDFR

AP 450MG/45ML (10MG/ML)

A 090475 003 Jul 29, 2009 May CDFR

AP 600MG/60ML (10MG/ML)

A 091268 002 Jul 28, 2010 May CDFR

AP CIPLA LTD 50MG/5ML (10MG/ML)

A 077861 001 Jan 18, 2007 May CDFR

AP 150MG/15ML (10MG/ML)

A 077861 002 Jan 18, 2007 May CDFR

AP 450MG/45ML (10MG/ML)

A 077861 003 Jan 18, 2007 May CDFR

AP 600MG/60ML (10MG/ML)

A 077861 004 Jan 18, 2007 May CDFR

AP EUGIA PHARMA 50MG/5ML (10MG/ML)

A 205487 001 Mar 28, 2016 May CDFR

AP 150MG/15ML (10MG/ML)

A 205487 002 Mar 28, 2016 May CDFR

AP 450MG/45ML (10MG/ML)

A 205487 003 Mar 28, 2016 May CDFR

@ FRESENIUS KABI USA 50MG/5ML (10MG/ML)

A 077432 001 Sep 29, 2006 Oct DISC

AP 50MG/5ML (10MG/ML)

A 077432 001 Sep 29, 2006 May CDFR

@ 150MG/15ML (10MG/ML)

A 077432 002 Sep 29, 2006 Oct DISC

AP 150MG/15ML (10MG/ML)

A 077432 002 Sep 29, 2006 May CDFR

@ 450MG/45ML (10MG/ML)

A 077432 003 Sep 29, 2006 Oct DISC

AP 450MG/45ML (10MG/ML)

A 077432 003 Sep 29, 2006 May CDFR

@ 50MG/5ML (10MG/ML)

A 077247 001 Oct 21, 2004 Mar CDFR

@ 50MG/5ML (10MG/ML)

A 077266 001 Feb 15, 2006 Mar CDFR

@ 150MG/15ML (10MG/ML)

A 077247 002 Oct 21, 2004 Mar CDFR

@ 150MG/15ML (10MG/ML)

A 077266 002 Feb 15, 2006 Mar CDFR

AP 450MG/45ML (10MG/ML)

A 077247 003 Oct 21, 2004 Mar CDFR

AP 450MG/45ML (10MG/ML)

A 077266 003 Feb 15, 2006 May CDFR

AP 600MG/60ML (10MG/ML)

A 077266 004 Feb 15, 2006 May CDFR

AP GLAND PHARMA LTD 150MG/15ML (10MG/ML)

A 207324 002 Feb 15, 2017 May CDFR

AP 450MG/45ML (10MG/ML)

A 207324 003 Feb 15, 2017 May CDFR

AP 600MG/60ML (10MG/ML)

A 207324 004 Feb 15, 2017 May CDFR

AP HONG KONG 50MG/5ML (10MG/ML)

A 077096 001 Jun 14, 2005 May CDFR

AP 150MG/15ML (10MG/ML)

A 077096 002 Jun 14, 2005 May CDFR

AP 450MG/45ML (10MG/ML)

A 077096 003 Jun 14, 2005 May CDFR

AP 600MG/60ML (10MG/ML)

A 077096 004 Jun 03, 2013 May CDFR

AP HOSPIRA 50MG/5ML (10MG/ML)

A 076517 001 Oct 14, 2004 May CDFR

AP 150MG/15ML (10MG/ML)

A 076517 002 Oct 14, 2004 May CDFR

AP 450MG/45ML (10MG/ML)

A 076517 003 Oct 14, 2004 May CDFR

AP 600MG/60ML (10MG/ML)

A 077059 001 Nov 23, 2004 May CDFR

AP INGENUS PHARMS LLC 50MG/5ML (10MG/ML)

A 208487 001 Apr 26, 2017 May CDFR

AP 150MG/15ML (10MG/ML)

A 208487 002 Apr 26, 2017 May CDFR

AP 450MG/45ML (10MG/ML)

A 208487 003 Apr 26, 2017 May CDFR

AP 600MG/60ML (10MG/ML)

A 208487 004 Apr 26, 2017 May CDFR

AP MEITHEAL 50MG/5ML (10MG/ML)

A 077096 001 Jun 14, 2005 Nov CAHN

AP 150MG/15ML (10MG/ML)

A 077096 002 Jun 14, 2005 Nov CAHN

AP 450MG/45ML (10MG/ML)

A 077096 003 Jun 14, 2005 Nov CAHN

AP 600MG/60ML (10MG/ML)

A 077096 004 Jun 03, 2013 Nov CAHN

@ MYLAN INSTITUTIONAL 50MG/5ML (10MG/ML)

A 077998 001 Apr 24, 2007 Apr CDFR

@ 150MG/15ML (10MG/ML)

A 077998 002 Apr 24, 2007 Apr CDFR

@ 450MG/45ML (10MG/ML)

A 077998 003 Apr 24, 2007 Apr CDFR

@ MYLAN LABS LTD 50MG/5ML (10MG/ML)

A 091063 001 Nov 09, 2011 Oct DISC

INJECTABLE; INTRAVENOUS								
CARBOPLATIN								
AP		50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May	CDFR	
	@	150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	Oct	DISC	
AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May	CDFR	
	@	450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	Oct	DISC	
AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May	CDFR	
	@	600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	Oct	DISC	
AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May	CDFR	
	@	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar	CDFR	
AP	!	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	May	CDFR
	@	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar	CDFR	
AP	!	150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	May	CDFR	
	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar	CDFR	
AP	!	450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	May	CDFR	
	@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar	CDFR	
AP	!	600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	May	CDFR	
AP		PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	May	CDFR
AP		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	May	CDFR	
AP		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	May	CDFR	
AP		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	May	CDFR	
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	May	CDFR
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	May	CDFR	
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	May	CDFR	
AP		SUN PHARM	50MG/5ML (10MG/ML)	A077926	001	Sep 19, 2008	May	CDFR
AP		150MG/15ML (10MG/ML)	A077926	002	Sep 19, 2008	May	CDFR	
AP		450MG/45ML (10MG/ML)	A077926	003	Sep 19, 2008	May	CDFR	
	@	TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar	CDFR
	@	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar	CDFR	
	@	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar	CDFR	
AP	!	TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May	CDFR
AP	!	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May	CDFR	
AP	!	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May	CDFR	
AP	!	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May	CDFR	
AP		WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	May	CDFR
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	May	CDFR	
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	May	CDFR	
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	May	CDFR	
PARAPLATIN								
	+	@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CDFR
	+	@	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CDFR
	+	@	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CDFR
	+	@	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CDFR
INJECTABLE; IV (INFUSION)								
CARBOPLATIN								
AP		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	May	CDFR
AP		HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Feb	CAHN
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Feb	CAHN	
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Feb	CAHN	
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Feb	CAHN	
	@	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar	DISC
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar	DISC	
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar	DISC	
CARBOPROST TROMETHAMINE								
INJECTABLE; INJECTION								
CARBOPROST TROMETHAMINE								
AP		DR REDDYS LABS LTD	EQ 0.25MG BASE/ML	A211941	001	Jul 02, 2019	Jun	NFTG
		HEMABATE						
AP	+	! PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001		Jun	CFTG
CARFILZOMIB								
POWDER; INTRAVENOUS								
CARFILZOMIB								
AP		DR REDDYS	60MG/VIAL	A209422	001	Sep 09, 2019	Aug	NFTG
		KYPROLIS						
AP	+	! ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012	Aug	CFTG

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+	!	RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	May CAHN
---	---	----------------	-------	---------	-----	--------------	----------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA		ALLIED	350MG	A040245	001	Sep 08, 1997	Aug CMFD
		@	350MG	A040245	001	Sep 08, 1997	Jun CAHN
		@ SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991	Oct DISC
		@ VINTAGE PHARMS	350MG	A040245	001	Sep 08, 1997	Feb DISC

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

AP		STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	Mar NEWA
----	--	----------------	------------	---------	-----	--------------	----------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

		@ BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000	May DISC
		! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May CTEC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB		RUBICON	3.125MG	A078165	001	Sep 05, 2007	Aug CAHN
AB			6.25MG	A078165	002	Sep 05, 2007	Aug CAHN
AB			12.5MG	A078165	003	Sep 05, 2007	Aug CAHN
AB			25MG	A078165	004	Sep 05, 2007	Aug CAHN
		@ SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Oct DISC
		@	6.25MG	A077346	001	Sep 05, 2007	Oct DISC
		@	12.5MG	A077346	002	Sep 05, 2007	Oct DISC
		@	25MG	A077346	003	Sep 05, 2007	Oct DISC

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS

CASPOFUNGIN ACETATE

		@ CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018	Jan DISC
		@	70MG/VIAL	A209489	002	Jul 12, 2018	Jan DISC
>A>	AP	JIANGSU HENGRUI MED	50MG/VIAL	A200833	001	Jun 28, 2018	Dec CAHN
>A>	AP		70MG/VIAL	A200833	002	Jun 28, 2018	Dec CAHN
>D>	AP	SANDOZ INC	50MG/VIAL	A200833	001	Jun 28, 2018	Dec CAHN
>D>	AP		70MG/VIAL	A200833	002	Jun 28, 2018	Dec CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

		+ @ BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	003	Jun 08, 1983	Aug CRLD
		+ @	EQ 20MG BASE/ML	N050566	004	Jun 08, 1983	Aug CRLD
		ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
		+ @ BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983	Aug CRLD
		+ @	EQ 20MG BASE/ML	N050566	002	Jun 08, 1983	Aug CRLD

CEFAZOLIN SODIUM

AP	!	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A065047	001	Sep 18, 2001	Nov CHRS
AP	!		EQ 1GM BASE/VIAL	A065047	002	Sep 18, 2001	Nov CHRS
		@ HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Nov DISC
		@	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Nov DISC
		@	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Oct DISC
		@	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Oct DISC
>D>	AP	!	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Dec DISC
>A>		@	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Dec DISC
>D>	AP	QILU	EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Dec CHRS
>A>	AP	!	EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Dec CHRS

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

@ HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Sep DISC
@	EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Sep DISC
@	EQ 1GM BASE/VIAL	A202268	001	Jul 30, 2012	Sep DISC
@	EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Sep DISC
@	EQ 2GM BASE/VIAL	A202268	002	Jul 30, 2012	Sep DISC

CEFIDEROCOL SULFATE TOSYLATE

POWDER; INTRAVENOUS

FETROJA

+! SHIONOGI INC	EQ 1GM BASE/VIAL	N209445	001	Nov 14, 2019	Nov NEWA
-----------------	------------------	---------	-----	--------------	----------

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

@ SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb DISC
@	200MG/5ML	A206144	002	Nov 17, 2017	Feb DISC
SUPRAX					
AB ! LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007	Apr CHRS

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

! HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Nov CTEC
!	EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Nov CTEC
!	EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Nov CTEC
!	EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Nov CTEC
@ WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006	Nov DISC
CEFOTAXIME SODIUM					
@ HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Sep DISC
@	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Sep DISC
@	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Sep DISC
@	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Sep DISC
@	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Sep DISC
@	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Sep DISC
@	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Sep DISC
@	EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Nov DISC
@ WOCKHARDT	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008	Nov DISC
@	EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008	Nov DISC

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

@ FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007	Nov DISC
@ WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011	Nov DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Sep DISC
@	EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Sep DISC
@	EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Sep DISC

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan CTEC
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CHRS
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CTEC
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan DISC
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan DISC

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

>D> AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Dec DISC
>A>	@	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Dec DISC
>D> AP		EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Dec DISC
>A>	@	EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Dec DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFTRIAXONE

>D>	AP		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Dec DISC
>A>	@		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Dec DISC
>D>	AP		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Dec DISC
>A>	@		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Dec DISC

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>D>	AB	ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Dec DISC
>A>	@		EQ 250MG BASE	A065190	001	Oct 18, 2004	Dec DISC
>D>	AB		EQ 500MG BASE	A065190	002	Oct 18, 2004	Dec DISC
>A>	@		EQ 500MG BASE	A065190	002	Oct 18, 2004	Dec DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

@ HOSPIRA INC

@

@

EQ 1.5GM BASE/VIAL
EQ 1.5GM BASE/VIAL
EQ 7.5GM BASE/VIAL

A065483 002 Oct 15, 2008 Sep DISC
A065503 001 Oct 15, 2008 Sep DISC
A065484 001 Oct 15, 2008 Sep DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

@ HOSPIRA INC

EQ 750MG BASE/VIAL

A065483 001 Oct 15, 2008 Sep DISC

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB CADILA PHARMS LTD

50MG

A208701 001 Nov 14, 2019 Nov NEWA

AB

100MG

A208701 002 Nov 14, 2019 Nov NEWA

AB

200MG

A208701 003 Nov 14, 2019 Nov NEWA

AB

400MG

A208701 004 Nov 14, 2019 Nov NEWA

AB QINGDAO BAHEAL PHARM

50MG

A208856 001 Aug 07, 2019 Jul NEWA

AB

100MG

A208856 002 Aug 07, 2019 Jul NEWA

AB

200MG

A208856 003 Aug 07, 2019 Jul NEWA

AB

400MG

A208856 004 Aug 07, 2019 Jul NEWA

TABLET; ORAL

CELECOXIB

AB UMEDICA LABS PVT LTD

50MG

A210628 001 Nov 27, 2019 Nov NEWA

AB

100MG

A210628 002 Nov 27, 2019 Nov NEWA

AB

200MG

A210628 003 Nov 27, 2019 Nov NEWA

AB

400MG

A210628 004 Nov 27, 2019 Nov NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

@ SUN PHARM INDS (IN)

@

EQ 250MG BASE
EQ 500MG BASE

A062791 001 Jun 11, 1987 Oct DISC
A062791 002 Jun 11, 1987 Oct DISC

FOR SUSPENSION; ORAL

CEPHALEXIN

AB ALKEM LABS LTD

EQ 125MG BASE/5ML

A210221 001 Mar 26, 2019 Mar NEWA

AB

EQ 250MG BASE/5ML

A210221 002 Mar 26, 2019 Mar NEWA

CERITINIB

CAPSULE; ORAL

ZYKADIA

+ @ NOVARTIS

150MG

N205755 001 Apr 29, 2014 Jun DISC

TABLET; ORAL

ZYKADIA

+! NOVARTIS

150MG

N211225 001 Mar 18, 2019 Mar NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

QUZYTIR

+! JDP

10MG/ML (10MG/ML)

N211415 001 Oct 04, 2019 Oct NEWA

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ LANNETT CO INC

5MG/5ML

A078496 001 Sep 25, 2009 May DISC

AA

MLV

5MG/5ML

A090191 001 Nov 12, 2009 Aug CAHN

AA

! PERRIGO PHARMS CO

5MG/5ML

A078398 001 Jun 17, 2008 May CAHN

@ TORRENT

5MG/5ML

A078870 001 Apr 27, 2009 Nov DISC

AA

5MG/5ML

A078870 001 Apr 27, 2009 Jan CAHN

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

+ @ PARKE DAVIS	10MG/GM; 666 UNITS/GM; 1 UNITS/GM	N050294	001		Aug	CRLD
-----------------	-----------------------------------	---------	-----	--	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION

LIBRIUM

@ BAUSCH	100MG/AMP	N012301	001		Mar	CAHN
----------	-----------	---------	-----	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

@ ACELLA	4MG/5ML; 5MG/5ML	A206891	001	Jun 09, 2017	Aug	DISC
----------	------------------	---------	-----	--------------	-----	------

VITUZ

+ @ PERSION	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Aug	DISC
-------------	------------------	---------	-----	--------------	-----	------

AA +!	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Apr	CAHN
-------	------------------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D> AA	MAYNE PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Dec	DISC
--------	------------------	----------------------------	---------	-----	--------------	-----	------

>A>	@	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Dec	DISC
-----	---	----------------------------	---------	-----	--------------	-----	------

>D> AA	!	PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Dec	CTEC
--------	---	-------------	----------------------------	---------	-----	--------------	-----	------

>A>	!		4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Dec	CTEC
-----	---	--	----------------------------	---------	-----	--------------	-----	------

AA	!		4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Jun	CHRS
----	---	--	----------------------------	---------	-----	--------------	-----	------

@ TORRENT	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Jan	CAHN
-----------	----------------------------	---------	-----	--------------	-----	------

ZUTRIPRO

+ @ PERSION	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Jul	DISC
-------------	----------------------------	---------	-----	--------------	-----	------

AA +!	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr	CAHN
-------	----------------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

@ HIKMA	30MG/ML	A088157	001	Apr 27, 1983	Sep	CAHN
---------	---------	---------	-----	--------------	-----	------

@	100MG/ML	A088158	001	Apr 27, 1983	Sep	CAHN
---	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	UPSHER SMITH LABS	10MG	A083386	001		Jul	CAHN
----	-------------------	------	---------	-----	--	-----	------

AB	!	25MG	A084112	001		Jul	CAHN
----	---	------	---------	-----	--	-----	------

AB		50MG	A084113	001		Jul	CAHN
----	--	------	---------	-----	--	-----	------

AB	!	100MG	A084114	001		Jul	CAHN
----	---	-------	---------	-----	--	-----	------

AB		200MG	A084115	001		Jul	CAHN
----	--	-------	---------	-----	--	-----	------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ MYLAN	100MG	A088549	002	Jun 01, 1984	May	DISC
---------	-------	---------	-----	--------------	-----	------

@	250MG	A088549	001	Jun 01, 1984	May	DISC
---	-------	---------	-----	--------------	-----	------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	AMNEAL PHARMS CO	25MG	A207204	001	Jul 01, 2019	Jun	NEWA
----	------------------	------	---------	-----	--------------	-----	------

AB		50MG	A207204	002	Jul 01, 2019	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	ARISE	25MG	A210742	001	Oct 12, 2018	Sep	CAHN
----	-------	------	---------	-----	--------------	-----	------

AB		50MG	A210742	002	Oct 12, 2018	Sep	CAHN
----	--	------	---------	-----	--------------	-----	------

AB	UNICHEM LABS LTD	25MG	A211627	001	Aug 06, 2019	Jul	NEWA
----	------------------	------	---------	-----	--------------	-----	------

AB		50MG	A211627	002	Aug 06, 2019	Jul	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	ZYDUS PHARMS	25MG	A207813	001	May 10, 2019	Apr	NEWA
----	--------------	------	---------	-----	--------------	-----	------

AB		50MG	A207813	002	May 10, 2019	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AB	!	MIKART	375MG	A040861	001	Jun 01, 2010	Nov	CTEC
----	---	--------	-------	---------	-----	--------------	-----	------

AB	!		750MG	A040861	002	Jun 01, 2010	Nov	CTEC
----	---	--	-------	---------	-----	--------------	-----	------

AB		NOVITIUM PHARMA	375MG	A212253	001	Nov 27, 2019	Nov	NEWA
----	--	-----------------	-------	---------	-----	--------------	-----	------

AA			500MG	A212254	001	Sep 12, 2019	Sep	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			750MG	A212253	002	Nov 27, 2019	Nov	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AA	!	WATSON LABS	500MG	A089859	001	May 04, 1988	Sep	CTEC
----	---	-------------	-------	---------	-----	--------------	-----	------

CHOLESTYRAMINEPOWDER; ORAL
LOCHOLEST LIGHT

>A>	@ INVATECH	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Dec CAHN
>A>	@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Dec CAHN
>D>	@ SANDOZ	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Dec CAHN
>D>	@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Dec CAHN

CHOLINE C-11INJECTABLE; INTRAVENOUS
CHOLINE C-11

AP	DECATUR	4-33.1mCi/ML	A206319	001	Nov 13, 2015	Apr CAHN
----	---------	--------------	---------	-----	--------------	----------

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE; ORAL
FENOFIBRIC ACID

AB	AUROBINDO PHARMA LTD	EQ 45MG FENOFIBRIC ACID	A212598	001	Jul 25, 2019	Jul NEWA
AB		EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Jul NEWA
AB	GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Jul NEWA
AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Jul NEWA
	@ MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	May DISC
	@	EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	May DISC
>D> AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Dec DISC
>A>	@	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Dec DISC
AB		EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Jun NEWA
>D> AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Dec DISC
>A>	@	EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Dec DISC
AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Jun NEWA

CHROMIC PHOSPHATE P-32INJECTABLE; INJECTION
PHOSPHOCOL P32

@ CURIUM	5mCi/ML	N017084	001		Jan CAHN
----------	---------	---------	-----	--	----------

CICLESONIDEAEROSOL, METERED; INHALATION
ALVESCO

+	COVIS PHARMA BV	0.08MG/INH	N021658	002	Jan 10, 2008	Mar CAHN
+		0.16MG/INH	N021658	003	Jan 10, 2008	Mar CAHN

AEROSOL, METERED; NASAL
ZETONNA

+	COVIS PHARMA BV	0.037MG/INH	N202129	001	Jan 20, 2012	Mar CAHN
---	-----------------	-------------	---------	-----	--------------	----------

SPRAY, METERED; NASAL
OMNARIS

+	COVIS PHARMA BV	0.05MG/INH	N022004	001	Oct 20, 2006	Mar CAHN
---	-----------------	------------	---------	-----	--------------	----------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	PERRIGO ISRAEL	0.77%	A077364	001	Mar 03, 2006	May CAHN
----	----------------	-------	---------	-----	--------------	----------

SHAMPOO; TOPICAL
LOPROX

AT	+	BAUSCH	1%	N021159	001	Feb 28, 2003	Apr CAHN
----	---	--------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL
CICLOPIROX

AT	ACELLA	8%	A078172	001	Sep 18, 2007	May CAHN
AT	ANDA REPOSITORY	8%	A077687	001	Sep 18, 2007	Aug CAHN
AT	NOVAST LABS	8%	A078124	001	Sep 18, 2007	Sep CAHN

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

	@ HOSPIRA INC	EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011	Sep DISC
	@	EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011	Sep DISC
>A> AP	HQ SPCLT PHARMA	EQ 500MG BASE/VIAL; 500MG/VIAL	A207594	001	Dec 12, 2019	Dec NEWA

CILASTATIN SODIUM; IMIPENEM; RELEBACTAMPOWDER; INTRAVENOUS
RECARBRIO+! MSD MERCK CO EQ 500MG
BASE/VIAL; 500MG/VIAL; 250MG/VIAL

N212819 001 Jul 16, 2019 Jul NEWA

CILOSTAZOLTABLET; ORAL
CILOSTAZOLAB SLATE 50MG
AB 100MGA077208 002 Mar 29, 2006 Aug CAHN
A077208 001 Mar 29, 2006 Aug CAHNCIMETIDINE HYDROCHLORIDESOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE>D> AA ANI PHARMS INC EQ 300MG BASE/5ML
>A> @ EQ 300MG BASE/5MLA074610 001 Sep 26, 1996 Dec DISC
A074610 001 Sep 26, 1996 Dec DISCCINACALCET HYDROCHLORIDETABLET; ORAL
CINACALCET HYDROCHLORIDEAB ALKEM LABS LTD EQ 30MG BASE
AB EQ 60MG BASE
AB EQ 90MG BASEA210570 001 May 17, 2019 May NEWA
A210570 002 May 17, 2019 May NEWA
A210570 003 May 17, 2019 May NEWACIPROFLOXACINFOR SUSPENSION; ORAL
CIPRO>D> AB + BAYER HLTHCARE 250MG/5ML
>A> + 250MG/5ML
>D> AB +! 500MG/5ML
>A> +! 500MG/5ML
>D> CIPROFLOXACINN020780 001 Sep 26, 1997 Dec CTEC
N020780 001 Sep 26, 1997 Dec CTEC
N020780 002 Sep 26, 1997 Dec CTEC
N020780 002 Sep 26, 1997 Dec CTEC>D> AB LUPIN LTD 250MG/5ML
>A> @ 250MG/5ML
>D> AB 500MG/5ML
>A> @ 500MG/5MLA200563 001 Mar 05, 2014 Dec DISC
A200563 001 Mar 05, 2014 Dec DISC
A200563 002 Mar 05, 2014 Dec DISC
A200563 002 Mar 05, 2014 Dec DISCINJECTABLE; INJECTION
CIPROFLOXACIN@ DR REDDYS 200MG/20ML (10MG/ML)
@ 400MG/40ML (10MG/ML)A077782 001 Aug 28, 2006 May CAHN
A077782 002 Aug 28, 2006 May CAHNCIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

@ RUBICON EQ 0.3% BASE

A075928 001 Jun 09, 2004 Jul CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB CHARTWELL EQ 250MG BASE
AB EQ 500MG BASE
AB EQ 750MG BASE
AB CHARTWELL MOLECULES EQ 250MG BASE
AB EQ 500MG BASE
AB EQ 750MG BASEA076896 001 Nov 04, 2004 Sep CAHN
A076896 002 Nov 04, 2004 Sep CAHN
A076896 003 Nov 04, 2004 Sep CAHN
A076896 001 Nov 04, 2004 Jul CAHN
A076896 002 Nov 04, 2004 Jul CAHN
A076896 003 Nov 04, 2004 Jul CAHNCIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
CIPROFLOXACIN EXTENDED RELEASE! ANCHEN PHARMS 212.6MG; EQ 287.5MG BASE
AB ! 212.6MG; EQ 287.5MG BASE
AB ! 425.2MG; EQ 574.9MG BASE
@ ANI PHARMS INC 212.6MG; EQ 287.5MG BASE
@ 425.2MG; EQ 574.9MG BASE
@ MYLAN PHARMS INC 212.6MG; EQ 287.5MG BASE
@ 425.2MG; EQ 574.9MG BASEA078166 002 Nov 27, 2007 May CTEC
A078166 002 Nov 27, 2007 May CHRS
A078166 001 Nov 27, 2007 May CHRS
A077417 001 Nov 30, 2010 May CAHN
A077809 001 Nov 30, 2010 May CAHN
A078183 001 Mar 22, 2007 May DISC
A078183 002 Mar 22, 2007 May DISC

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb DISC
AP	ANDA REPOSITORY	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Sep CAHN
AP	HOSPIRA INC	EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Nov CMFD
AP		EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Nov CMFD
AP	MEITHEAL	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Nov CAHN
AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Nov CAHN
AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Nov CAHN
AP	NANJING KING-FRIEND	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr NEWA
AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr NEWA
AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr NEWA
AP	SOMERSET	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Oct CAHN
AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Apr NEWA
AP	ZYDUS PHARMS	EQ 2MG BASE/ML	A212171	001	Nov 04, 2019	Oct NEWA
AP		EQ 10MG BASE/ML	A212171	002	Nov 04, 2019	Oct NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
	@ ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb DISC
	@	EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb DISC
AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb NEWA
AP		EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb NEWA
	NIMBEX PRESERVATIVE FREE					
AP	+! ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb CTEC

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

	@ MYLAN LABS LTD	1MG/ML	A091062	001	Apr 18, 2012	Oct DISC
--	------------------	--------	---------	-----	--------------	----------

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

	@ HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004	May CAHN
	@	EQ 10MG BASE	A077213	001	Mar 31, 2006	May CAHN
>D> AB		EQ 10MG BASE	A077232	001	Oct 31, 2005	Dec DISC
>A>	@	EQ 10MG BASE	A077232	001	Oct 31, 2005	Dec DISC
AB		EQ 10MG BASE	A077232	001	Oct 31, 2005	May CAHN
	@	EQ 20MG BASE	A077033	002	Oct 28, 2004	May CAHN
	@	EQ 20MG BASE	A077213	002	Mar 31, 2006	May CAHN
>D> AB		EQ 20MG BASE	A077232	002	Oct 31, 2005	Dec DISC
>A>	@	EQ 20MG BASE	A077232	002	Oct 31, 2005	Dec DISC
AB		EQ 20MG BASE	A077232	002	Oct 31, 2005	May CAHN
	@	EQ 40MG BASE	A077033	003	Oct 28, 2004	May CAHN
	@	EQ 40MG BASE	A077213	003	Mar 31, 2006	May CAHN
>D> AB		EQ 40MG BASE	A077232	003	Oct 31, 2005	Dec DISC
>A>	@	EQ 40MG BASE	A077232	003	Oct 31, 2005	Dec DISC
AB		EQ 40MG BASE	A077232	003	Oct 31, 2005	May CAHN
	@ SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004	Oct DISC
	@	EQ 20MG BASE	A077032	002	Nov 12, 2004	Oct DISC
	@	EQ 40MG BASE	A077032	003	Nov 12, 2004	Oct DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

	+ @ FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Sep DISC
	+!	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Jun CMFD
	+ @	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Apr DISC

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP	HISUN PHARM HANGZHOU	1MG/ML	A210856	001	Nov 25, 2019	Nov NEWA
	TABLET; ORAL					
	MAVENCLAD					
	+! EMD SERONO INC	10MG	N022561	001	Mar 29, 2019	Mar NEWA

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

		@ AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Sep DISC
AB			250MG	A206714	001	Apr 25, 2019	Apr NEWA
		@	500MG	A206714	002	Apr 25, 2019	Sep DISC
AB			500MG	A206714	002	Apr 25, 2019	Apr NEWA
AB		CHARTWELL	250MG	A065384	001	Aug 20, 2007	Aug CAHN
AB			500MG	A065384	002	Aug 20, 2007	Aug CAHN
AB		STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb CAHN
AB			500MG	A202710	002	Jun 10, 2013	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

>D>	AB	LUPIN LTD	500MG	A202532	001	Sep 15, 2015	Dec DISC
>A>		@	500MG	A202532	001	Sep 15, 2015	Dec DISC
	AB	NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016	Jul CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

		@ MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar DISC
--	--	---------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAGEL

BT	+	BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	May CAHN
----	---	--------	------------	---------	-----	--------------	----------

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		CADILA	EQ 1% BASE	A208767	001	Jul 16, 2018	Oct CAHN
AT		ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

VELTIN

BX	+	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CAHN
----	---	----------	-------------	---------	-----	--------------	----------

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

		@ TARO	2.5MG/ML	A210978	001	Apr 15, 2019	Sep DISC
AB			2.5MG/ML	A210978	001	Apr 15, 2019	Apr NEWA
AB		VISTAPHARM	2.5MG/ML	A210746	001	Jul 10, 2019	Jun NEWA

TABLET;ORAL

CLOBAZAM

>D>	AB	ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019	Dec DISC
>A>		@	10MG	A212398	001	May 23, 2019	Dec DISC
	AB		10MG	A212398	001	May 23, 2019	May NEWA
>D>	AB		20MG	A212398	002	May 23, 2019	Dec DISC
>A>		@	20MG	A212398	002	May 23, 2019	Dec DISC
	AB		20MG	A212398	002	May 23, 2019	May NEWA
AB		ALKEM LABS LTD	10MG	A212714	001	Sep 06, 2019	Aug NEWA
AB			20MG	A212714	002	Sep 06, 2019	Aug NEWA
AB		LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Oct NEWA
AB			20MG	A212092	002	Oct 30, 2019	Oct NEWA
AB		MICRO LABS	10MG	A211711	001	Jan 30, 2019	Jan NEWA
AB			20MG	A211711	002	Jan 30, 2019	Jan NEWA
		@ TARO	10MG	A209440	001	Oct 22, 2018	Jul DISC
		@	20MG	A209440	002	Oct 22, 2018	Jul DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb NEWA
AB2			0.05%	A211450	001	Sep 09, 2019	Aug NEWA
AB2		PERRIGO UK FINCO	0.05%	A201402	001	Aug 14, 2012	May CAHN

CREAM;TOPICAL

CLOBETASOL PROPIONATE

	AB1	RISING	0.05%	A211401	001	Jan 11, 2019	Sep CAHN
>A>	AB1	TORRENT	0.05%	A211836	001	Dec 30, 2019	Dec NEWA
	AB1	XIROMED	0.05%	A210034	001	Jun 15, 2018	Aug CAHN

CREAM; TOPICAL							
CLOBETASOL PROPIONATE (EMOLLIENT)							
>D>	@ NOVAST LABS	0.05%	A075733	001	Aug 22, 2001	Dec	CMFD
>A>	AB2	0.05%	A075733	001	Aug 22, 2001	Dec	CMFD
LOTION; TOPICAL							
CLOBETASOL PROPIONATE							
>A>	AB	CADILA	0.05%	A205249	001	Sep 24, 2019	Dec CAHN
		@ HI TECH	0.05%	A211348	001	Oct 26, 2018	Jul DISC
>D>	AB	ZYDUS PHARMS	0.05%	A205249	001	Sep 24, 2019	Dec CAHN
	AB		0.05%	A205249	001	Sep 24, 2019	Sep NEWA
OINTMENT; TOPICAL							
CLOBETASOL PROPIONATE							
	AB	ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb NEWA
		@ AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb DISC
	AB	ENCUBE	0.05%	A211295	001	Nov 15, 2019	Nov NEWA
	AB	TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan NEWA
	AB	TORRENT	0.05%	A212926	001	Oct 25, 2019	Oct NEWA
	AB	XIROMED	0.05%	A209701	001	Apr 17, 2018	Aug CAHN
SOLUTION; TOPICAL							
CLOBETASOL PROPIONATE							
AT		ALEOR DERMACEUTICALS	0.05%	A212881	001	Oct 21, 2019	Oct NEWA
AT		SAPTALIS PHARMS	0.05%	A211494	001	Oct 02, 2019	Sep NEWA
SPRAY; TOPICAL							
CLOBETASOL PROPIONATE							
AT		ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Sep NEWA
AT		GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Aug CAHN
<u>CLOFARABINE</u>							
SOLUTION; INTRAVENOUS							
CLOFARABINE							
AP		ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb NEWA
		@ HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb DISC
<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
CLOMIPRAMINE HYDROCHLORIDE							
AB		JUBILANT CADISTA	25MG	A212218	001	Oct 21, 2019	Oct NEWA
AB			50MG	A212218	002	Oct 21, 2019	Oct NEWA
AB			75MG	A212218	003	Oct 21, 2019	Oct NEWA
		@ MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Oct DISC
AB			25MG	A211767	001	Apr 08, 2019	Mar NEWA
		@	50MG	A211767	002	Apr 08, 2019	Oct DISC
AB			50MG	A211767	002	Apr 08, 2019	Mar NEWA
		@	75MG	A211767	003	Apr 08, 2019	Oct DISC
AB			75MG	A211767	003	Apr 08, 2019	Mar NEWA
<u>CLONAZEPAM</u>							
TABLET; ORAL							
CLONAZEPAM							
	@ RUBICON	0.5MG	A075468	001	Oct 06, 2000	Aug	CAHN
	@	1MG	A075468	002	Oct 06, 2000	Aug	CAHN
	@	2MG	A075468	003	Oct 06, 2000	Aug	CAHN
	@ SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Oct	DISC
	@	1MG	A075423	002	Apr 27, 2001	Oct	DISC
	@	2MG	A075423	003	Apr 27, 2001	Oct	DISC
TABLET, ORALLY DISINTEGRATING; ORAL							
CLONAZEPAM							
AB		ALEMBIC PHARMS LTD	0.125MG	A211033	001	Jun 28, 2019	Jun NEWA
AB			0.25MG	A211033	002	Jun 28, 2019	Jun NEWA
AB			0.5MG	A211033	003	Jun 28, 2019	Jun NEWA
AB			1MG	A211033	004	Jun 28, 2019	Jun NEWA
AB			2MG	A211033	005	Jun 28, 2019	Jun NEWA
<u>CLONIDINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CLONIDINE HYDROCHLORIDE							
	@ LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb	DISC
	@	5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb	DISC
TABLET; ORAL							
CLONIDINE HYDROCHLORIDE							
AB		FRONTIDA BIOPHARM	0.1MG	A070923	003	Sep 04, 1987	Apr CMS1
AB			0.2MG	A070923	002	Sep 04, 1987	Apr CMS1

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ SUN PHARM INDS INC 0.1MG
 @ 0.2MG
 @ 0.3MG

A090329 001 Jul 03, 2014 Oct DISC
 A090329 002 Jul 03, 2014 Oct DISC
 A090329 003 Jul 03, 2014 Oct DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1 NOVAST LABS 0.1MG
 @ UPSHER SMITH LABS 0.1MG

A209675 001 Mar 05, 2019 Feb NEWA
 A211433 001 Oct 12, 2018 May DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

>D> AB ANI PHARMS INC EQ 300MG BASE
 >A> @ EQ 300MG BASE
 >D> AB EQ 300MG BASE
 >A> @ EQ 300MG BASE
 AB EQ 300MG BASE
 @ CADILA EQ 75MG BASE
 AB EQ 75MG BASE
 AB CELLTRION EQ 75MG BASE
 AB EQ 300MG BASE
 @ MYLAN PHARMS INC EQ 75MG BASE
 @ EQ 300MG BASE
 @ SUN PHARM INDUSTRIES EQ 75MG BASE

A090625 001 May 17, 2012 Dec DISC
 A090625 001 May 17, 2012 Dec DISC
 A091216 001 May 17, 2012 Dec DISC
 A091216 001 May 17, 2012 Dec DISC
 A091216 001 May 17, 2012 May CAHN
 A201686 001 Oct 10, 2012 Jun DISC
 A201686 001 Oct 10, 2012 Apr CAHN
 A202266 001 Aug 14, 2012 Aug CAHN
 A202266 002 Nov 20, 2012 Aug CAHN
 A077665 001 May 17, 2012 Sep DISC
 A077665 002 May 17, 2012 Feb DISC
 A078133 001 Jun 10, 2013 Oct DISC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG
 @ 7.5MG

A072514 002 May 11, 1990 Jan CMS1
 A072514 003 May 11, 1990 Jan CMS1

CLOTTRIMAZOLE

SOLUTION;TOPICAL

CLOTTRIMAZOLE

AT NOVITIUM PHARMA 1%
 AT TASMAN PHARMA 1%

A209815 001 Feb 14, 2019 Feb NEWA
 A212281 001 Jul 25, 2019 Jul NEWA

CLOZAPINE

TABLET;ORAL

CLOZARIL

AB + HERITAGE LIFE 50MG
 AB + 200MG

N019758 003 May 20, 2019 May NEWA
 N019758 004 May 20, 2019 May NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB BARR LABS INC 12.5MG
 ! 100MG
 TEVA PHARMS USA 150MG
 200MG

A090308 003 Apr 09, 2018 Nov CTEC
 A090308 002 Nov 25, 2015 Nov CHRS
 A203039 001 Nov 25, 2015 Nov CTEC
 A203039 002 Nov 25, 2015 Nov CTEC

FAZACLO ODT

+ @ JAZZ 12.5MG
 AB + 12.5MG
 + @ 25MG
 AB + 25MG
 @ 50MG
 + @ 100MG
 AB +! 100MG
 + @ 150MG
 AB + 150MG
 + @ 200MG
 AB + 200MG

N021590 004 May 30, 2007 Nov DISC
 N021590 004 May 30, 2007 Jun CAHN
 N021590 001 Feb 10, 2004 Nov DISC
 N021590 001 Feb 10, 2004 Jun CAHN
 N021590 003 Jun 03, 2005 Jun CAHN
 N021590 002 Feb 10, 2004 Nov DISC
 N021590 002 Feb 10, 2004 Jun CAHN
 N021590 005 Jul 09, 2010 Nov DISC
 N021590 005 Jul 09, 2010 Jun CAHN
 N021590 006 Jul 09, 2010 Nov DISC
 N021590 006 Jul 09, 2010 Jun CAHN

COBICISTAT; DARUNAVIR

TABLET;ORAL

PREZCOBIX

+! JANSSEN PRODS 150MG;800MG

N205395 001 Jan 29, 2015 Sep CAIN

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYMITUZA

+	!	JANSSEN PRODS	150MG;800MG;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Oct CAIN
+	!		150MG;EQ 800MG BASE;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Oct CAIN

COLCHICINE

CAPSULE;ORAL

COLCHICINE

@	PAR PHARM INC	0.6MG	A208678	001	Nov 29, 2018	May DISC
---	---------------	-------	---------	-----	--------------	----------

MITIGARE

+	!	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	May CTEC
---	---	-------------------	-------	---------	-----	--------------	----------

SOLUTION;ORAL

GLOPERBA

+	!	AVION PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jul CAHN
---	---	--------------	-----------	---------	-----	--------------	----------

+	!	ROMEG THERAPS LLC	0.6MG/5ML	N210942	001	Jan 30, 2019	Jan NEWA
---	---	-------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

COLCHICINE

AB		ALKEM LABS LTD	0.6MG	A211250	001	Feb 08, 2019	Feb NEWA
----	--	----------------	-------	---------	-----	--------------	----------

AB		DR REDDYS	0.6MG	A209876	001	Sep 06, 2019	Aug NEWA
----	--	-----------	-------	---------	-----	--------------	----------

AB		MYLAN	0.6MG	A209470	001	Sep 16, 2019	Sep NEWA
----	--	-------	-------	---------	-----	--------------	----------

AB		WATSON LABS INC	0.6MG	A204461	001	Jul 31, 2019	Jul NEWA
----	--	-----------------	-------	---------	-----	--------------	----------

@	ZYDUS PHARMS	0.6MG	A211519	001	Feb 19, 2019	Jul DISC
---	--------------	-------	---------	-----	--------------	----------

AB			0.6MG	A211519	001	Feb 19, 2019	Feb NEWA
----	--	--	-------	---------	-----	--------------	----------

COLCRYS

AB	+	!	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Jan CTEC
----	---	---	-------------------	-------	---------	-----	--------------	----------

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL

WELCHOL

+	!	DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019	Apr NEWA
---	---	--------------------	--------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	3.75GM/PACKET	A210316	001	May 06, 2019	Apr NEWA
----	--	----------------	---------------	---------	-----	--------------	----------

		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Mar CTEC
--	--	---------------------	----------------	---------	-----	--------------	----------

WELCHOL

+	@	DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Mar DISC
---	---	----------------	----------------	---------	-----	--------------	----------

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		BIONPHARMA INC	625MG	A208670	001	Sep 13, 2019	Sep NEWA
----	--	----------------	-------	---------	-----	--------------	----------

AB		ZYDUS PHARMS	625MG	A207765	001	Oct 07, 2019	Sep NEWA
----	--	--------------	-------	---------	-----	--------------	----------

CROMOLYN SODIUM

SOLUTION;INHALATION

CROMOLYN SODIUM

@	MYLAN SPECIALITY LP	10MG/ML	A074209	001	Apr 26, 1994	Mar DISC
---	---------------------	---------	---------	-----	--------------	----------

CROTAMITON

CREAM;TOPICAL

EURAX

+	@	SUN PHARM INDS INC	10%	N006927	001		Aug DISC
---	---	--------------------	-----	---------	-----	--	----------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMRIX

AB	+	TEVA PHARMS INTL	15MG	N021777	001	Feb 01, 2007	Mar CTEC
----	---	------------------	------	---------	-----	--------------	----------

	+		15MG	N021777	001	Feb 01, 2007	Jan CTEC
--	---	--	------	---------	-----	--------------	----------

AB	+	!	30MG	N021777	002	Feb 01, 2007	Mar CTEC
----	---	---	------	---------	-----	--------------	----------

	+		30MG	N021777	002	Feb 01, 2007	Jan CTEC
--	---	--	------	---------	-----	--------------	----------

CYCLOBENZAPRINE HYDROCHLORIDE

AB		APOTEX	15MG	A206703	001	Jul 24, 2018	Feb CMFD
----	--	--------	------	---------	-----	--------------	----------

AB			30MG	A206703	002	Jul 24, 2018	Feb CMFD
----	--	--	------	---------	-----	--------------	----------

@	APOTEX INC	15MG	A206703	001	Jul 24, 2018	Jan DISC
---	------------	------	---------	-----	--------------	----------

@		30MG	A206703	002	Jul 24, 2018	Jan DISC
---	--	------	---------	-----	--------------	----------

AB		TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Mar CMFD
----	--	----------------	------	---------	-----	--------------	----------

AB			30MG	A091281	002	Jan 31, 2013	Mar CMFD
----	--	--	------	---------	-----	--------------	----------

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ANDA REPOSITORY	5MG	A073541	002	Apr 06, 2006	Aug CAHN
----	--	-----------------	-----	---------	-----	--------------	----------

AB			10MG	A073541	001	May 23, 1995	Aug CAHN
----	--	--	------	---------	-----	--------------	----------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB	CIPLA	25MG	A211608	001	Jan 18, 2019	Jan NEWA
AB		50MG	A211608	002	Jan 18, 2019	Jan NEWA
AB	+ HIKMA	25MG	N203856	001	Sep 16, 2013	Oct CAHN
AB	+!	50MG	N203856	002	Sep 16, 2013	Oct CAHN

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

!	PURDUE	250MG	A060593	001		Aug CAHN
---	--------	-------	---------	-----	--	----------

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	APOTEX	25MG	A210721	001	Jul 10, 2019	Jun NEWA
AB1		50MG	A210721	002	Jul 10, 2019	Jun NEWA
AB1		100MG	A210721	003	Jul 10, 2019	Jun NEWA
AB1	IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	Jun CTEC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	ANDA REPOSITORY	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
AA	ELYSIUM	2MG/5ML	A209108	001	Oct 16, 2018	Sep CAHN
AA	PATRIN PHARMA INC	2MG/5ML	A204823	001	Dec 27, 2016	Jul CAHN
AA	QUAGEN	2MG/5ML	A212423	001	May 22, 2019	May NEWA
AA	TORRENT	2MG/5ML	A204823	001	Dec 27, 2016	Jan CAHN

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	BEXIMCO PHARMS USA	4MG	A206676	001	Apr 12, 2019	Apr NEWA
AA	ELYSIUM	4MG	A207555	001	Jan 31, 2017	Sep CAHN
AA	! HERITAGE PHARMA	4MG	A087056	001		Feb CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

	+!	EXELA PHARMA SCS LLC	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr NEWA
>A>		NOURESS					
>A>		AVADEL LEGACY	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	Dec NEWA

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>A>	AP	GLAND PHARMA LTD	100MG/VIAL	A211937	001	Dec 23, 2019	Dec NEWA
>A>	AP		2GM/VIAL	A211938	001	Dec 23, 2019	Dec NEWA
	AP	MEITHEAL	20MG/ML	A206190	001	Nov 09, 2017	Nov CAHN
	AP		100MG/ML	A205696	001	Jul 17, 2018	Nov CAHN
	@	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Sep DISC
>D>		WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Dec CTEC
>A>	AP		100MG/VIAL	A071471	001	Aug 02, 1989	Dec CTEC
>D>	!		2GM/VIAL	A074245	002	Aug 31, 1994	Dec CTEC
>A>	AP	!	2GM/VIAL	A074245	002	Aug 31, 1994	Dec CTEC

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

+	@	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jun DISC
+	@		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun DISC
+	@		EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb DISC

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AP	HISUN PHARM HANGZHOU	0.5MG/VIAL	A207232	001	Jul 16, 2019	Jul NEWA
AP	X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	May NEWA

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL
DALFAMPRIDINE

AB	MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb NEWA
AB	SUN PHARM	10MG	A208292	001	May 21, 2019	May NEWA

DANTROLENE SODIUM

INJECTABLE; INJECTION
DANTROLENE SODIUM

@ MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar DISC
-----------------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

QTERNMET XR

+	ASTRAZENECA AB	2.5MG; 1GM; EQ 2.5MG BASE	N210874	001	May 02, 2019	May NEWA
+		5MG; 1GM; EQ 2.5MG BASE	N210874	002	May 02, 2019	May NEWA
+		5MG; 1GM; EQ 5MG BASE	N210874	003	May 02, 2019	May NEWA
+	!	10MG; 1GM; EQ 5MG BASE	N210874	004	May 02, 2019	May NEWA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

QTERN

+	ASTRAZENECA AB	5MG; EQ 5MG BASE	N209091	002	May 02, 2019	May NEWA
---	----------------	------------------	---------	-----	--------------	----------

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

@ BARADAINA LLC	0.5%	A204902	001	May 30, 2019	Oct DISC
	0.5%	A204902	001	May 30, 2019	May NEWA

DAPSONE

GEL; TOPICAL

ACZONE

AB	+	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Nov CTEC
	+		7.5%	N207154	001	Feb 24, 2016	Jun CFTG
	+		7.5%	N207154	001	Feb 24, 2016	Feb CAHN

DAPSONE

AB	@	TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Nov DISC
			7.5%	A210191	001	Jun 26, 2019	Jun NFTG

TABLET; ORAL

DAPSONE

AB		SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Apr NEWA
	@	TARO	25MG	A209430	001	Mar 01, 2019	May DISC
	@		100MG	A209430	002	Mar 01, 2019	May DISC
AB		TARO PHARM	25MG	A209430	001	Mar 01, 2019	Feb NEWA
AB			100MG	A209430	002	Mar 01, 2019	Feb NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

@ CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003	Oct CDFR
---------------------	------------	---------	-----	--------------	----------

DAPTOMYCIN

AP		ACCORD HLTHCARE	500MG/VIAL	A211961	001	Jun 24, 2019	Jun NEWA
AP		BE PHARMS	500MG/VIAL	A212513	001	Jun 26, 2019	Jun NEWA
AP		DR REDDYS	500MG/VIAL	A208375	001	May 01, 2019	Apr NEWA
AP		JIANGSU HENGRUI MED	500MG/VIAL	A212022	001	Aug 22, 2019	Aug NEWA
AP		SAGENT PHARMS INC	500MG/VIAL	A207104	001	Nov 15, 2019	Nov NEWA
AP		XELLIA PHARMS APS	500MG/VIAL	A206005	001	Jun 15, 2016	Mar CAHN

POWDER; IV (INFUSION)

DAPTOMYCIN

AP		ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019	Jul NFTG
AP	+	SAGENT PHARMS INC	350MG/VIAL	N208385	001	Sep 12, 2017	Jul CTEC

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

AB		ALAN LABS INC	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Oct NEWA
AB			EQ 15MG BASE	A209571	001	Oct 22, 2019	Oct NEWA
>A> AB		POLYGEN PHARMS	EQ 7.5MG BASE	A211045	001	Jan 06, 2020	Dec NEWA
>A> AB			EQ 15MG BASE	A211045	002	Jan 06, 2020	Dec NEWA

DAROLUTAMIDETABLET; ORAL
NUBEQA

+! BAYER HEALTHCARE 300MG N212099 001 Jul 30, 2019 Jul NEWA

DARUNAVIRSUSPENSION; ORAL
PREZISTA

+! JANSSEN PRODS 100MG/ML N202895 001 Dec 16, 2011 Sep CAIN

TABLET; ORAL
DARUNAVIR

AB TEVA PHARMS USA 600MG A202118 001 Nov 21, 2017 Oct CTNA

AB 600MG A202118 001 Nov 21, 2017 Sep CAIN

PREZISTA

+ JANSSEN PRODS 75MG N021976 004 Dec 18, 2008 Sep CAIN

+ 150MG N021976 005 Dec 18, 2008 Sep CAIN

+ @ 300MG N021976 001 Jun 23, 2006 Sep CAIN

+ @ 400MG N021976 003 Oct 21, 2008 Sep CAIN

AB + 600MG N021976 002 Feb 25, 2008 Sep CAIN

+! 800MG N021976 006 Nov 09, 2012 Sep CAIN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+ @ ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Apr DISC

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DAUNORUBICIN HYDROCHLORIDE

AP HISUN PHARM HANGZHOU EQ 5MG BASE/ML A208759 001 Apr 12, 2019 Apr NEWA

@ EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Oct DISC

AP EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Apr NEWA

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP INGENUS PHARMS LLC 50MG/VIAL A210984 001 Sep 16, 2019 Sep NEWA

AP MSN 50MG/VIAL A212265 001 Aug 28, 2019 Aug NEWA

AP WOCKHARDT BIO AG 50MG/VIAL A209056 001 Apr 09, 2019 Mar NEWA

DEFERASIROXTABLET; ORAL
DEFERASIROX

>A> AB ACTAVIS ELIZABETH 90MG A208697 001 Dec 13, 2019 Dec NEWA

>A> AB 180MG A208697 002 Dec 13, 2019 Dec NFTG

>A> AB 360MG A208697 003 Dec 13, 2019 Dec NEWA

AB ALEMBIC PHARMS LTD 90MG A211824 001 Nov 20, 2019 Nov NFTG

AB 360MG A211824 002 Nov 20, 2019 Nov NFTG

>A> AB AMNEAL PHARMS CO 90MG A210727 001 Dec 27, 2019 Dec NEWA

>A> AB 360MG A210727 002 Dec 27, 2019 Dec NEWA

AB MSN 90MG A210945 001 Nov 20, 2019 Nov NFTG

AB 360MG A210945 002 Nov 20, 2019 Nov NFTG

>A> AB PIRAMAL HLTHCARE UK 90MG A212995 001 Dec 30, 2019 Dec NEWA

>A> AB 360MG A212995 002 Dec 30, 2019 Dec NEWA

>A> AB SUN PHARM 90MG A211641 001 Jan 02, 2020 Dec NEWA

>A> AB 360MG A211641 002 Jan 02, 2020 Dec NEWA

AB TEVA PHARMS USA 90MG A209223 001 Nov 25, 2019 Nov NEWA

AB 360MG A209223 002 Nov 25, 2019 Nov NEWA

AB ZYDUS PHARMS 90MG A211383 001 Nov 20, 2019 Nov NFTG

AB 360MG A211383 002 Nov 20, 2019 Nov NFTG

JADENU

AB + NOVARTIS PHARMS CORP 90MG N206910 001 Mar 30, 2015 Nov CFTG

>D> + 180MG N206910 002 Mar 30, 2015 Dec CFTG

>A> AB + 180MG N206910 002 Mar 30, 2015 Dec CFTG

AB +! 360MG N206910 003 Mar 30, 2015 Nov CFTG

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB ALEMBIC PHARMS LTD 125MG A210060 001 Nov 20, 2019 Nov NEWA

AB 250MG A210060 002 Nov 20, 2019 Nov NEWA

AB 500MG A210060 003 Nov 20, 2019 Nov NEWA

AB ALKEM LABS LTD 125MG A210519 001 Nov 20, 2019 Nov NEWA

TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

AB		250MG	A210519	002	Nov 20, 2019	Nov	NEWA
AB		500MG	A210519	003	Nov 20, 2019	Nov	NEWA
AB	BIONPHARMA INC	125MG	A210920	001	Nov 20, 2019	Nov	NEWA
AB		250MG	A210920	002	Nov 20, 2019	Nov	NEWA
AB		500MG	A210920	003	Nov 20, 2019	Nov	NEWA
>A>	AB	125MG	A209433	001	Jan 06, 2020	Dec	NEWA
>A>	AB	250MG	A209433	002	Jan 06, 2020	Dec	NEWA
>A>	AB	500MG	A209433	003	Jan 06, 2020	Dec	NEWA
AB	MSN	125MG	A209878	001	Nov 20, 2019	Nov	NEWA
AB		250MG	A209878	002	Nov 20, 2019	Nov	NEWA
AB		500MG	A209878	003	Nov 20, 2019	Nov	NEWA
AB	SUN PHARM	125MG	A209782	001	Nov 20, 2019	Nov	NEWA
AB		250MG	A209782	002	Nov 20, 2019	Nov	NEWA
AB		500MG	A209782	003	Nov 20, 2019	Nov	NEWA

DEFERIPRONE

TABLET;ORAL
DEFERIPRONE

	@ TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019	May	DISC
AB		500MG	A208800	001	Feb 08, 2019	Feb	NFTG
	FERRIPROX						
	+! AOPHARMA INC	500MG	N021825	001	Oct 14, 2011	May	CTEC
AB	+!	500MG	N021825	001	Oct 14, 2011	Feb	CFTG
	+	1GM	N021825	002	Jul 25, 2019	Jul	NEWA

DELAVIDINE MESYLATE

TABLET;ORAL
RESCRIPTOR

	+ @ VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997	Jun	DISC
--	-------------------	-------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

AB	NOVAST LABS	10MG	A204963	001	Dec 26, 2017	Sep	CAHN
AB		25MG	A204963	002	Dec 26, 2017	Sep	CAHN
AB		50MG	A204963	003	Dec 26, 2017	Sep	CAHN
AB		75MG	A204963	004	Dec 26, 2017	Sep	CAHN
AB		100MG	A204963	005	Dec 26, 2017	Sep	CAHN
AB		150MG	A204963	006	Dec 26, 2017	Sep	CAHN

DESLORATADINE

TABLET;ORAL
DESLORATADINE

	@ MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	May	DISC
AB	PERRIGO	5MG	A078361	001	Dec 22, 2011	Apr	CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION
DESMOPRESSIN ACETATE

AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Mar	CMFD
	SOLUTION;NASAL						
	DDAVP						
	+! FERRING PHARMS INC	0.01%	N017922	001		Jul	CTEC
	DESMOPRESSIN ACETATE						
	@ SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Jul	DISC
	SPRAY, METERED;NASAL						
	NOCTIVA						
	+ @ ALYVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Jun	DISC
	+	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Apr	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Jun	DISC
	+!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Apr	CAHN
	TABLET;ORAL						
	DESMOPRESSIN ACETATE						
AB	ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019	Jan	NEWA
AB		0.2MG	A210371	002	Jan 28, 2019	Jan	NEWA
AB	NOVAST LABS	0.1MG	A208357	001	Jun 06, 2019	May	NEWA
AB		0.2MG	A208357	002	Jun 06, 2019	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28		DESOGESTREL AND ETHINYL ESTRADIOL			
	@ ACCORD HLTHCARE	0.15MG;0.03MG	A207067	001	Sep 13, 2018 Mar DISC
ISIBLOOM					
AB	XIROMED	0.15MG;0.03MG	A202789	001	Aug 12, 2015 Aug CAHN
VOLNEA					
AB	XIROMED	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016 Aug CAHN

DESONIDE

AEROSOL, FOAM; TOPICAL		VERDESO			
	+! ALMIRALL	0.05%	N021978	001	Sep 19, 2006 Feb CAHN
CREAM; TOPICAL					
DESONIDE					
>A> AB	CADILA	0.05%	A210198	001	Nov 20, 2019 Dec CAHN
>D> AB	ZYDUS PHARMS	0.05%	A210198	001	Nov 20, 2019 Dec CAHN
AB		0.05%	A210198	001	Nov 20, 2019 Nov NEWA
OINTMENT; TOPICAL					
DESONIDE					
AB	ALEOR DERMACEUTICALS	0.05%	A212473	001	Oct 23, 2019 Oct NEWA
AB	ENCUBE ETHICALS	0.05%	A210998	001	Jan 30, 2019 Jan NEWA
AB	TELIGENT PHARMA INC	0.05%	A212002	001	Mar 12, 2019 Feb NEWA

DESOXIMETASONE

CREAM; TOPICAL		DESOXIMETASONE			
>D> AB	ANDA REPOSITORY	0.25%	A205594	001	Jul 02, 2018 Dec CAHN
>A>	@ CADILA	0.25%	A205620	001	Sep 28, 2018 Dec CAHN
>A> AB	RISING	0.25%	A205594	001	Jul 02, 2018 Dec CAHN
>D>	@ ZYDUS PHARMS	0.25%	A205620	001	Sep 28, 2018 Dec CAHN
	@	0.25%	A205620	001	Sep 28, 2018 Feb DISC

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL		DESVENLAFAXINE			
	+! ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013 May CTEC
	+!	100MG	N204150	002	Mar 04, 2013 May CTEC
KHEDEZLA					
	@ OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013 May DISC
	@	100MG	N204683	002	Jul 10, 2013 May DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL		DESVENLAFAXINE SUCCINATE			
AB	INTELLIPHARMACEUTICS	EQ 50MG BASE	A204805	001	May 07, 2019 Apr NEWA
AB		EQ 100MG BASE	A204805	002	May 07, 2019 Apr NEWA
AB	MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015 Jul CMFD
	@	EQ 50MG BASE	A204095	001	Jun 29, 2015 May DISC
	@	EQ 100MG BASE	A204095	002	Jun 29, 2015 May DISC
	@ YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018 Mar DISC
	@	EQ 100MG BASE	A210014	002	Oct 01, 2018 Mar DISC

DEXAMETHASONE

ELIXIR; ORAL		DEXAMETHASONE			
AA	! ANIMA	0.5MG/5ML	A084754	001	Sep CAHN
TABLET; ORAL					
HEMADY					
	+! DEXCEL PHARMA	20MG	N211379	001	Oct 03, 2019 Oct NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION		DEXAMETHASONE SODIUM PHOSPHATE			
AP	ANDA REPOSITORY	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018 Sep CAHN
>D> AP	AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019 Dec DISC
>A>	@	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019 Dec DISC
AP		EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019 May NEWA
AP	! FRESSENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001	Feb CHRS
	@ LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982 Feb DISC
AP	SOMERSET	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018 Oct CAHN

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE						
AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A211036	001	May 10, 2019	Apr NEWA
SOLUTION/DROPS;OPHTHALMIC, OTIC						
DECADRON						
+	@ MERCK	EQ 0.1% PHOSPHATE	N011984	001		Oct CRLD
DEXAMETHASONE SODIUM PHOSPHATE						
!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	May CTEC
@	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	May DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE						
	@ CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jul DISC
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan NEWA
AP	SLAYBACK PHARMA LLC	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212791	001	Dec 04, 2019	Nov NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A212791	002	Dec 04, 2019	Nov NEWA
SOLUTION;INTRAVENOUS						
DEXMEDETOMIDINE HYDROCHLORIDE						
+	HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE						
AB	ALKEM LABS LTD	2.5MG	A212631	001	Jul 19, 2019	Jul NEWA
AB		5MG	A212631	002	Jul 19, 2019	Jul NEWA
AB		10MG	A212631	003	Jul 19, 2019	Jul NEWA
>D> AB	LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017	Dec DISC
>A>	@	2.5MG	A209468	001	Sep 25, 2017	Dec DISC
>D> AB		5MG	A209468	002	Sep 25, 2017	Dec DISC
>A>	@	5MG	A209468	002	Sep 25, 2017	Dec DISC
>D> AB		10MG	A209468	003	Sep 25, 2017	Dec DISC
>A>	@	10MG	A209468	003	Sep 25, 2017	Dec DISC
	@ TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007	May DISC
	@	5MG	A077107	001	Jan 29, 2007	May DISC
	@	10MG	A077107	002	Jan 29, 2007	May DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE						
>A> AP	GLAND PHARMA LTD	EQ 250MG BASE/VIAL	A207321	002	Dec 16, 2019	Dec NEWA
TOTECT						
>A>	+! CLINIGEN	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Dec CAHN
>D>	+! CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Dec CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE						
>D> AB	ANDA REPOSITORY	5MG	A205077	001	Jun 21, 2019	Dec CAHN
AB		5MG	A205077	001	Jun 21, 2019	Aug CAHN
>D> AB		10MG	A205077	002	Jun 21, 2019	Dec CAHN
AB		10MG	A205077	002	Jun 21, 2019	Aug CAHN
>D> AB		15MG	A205077	003	Jun 21, 2019	Dec CAHN
AB		15MG	A205077	003	Jun 21, 2019	Aug CAHN
	@ MYLAN	5MG	A206735	001	Jan 27, 2016	Aug DISC
	@	10MG	A206735	002	Jan 27, 2016	Aug DISC
	@	15MG	A206735	003	Jan 27, 2016	Aug DISC
>A> AB	PII	5MG	A205077	001	Jun 21, 2019	Dec CAHN
AB		5MG	A205077	001	Jun 21, 2019	Jun NEWA
>A> AB		10MG	A205077	002	Jun 21, 2019	Dec CAHN
AB		10MG	A205077	002	Jun 21, 2019	Jun NEWA
>A> AB		15MG	A205077	003	Jun 21, 2019	Dec CAHN
AB		15MG	A205077	003	Jun 21, 2019	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

@ VINTAGE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	May DISC
-----------	----------------------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 70% IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE	70GM/100ML	N017521	006	Mar 26, 1982	Sep DISC
---------------------	------------	---------	-----	--------------	----------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371	003		Jul DISC
-------------------	------------------------	---------	-----	--	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371	002		Jul DISC
-------------------	------------------------	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Jul DISC
---------------------	--------------------------------------	---------	-----	--------------	----------

+ @	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Jul DISC
-----	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17, 1986	Jul DISC
-------------------	--------------------------------------	---------	-----	--------------	----------

@	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28, 1988	Jul DISC
---	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Jul DISC
---------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988	Jul DISC
-------------------	--------------------------------------	---------	-----	--------------	----------

@	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988	Jul DISC
---	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jul DISC
-------------------	--------------------------------------	---------	-----	--------------	----------

@	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jul DISC
---	-------------------------------------	---------	-----	--------------	----------

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>A> AP	FRESENIUS KABI USA	2.5GM/100ML; 450MG/100ML	A211190	001	Dec 20, 2019	Dec NEWA
--------	--------------------	--------------------------	---------	-----	--------------	----------

DIAZEPAM

GEL; RECTAL

DIASTAT

+ BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb CAHN
----------	----------------------	---------	-----	--------------	----------

+ @	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb CAHN
-----	-----------------	---------	-----	--------------	----------

+ @	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb CAHN
-----	-------------------	---------	-----	--------------	----------

+ @	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb CAHN
-----	-------------------	---------	-----	--------------	----------

+ @	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb CAHN
-----	-------------------	---------	-----	--------------	----------

DIASTAT ACUDIAL

+ BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb CAHN
----------	-------------------	---------	-----	--------------	----------

+!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb CAHN
----	-------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

DIAZEPAM

AP	BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Mar NEWA
----	--------------	-------------------	---------	-----	--------------	----------

>A> AP		50MG/10ML (5MG/ML)	A211998	001	Dec 26, 2019	Dec NEWA
--------	--	--------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

DIAZEPAM

AP	!	HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Mar CTEC
>D>	!		50MG/10ML (5MG/ML)	A071583	001	Oct 13, 1987	Dec CTEC
>A>	AP	!	50MG/10ML (5MG/ML)	A071583	001	Oct 13, 1987	Dec CTEC
TABLET; ORAL							
DIAZEPAM							
>A>		@ NUVO PHARM	10MG	A070464	001	Feb 25, 1986	Dec CAHN
>D>		@ VIRTUS PHARMS	10MG	A070464	001	Feb 25, 1986	Dec CAHN

DIAZOXIDE

SUSPENSION; ORAL

DIAZOXIDE

>A>							
>A>	AB	E5 PHARMA INC	50MG/ML	A211050	001	Dec 20, 2019	Dec NFTG
PROGLYCEM							
>D>	+	TEVA BRANDED PHARM	50MG/ML	N017453	001		Dec CFTG
>A>	AB	+	50MG/ML	N017453	001		Dec CFTG

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

+		EGALET	18MG	N204592	001	Oct 18, 2013	Feb CAHN
+	!		35MG	N204592	002	Oct 18, 2013	Feb CAHN
+		ZYLA	18MG	N204592	001	Oct 18, 2013	Jul CAHN
+	!		35MG	N204592	002	Oct 18, 2013	Jul CAHN

DICLOFENAC EPOLAMINE

SYSTEM; TOPICAL

LICART

+		@ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb DISC
---	--	-----------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB		STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019	Nov NEWA
TABLET; ORAL							
DICLOFENAC POTASSIUM							
AB		AMICI	50MG	A076561	001	Mar 18, 2004	May CAHN

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB		MYLAN	1%	A204306	001	May 06, 2019	Apr NEWA
AB		PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	May NEWA

SOLUTION; INTRAVENOUS

DICLOFENAC SODIUM

		@ MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jul DISC
			37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jun NEWA

SOLUTION; TOPICAL

DICLOFENAC SODIUM

>A>	AT	CADILA	1.5%	A206411	001	Apr 17, 2018	Dec CAHN
		@ RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Oct DISC
>D>	AT	ZYDUS PHARMS	1.5%	A206411	001	Apr 17, 2018	Dec CAHN
PENNSAID							
>A>	+	HORIZON	2%	N204623	001	Jan 16, 2014	Dec CAHN
>D>	+	HZNP	2%	N204623	001	Jan 16, 2014	Dec CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

		@ CASI PHARMS INC	25MG	A074376	001	Sep 28, 1995	Nov DISC
		@	50MG	A074376	002	Sep 28, 1995	Nov DISC
		@	75MG	A074394	001	Nov 30, 1995	Nov DISC
AB	!	UNIQUE PHARM LABS	25MG	A090066	001	Dec 01, 2010	Nov CHRS
AB	!		50MG	A090066	002	Dec 01, 2010	Nov CHRS
AB	!		75MG	A077863	003	Jun 08, 2007	Nov CHRS

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

		@ MYLAN	100MG	A076152	001	Dec 13, 2001	Jun DISC
--	--	---------	-------	---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

@ EXELA HOLDINGS 50MG;0.2MG
@ 75MG;0.2MGA200540 001 Mar 14, 2014 Sep DISC
A200540 002 Mar 14, 2014 Sep DISCDICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

>D>
>D> AB +! ALLERGAN 10MG N007409 003 Oct 15, 1984 Dec DISC
>A> + @ 10MG N007409 003 Oct 15, 1984 Dec DISC

DICYCLOMINE HYDROCHLORIDE

>D> AB LANNETT 10MG A084285 001 Dec CHRS
>A> AB ! 10MG A084285 001 Dec CHRS

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

AP @ APC PHARMS LLC 10MG/ML A210979 001 Jul 02, 2018 Feb DISC
AP CUSTOPHARM INC 10MG/ML A210788 001 Feb 11, 2019 Jan NEWA
>D> @ FOSUN PHARMA 10MG/ML A210979 001 Jul 02, 2018 Dec CMFD
>A> AP 10MG/ML A210979 001 Jul 02, 2018 Dec CMFD
@ 10MG/ML A210979 001 Jul 02, 2018 Sep CAHN
AP FRESENIUS KABI USA 10MG/ML A210257 001 Jan 25, 2019 Jan NEWA
AP NEXUS PHARMS 10MG/ML A206468 001 Feb 01, 2019 Jan NEWA
AP SLATE 10MG/ML A207076 001 Nov 02, 2018 Feb CAHN
AP SUNGEN PHARMA 10MG/ML A212058 001 Apr 26, 2019 Apr NEWA

TABLET;ORAL

BENTYL

>D>
>D> AB +! ALLERGAN 20MG N007409 001 Oct 15, 1984 Dec DISC
>A> + @ 20MG N007409 001 Oct 15, 1984 Dec DISC

DICYCLOMINE HYDROCHLORIDE

>D> AB WATSON LABS 20MG A085223 001 Jul 30, 1986 Dec CHRS
>A> AB ! 20MG A085223 001 Jul 30, 1986 Dec CHRSDIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

AA ! LANNETT CO INC 25MG A200177 001 Jul 18, 2011 Jul CHRS
TENUATE

+ @ TEVA BRANDED PHARM 25MG N011722 002 Jul DISC

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

AB ! LANNETT CO INC 75MG A091680 001 Oct 24, 2011 Jul CHRS
TENUATE DOSPAN

+ @ TEVA BRANDED PHARM 75MG N012546 001 Jul DISC

DIGOXIN

ELIXIR;ORAL

DIGOXIN

AA NOVITIUM PHARMA 0.05MG/ML A213000 001 Oct 04, 2019 Sep NFTG
AA VISTAPHARM 0.05MG/ML A213000 001 Oct 04, 2019 Nov CAHNDIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

D.H.E. 45

AP +! BAUSCH 1MG/ML N005929 001 Apr CAHN

DIHYDROERGOTAMINE MESYLATE

>A> AP APOLLO 1MG/ML A212046 001 Jan 07, 2020 Dec CAHN
>A> AP 1MG/ML A212046 001 Jan 07, 2020 Dec NEWA

SPRAY, METERED;NASAL

MIGRANAL

+! BAUSCH 0.5MG/SPRAY N020148 001 Dec 08, 1997 Apr CAHN
+! VALEANT 0.5MG/SPRAY N020148 001 Dec 08, 1997 Jan CPOTDILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CARDIZEM CD

AB3 + BAUSCH 120MG N020062 001 Aug 10, 1992 Feb CAHN
AB3 + 180MG N020062 002 Dec 27, 1991 Feb CAHN
AB3 + 240MG N020062 003 Dec 27, 1991 Feb CAHN
AB3 + 300MG N020062 004 Dec 27, 1991 Feb CAHN
AB3 +! 360MG N020062 005 Aug 24, 1999 Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL									
DILTIAZEM HYDROCHLORIDE									
AB2	!	APOTEX	120MG	A074943	003	Dec 19, 2000	Aug	CTEC	
			240MG	A074943	001	Aug 06, 1998	May	CHRS	
		@ MYLAN	120MG	A075124	002	Mar 18, 1998	Aug	DISC	
		@	180MG	A075124	003	Mar 18, 1998	Oct	DISC	
		@	240MG	A075124	001	Mar 18, 1998	Oct	DISC	
AB2			240MG	A075124	001	Mar 18, 1998	May	CHRS	
AB3		NOVAST LABS	120MG	A208783	001	Jun 14, 2019	Jun	NEWA	
AB3			180MG	A208783	002	Jun 14, 2019	Jun	NEWA	
AB3			240MG	A208783	003	Jun 14, 2019	Jun	NEWA	
AB3			300MG	A208783	004	Jun 14, 2019	Jun	NEWA	
AB3			360MG	A208783	005	Jun 14, 2019	Jun	NEWA	
		@ PAR PHARM	360MG	A209766	001	May 30, 2018	Mar	DISC	
TIAZAC									
AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN	
AB4	+		180MG	N020401	002	Sep 11, 1995	Feb	CAHN	
AB4	+		240MG	N020401	003	Sep 11, 1995	Feb	CAHN	
AB4	+		300MG	N020401	004	Sep 11, 1995	Feb	CAHN	
AB4	+		360MG	N020401	005	Sep 11, 1995	Feb	CAHN	
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN	
INJECTABLE;INJECTION									
DILTIAZEM HYDROCHLORIDE									
		@ DR REDDYS	5MG/ML	A074894	001	Aug 26, 1997	May	CAHN	
TABLET;ORAL									
CARDIZEM									
AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar	CAHN	
AB	+		60MG	N018602	002	Nov 05, 1982	Mar	CAHN	
AB	+		90MG	N018602	003	Dec 08, 1986	Mar	CAHN	
AB	+		120MG	N018602	004	Dec 08, 1986	Mar	CAHN	
DILTIAZEM HYDROCHLORIDE									
AB		EDENBRIDGE PHARMS	30MG	A211596	001	Nov 18, 2019	Nov	NEWA	
AB			60MG	A211596	002	Nov 18, 2019	Nov	NEWA	
AB			90MG	A211596	003	Nov 18, 2019	Nov	NEWA	
AB			120MG	A211596	004	Nov 18, 2019	Nov	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
CARDIZEM LA									
AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar	CAHN	
AB	+		180MG	N021392	002	Feb 06, 2003	Mar	CAHN	
AB	+		240MG	N021392	003	Feb 06, 2003	Mar	CAHN	
AB	+		300MG	N021392	004	Feb 06, 2003	Mar	CAHN	
AB	+		360MG	N021392	005	Feb 06, 2003	Mar	CAHN	
AB	+		420MG	N021392	006	Feb 06, 2003	Mar	CAHN	
<u>DIMETHYL SULFOXIDE</u>									
SOLUTION;INTRAVESICAL									
DIMETHYL SULFOXIDE									
		@ MYLAN INSTITUTIONAL	50%	A076185	001	Nov 29, 2002	Mar	DISC	
		RIMSO-50							
	+	MYLAN INSTITUTIONAL	50%	N017788	001		Mar	CTEC	
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
DIPHENHYDRAMINE HYDROCHLORIDE									
		@ HERITAGE PHARMA	50MG	A080738	001		Oct	DISC	
	!		50MG	A080738	001		May	CAHN	
INJECTABLE;INJECTION									
DIPHENHYDRAMINE HYDROCHLORIDE									
		@ DR REDDYS	10MG/ML	A080873	001		May	CAHN	
		@	50MG/ML	A080873	002		May	CAHN	
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE									
		@ DR REDDYS	50MG/ML	A080873	003		May	CAHN	
<u>DIPYRIDAMOLE</u>									
INJECTABLE;INJECTION									
DIPYRIDAMOLE									
		@ DR REDDYS	5MG/ML	A074952	001	Nov 26, 1997	May	CAHN	

DIROXIMEL FUMARATECAPSULE, DELAYED RELEASE;ORAL
VUMERITY

+! BIOGEN 231MG N211855 001 Oct 29, 2019 Oct NEWA

DISULFIRAMTABLET;ORAL
DISULFIRAM@ MYLAN 250MG A203916 001 Mar 04, 2015 Oct DISC
@ 500MG A203916 002 Mar 04, 2015 Oct DISCDIVALPROEX SODIUMTABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

AB	CELLTRION	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Aug	CAHN
AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Aug	CAHN
AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Aug	CAHN
>A> AB	INVATECH	EQ 125MG VALPROIC ACID	A078290	003	Jul 29, 2008	Dec	CAHN
>A> AB		EQ 250MG VALPROIC ACID	A078290	002	Jul 29, 2008	Dec	CAHN
>A> AB		EQ 500MG VALPROIC ACID	A078290	001	Jul 29, 2008	Dec	CAHN
>D> AB	SANDOZ	EQ 125MG VALPROIC ACID	A078290	003	Jul 29, 2008	Dec	CAHN
>D> AB		EQ 250MG VALPROIC ACID	A078290	002	Jul 29, 2008	Dec	CAHN
>D> AB		EQ 500MG VALPROIC ACID	A078290	001	Jul 29, 2008	Dec	CAHN
	@ TEVA	EQ 125MG VALPROIC ACID	A076941	001	Jul 29, 2008	Sep	DISC
	@	EQ 250MG VALPROIC ACID	A076941	002	Jul 29, 2008	Sep	DISC
	@	EQ 500MG VALPROIC ACID	A076941	003	Jul 29, 2008	Sep	DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

	@ ANCHEN PHARMS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009	Sep	DISC
	@	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009	Sep	DISC
AB	LUPIN LTD	EQ 250MG VALPROIC ACID	A209286	001	Oct 18, 2019	Oct	NEWA
AB		EQ 500MG VALPROIC ACID	A209286	002	Oct 18, 2019	Oct	NEWA

DOCETAXELINJECTABLE;INJECTION
DOCETAXEL

AP	ACTAVIS LLC	160MG/8ML (20MG/ML)	N203551	004	Sep 21, 2015	Jun	NEWA
	@ CIPLA	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Mar	DISC
	@	80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Mar	DISC
	@	160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Mar	DISC
AP	MYLAN LABS LTD	160MG/8ML (20MG/ML)	A208137	001	Apr 01, 2019	Mar	NEWA
	@ SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Oct	DISC
AP		20MG/ML (20MG/ML)	A210327	001	May 16, 2019	May	NEWA
	@	80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Oct	DISC
AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	May	NEWA
	@	160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Oct	DISC
AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	May	NEWA
AP	TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Mar	CAHN
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Mar	CAHN
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Mar	CAHN
	@ TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Nov	DISC
	@	80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Nov	DISC

SOLUTION;INTRAVENOUS
DOCETAXEL

AP	SUN PHARMA GLOBAL	20MG/ML (20MG/ML)	N022534	003	Jan 08, 2019	Jan	NEWA
AP		80MG/4ML (20MG/ML)	N022534	004	Jan 08, 2019	Jan	NEWA
AP		160MG/8ML (20MG/ML)	N022534	005	Jan 08, 2019	Jan	NEWA

DOFETILIDECAPSULE;ORAL
DOFETILIDE

AB	AUROBINDO PHARMA LTD	0.125MG	A210740	001	Jan 22, 2019	Jan	NEWA
AB		0.25MG	A210740	002	Jan 22, 2019	Jan	NEWA
AB		0.5MG	A210740	003	Jan 22, 2019	Jan	NEWA

DOFETILIDE

>A> AB	PRINSTON INC	0.125MG	A211223	001	Dec 17, 2019	Dec	NEWA
>A> AB		0.25MG	A211223	002	Dec 17, 2019	Dec	NEWA
>A> AB		0.5MG	A211223	003	Dec 17, 2019	Dec	NEWA
>A> AB	RICONPHARMA LLC	0.125MG	A212410	001	Dec 27, 2019	Dec	NEWA
>A> AB		0.25MG	A212410	002	Dec 27, 2019	Dec	NEWA
>A> AB		0.5MG	A212410	003	Dec 27, 2019	Dec	NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL

DOVATO

+	!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019	Apr NEWA
---	---	---------------	--------------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB		CADILA	5MG	A090100	001	Oct 24, 2012	Mar CAHN
AB			10MG	A090100	002	Oct 24, 2012	Mar CAHN
AB		HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	May CAHN
AB			10MG	A077344	002	May 31, 2011	May CAHN
	@	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar DISC
	@	PAR PHARM	23MG	A202542	001	Jul 24, 2013	Nov DISC
AB		STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr CAHN
AB			10MG	A090551	002	May 31, 2011	Apr CAHN
	@	SUN PHARM	23MG	A204293	001	Jun 05, 2015	Jul DISC
TABLET, ORALLY DISINTEGRATING; ORAL							
DONEPEZIL HYDROCHLORIDE							
	@	HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010	May CAHN
	@		10MG	A078388	001	Nov 26, 2010	May CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		ALEMBIC PHARMS LTD	EQ 2% BASE	A212639	001	Aug 09, 2019	Jul NEWA
AT		FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019	Jan NEWA
	@	LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009	Mar DISC
AT		MICRO LABS	EQ 2% BASE	A204778	001	Nov 08, 2019	Oct NEWA
	@	RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT		ANDA REPOSITORY	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Sep CAHN
>D>	AT	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Dec DISC
>A>		@	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Dec DISC
AT			EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Jun NEWA
	@	RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Jul CAHN
AT		SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Oct CAHN
AT		SOMERSET THERAPS LLC	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Jun NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+	!	HIKMA	20MG/ML	N014879	001	Mar CAHN
----	---	---	-------	---------	---------	-----	----------

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 10MG BASE	A212624	001	Sep 13, 2019	Sep NEWA
AB			EQ 25MG BASE	A212624	002	Sep 13, 2019	Sep NEWA
AB			EQ 50MG BASE	A212624	003	Sep 13, 2019	Sep NEWA
AB			EQ 75MG BASE	A212624	004	Sep 13, 2019	Sep NEWA
AB			EQ 100MG BASE	A212624	005	Sep 13, 2019	Sep NEWA
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A211603	001	Mar 27, 2019	Mar NEWA
AB			EQ 25MG BASE	A211603	002	Mar 27, 2019	Mar NEWA
AB			EQ 50MG BASE	A211603	003	Mar 27, 2019	Mar NEWA
AB			EQ 75MG BASE	A211603	004	Mar 27, 2019	Mar NEWA
AB			EQ 100MG BASE	A211603	005	Mar 27, 2019	Mar NEWA
AB		PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Aug CMS1
AB			EQ 25MG BASE	A071422	003	Nov 09, 1987	Aug CMS1
AB			EQ 50MG BASE	A071422	004	Nov 09, 1987	Aug CMS1
AB			EQ 75MG BASE	A071422	005	Nov 09, 1987	Aug CMS1
	!		EQ 150MG BASE	A071422	006	Nov 09, 1987	Nov CHRS
AB			EQ 150MG BASE	A071422	006	Nov 09, 1987	Aug CMS1
TABLET; ORAL							
DOXEPIN HYDROCHLORIDE							
>D>		@	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013
>A>	AB			EQ 3MG BASE	A201951	001	Jul 26, 2013
>D>		@		EQ 6MG BASE	A201951	002	Jul 26, 2013

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB		EQ 6MG BASE	A201951	002	Jul 26, 2013	Dec CMFD
		SILENOR					
>D>	+	CURRAX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Dec CTEC
>A>	AB	+	EQ 3MG BASE	N022036	001	Mar 17, 2010	Dec CTEC
		+	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr CAHN
>D>	+	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Dec CTEC
>A>	AB	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Dec CTEC
		+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr CAHN
		+	PERNIX	N022036	001	Mar 17, 2010	Feb CAHN
		+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Feb CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		GLAND PHARMA LTD	4MCG/2ML (2MCG/ML)	A210452	001	Sep 26, 2019	Sep NEWA
		+ @ HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jun DISC
AP		SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019	Nov NEWA
AP			4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019	Nov NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		@ HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019	Oct DISC
			20MG/VIAL	A206062	001	May 13, 2019	Apr NEWA
		@ HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012	Sep CAHN
		@ MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012	Sep DISC

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)

AB	+	BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Aug CAHN
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Aug CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	!	SUN PHARM INDS LTD	EQ 100MG BASE	A065053	002	Nov 22, 2000	Oct CHRS
		MONODOX					
		+ @ ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Oct DISC
AB	+		EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb CAHN
		+ @	EQ 75MG BASE	N050641	003	Oct 18, 2006	Oct DISC
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb CAHN
		+ @	EQ 100MG BASE	N050641	001	Dec 29, 1989	Oct DISC
AB	+		EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb CAHN

TABLET;ORAL

DOXYCYCLINE

>D>	AB	HERITAGE PHARMS INC	EQ 150MG BASE	A091605	004	Dec 20, 2011	Dec CHRS
>A>	AB	!	EQ 150MG BASE	A091605	004	Dec 20, 2011	Dec CHRS
		@ MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006	Apr DISC
		@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Apr DISC
		@	EQ 100MG BASE	A065377	003	Nov 07, 2006	May DISC
		@	EQ 150MG BASE	A065427	001	Jun 07, 2007	May DISC
>D>	AB	PAR PHARM	EQ 50MG BASE	A065070	001	Dec 15, 2000	Dec DISC
>A>		@	EQ 50MG BASE	A065070	001	Dec 15, 2000	Dec DISC
>D>	AB		EQ 75MG BASE	A065070	003	Dec 30, 2002	Dec DISC
>A>		@	EQ 75MG BASE	A065070	003	Dec 30, 2002	Dec DISC
>D>	AB		EQ 100MG BASE	A065070	002	Dec 15, 2000	Dec DISC
>A>		@	EQ 100MG BASE	A065070	002	Dec 15, 2000	Dec DISC
>D>	AB	!	EQ 150MG BASE	A065070	004	Jul 14, 2005	Dec DISC
>A>		@	EQ 150MG BASE	A065070	004	Jul 14, 2005	Dec DISC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

		+ @ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb CAHN
		DOXYCYCLINE HYCLATE					
		@ AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar DISC
		@	EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar DISC
AB		CHANGZHOU PHARM	EQ 100MG BASE	A209402	001	Oct 07, 2019	Sep NEWA
		@ MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Apr DISC
		@	EQ 100MG BASE	A062337	002	Mar 29, 1982	Apr DISC

TABLET;ORAL
ACTICLATE

AB	+	ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb CAHN
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb CAHN
DOXYCYCLINE HYCLATE							
AB		APOTEX	EQ 75MG BASE	A209243	001	Apr 15, 2019	Apr NEWA
AB			EQ 150MG BASE	A209243	002	Apr 15, 2019	Apr NEWA
AB		CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb CAHN
AB		CHANGZHOU PHARM	EQ 100MG BASE	A211343	001	Oct 09, 2019	Sep NEWA
AB		EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	Aug CMFD
AB		HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	May CAHN

TABLET, DELAYED RELEASE;ORAL
DOXYCYCLINE HYCLATE

@	MYLAN	EQ 75MG BASE	A090431	001	Dec 28, 2010	Jul DISC
@		EQ 100MG BASE	A090431	002	Dec 28, 2010	Jul DISC
@		EQ 200MG BASE	A090431	005	May 19, 2016	Jul DISC
@	MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Sep DISC
@	ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018	May DISC
@		EQ 100MG BASE	A206772	002	Dec 21, 2018	May DISC
@		EQ 150MG BASE	A206772	003	Dec 21, 2018	May DISC

DROSPIRENONE

TABLET;ORAL
SLYND

+	!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019	May NEWA
---	---	-----------------	-----	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL							
AB		ANDA REPOSITORY	3MG;0.02MG	A203291	001	Jul 18, 2017	Aug CAHN
AB		HETERO LABS LTD	3MG;0.02MG	A211944	001	Mar 22, 2019	Mar NEWA
KYRA							
AB		SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Jul NEWA
LORYNA							
AB		XIROMED	3MG;0.02MG	A079221	001	Mar 28, 2011	Aug CAHN
TABLET;ORAL-28							
KEMEYA							
AB		SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb NEWA
SYEDA							
AB		XIROMED	3MG;0.03MG	A090114	001	Mar 28, 2011	Aug CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE							
AB	AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb	NEWA
AB	INVENTIA	EQ 20MG BASE	A202336	001	Oct 28, 2015	Aug	CAHN
AB		EQ 30MG BASE	A202336	002	Oct 28, 2015	Aug	CAHN
AB		EQ 60MG BASE	A202336	003	Oct 28, 2015	Aug	CAHN
AB	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	Apr	NEWA
AB		EQ 30MG BASE	A210599	002	Apr 17, 2019	Apr	NEWA
AB		EQ 60MG BASE	A210599	003	Apr 17, 2019	Apr	NEWA
	@ TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013	Aug	DISC
	@	EQ 30MG BASE	A090783	002	Dec 11, 2013	Aug	DISC
	@	EQ 60MG BASE	A090783	003	Dec 11, 2013	Aug	DISC
AB	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Aug	NEWA
AB		EQ 30MG BASE	A207219	002	Aug 16, 2019	Aug	NEWA
AB		EQ 60MG BASE	A207219	003	Aug 16, 2019	Aug	NEWA

CAPSULE, DELAYED RELEASE;ORAL
DRIZALMA SPRINKLE

+		SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Jul NEWA
+			EQ 30MG BASE	N212516	002	Jul 19, 2019	Jul NEWA
+			EQ 40MG BASE	N212516	003	Jul 19, 2019	Jul NEWA
+	!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Jul NEWA

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

	@	BRECKENRIDGE	0.5MG	A204705	001	Nov 20, 2015	Jun DISC
>D>	@		0.5MG	A208227	001	Jun 22, 2018	Dec CAHN
	@		0.5MG	A208227	001	Jun 22, 2018	Jun DISC
AB		CADILA	0.5MG	A204373	001	Oct 04, 2017	Feb CAHN
>A>	@	PII	0.5MG	A208227	001	Jun 22, 2018	Dec CAHN

ECONAZOLE NITRATE

	CREAM; TOPICAL						
	ECONAZOLE NITRATE						
	@ CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Jun	DISC
AB	! PERRIGO ISRAEL	1%	A076479	001	Jun 23, 2004	May	CAHN

EFAVIRENZ

	TABLET; ORAL						
	EFAVIRENZ						
>D>	@ AUROBINDO PHARMA LTD	600MG	A077673	001	Sep 21, 2018	Dec	CMFD
>A> AB		600MG	A077673	001	Sep 21, 2018	Dec	CMFD
	@	600MG	A077673	001	Sep 21, 2018	Feb	DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET; ORAL						
	EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE						
AB	CIPLA	600MG; 200MG; 300MG	A206894	001	Jun 03, 2019	May	NEWA
	@ TEVA PHARMS USA	600MG; 200MG; 300MG	A091215	001	Nov 09, 2018	May	DISC

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET; ORAL						
	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE						
	@ MACLEODS PHARMS LTD	400MG; 300MG; 300MG	N210649	001	Mar 15, 2019	Jun	DISC
		400MG; 300MG; 300MG	N210649	001	Mar 15, 2019	Mar	NEWA

EFINACONAZOLE

	SOLUTION; TOPICAL						
	JUBLIA						
+!	BAUSCH	10%	N203567	001	Jun 06, 2014	Feb	CAHN

ELEXACFTOR, IVACFTOR, TEZACFTOR; IVACFTOR

	TABLET, TABLET; ORAL						
	TRIKAFTA (COPACKAGED)						
+!	VERTEX PHARMS INC	100MG, 75MG, 50MG; N/A, 150MG, N/A	N212273	001	Oct 21, 2019	Oct	NEWA

ELTROMBOPAG OLAMINE

	TABLET; ORAL						
	PROMACTA						
+	@ NOVARTIS	EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb	DISC

EMEDASTINE DIFUMARATE

	SOLUTION/DROPS; OPHTHALMIC						
	EMADINE						
+	@ NOVARTIS	0.05%	N020706	001	Dec 29, 1997	Jul	DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET; ORAL						
	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
	@ AMNEAL PHARMS CO	100MG; 150MG	A209721	001	Aug 22, 2018	Feb	DISC
	@	133MG; 200MG	A209721	002	Aug 22, 2018	Feb	DISC
	@	167MG; 250MG	A209721	003	Aug 22, 2018	Feb	DISC
	@	200MG; 300MG	A209721	004	Aug 22, 2018	Feb	DISC
	@ LAURUS LABS LTD	200MG; 300MG	A212114	001	Jul 26, 2019	Aug	DISC
AB		200MG; 300MG	A212114	001	Jul 26, 2019	Jul	NEWA
	TRUVADA						
+	GILEAD	100MG; 150MG	N021752	002	Mar 10, 2016	Feb	CTEC
+		133MG; 200MG	N021752	003	Mar 10, 2016	Feb	CTEC
+		167MG; 250MG	N021752	004	Mar 10, 2016	Feb	CTEC

ENALAPRIL MALEATE

	FOR SOLUTION; ORAL						
	EPANED KIT						
+	@ SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Mar	DISC
	TABLET; ORAL						
	ENALAPRIL MALEATE						
	@ BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000	Feb	CAHN
	@	5MG	A075621	002	Aug 22, 2000	Feb	CAHN
	@	10MG	A075621	003	Aug 22, 2000	Feb	CAHN
	@	20MG	A075621	004	Aug 22, 2000	Feb	CAHN
AB	HERITAGE PHARMA	2.5MG	A075479	001	Aug 22, 2000	Feb	CAHN
AB		5MG	A075479	002	Aug 22, 2000	Feb	CAHN

TABLET;ORAL									
ENALAPRIL MALEATE									
AB		10MG	A075479	003	Aug 22, 2000	Feb	CAHN		
AB		20MG	A075479	004	Aug 22, 2000	Feb	CAHN		
	@ MYLAN	5MG	A075480	002	Aug 22, 2000	Jun	DISC		
	@	10MG	A075480	003	Aug 22, 2000	Feb	DISC		
AB	NOSTRUM LABS INC	2.5MG	A075178	002	Mar 23, 2001	Oct	CAHN		
AB		5MG	A075178	001	Mar 23, 2001	Oct	CAHN		
AB		10MG	A075178	003	Mar 23, 2001	Oct	CAHN		
AB		20MG	A075178	004	Mar 23, 2001	Oct	CAHN		
VASOTEC									
AB	+ BAUSCH	2.5MG	N018998	005	Jul 26, 1988	Mar	CAHN		
AB	+	5MG	N018998	001	Dec 24, 1985	Mar	CAHN		
AB	+	10MG	N018998	002	Dec 24, 1985	Mar	CAHN		
AB	+	20MG	N018998	003	Dec 24, 1985	Mar	CAHN		
<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>									
TABLET;ORAL									
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE									
AB	NOSTRUM LABS INC	5MG;12.5MG	A076486	001	Oct 27, 2004	Oct	CAHN		
AB		10MG;25MG	A076486	002	Oct 27, 2004	Oct	CAHN		
VASERETIC									
AB	+ BAUSCH	5MG;12.5MG	N019221	003	Jul 12, 1995	Mar	CAHN		
AB	+	10MG;25MG	N019221	001	Oct 31, 1986	Mar	CAHN		
<u>ENALAPRILAT</u>									
INJECTABLE;INJECTION									
ENALAPRILAT									
AP	DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	May	CAHN		
<u>ENCORAFENIB</u>									
CAPSULE;ORAL									
BRAFTOVI									
	+ @ ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jul	DISC		
<u>ENOXAPARIN SODIUM</u>									
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS									
ENOXAPARIN SODIUM									
AB	AMPHASTAR PHARMS INC	300MG/3ML (100MG/ML)	A208600	001	Mar 14, 2019	Mar	NEWA		
INJECTABLE;SUBCUTANEOUS									
ENOXAPARIN SODIUM (PRESERVATIVE FREE)									
AP	NANJING KING-FRIEND	30MG/0.3ML (100MG/ML)	A206834	001	Nov 29, 2019	Nov	NEWA		
AP		40MG/0.4ML (100MG/ML)	A206834	002	Nov 29, 2019	Nov	NEWA		
AP		60MG/0.6ML (100MG/ML)	A206834	003	Nov 29, 2019	Nov	NEWA		
AP		80MG/0.8ML (100MG/ML)	A206834	004	Nov 29, 2019	Nov	NEWA		
AP		100MG/ML (100MG/ML)	A206834	005	Nov 29, 2019	Nov	NEWA		
AP		120MG/0.8ML (150MG/ML)	A206834	006	Nov 29, 2019	Nov	NEWA		
AP		150MG/ML (150MG/ML)	A206834	007	Nov 29, 2019	Nov	NEWA		
<u>ENTECAVIR</u>									
TABLET;ORAL									
ENTECAVIR									
AB	BRIGHTGENE	0.5MG	A212126	001	Sep 25, 2019	Sep	NEWA		
AB		1MG	A212126	002	Sep 25, 2019	Sep	NEWA		
AB	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Mar	NEWA		
AB		1MG	A206226	002	Mar 26, 2019	Mar	NEWA		
	@ PAR PHARM INC	0.5MG	A206294	001	Nov 23, 2016	Nov	DISC		
	@	1MG	A206294	002	Nov 23, 2016	Nov	DISC		
AB	YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Oct	NEWA		
AB		1MG	A212201	002	Nov 04, 2019	Oct	NEWA		
<u>ENTRECTINIB</u>									
CAPSULE;ORAL									
ROZLYTREK									
	+ GENENTECH INC	100MG	N212725	001	Aug 15, 2019	Aug	NEWA		
	+	200MG	N212725	002	Aug 15, 2019	Aug	NEWA		

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
AKOAZ

AP	+	AVADEL LEGACY	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Nov CAHN
AP		EPHEDRINE SULFATE					
AP		AMNEAL	50MG/ML (50MG/ML)	A212932	001	Oct 23, 2019	Nov CAHN
AP		AMNEAL PHARMS CO	50MG/ML (50MG/ML)	A212932	001	Oct 23, 2019	Oct NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

@	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Jun DISC
@	SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011	Jul DISC

EPINEPHRINEINJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE (AUTOINJECTOR)

AB		TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul CMFD
	@		0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar DISC
		EPIPEN JR.					
AB	+	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CTEC
	+		0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar CTEC
		SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
		ADRENALIN					
	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CTEC
AP	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan CDFR
	+		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan CDFR
		SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS					
		EPINEPHRINE					
	@	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Aug DISC
		SOLUTION; INTRAVENOUS					
		EPINEPHRINE (COPACKAGED)					
	+	HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019	Nov NEWA
		SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS					
		EPINEPHRINE					
	+	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	May CDFR

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

@	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Sep DISC
	FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007	Sep CTEC
		150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar CTEC
@		200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007	Oct DISC
@		50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007	Oct DISC
@	MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Sep DISC
@		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Sep DISC
@	ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Sep CAHN
@		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Sep CAHN

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

AP		BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan CAHN
AP			75MG/100ML	A208554	002	Nov 23, 2018	Jan CAHN
AP		HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan NEWA
AP			75MG/100ML	A209864	002	Jan 25, 2019	Jan NEWA
	@	USV	2MG/ML	A204361	001	Mar 14, 2019	Oct DISC
AP			2MG/ML	A204361	001	Mar 14, 2019	Mar NEWA
	@		2MG/ML	A204362	001	Mar 11, 2019	Oct DISC
AP			2MG/ML	A204362	001	Mar 11, 2019	Feb NEWA
	@		75MG/100ML	A204361	002	Mar 14, 2019	Oct DISC
AP			75MG/100ML	A204361	002	Mar 14, 2019	Mar NEWA

ERDAFITINIBTABLET; ORAL
BALVERSA

+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019	Apr NEWA
+		4MG	N212018	002	Apr 12, 2019	Apr NEWA
+		5MG	N212018	003	Apr 12, 2019	Apr NEWA

ERGOCALCIFEROL

CAPSULE;ORAL

ERGOCALCIFEROL

>D>	AA	PURACAP PHARM LLC	50000IU	A204276	001	Dec 07, 2018	Dec CPOT
>A>	AA		50,000 IU	A204276	001	Dec 07, 2018	Dec CPOT

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB		APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Oct NEWA
AB			EQ 100MG BASE	A208396	002	Nov 05, 2019	Oct NEWA
AB			EQ 150MG BASE	A208396	003	Nov 05, 2019	Oct NEWA
AB		MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb CMFD
AB			EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb CMFD
AB			EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb CMFD
AB		NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Oct NEWA
AB			EQ 100MG BASE	A208488	002	Nov 05, 2019	Oct NEWA
AB			EQ 150MG BASE	A208488	003	Nov 05, 2019	Oct NEWA
AB		SHILPA MEDICARE LTD	EQ 25MG BASE	A211960	001	Nov 05, 2019	Oct NEWA
AB			EQ 100MG BASE	A211960	002	Nov 05, 2019	Oct NEWA
AB			EQ 150MG BASE	A211960	003	Nov 05, 2019	Oct NEWA
AB		SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Oct NEWA
AB			EQ 100MG BASE	A210300	002	Nov 05, 2019	Oct NEWA
AB			EQ 150MG BASE	A210300	003	Nov 05, 2019	Oct NEWA
AB		TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar CMFD
AB			EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar CMFD
TARCEVA							
AB	+	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar CAHN
AB	+		EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb CTEC
AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar CAHN
AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb CTEC
AB	+		EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar CAHN
AB	+		EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP		SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019	Mar NEWA
----	--	---------------------	------------------	---------	-----	--------------	----------

ERYTHROMYCIN

OINTMENT;TOPICAL

AKNE-MYCIN

+	@	BAUSCH	2%	N050584	001	Jan 10, 1985	Apr CAHN
---	---	--------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL

ERYTHRA-DERM

@ MLV 2%

A062687	001	Feb 05, 1988	Aug CAHN
---------	-----	--------------	----------

@ SAPTALIS PHARMS 2%

A062687	001	Feb 05, 1988	Feb CAHN
---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB		ARBOR PHARMS LLC	250MG	A062298	001		Jun CTEC
AB			333MG	A062298	003	Mar 29, 1982	Jun CTEC
AB	!		500MG	A062298	002		Jun CTEC

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	250MG	A210954	001	Jul 02, 2019	Jun NEWA
AB			333MG	A210954	002	Jul 02, 2019	Jun NEWA
AB			500MG	A210954	003	Jul 02, 2019	Jun NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001		Sep CTEC
		ERYPED					

AB	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Sep CTEC
		ERYTHROMYCIN ETHYLSUCCINATE					

AB		AMNEAL PHARMS	EQ 200MG BASE/5ML	A211204	001	Nov 01, 2019	Oct NEWA
AB			EQ 400MG BASE/5ML	A211204	002	Nov 01, 2019	Oct NEWA
AB		ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001		Sep CTEC
AB			EQ 200MG BASE/5ML	A062055	003	Nov 02, 2018	Sep CTEC
AB		PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	Oct NEWA
AB			EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	Oct NEWA

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA	ALLIED	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Sep CAHN
	TABLET;ORAL					
	ESCITALOPRAM OXALATE					
AB	CADILA	EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr CAHN
AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr CAHN
AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr CAHN
AB	GRAVITI PHARMS	EQ 5MG BASE	A078777	001	Sep 11, 2012	Nov CAHN
AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Nov CAHN
AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Nov CAHN

ESKETAMINE HYDROCHLORIDE

SPRAY;NASAL

SPRAVATO

+	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019	Mar NEWA
---	----------------	--------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	10MG/ML	A208538	001	Aug 14, 2019	Jul NEWA
----	------------------	---------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	@ AMNEAL PHARMS NY	EQ 20MG BASE	A209647	001	Apr 10, 2019	Jun DISC
AB		EQ 20MG BASE	A209647	001	Apr 10, 2019	Mar NEWA
	@	EQ 40MG BASE	A209647	002	Apr 10, 2019	Jun DISC
AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Mar NEWA
AB	GLENMARK PHARMS	EQ 20MG BASE	A209495	001	May 10, 2019	Apr NEWA
AB		EQ 40MG BASE	A209495	002	May 10, 2019	Apr NEWA
	@ HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Mar DISC
	@	EQ 40MG BASE	A207265	001	May 18, 2018	Mar DISC
AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Jun CTEC
AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Jun CTEC
AB	ZYDUS PHARMS	EQ 20MG BASE	A206296	001	May 22, 2019	May NEWA
AB		EQ 40MG BASE	A206296	002	May 22, 2019	May NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

+	@ R2 PHARMA LLC	49.3MG	N202342	002	Aug 06, 2013	Aug DISC
---	-----------------	--------	---------	-----	--------------	----------

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADIOL

AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan NEWA
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan NEWA
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Jan NEWA
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Jan NEWA
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Jan NEWA

GEL;TRANSDERMAL

DIVIGEL

+	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jan CHRS
---	---------------------	------	---------	-----	--------------	----------

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

@	DR REDDYS	40MG/ML	A083714	001		May CAHN
---	-----------	---------	---------	-----	--	----------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

	@ ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Mar DISC
AB	NOVAST LABS	0.5MG;0.1MG	A210612	001	Apr 03, 2019	Mar NEWA
AB		1MG;0.5MG	A210612	002	Apr 03, 2019	Mar NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

+	@	ASPEN	0.3MG	N020992	001	Jun 21, 2002	Feb CAHN
+	@		0.45MG	N020992	005	Feb 05, 2004	Feb CAHN
+	@		0.625MG	N020992	002	Mar 24, 1999	Feb CAHN
+	@		0.9MG	N020992	003	Mar 24, 1999	Feb CAHN
+	@		1.25MG	N020992	004	Mar 13, 2000	Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

@	ASPEN	0.3MG	N021443	001	Dec 20, 2004	Feb CAHN
@		0.45MG	N021443	002	Dec 20, 2004	Feb CAHN
@		0.625MG	N021443	003	May 10, 2004	Feb CAHN
@		0.9MG	N021443	005	Apr 27, 2007	Feb CAHN
@		1.25MG	N021443	004	May 10, 2004	Feb CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

@	BRECKENRIDGE	1MG	A203087	001	May 08, 2019	May DISC
@		2MG	A203087	002	May 08, 2019	May DISC
@		3MG	A203087	003	May 08, 2019	May DISC
AB	BRECKENRIDGE PHARM	1MG	A203087	001	May 08, 2019	Apr NEWA
AB		2MG	A203087	002	May 08, 2019	Apr NEWA
AB		3MG	A203087	003	May 08, 2019	Apr NEWA

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECIN

AP	+	!	BAUSCH	EQ 50MG BASE/VIAL	N016093	001	Mar CAHN
AP	+	!	VALEANT PHARMS INTL	EQ 50MG BASE/VIAL	N016093	001	Jan CAHN

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

AB	+	!	BAUSCH	25MG	N016092	001	Mar CAHN
			@	50MG	N016092	002	Mar CAHN
AB	+	!	VALEANT PHARMS INTL	25MG	N016092	001	Jan CAHN
			@	50MG	N016092	002	Jan CAHN

ETHACRYNIC ACID

AB			AGNITIO	25MG	A211809	001	Jul 12, 2019	Jul NEWA
AB			LUPIN LTD	25MG	A211719	001	Sep 06, 2019	Aug NEWA
AB			SCIEGEN PHARMS INC	25MG	A211232	001	Aug 27, 2019	Aug NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

LO-MALMOREDE

AB			NOVAST LABS	0.035MG; 1MG	A209548	001	Feb 11, 2019	Jan NEWA
----	--	--	-------------	--------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

ELURYNG

AB			AMNEAL PHARMS LLC	0.015MG/24HR; 0.12MG/24HR	A210830	001	Dec 11, 2019	Nov NFTG
			NUVARING					
AB	+	!	ORGANON SUB MERCK	0.015MG/24HR; 0.12MG/24HR	N021187	001	Oct 03, 2001	Nov CFTG

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

INTROVALE

AB			XIROMED	0.03MG; 0.15MG	A079064	001	Sep 27, 2010	Aug CAHN
			JAIMIESS					
AB			XIROMED	0.03MG, 0.01MG; 0.15MG, N/A	A203770	001	Dec 27, 2017	Aug CAHN
			LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
AB			XIROMED	0.02MG, 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Aug CAHN
			SYLEVIA					
AB			SUN PHARM	0.03MG; 0.15MG	A202988	001	Feb 06, 2019	Jan NEWA

ETIDRONATE DISODIUM

TABLET; ORAL

ETIDRONATE DISODIUM

@ MYLAN	200MG	A075800	001	Jan 24, 2003	Nov DISC
@	400MG	A075800	002	Jan 24, 2003	Nov DISC

ETODOLAC

TABLET; ORAL

ETODOLAC

>A>	@ INVATECH	400MG	A074839	001	Jul 11, 1997	Dec CAHN
>A>	@	400MG	A074846	001	Feb 28, 1997	Dec CAHN
>D>	@ SANDOZ	400MG	A074839	001	Jul 11, 1997	Dec CAHN
>D>	@	400MG	A074846	001	Feb 28, 1997	Dec CAHN

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

@ LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009	Feb DISC
@ PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Apr DISC

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+! CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996	May CAHN
----------------	--------------------	---------	-----	--------------	----------

EVEROLIMUS

TABLET; ORAL

AFINITOR

AB	+	NOVARTIS	2.5MG	N022334	003	Jul 09, 2010	Nov CFTG
AB	+	!	5MG	N022334	001	Mar 30, 2009	Nov CFTG
		!	5MG	N022334	001	Mar 30, 2009	Apr CHRS
AB	+		7.5MG	N022334	004	Mar 30, 2012	Nov CFTG
AB	+		10MG	N022334	002	Mar 30, 2009	Nov CFTG
	+		10MG	N022334	002	Mar 30, 2009	Apr CHRS

EVEROLIMUS

AB		PAR PHARM	2.5MG	A207934	001	Dec 09, 2019	Nov NFTG
AB			5MG	A207934	002	Dec 09, 2019	Nov NFTG
AB			7.5MG	A207934	003	Dec 09, 2019	Nov NFTG
AB		TEVA PHARMS USA	2.5MG	A210050	001	Dec 09, 2019	Nov NFTG
AB			5MG	A210050	002	Dec 09, 2019	Nov NFTG
AB			7.5MG	A210050	003	Dec 09, 2019	Nov NFTG
AB			10MG	A210050	004	Dec 09, 2019	Nov NFTG

ZORTRESS

+	NOVARTIS	1MG	N021560	004	Aug 10, 2018	Mar NEWA
---	----------	-----	---------	-----	--------------	----------

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

	+	NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012	Apr CTEC
AB	+		2MG	N203985	001	Aug 29, 2012	Apr CFTG
	+		3MG	N203985	002	Aug 29, 2012	Apr CTEC
AB	+		3MG	N203985	002	Aug 29, 2012	Apr CFTG
	+	!	5MG	N203985	003	Aug 29, 2012	Apr CTEC
AB	+	!	5MG	N203985	003	Aug 29, 2012	Apr CFTG

EVEROLIMUS

@ MYLAN	2MG	A210130	001	Apr 19, 2019	Apr NFTG
@	3MG	A210130	002	Apr 19, 2019	Apr NFTG
@	5MG	A210130	003	Apr 19, 2019	Apr NFTG

EXEMESTANE

TABLET; ORAL

EXEMESTANE

	@ AMNEAL PHARMS	25MG	A206421	001	Dec 28, 2018	Jul DISC
>D>	@ BRECKENRIDGE	25MG	A211031	001	Feb 21, 2019	Dec CMFD
>A>	AB	25MG	A211031	001	Feb 21, 2019	Dec CMFD
	@	25MG	A211031	001	Feb 21, 2019	May DISC
AB	BRECKENRIDGE PHARM	25MG	A211031	001	Feb 21, 2019	Feb NEWA
AB	MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jul NEWA

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB	ACCORD HLTHCARE	10MG	A211550	001	Oct 26, 2018	Nov	CMFD
	@	10MG	A211550	001	Oct 26, 2018	Apr	DISC
AB	MYLAN	10MG	A201790	001	Apr 26, 2019	Apr	NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB	GLENMARK PHARMS LTD	10MG; 10MG	A208699	001	Jun 27, 2019	Jun	NEWA
AB		10MG; 20MG	A208699	002	Jun 27, 2019	Jun	NEWA
AB		10MG; 40MG	A208699	003	Jun 27, 2019	Jun	NEWA
AB		10MG; 80MG	A208699	004	Jun 27, 2019	Jun	NEWA

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB	! LUPIN LTD	40MG/5ML	A090440	001	Jun 29, 2010	Nov	CHRS
	PEPCID						
	+ @ SALIX PHARMS	40MG/5ML	N019527	001	Feb 02, 1987	Nov	DISC
	TABLET; ORAL						
	FAMOTIDINE						
AB	CELLTRION	20MG	A075786	001	Apr 16, 2001	Aug	CAHN
AB		40MG	A075786	002	Apr 16, 2001	Aug	CAHN
	@ MYLAN	40MG	A075704	002	Apr 16, 2001	Apr	DISC

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

AB	ALEMBIC PHARMS LTD	40MG	A205421	001	Jul 01, 2019	Jun	NFTG
AB		80MG	A205421	002	Jul 01, 2019	Jun	NFTG
AB	HIKMA	40MG	A205414	001	Oct 15, 2019	Nov	CAHN
AB		80MG	A205414	002	Oct 15, 2019	Nov	CAHN
>A> AB	INDOCO REMEDIES	40MG	A210292	001	Dec 30, 2019	Dec	NEWA
>A> AB		80MG	A210292	002	Dec 30, 2019	Dec	NEWA
>A> AB	MSN	40MG	A210461	001	Dec 30, 2019	Dec	NEWA
>A> AB		80MG	A210461	002	Dec 30, 2019	Dec	NEWA
AB	MYLAN	40MG	A205385	001	Jul 01, 2019	Jun	NFTG
AB		80MG	A205385	002	Jul 01, 2019	Jun	NFTG
AB	SUN PHARM	40MG	A205467	001	Jul 01, 2019	Jun	NFTG
AB		80MG	A205467	002	Jul 01, 2019	Jun	NFTG
AB	WEST-WARD PHARMS INT	40MG	A205414	001	Oct 15, 2019	Sep	NEWA
AB		80MG	A205414	002	Oct 15, 2019	Sep	NEWA
	ULORIC						
AB	+ TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Jun	CFTG
AB	+!	80MG	N021856	002	Feb 13, 2009	Jun	CFTG

FEDRATINIB HYDROCHLORIDE

CAPSULE; ORAL

INREBIC

+!	IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019	Aug	NEWA
----	--------	---------------	---------	-----	--------------	-----	------

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

AB	VISTAPHARM	600MG/5ML	A211333	001	May 31, 2019	May	NEWA
	TABLET; ORAL						
	FELBAMATE						
AB	CADILA	400MG	A208970	001	May 30, 2017	Jul	CAHN
AB		600MG	A208970	002	May 30, 2017	Jul	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

	@ MYLAN	2.5MG	A078855	001	Apr 17, 2008	Oct	DISC
	@	5MG	A078855	002	Apr 17, 2008	Oct	DISC
	@	10MG	A078855	003	Apr 17, 2008	Oct	DISC
AB	! TORRENT PHARMS LTD	10MG	A202170	003	Nov 28, 2011	Oct	CHRS
AB	YUNG SHIN PHARM	2.5MG	A204800	001	Apr 29, 2019	Apr	NEWA
AB		5MG	A204800	002	Apr 29, 2019	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL						
FELODIPINE						
AB		10MG	A204800	003	Apr 29, 2019	Apr NEWA
<u>FENOFIBRATE</u>						
CAPSULE;ORAL						
FENOFIBRATE (MICRONIZED)						
AB	AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan CAHN
AB		134MG	A207805	002	Nov 16, 2017	Jan CAHN
AB		200MG	A207805	003	Nov 16, 2017	Jan CAHN
AB	INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	Apr NEWA
AB		134MG	A207564	002	Apr 19, 2019	Apr NEWA
AB		200MG	A207564	003	Apr 19, 2019	Apr NEWA
	@ NOVAST LABS	67MG	A207564	001	Apr 19, 2019	Oct DISC
AB		67MG	A207564	001	Apr 19, 2019	Sep CAHN
	@	134MG	A207564	002	Apr 19, 2019	Oct DISC
AB		134MG	A207564	002	Apr 19, 2019	Sep CAHN
	@	200MG	A207564	003	Apr 19, 2019	Oct DISC
AB		200MG	A207564	003	Apr 19, 2019	Sep CAHN
TABLET;ORAL						
FENOFIBRATE						
AB	ALEMBIC PHARMS LTD	48MG	A210476	001	Aug 09, 2019	Jul NEWA
AB		145MG	A210476	002	Aug 09, 2019	Jul NEWA
AB	APPCO PHARMA LLC	54MG	A210670	001	Sep 06, 2019	Aug NEWA
AB		160MG	A210670	002	Sep 06, 2019	Aug NEWA
AB	AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan CAHN
AB		160MG	A207803	002	Dec 19, 2017	Jan CAHN
AB	NUVO PHARM	54MG	A210670	001	Sep 06, 2019	Sep CAHN
AB		160MG	A210670	002	Sep 06, 2019	Sep CAHN
AB	ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan NEWA
AB		160MG	A209660	002	Feb 11, 2019	Jan NEWA
FENOGLIDE						
AB	+ SALIX	40MG	N022118	001	Aug 10, 2007	Mar CAHN
AB	+!	120MG	N022118	002	Aug 10, 2007	Mar CAHN
TRIGLIDE						
BX	+ SKYEPHARMA AG	160MG	N021350	002	May 07, 2005	Oct CMFD
	+ @	160MG	N021350	002	May 07, 2005	Sep DISC
<u>FENOFIBRIC ACID</u>						
TABLET;ORAL						
FIBRICOR						
	+ ATHENA	35MG	N022418	001	Aug 14, 2009	Feb CAHN
	+!	105MG	N022418	002	Aug 14, 2009	Feb CAHN
<u>FENOPROFEN CALCIUM</u>						
TABLET;ORAL						
FENOPROFEN CALCIUM						
	@ ANI PHARMS INC	EQ 600MG BASE	A072274	001	May 02, 1988	May CAHN
<u>FENTANYL</u>						
SPRAY;SUBLINGUAL						
SUBSYS						
	+ BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012	Sep CAHN
	+	0.2MG	N202788	002	Jan 04, 2012	Sep CAHN
	+!	0.4MG	N202788	003	Jan 04, 2012	Sep CAHN
	+	0.6MG	N202788	004	Jan 04, 2012	Sep CAHN
	+	0.8MG	N202788	005	Jan 04, 2012	Sep CAHN
	+	1.2MG	N202788	006	Aug 30, 2012	Sep CAHN
	+	1.6MG	N202788	007	Aug 30, 2012	Sep CAHN
<u>FENTANYL CITRATE</u>						
INJECTABLE;INJECTION						
FENTANYL CITRATE PRESERVATIVE FREE						
AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr NEWA
SPRAY, METERED;NASAL						
LAZANDA						
	+ BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep CAHN
	+ @	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep DISC
	+ @	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep CAHN
	+!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep CAHN

TABLET;SUBLINGUAL									
ABSTRAL									
	+ @	SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Oct	DISC	
	+ @		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Oct	DISC	
	+ @		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Oct	DISC	
	+ @		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Oct	DISC	
	+ @		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Oct	DISC	
	+ @		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Oct	DISC	
FENTANYL CITRATE									
	@	ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017	Oct	DISC	
	@		EQ 0.2MG BASE	A207338	002	Nov 17, 2017	Oct	DISC	
	@		EQ 0.3MG BASE	A207338	003	Nov 17, 2017	Oct	DISC	
	@		EQ 0.4MG BASE	A207338	004	Nov 17, 2017	Oct	DISC	
	@		EQ 0.6MG BASE	A207338	005	Nov 17, 2017	Oct	DISC	
	@		EQ 0.8MG BASE	A207338	006	Nov 17, 2017	Oct	DISC	
<u>FERRIC CARBOXYMALTOSE</u>									
INJECTABLE;INTRAVENOUS									
INJECTAFER									
	+	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jun	CAHN	
<u>FERRIC MALTOL</u>									
CAPSULE;ORAL									
ACCRUFER									
	+	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019	Jul	NEWA	
<u>FESOTERODINE FUMARATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
FESOTERODINE FUMARATE									
AB		DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Jul	NEWA	
AB			8MG	A204975	002	Aug 13, 2019	Jul	NEWA	
<u>FEXOFENADINE HYDROCHLORIDE</u>									
SUSPENSION;ORAL									
FEXOFENADINE HYDROCHLORIDE									
	@	P AND L	30MG/5ML	A201311	001	Jul 25, 2012	Aug	CAHN	
TABLET;ORAL									
FEXOFENADINE HYDROCHLORIDE									
	@	MYLAN	30MG	A077081	002	Apr 11, 2008	Jul	DISC	
<u>FINAFLOXACIN</u>									
SUSPENSION/DROPS;OTIC									
XTORO									
	+	@ MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014	Apr	DISC	
<u>FINASTERIDE</u>									
TABLET;ORAL									
FINASTERIDE									
	@	MYLAN	5MG	A077578	001	Dec 18, 2006	Jul	DISC	
<u>FINGOLIMOD HYDROCHLORIDE</u>									
CAPSULE;ORAL									
FINGOLIMOD HYDROCHLORIDE									
AB		BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Nov	NFTG	
AB		HEC PHARM CO LTD	EQ 0.5MG BASE	A207939	001	Dec 04, 2019	Nov	NFTG	
AB		SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Nov	NFTG	
GILENYA									
AB	+	NOVARTIS	EQ 0.5MG BASE	N022527	001	Sep 21, 2010	Nov	CFTG	
<u>FLOXURIDINE</u>									
INJECTABLE;INJECTION									
FLOXURIDINE									
	@	LUITPOLD	500MG/VIAL	A203008	001	Nov 22, 2017	Mar	DISC	
<u>FLUCONAZOLE</u>									
INJECTABLE;INJECTION									
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER									
AP		WOODWARD	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Oct	CAHN	
AP			400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Oct	CAHN	
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%									
	@	DR REDDYS	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	May	CAHN	
	@		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May	CAHN	

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	May CAHN
	@	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	May CAHN
	WOODWARD	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Oct CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Oct CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Oct CAHN

TABLET; ORAL

FLUCONAZOLE

AB	CHARTWELL	50MG	A076665	001	Jul 29, 2004	Jun CAHN
AB		100MG	A076665	002	Jul 29, 2004	Jun CAHN
AB		150MG	A076665	003	Jul 29, 2004	Jun CAHN
AB		200MG	A076665	004	Jul 29, 2004	Jun CAHN

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

AB	+ BAUSCH	250MG	N017001	001		Feb CAHN
AB	+!	500MG	N017001	002		Feb CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

	@ MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	Oct DISC
--	------------------	--------------------	---------	-----	--------------	----------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	DECATUR	20-300mCi/ML	A204463	001	Oct 21, 2014	Apr CAHN
----	---------	--------------	---------	-----	--------------	----------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

	@ DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	May CAHN
	@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	May CAHN
AP	! HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A078527	002	Mar 23, 2009	Aug CHRS
	@ MYLAN LABS LTD	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Aug DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

	+ @ MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Jul DISC
--	-------------------------	-------------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

FLUNISOLIDE

	@ APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Nov DISC
		0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD
AB	APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

>A>	@ INVATECH	0.01%	A088047	001	Dec 16, 1982	Dec CAHN
>A>	@	0.025%	A088045	001	Dec 16, 1982	Dec CAHN
>D>	@ PHARMADERM	0.01%	A088047	001	Dec 16, 1982	Dec CAHN
>D>	@	0.025%	A088045	001	Dec 16, 1982	Dec CAHN

OIL/DROPS; OTIC

FLAC

AT	ANDA REPOSITORY	0.01%	A210736	001	Apr 11, 2018	Sep CAHN
----	-----------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

	@ ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Mar DISC
AT	ENCUBE ETHICALS	0.01%	A209913	001	Feb 13, 2019	Jan NEWA
AT	GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Jan CMFD
>A>	@ INVATECH	0.01%	A088048	001	Dec 16, 1982	Dec CAHN
AT	LUPIN	0.01%	A206422	001	Sep 02, 2015	Feb CAHN
>D>	@ PHARMADERM	0.01%	A088048	001	Dec 16, 1982	Dec CAHN

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE

	@ AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Feb DISC
AB	TELIGENT PHARMA INC	0.1%	A211758	001	Apr 03, 2019	Mar NEWA

OINTMENT; TOPICAL
FLUOCINONIDE

>D>	AB	CHEMO RESEARCH SL	0.05%	A212976	001	Nov 26, 2019	Dec CAHN
	AB		0.05%	A212976	001	Nov 26, 2019	Nov NEWA
>A>	AB	XIROMED	0.05%	A212976	001	Nov 26, 2019	Dec CAHN

SOLUTION; TOPICAL
FLUOCINONIDE

AT	TELIGENT PHARMA INC	0.05%	A207554	001	Mar 18, 2019	Mar NEWA
----	---------------------	-------	---------	-----	--------------	----------

FLUORODOPA F-18SOLUTION; INTRAVENOUS
FLUORODOPA F18

+	FEINSTEIN	0.42-8.33mCi/ML	N200655	001	Oct 10, 2019	Oct NEWA
---	-----------	-----------------	---------	-----	--------------	----------

FLUOROMETHOLONESUSPENSION/DROPS; OPHTHALMIC
FML FORTE

+	ALLERGAN	0.25%	N019216	001	Apr 23, 1986	Jun CHRS
+		0.25%	N019216	001	Apr 23, 1986	Jun CRLD

FLUOROMETHOLONE ACETATESUSPENSION/DROPS; OPHTHALMIC
FLAREX

+	EYEVANCE	0.1%	N019079	001	Feb 11, 1986	Feb CAHN
---	----------	------	---------	-----	--------------	----------

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS; OPHTHALMIC
TOBRASONE

@	EYEVANCE	0.1%; 0.3%	N050628	001	Jul 21, 1989	May CAHN
---	----------	------------	---------	-----	--------------	----------

FLUOROURACILCREAM; TOPICAL
EFUDEX

AB	+	BAUSCH	5%	N016831	003	Aug CAHN
	+	ALMIRALL	1%	N016988	001	Feb CAHN

INJECTABLE; INJECTION
ADRUCIL

>D>	@	PHARMACIA AND UPJOHN	50MG/ML	N017959	001	Dec CRLD
>A>	+	@	50MG/ML	N017959	001	Dec CRLD

FLUOROURACIL

>A>	AP	INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	Dec NEWA
	AP		500MG/10ML (50MG/ML)	A209271	001	Dec 11, 2019	Nov NEWA
>A>	AP		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	Dec NEWA
	AP		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	Nov NEWA
	@	MYLAN LABS LTD	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Sep DISC
	@		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Sep DISC

SOLUTION; TOPICAL
EFUDEX

AT	+	BAUSCH	2%	N016831	001	Aug CAHN
AT	+		5%	N016831	002	Aug CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1		APNAR PHARMA LP	EQ 10MG BASE	A075049	001	Aug 02, 2001	Jun CAHN
AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002	Jun CAHN
AB			EQ 40MG BASE	A075049	003	Jan 29, 2002	Jun CAHN
	@	BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002	Feb CAHN
	@		EQ 20MG BASE	A075807	002	Jan 29, 2002	Feb CAHN
AB1		CADILA PHARMS LTD	EQ 10MG BASE	A206993	001	May 23, 2019	May NEWA
AB1			EQ 20MG BASE	A206993	002	May 23, 2019	May NEWA
AB			EQ 40MG BASE	A206993	003	May 23, 2019	May NEWA
	@	CELLTRION	EQ 10MG BASE	A078143	001	Jan 16, 2008	Aug CAHN
	@		EQ 20MG BASE	A078143	002	Jan 16, 2008	Aug CAHN
	@		EQ 40MG BASE	A078143	003	Jan 16, 2008	Aug CAHN

CAPSULE;ORAL									
FLUOXETINE HYDROCHLORIDE									
>D>	AB1	HERITAGE PHARMS INC	EQ 10MG BASE	A201336	001	Oct 01, 2012	Dec	DISC	
>A>	@		EQ 10MG BASE	A201336	001	Oct 01, 2012	Dec	DISC	
>D>	AB1		EQ 20MG BASE	A201336	002	Oct 01, 2012	Dec	DISC	
>A>	@		EQ 20MG BASE	A201336	002	Oct 01, 2012	Dec	DISC	
>D>	AB		EQ 40MG BASE	A201336	003	Oct 01, 2012	Dec	DISC	
>A>	@		EQ 40MG BASE	A201336	003	Oct 01, 2012	Dec	DISC	
	@	MYLAN	EQ 10MG BASE	A078045	001	Nov 17, 2008	Oct	DISC	
	@		EQ 20MG BASE	A078045	002	Nov 17, 2008	Oct	DISC	
	@	PAR PHARM	EQ 40MG BASE	A076922	003	Dec 16, 2004	Mar	DISC	
CAPSULE, DELAYED REL PELLETS;ORAL									
FLUOXETINE HYDROCHLORIDE									
	@	BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010	Apr	DISC	
	!	DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr	CTEC	
AB	!		EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr	CHRS	
SOLUTION;ORAL									
FLUOXETINE HYDROCHLORIDE									
	@	NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	May	CAHN	
TABLET;ORAL									
FLUOXETINE HYDROCHLORIDE									
AB		APPCO PHARMA LLC	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jan	NEWA	
AB			EQ 20MG BASE	A211696	002	Jan 30, 2019	Jan	NEWA	
AB		DR REDDYS LABS LTD	EQ 60MG BASE	A211721	001	Jan 25, 2019	Jan	NEWA	
AB		G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Jun	NEWA	
AB		LUPIN LTD	EQ 10MG BASE	A211653	001	Apr 15, 2019	Apr	NEWA	
AB			EQ 20MG BASE	A211653	002	Apr 15, 2019	Apr	NEWA	
AB			EQ 60MG BASE	A211632	001	Feb 08, 2019	Feb	NEWA	
AB		SCIEGEN PHARMS INC	EQ 10MG BASE	A210935	001	Mar 20, 2019	Mar	NEWA	
AB			EQ 20MG BASE	A210935	002	Mar 20, 2019	Mar	NEWA	
AB		TARO	EQ 60MG BASE	A211477	001	Nov 21, 2018	Sep	CAHN	
AB		UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May	CAHN	
AB			EQ 20MG BASE	A211696	002	Jan 30, 2019	May	CAHN	
<u>FLUOXYMESTERONE</u>									
TABLET;ORAL									
FLUOXYMESTERONE									
	!	UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jul	CAHN	
<u>FLUPHENAZINE HYDROCHLORIDE</u>									
TABLET;ORAL									
FLUPHENAZINE HYDROCHLORIDE									
AB	!	LANNETT CO INC	10MG	A089743	001	Aug 25, 1988	May	CHRS	
AB		MYLAN	10MG	A089804	001	Aug 12, 1988	May	CHRS	
<u>FLURANDRENOLIDE</u>									
CREAM;TOPICAL									
CORDRAN SP									
	+	ALMIRALL	0.025%	N012806	003		Feb	CAHN	
AT	+		0.05%	N012806	002		Feb	CAHN	
LOTION;TOPICAL									
CORDRAN									
AT	+	ALMIRALL	0.05%	N013790	001		Feb	CAHN	
OINTMENT;TOPICAL									
CORDRAN									
	+	@ ALMIRALL	0.025%	N012806	004		Feb	CAHN	
AT	+		0.05%	N012806	001		Feb	CAHN	
TAPE;TOPICAL									
CORDRAN									
	+	ALMIRALL	0.004MG/SQ CM	N016455	001		Feb	CAHN	
<u>FLURBIPROFEN</u>									
TABLET;ORAL									
FLURBIPROFEN									
		MYLAN	50MG	A074358	001	Jun 20, 1994	Oct	CTEC	
	@	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001	Oct	DISC	
	@		100MG	A075058	002	Apr 27, 2001	Oct	DISC	

FLUTAMIDECAPSULE;ORAL
FLUTAMIDE

@ ACTAVIS LABS FL INC 125MG

A075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATECREAM;TOPICAL
FLUTICASONE PROPIONATE

AB ! PERRIGO ISRAEL 0.05%

A076793 001 May 14, 2004 May CAHN

POWDER;INHALATION

ARMONAIR RESPICLICK

+ @ TEVA PHARM 0.055MG/INH

N208798 001 Jan 27, 2017 Sep DISC

+ @ 0.113MG/INH

N208798 002 Jan 27, 2017 Jul DISC

+ @ 0.232MG/INH

N208798 003 Jan 27, 2017 Sep DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

ADVAIR DISKUS 100/50

AB +! GLAXO GRP LTD 0.1MG/INH;EQ 0.05MG BASE/INH

N021077 001 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 250/50

AB +! GLAXO GRP LTD 0.25MG/INH;EQ 0.05MG BASE/INH

N021077 002 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 500/50

AB +! GLAXO GRP LTD 0.5MG/INH;EQ 0.05MG BASE/INH

N021077 003 Aug 24, 2000 Jan CFTG

AIRDUO DIGIHALER

+ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH

N208799 004 Jul 12, 2019 Jul NEWA

+ 0.113MG/INH;EQ 0.014MG BASE/INH

N208799 005 Jul 12, 2019 Jul NEWA

+ 0.232MG/INH;EQ 0.014MG BASE/INH

N208799 006 Jul 12, 2019 Jul NEWA

AIRDUO RESPICLICK

+! TEVA PHARM 0.232MG/INH;EQ 0.014MG BASE/INH

N208799 003 Jan 27, 2017 Jul CMS1

WIXELA INHUB

AB MYLAN 0.1MG/INH;EQ 0.05MG BASE/INH

A208891 001 Jan 30, 2019 Jan NFTG

AB 0.25MG/INH;EQ 0.05MG BASE/INH

A208891 002 Jan 30, 2019 Jan NFTG

AB 0.5MG/INH;EQ 0.05MG BASE/INH

A208891 003 Jan 30, 2019 Jan NFTG

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

@ MYLAN EQ 80MG BASE

A202458 001 Sep 11, 2015 Jun DISC

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

>D> AB ANI PHARMS INC 25MG

A075897 001 Jan 25, 2001 Dec DISC

>A> @ 25MG

A075897 001 Jan 25, 2001 Dec DISC

>D> AB 50MG

A075897 002 Jan 25, 2001 Dec DISC

>A> @ 50MG

A075897 002 Jan 25, 2001 Dec DISC

>D> AB 100MG

A075897 003 Jan 25, 2001 Dec DISC

>A> @ 100MG

A075897 003 Jan 25, 2001 Dec DISC

@ MYLAN 25MG

A075889 001 Nov 29, 2000 May DISC

@ 50MG

A075889 002 Nov 29, 2000 May DISC

@ 100MG

A075889 003 Nov 29, 2000 May DISC

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

AP EXELA PHARMA SCS LLC 5MG/ML

A202522 001 Nov 06, 2019 Oct NEWA

AP ! FRESENIUS KABI USA 5MG/ML

A089202 001 Feb 18, 1986 Oct CTEC

FOLVITE

+ @ WYETH PHARMS INC 5MG/ML

N005897 008 Nov CRLD

TABLET;ORAL

FOLIC ACID

AA QINGDAO BAHEAL PHARM 1MG

A091145 001 Jul 12, 2013 May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

GONAL-F RFF REDI-JECT

+! EMD SERONO 150 IU/0.25ML

N021684 004 Nov 25, 2019 Nov NEWA

FOMEPIZOLE

	INJECTABLE; INJECTION						
	ANTIZOL						
	+ @ PAR PHARM INC	1.5GM/1.5ML (1GM/ML)	N020696	001	Dec 04, 1997	Jun	DISC
	FOMEPIZOLE						
AP	! MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A078639	001	Mar 03, 2008	Jun	CHRS

FORMOTEROL FUMARATE; MOMETASONE FUROATE

	AEROSOL, METERED; INHALATION						
	DULERA						
	+ MERCK SHARP DOHME	0.005MG/INH; 0.05MG/INH	N022518	003	Aug 12, 2019	Aug	NEWA

FOSAMPRENAVIR CALCIUM

	TABLET; ORAL						
	FOSAMPRENAVIR CALCIUM						
AB	SUN PHARM	EQ 700MG BASE	A204024	001	Nov 20, 2019	Nov	NEWA

FOSAPREPITANT

	POWDER; INTRAVENOUS						
	FOSAPREPITANT DIMEGLUMINE						
	TEVA PHARMS USA	150MG/VIAL	N210064	001	Sep 05, 2019	Sep	NEWA

FOSAPREPITANT DIMEGLUMINE

	POWDER; INTRAVENOUS						
	FOSAPREPITANT DIMEGLUMINE						
AP	APOTEX	EQ 150MG BASE/VIAL	A205020	001	Sep 05, 2019	Aug	NEWA
AP	BAXTER HLTHCARE CORP	EQ 150MG BASE/VIAL	A211860	001	Sep 05, 2019	Aug	NEWA
AP	BE PHARMS	EQ 150MG BASE/VIAL	A212309	001	Sep 05, 2019	Aug	NEWA
AP	LUPIN LTD	EQ 150MG BASE/VIAL	A210689	001	Sep 05, 2019	Aug	NEWA
AP	MSN	EQ 150MG BASE/VIAL	A209965	001	Sep 05, 2019	Aug	NEWA
	MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Aug	NFTG
AP		EQ 150MG BASE/VIAL	A204015	002	Sep 05, 2019	Aug	NEWA
AP	SUNGEN PHARMA	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Aug	NEWA
	TEVA PHARMS USA	EQ 150MG BASE/VIAL	N210064	001	Sep 05, 2019	Oct	CPOT
		150MG/VIAL	N210064	001	Sep 05, 2019	Oct	CAIN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

	TABLET; ORAL						
	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
	@ ANI PHARMS INC	10MG; 12.5MG	A076608	001	Dec 03, 2004	May	CAHN
	@	20MG; 12.5MG	A076608	002	Dec 03, 2004	May	CAHN

FOSPHENYTOIN SODIUM

	INJECTABLE; INJECTION						
	FOSPHENYTOIN SODIUM						
	@ DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May	CAHN
	@ LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007	Feb	DISC
	@	EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010	Feb	DISC

FROVATRIPTAN SUCCINATE

	TABLET; ORAL						
	FROVATRIPTAN SUCCINATE						
AB	AMNEAL PHARMS CO	EQ 2.5MG BASE	A211292	001	Nov 06, 2018	Aug	CMFD
	@	EQ 2.5MG BASE	A211292	001	Nov 06, 2018	May	DISC

FULVESTRANT

	INJECTABLE; INTRAMUSCULAR						
	FASLODEX						
AO	+! ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002	Apr	CMS1
AP	+!	50MG/ML	N021344	001	Apr 25, 2002	Feb	CFTG
	FULVESTRANT						
AO	GLENMARK PHARMS INC	50MG/ML	A207754	001	Aug 22, 2019	Aug	NEWA
AO	HBT LABS INC	50MG/ML	A209714	001	Nov 21, 2019	Nov	NEWA
AO	MYLAN INSTITUTIONAL	50MG/ML	A208811	001	Jul 23, 2019	Jul	NEWA
AO	SAGENT PHARMS INC	50MG/ML	A205871	001	Aug 22, 2019	Aug	NEWA
AO	SANDOZ INC	50MG/ML	A205935	001	May 14, 2019	Apr	NEWA
	SOLUTION; INTRAMUSCULAR						
	FULVESTRANT						
	FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019	May	NEWA
	TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Aug	NEWA

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP	AUROBINDO PHARMA LTD	10MG/ML	A212174	001	May 03, 2019	Apr NEWA
	TABLET; ORAL					
	FUROSEMIDE					
	@ ANI PHARMS INC	20MG	A071379	001	Jan 02, 1987	Jul CAHN
	@	40MG	A070413	001	Feb 26, 1986	Sep CAHN
AB	AVET	20MG	N018413	001	Nov 30, 1983	Oct CAHN
AB		40MG	N018413	002	Nov 30, 1983	Oct CAHN
AB	HERITAGE PHARMA	20MG	N018413	001	Nov 30, 1983	Feb CAHN
AB		40MG	N018413	002	Nov 30, 1983	Feb CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB	GRANULES INDIA LTD	100MG	A075360	001	Apr 06, 2005	Jun CAHN
AB		300MG	A075360	002	Apr 06, 2005	Jun CAHN
AB		400MG	A075360	003	Apr 06, 2005	Jun CAHN

SOLUTION; ORAL
GABAPENTIN

AA	VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	Nov NEWA
	TABLET; ORAL					
	GABAPENTIN					
>A>	@ INVATECH	600MG	A076877	001	Jul 06, 2006	Dec CAHN
>A>	@	800MG	A076877	002	Jul 06, 2006	Dec CAHN
	@ IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005	Jul DISC
	@	800MG	A076017	005	Apr 29, 2005	Jul DISC
	@ LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Mar DISC
	@	800MG	A209306	002	Aug 24, 2018	Mar DISC
AB	RUBICON	600MG	A077661	004	Sep 13, 2006	Aug CAHN
AB		800MG	A077661	005	Sep 13, 2006	Aug CAHN
>D>	@ SANDOZ	600MG	A076877	001	Jul 06, 2006	Dec CAHN
>D>	@	800MG	A076877	002	Jul 06, 2006	Dec CAHN

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS
CLARISCAN

AP	GE HEALTHCARE	7.538GM/20ML (376.9MG/ML)	A210016	003	Nov 01, 2019	Oct NFTG
AP		3.769GM/10ML (376.9MG/ML)	A210016	001	Nov 01, 2019	Oct NFTG
AP		5.6535GM/15ML (376.9MG/ML)	A210016	002	Nov 01, 2019	Oct NFTG
	DOTAREM					
AP	+! GUERBET	3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Oct CFTG
AP	+!	5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Oct CFTG
AP	+!	7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Oct CFTG

GALANTAMINE HYDROBROMIDE

TABLET; ORAL
GALANTAMINE HYDROBROMIDE

	@ HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009	May CAHN
	@	EQ 4MG BASE	A077587	001	Jul 09, 2009	Sep DISC
AB		EQ 4MG BASE	A077587	001	Jul 09, 2009	May CAHN
	@	EQ 8MG BASE	A077585	002	Sep 15, 2009	May CAHN
	@	EQ 8MG BASE	A077587	002	Jul 09, 2009	Sep DISC
AB		EQ 8MG BASE	A077587	002	Jul 09, 2009	May CAHN
	@	EQ 12MG BASE	A077585	003	Sep 15, 2009	May CAHN
	@	EQ 12MG BASE	A077587	003	Jul 09, 2009	Sep DISC
AB		EQ 12MG BASE	A077587	003	Jul 09, 2009	May CAHN
>D> AB	MYLAN	EQ 4MG BASE	A077590	001	May 29, 2009	Dec DISC
>A>	@	EQ 4MG BASE	A077590	001	May 29, 2009	Dec DISC
>D> AB		EQ 8MG BASE	A077590	002	May 29, 2009	Dec DISC
>A>	@	EQ 8MG BASE	A077590	002	May 29, 2009	Dec DISC
>D> AB		EQ 12MG BASE	A077590	003	May 29, 2009	Dec DISC
>A>	@	EQ 12MG BASE	A077590	003	May 29, 2009	Dec DISC

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

BS	CURIUM	2mCi/ML	N018058	001		Jan CAHN
----	--------	---------	---------	-----	--	----------

GALLIUM DOTATOC GA-68

SOLUTION;INTRAVENOUS
GALLIUM DOTATOC GA 68

+! UIHC PET IMAGING 0.5-4mCi/ML N210828 001 Aug 21, 2019 Aug NEWA

GALLIUM NITRATE

INJECTABLE;INJECTION
GANITE

@ CHEPLAPHARM 25MG/ML N019961 002 Jan 17, 1991 Aug CAHN

GANCICLOVIR

SOLUTION;INTRAVENOUS
GANZYK-RTU

+! EXELA PHARMA SCS LLC 500MG/250ML (2MG/ML) N209347 001 Feb 17, 2017 Sep CTNA

GANCICLOVIR SODIUM

INJECTABLE;INJECTION
CYTOVENE

AP +! CHEPLAPHARM EQ 500MG BASE/VIAL N019661 001 Jun 23, 1989 Aug CAHN

GANCICLOVIR SODIUM

>D> AP CUSTOPHARM INC EQ 500MG BASE/VIAL A212001 001 Jun 20, 2019 Dec DISC

>A> @ EQ 500MG BASE/VIAL A212001 001 Jun 20, 2019 Dec DISC

AP EQ 500MG BASE/VIAL A212001 001 Jun 20, 2019 Jun NEWA

AP FRESENIUS KABI USA EQ 500MG BASE/VIAL A090658 001 Jun 21, 2010 Jul CTNA

AP HAINAN POLY PHARM EQ 500MG BASE/VIAL A204204 001 Nov 08, 2018 Jul CTNA

@ LUITPOLD EQ 500MG BASE/VIAL A202624 001 Sep 18, 2013 Jul CTNA

@ EQ 500MG BASE/VIAL A202624 001 Sep 18, 2013 Feb DISC

AP MYLAN LABS LTD EQ 500MG BASE/VIAL A204560 001 Nov 17, 2017 Jul CTNA

AP PAR STERILE PRODUCTS EQ 500MG BASE/VIAL A204950 001 Dec 06, 2016 Jul CTNA

GANIRELIX ACETATE

INJECTABLE;INJECTION
GANIRELIX ACETATE

AP +! ORGANON USA INC 250MCG/0.5ML N021057 001 Jul 29, 1999 Mar CPOT

AP SUN PHARM 250MCG/0.5ML A204246 001 Nov 30, 2018 Mar CPOT

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

>D> AP ACTAVIS INC 200MG/5.26ML (38MG/ML) A204549 001 Apr 11, 2016 Dec DISC

>A> @ 200MG/5.26ML (38MG/ML) A204549 001 Apr 11, 2016 Dec DISC

>D> AP 1GM/26.3ML (38MG/ML) A204549 002 Apr 11, 2016 Dec DISC

>A> @ 1GM/26.3ML (38MG/ML) A204549 002 Apr 11, 2016 Dec DISC

>D> AP 2GM/52.6ML (38MG/ML) A204549 003 Apr 11, 2016 Dec DISC

>A> @ 2GM/52.6ML (38MG/ML) A204549 003 Apr 11, 2016 Dec DISC

>D> AP ACTAVIS TOTOWA EQ 200MG BASE/VIAL A079160 001 Jul 25, 2011 Dec DISC

>A> @ EQ 200MG BASE/VIAL A079160 001 Jul 25, 2011 Dec DISC

>D> AP EQ 1GM BASE/VIAL A079160 002 Jul 25, 2011 Dec DISC

>A> @ EQ 1GM BASE/VIAL A079160 002 Jul 25, 2011 Dec DISC

>D> AP EQ 2GM BASE/VIAL A079160 003 Jul 28, 2016 Dec DISC

>A> @ EQ 2GM BASE/VIAL A079160 003 Jul 28, 2016 Dec DISC

AP FRESENIUS KABI USA EQ 200MG BASE/VIAL A090799 001 Jul 25, 2011 Jan CAHN

AP EQ 1GM BASE/VIAL A090799 002 Jul 25, 2011 Jan CAHN

AP EQ 2GM BASE/VIAL A090799 003 May 16, 2011 Jan CAHN

@ INGENUS PHARMS LLC 200MG/5.26ML (38MG/ML) A210383 001 Feb 14, 2019 Oct DISC

AP 200MG/5.26ML (38MG/ML) A210383 001 Feb 14, 2019 Feb NEWA

@ 1GM/26.3ML (38MG/ML) A210383 002 Feb 14, 2019 Oct DISC

AP 1GM/26.3ML (38MG/ML) A210383 002 Feb 14, 2019 Feb NEWA

@ 2GM/52.6ML (38MG/ML) A210383 003 Feb 14, 2019 Oct DISC

AP 2GM/52.6ML (38MG/ML) A210383 003 Feb 14, 2019 Feb NEWA

@ LUITPOLD EQ 200MG BASE/VIAL A202031 001 May 07, 2013 Feb DISC

@ EQ 1GM BASE/VIAL A202031 002 May 07, 2013 Feb DISC

@ SHILPA MEDICARE LTD EQ 200MG BASE/VIAL A207575 001 Feb 22, 2019 Oct DISC

AP EQ 200MG BASE/VIAL A207575 001 Feb 22, 2019 Feb NEWA

AP 200MG/5.26ML (38MG/ML) A210991 001 Oct 04, 2019 Sep NEWA

@ EQ 1GM BASE/VIAL A207575 002 Feb 22, 2019 Oct DISC

AP EQ 1GM BASE/VIAL A207575 002 Feb 22, 2019 Feb NEWA

AP 1GM/26.3ML (38MG/ML) A210991 002 Oct 04, 2019 Sep NEWA

AP 2GM/52.6ML (38MG/ML) A210991 003 Oct 04, 2019 Sep NEWA

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

@ SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Oct DISC
----------------------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATECREAM; TOPICAL
GENTAMICIN SULFATE

AT	TELIGENT PHARMA INC	EQ 0.1% BASE	A209304	001	Oct 18, 2019	Oct NEWA
----	---------------------	--------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	! FRESenius KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Jul CHRS
----	----------------------	-----------------	---------	-----	--------------	----------

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

AT	FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Sep CAHN
----	-----------------	--------------	---------	-----	--------------	----------

GIVOSIRAN SODIUMSOLUTION; SUBCUTANEOUS
GIVLAARI

+	! ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194	001	Nov 20, 2019	Nov NEWA
---	----------------------	-------------------------------------	---------	-----	--------------	----------

GLASDEGIB MALEATETABLET; ORAL
DAURISMO

+	PFIZER INC	EQ 25MG BASE	N210656	001	Nov 21, 2018	Feb CAIN
+	!	EQ 100MG BASE	N210656	002	Nov 21, 2018	Feb CAIN

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

AB	MICRO LABS	1MG	A091220	001	Jun 29, 2012	Mar CAHN
AB		2MG	A091220	002	Jun 29, 2012	Mar CAHN
		3MG	A091220	003	Jun 29, 2012	Mar CAHN
AB		4MG	A091220	004	Jun 29, 2012	Mar CAHN
		6MG	A091220	005	Jun 29, 2012	Mar CAHN
AB		8MG	A091220	006	Jun 29, 2012	Mar CAHN
	@ TEVA	1MG	A076802	001	Oct 06, 2005	Oct DISC
	@	2MG	A076802	002	Oct 06, 2005	Oct DISC
	@	4MG	A076802	003	Oct 06, 2005	Oct DISC

GLIPIZIDETABLET; ORAL
GLIPIZIDE

>D>	AB	ANI PHARMS INC	5MG	A074497	001	Aug 31, 1995	Dec DISC
>A>		@	5MG	A074497	001	Aug 31, 1995	Dec DISC
>D>	AB		10MG	A074497	002	Aug 31, 1995	Dec DISC
>A>		@	10MG	A074497	002	Aug 31, 1995	Dec DISC
	@	BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb CAHN
	@		10MG	A074542	002	Jun 20, 1995	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

@	MYLAN	2.5MG	A202298	001	May 19, 2015	Feb DISC
@		5MG	A202298	002	May 19, 2015	Feb DISC
@		10MG	A202298	003	May 19, 2015	Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@	MYLAN	2.5MG; 250MG	A078083	001	Apr 12, 2007	Apr DISC
@		2.5MG; 500MG	A078083	002	Apr 12, 2007	Nov DISC
@		5MG; 500MG	A078083	003	Apr 12, 2007	Nov DISC
@	SUN PHARM INDS INC	2.5MG; 250MG	A077620	001	Jan 11, 2008	Oct DISC
@		2.5MG; 500MG	A077620	002	Jan 11, 2008	Oct DISC
@		5MG; 500MG	A077620	003	Jan 11, 2008	Oct DISC

GLUCAGONPOWDER;NASAL
BAQSIMI+! ELI LILLY AND CO
SOLUTION;SUBCUTANEOUS
GVOKE HYPOPEN

3MG

N210134 001 Jul 24, 2019 Jul NEWA

+! XERIS
+! 1MG/0.2ML (1MG/0.2ML)

N212097 003 Sep 10, 2019 Sep NEWA

N212097 004 Sep 10, 2019 Sep NEWA

GVOKE PFS

+! XERIS
+! 1MG/0.2ML (1MG/0.2ML)

N212097 001 Sep 10, 2019 Sep NEWA

N212097 002 Sep 10, 2019 Sep NEWA

GLYBURIDETABLET;ORAL
GLYBURIDEAB1 @ ORIENT PHARMA CO LTD 1.25MG
1.25MG
@ 2.5MG
AB1 2.5MG
@ 5MG
AB1 5MG

A206483 001 Feb 22, 2019 Jul DISC

A206483 001 Feb 22, 2019 Feb NEWA

A206483 002 Feb 22, 2019 Jul DISC

A206483 002 Feb 22, 2019 Feb NEWA

A206483 003 Feb 22, 2019 Jul DISC

A206483 003 Feb 22, 2019 Feb NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ HERITAGE PHARMS INC 1.25MG;250MG
@ 2.5MG;500MG
@ 5MG;500MG

A079009 001 Jun 03, 2009 Aug DISC

A079009 002 Jun 03, 2009 Aug DISC

A079009 003 Jun 03, 2009 Aug DISC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+! HORIZON THERAP 1.1GM/ML

N203284 001 Feb 01, 2013 Feb CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP APOTEX 0.2MG/ML
AP CAPLIN 0.2MG/ML
AP GLAND PHARMA LTD 0.2MG/ML
AP PIRAMAL CRITICAL 0.2MG/ML
AP SANDOZ INC 0.2MG/ML
ROBINUL
+ @ HIKMA 0.2MG/ML

A210246 001 Oct 29, 2019 Oct NEWA

A211705 001 Mar 20, 2019 Mar NEWA

A212612 001 Sep 30, 2019 Sep NEWA

A210842 001 Oct 25, 2018 Jun CAHN

A211334 001 May 14, 2019 Apr NEWA

N017558 001 Aug CAHN

TABLET;ORAL

GLYCOPYRROLATE

AA AUROLIFE PHARMA LLC 2MG
AA KENTON 1MG
AA 2MG

A202675 002 Oct 30, 2018 May NEWA

A091182 001 Feb 03, 2014 Mar CAHN

A091182 002 Feb 03, 2014 Mar CAHN

>A> GOLODIRSEN

>A> SOLUTION;INTRAVENOUS

>A> VYONDYS 53

>A> +! SAREPTA THERAPS INC 100MG/2ML (50MG/ML)

N211970 001 Dec 12, 2019 Dec NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP BIONPHARMA INC EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)
AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
AP ! DR REDDYS EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)
AP ! EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
@ LUITPOLD EQ 1MG BASE/ML (EQ 1MG BASE/ML)
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE
AP BIONPHARMA INC EQ 1MG BASE/ML (EQ 1MG BASE/ML)
@ DR REDDYS EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A078863 001 Jun 30, 2008 Apr CAHN

A078880 001 Jun 30, 2008 Apr CAHN

A078392 001 Dec 31, 2007 May CAHN

A077297 001 Jun 30, 2008 May CAHN

A091274 001 Sep 22, 2010 Feb DISC

A078863 002 Jun 30, 2008 Apr CAHN

A077165 001 Dec 31, 2007 May CAHN

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

@ TEVA PHARMS EQ 1MG BASE

A078080 001 Dec 31, 2007 Jan DISC

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

OBREDON

+ @ SOVEREIGN PHARMS 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014 Jun DISC

TABLET; ORAL

XTRELUS

+ @ ECI PHARMS LLC 400MG; 5MG N208085 001 Apr 25, 2018 Jun DISC

>D> GUANABENZ ACETATE

>D> TABLET; ORAL

>D> GUANABENZ ACETATE

>D> ANI PHARMS INC EQ 4MG BASE A074149 001 Apr 07, 1995 Dec DISC

>A> @ EQ 4MG BASE A074149 001 Apr 07, 1995 Dec DISC

>D> ! EQ 8MG BASE A074149 002 Apr 07, 1995 Dec DISC

>A> @ EQ 8MG BASE A074149 002 Apr 07, 1995 Dec DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB EPIC PHARMA LLC EQ 1MG BASE A074673 001 Feb 28, 1997 Apr CMFD

AB EQ 2MG BASE A074673 002 Feb 28, 1997 Apr CMFD

>D> AB ! MYLAN EQ 1MG BASE A074796 001 Jan 27, 1997 Dec CHRS

>A> AB EQ 1MG BASE A074796 001 Jan 27, 1997 Dec CHRS

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

@ MYLAN EQ 1MG BASE A202578 001 Jun 02, 2015 May DISC

@ EQ 2MG BASE A202578 002 Jun 02, 2015 May DISC

@ EQ 3MG BASE A202578 003 Jun 02, 2015 May DISC

@ EQ 4MG BASE A202578 004 Jun 02, 2015 May DISC

HALCINONIDE

CREAM; TOPICAL

HALCINONIDE

AB MYLAN 0.1% A211027 001 Aug 12, 2019 Jul NEWA

HALOG

AB +! SUN PHARM INDS INC 0.1% N017556 001 Aug CFTG

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

LEXETTE

+! MAYNE PHARMA 0.05% N210566 001 May 24, 2018 Sep CTNA

CREAM; TOPICAL

ULTRAVATE

+ @ SUN PHARM INDS INC 0.05% N019967 001 Dec 27, 1990 Nov DISC

LOTION; TOPICAL

BRYHALI

+! BAUSCH 0.01% N209355 001 Nov 06, 2018 Apr CAHN

+! DOW PHARM 0.01% N209355 001 Nov 06, 2018 Jan CHRS

+ 0.01% N209355 001 Nov 06, 2018 Jan CRLD

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL

DUOBRII

+! BAUSCH 0.01%; 0.045% N209354 001 Apr 25, 2019 Apr NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A> AB APPCO 0.5MG A211061 001 Jan 08, 2020 Dec NEWA

>A> AB 1MG A211061 002 Jan 08, 2020 Dec NEWA

>A> AB 2MG A211061 003 Jan 08, 2020 Dec NEWA

>A> AB 5MG A211061 004 Jan 08, 2020 Dec NEWA

>A> AB 10MG A211061 005 Jan 08, 2020 Dec NEWA

>A> AB 20MG A211061 006 Jan 08, 2020 Dec NEWA

AB INNOGENIX 0.5MG A071173 002 Jan 02, 1987 Oct CMFD

@ 0.5MG A071173 002 Jan 02, 1987 May CMS1

AB 1MG A071173 003 Jan 02, 1987 Oct CMFD

@ 1MG A071173 003 Jan 02, 1987 May CMS1

AB 2MG A071173 004 Jan 02, 1987 Oct CMFD

@ 2MG A071173 004 Jan 02, 1987 May CMS1

AB 5MG A071173 005 Jan 07, 1988 Oct CMFD

TABLET;ORAL
HALOPERIDOL

	@	5MG	A071173	005	Jan 07, 1988	May CMS1	
AB		10MG	A071173	001	Jan 07, 1988	Oct CMFD	
	@	10MG	A071173	001	Jan 07, 1988	Mar CAHN	
AB		20MG	A071173	006	Jan 07, 1988	Oct CMFD	
	@	20MG	A071173	006	Jan 07, 1988	May CMS1	
>D>	!	MYLAN	2MG	A070278	001	Jun 10, 1986	Dec CTEC
>A>	AB	!	2MG	A070278	001	Jun 10, 1986	Dec CTEC
		!	2MG	A070278	001	Jun 10, 1986	Jan CTEC
AB	!	2MG	A070278	001	Jun 10, 1986	Jan CHRS	
	@	SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan DISC

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

AO	ZYDUS PHARMS	EQ 50MG BASE/ML	A211180	001	Oct 22, 2019	Oct NEWA
AO		EQ 100MG BASE/ML	A211180	002	Oct 22, 2019	Oct NEWA

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL

AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CHRS
	@	TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988	May DISC
		HALOPERIDOL INTENSOL					
	@	HIKMA	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	Sep CAHN

INJECTABLE;INJECTION
HALOPERIDOL

>D>	AP	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Dec DISC
>A>		@	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Dec DISC
	AP		EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Jun NEWA

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Aug CAHN
AP	+	!	1,000 UNITS/ML	N017037	001		Feb CAHN
AP	+		5,000 UNITS/ML	N017037	002		Feb CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb CAHN
AP	+		10,000 UNITS/ML	N017037	003		Feb CAHN
AP		NANJING KING-FRIEND	1,000 UNITS/ML	A211007	001	May 28, 2019	May NEWA
AP			5,000 UNITS/ML	A211007	002	May 28, 2019	May NEWA
AP			10,000 UNITS/ML	A211007	003	May 28, 2019	May NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL
HYCODAN

AA	+	GENUS	1.5MG/5ML;5MG/5ML	N005213	002	Jul 26, 1988	Jun CMFD
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
	@	BRECKENRIDGE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Jul DISC
AA		BRECKENRIDGE PHARM	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	May NEWA
	@	TORRENT	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Nov DISC
AA			1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	May CMFD
	@		1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jan CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

	@	LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb DISC
--	---	----------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	Jun CAHN
AA			25MG	A209251	002	Jul 09, 2018	Jun CAHN
AA			50MG	A209251	003	Jul 09, 2018	Jun CAHN
AA			100MG	A209251	004	Jul 09, 2018	Jun CAHN

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	!	ACCORD HLTHCARE	12.5MG	A202556	001	Sep 24, 2012	Nov CHRS
	@	SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008	Oct DISC
	@		25MG	A040810	001	Mar 27, 2007	Oct DISC

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@	50MG	A040810	002	Mar 27, 2007	Oct DISC
---	------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

@ APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012	Jul DISC
--------------	--------------	---------	-----	--------------	----------

@	12.5MG;300MG	A201505	002	Oct 15, 2012	Jul DISC
---	--------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

@ HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002	Aug DISC
-------------------	-------------	---------	-----	--------------	----------

AB					
	12.5MG;10MG	A075776	001	Jul 01, 2002	Feb CAHN

@	12.5MG;20MG	A075776	002	Jul 01, 2002	Aug DISC
---	-------------	---------	-----	--------------	----------

AB					
	12.5MG;20MG	A075776	002	Jul 01, 2002	Feb CAHN

@	25MG;20MG	A075776	003	Jul 01, 2002	Aug DISC
---	-----------	---------	-----	--------------	----------

AB					
	25MG;20MG	A075776	003	Jul 01, 2002	Feb CAHN

>D> AB	MYLAN	12.5MG;10MG	A076113	001	Jul 01, 2002	Dec DISC
--------	-------	-------------	---------	-----	--------------	----------

>A>	@	12.5MG;10MG	A076113	001	Jul 01, 2002	Dec DISC
-----	---	-------------	---------	-----	--------------	----------

>D> AB		12.5MG;20MG	A076113	002	Jul 01, 2002	Dec DISC
--------	--	-------------	---------	-----	--------------	----------

>A>	@	12.5MG;20MG	A076113	002	Jul 01, 2002	Dec DISC
-----	---	-------------	---------	-----	--------------	----------

>D> AB		25MG;20MG	A076113	003	Jul 01, 2002	Dec DISC
--------	--	-----------	---------	-----	--------------	----------

>A>	@	25MG;20MG	A076113	003	Jul 01, 2002	Dec DISC
-----	---	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

@ ACCORD HLTHCARE	12.5MG;20MG	A209281	001	Feb 07, 2019	Aug DISC
-------------------	-------------	---------	-----	--------------	----------

AB					
	12.5MG;20MG	A209281	001	Feb 07, 2019	Jan NEWA

@	12.5MG;40MG	A209281	002	Feb 07, 2019	Aug DISC
---	-------------	---------	-----	--------------	----------

AB					
	12.5MG;40MG	A209281	002	Feb 07, 2019	Jan NEWA

@	25MG;40MG	A209281	003	Feb 07, 2019	Aug DISC
---	-----------	---------	-----	--------------	----------

AB					
	25MG;40MG	A209281	003	Feb 07, 2019	Jan NEWA

@ MYLAN	12.5MG;20MG	A078827	001	Oct 26, 2016	Nov DISC
---------	-------------	---------	-----	--------------	----------

@	12.5MG;40MG	A078827	002	Oct 26, 2016	Nov DISC
---	-------------	---------	-----	--------------	----------

@	25MG;40MG	A078827	003	Oct 26, 2016	Nov DISC
---	-----------	---------	-----	--------------	----------

@ TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Jul DISC
-------------------	-------------	---------	-----	--------------	----------

@	25MG;40MG	A200532	003	Apr 24, 2017	Jul DISC
---	-----------	---------	-----	--------------	----------

AB	UMEDICA LABS PVT LTD	12.5MG;20MG	A208847	001	Sep 17, 2019	Sep NEWA
----	----------------------	-------------	---------	-----	--------------	----------

AB		12.5MG;40MG	A208847	003	Sep 17, 2019	Sep NEWA
----	--	-------------	---------	-----	--------------	----------

AB		25MG;40MG	A208847	002	Sep 17, 2019	Sep NEWA
----	--	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005	May DISC
---------	---------------------	---------	-----	--------------	----------

@	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005	May DISC
---	---------------------	---------	-----	--------------	----------

@	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005	May DISC
---	-------------------	---------	-----	--------------	----------

QUINARETIC

AB	LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb CAHN
----	-------	---------------------	---------	-----	--------------	----------

AB		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb CAHN
----	--	---------------------	---------	-----	--------------	----------

AB		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb CAHN
----	--	-------------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019	Feb NEWA
----	---------------------	-------------	---------	-----	--------------	----------

AB		12.5MG;80MG	A202544	002	Mar 04, 2019	Feb NEWA
----	--	-------------	---------	-----	--------------	----------

AB		25MG;80MG	A202544	003	Mar 04, 2019	Feb NEWA
----	--	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC	25MG;50MG	A074259	001	Mar 30, 1995	Jun DISC
------------------	-----------	---------	-----	--------------	----------

@ CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Jun DISC
-------------------	-----------	---------	-----	--------------	----------

AB	ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Jan NEWA
----	--------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>D> AB	ANI PHARMS INC	50MG;75MG	A073467	001	Jan 31, 1996	Dec DISC
--------	----------------	-----------	---------	-----	--------------	----------

>A>	@	50MG;75MG	A073467	001	Jan 31, 1996	Dec DISC
-----	---	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL							
VALSARTAN AND HYDROCHLOROTHIAZIDE							
	@ ZYDUS PHARMS	12.5MG; 80MG	A203000	001	Mar 15, 2019	Aug	DISC
AB		12.5MG; 80MG	A203000	001	Mar 15, 2019	Mar	NEWA
	@	12.5MG; 160MG	A203000	002	Mar 15, 2019	Aug	DISC
AB		12.5MG; 160MG	A203000	002	Mar 15, 2019	Mar	NEWA
	@	12.5MG; 320MG	A203000	003	Mar 15, 2019	Aug	DISC
AB		12.5MG; 320MG	A203000	003	Mar 15, 2019	Mar	NEWA
	@	25MG; 160MG	A203000	004	Mar 15, 2019	Aug	DISC
AB		25MG; 160MG	A203000	004	Mar 15, 2019	Mar	NEWA
	@	25MG; 320MG	A203000	005	Mar 15, 2019	Aug	DISC
AB		25MG; 320MG	A203000	005	Mar 15, 2019	Mar	NEWA

HYDROCODONE BITARTRATECAPSULE, EXTENDED RELEASE; ORAL
ZOHYDRO ER

+!	PERSION	10MG	N202880	001	Oct 25, 2013	Apr CAHN
+		15MG	N202880	002	Oct 25, 2013	Apr CAHN
+		20MG	N202880	003	Oct 25, 2013	Apr CAHN
+		30MG	N202880	004	Oct 25, 2013	Apr CAHN
+		40MG	N202880	005	Oct 25, 2013	Apr CAHN
+		50MG	N202880	006	Oct 25, 2013	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL
HYSINGLA ER

+!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Jul CMS1
+		30MG	N206627	002	Nov 20, 2014	Jul CMS1
+		40MG	N206627	003	Nov 20, 2014	Jul CMS1
+		60MG	N206627	004	Nov 20, 2014	Jul CMS1
+		80MG	N206627	005	Nov 20, 2014	Jul CMS1
+		100MG	N206627	006	Nov 20, 2014	Jul CMS1
+		120MG	N206627	007	Nov 20, 2014	Jul CMS1

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

@	ANI PHARMS INC	5MG; 200MG	A077454	001	Jun 23, 2010	May CAHN
@	SUN PHARM INDS INC	2.5MG; 200MG	A091633	001	May 28, 2013	Oct DISC
@		5MG; 200MG	A091633	002	May 28, 2013	Oct DISC
@		7.5MG; 200MG	A091633	003	May 28, 2013	Oct DISC
@		10MG; 200MG	A091633	004	May 28, 2013	Oct DISC

REPREXAIN

AMNEAL PHARMS NY	2.5MG; 200MG	A076642	003	Oct 19, 2007	Oct CTEC
------------------	--------------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	@ MAYNE PHARMA INC	5MG/5ML; 60MG/5ML	A205658	001	Nov 17, 2015	Jun DISC
	@ PADDOCK LLC	5MG/5ML; 60MG/5ML	A204658	001	Apr 29, 2014	Jun DISC
	@ TORRENT	5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Feb DISC
		5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Jan NEWA
	REZIRA					
	+ @ PERSION	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011	Jun DISC
AA	+!	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011	Apr CAHN

HYDROCORTISONE

CREAM; TOPICAL

NUTRACORT

@ BAUSCH	0.5%	A080442	002		Feb CAHN
@	1%	A080442	003		Feb CAHN

LOTION; TOPICAL

ALA-SCALP

>D>	CROWN LABS	2%	A083231	001	Dec	CAHN
>A>	MARNEL PHARMS	2%	A083231	001	Dec	CAHN
	CETACORT					
@	BAUSCH	0.5%	A080426	002	Feb	CAHN
@		1%	A080426	001	Feb	CAHN

TABLET; ORAL

HYDROCORTISONE

>D>	AB	BRECKENRIDGE	5MG	A207029	001	Apr 27, 2017	Dec CAHN
	AB		5MG	A207029	001	Apr 27, 2017	Aug CAHN

TABLET;ORAL
HYDROCORTISONE

>D>	AB	10MG	A207029	002	Apr 27, 2017	Dec CAHN
	AB	10MG	A207029	002	Apr 27, 2017	Aug CAHN
>D>	AB	20MG	A207029	003	Apr 27, 2017	Dec CAHN
	AB	20MG	A207029	003	Apr 27, 2017	Aug CAHN
>A>	AB	PII 5MG	A207029	001	Apr 27, 2017	Dec CAHN
>A>	AB	10MG	A207029	002	Apr 27, 2017	Dec CAHN
>A>	AB	20MG	A207029	003	Apr 27, 2017	Dec CAHN

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL
LOCOID

AB1	+	BAUSCH	0.1%	N018514	001	Mar 31, 1982	May CAHN
		LOTION;TOPICAL LOCOID					
AB	+	BAUSCH	0.1%	N022076	001	May 18, 2007	May CAHN
		SOLUTION;TOPICAL LOCOID					
AT	+	BAUSCH	0.1%	N019116	001	Feb 25, 1987	May CAHN

HYDROCORTISONE VALERATE

CREAM;TOPICAL
HYDROCORTISONE VALERATE

AB		LUPIN LTD	0.2%	A210307	001	Aug 15, 2019	Aug NEWA
AB		PERRIGO ISRAEL	0.2%	A075666	001	May 24, 2000	May CAHN

HYDROGEN PEROXIDE

SOLUTION;TOPICAL
ESKATA

	+	@ ACLARIS	40%	N209305	001	Dec 14, 2017	Aug DISC
--	---	-----------	-----	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
EXALGO

	+	@ SPECGX LLC	8MG	N021217	001	Mar 01, 2010	Mar DISC
	+	@	12MG	N021217	002	Mar 01, 2010	Mar DISC
	+	@	16MG	N021217	003	Mar 01, 2010	Mar DISC
	+	@	32MG	N021217	004	Aug 24, 2012	Mar DISC
		HYDROMORPHONE HYDROCHLORIDE					
AB	!	OSMOTICA	32MG	A205629	004	Jul 07, 2016	Mar CHRS

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL
HYDROXYCHLOROQUINE SULFATE

>A>	@	INVATECH	200MG	A040150	001	Jan 27, 1996	Dec CAHN
	@	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Sep DISC
AB			200MG	A210959	001	Jan 15, 2019	Jan CAHN
	@	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Feb DISC
>D>	@	SANDOZ	200MG	A040150	001	Jan 27, 1996	Dec CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR
HYDROXYPROGESTERON CAPROATE

AP1		AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jul NEWA
		HYDROXYPROGESTERONE CAPROATE					
AP		ASPEN	250MG/ML (250MG/ML)	A211777	001	Aug 08, 2019	Jul NEWA
	!	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Nov CTEC
AP2	!		1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr CPOT
AP2	!		250MG/ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr CTEC
AP		EUGIA PHARMA	250MG/ML (250MG/ML)	A211071	001	Apr 16, 2019	Apr NEWA
AP1			1250MG/5ML (250MG/ML)	A211070	001	Apr 16, 2019	Apr NEWA
	@		1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019	Nov DISC
AP2			1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019	Apr NEWA
AP		SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)	A210877	001	Mar 22, 2019	Mar NEWA
AP1			1250MG/5ML (250MG/ML)	A210618	001	Dec 28, 2018	Apr CTEC
AP1		SUN PHARM	1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Apr CTEC
AP			1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Mar NEWA
		MAKENA					
AP1	+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Apr CTEC

HYDROXYPROPYL CELLULOSEINSERT;OPHTHALMIC
LACRISERT

+! VALEANT PHARMS INTL 5MG

N018771 001

Jan CAHN

HYDROXYZINE HYDROCHLORIDEINJECTABLE;INJECTION
HYDROXYZINE HYDROCHLORIDE

! LUITPOLD 50MG/ML

A087408 002

Mar CMFD

@ 50MG/ML

A087408 002

Feb DISC

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

@ ANIMA 10MG/5ML

A086880 001

Sep CAHN

@ TORRENT 10MG/5ML

A210634 001

Feb 26, 2019

Nov DISC

AA 10MG/5ML

A210634 001

Feb 26, 2019

Feb NEWA

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB EPIC PHARMA LLC 10MG

A040604 002

Dec 28, 2004

Jan CAHN

AB 25MG

A040604 003

Dec 28, 2004

Jan CAHN

AB 50MG

A040604 001

Dec 28, 2004

Jan CAHN

AB KVK TECH 25MG

A040786 002

Mar 20, 2007

Feb CMS1

AB 50MG

A040786 003

Mar 20, 2007

Feb CMS1

@ MYLAN 10MG

A091176 001

Jun 07, 2010

Aug DISC

@ 25MG

A091176 002

Jun 07, 2010

Aug DISC

@ 50MG

A091176 003

Jun 07, 2010

Aug DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB @ BEXIMCO PHARMS USA EQ 25MG HYDROCHLORIDE

A081127 001

Jun 28, 1991

Feb CAHN

! SANDOZ EQ 50MG HYDROCHLORIDE

A086183 001

Nov CHRS

VISTARIL

+ @ PFIZER EQ 25MG HYDROCHLORIDE

N011459 002

Nov DISC

+ @ EQ 50MG HYDROCHLORIDE

N011459 004

Nov DISC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

@ EMCURE PHARMS LTD EQ 3MG BASE/3ML

A203987 001

Sep 02, 2014

Nov DISC

TABLET;ORAL

IBANDRONATE SODIUM

@ SUN PHARM INDUSTRIES EQ 150MG BASE

A078996 001

Aug 15, 2012

Oct DISC

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

+! CUMBERLAND PHARMS 800MG/200ML (4MG/ML)

N022348 003

Jan 25, 2019

Jan NEWA

SUSPENSION;ORAL

CHILDREN'S ADVIL

@ GLAXOSMITHKLINE 100MG/5ML

N019833 002

Sep 19, 1989

Nov CAHN

IBUPROFEN

AB L PERRIGO CO 100MG/5ML

A076925 001

Sep 23, 2004

May CAHN

TABLET;ORAL

IBUPROFEN

@ HEC PHARM 400MG

A204062 001

Sep 10, 2018

Mar DISC

@ 600MG

A204062 002

Sep 10, 2018

Mar DISC

@ 800MG

A204062 003

Sep 10, 2018

Mar DISC

AB PERRIGO PHARMS CO 400MG

A077114 001

Jul 18, 2005

May CAHN

AB 600MG

A077114 002

Jul 18, 2005

May CAHN

AB 800MG

A077114 003

Jul 18, 2005

May CAHN

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

@ LUITPOLD 0.1MG/ML

A090240 001

Jan 11, 2010

Feb DISC

ICATIBANT ACETATEINJECTABLE;SUBCUTANEOUS
FIRAZYR

AP	+!	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CFTG
		ICATIBANT ACETATE					
AP		TEVA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A210118	001	Jul 15, 2019	Jul NFTG

IDARUBICIN HYDROCHLORIDEINJECTABLE;INJECTION
IDARUBICIN HYDROCHLORIDE
@ MYLAN LABS LTD

1MG/ML

A200144 001 Oct 11, 2012 Oct DISC

IFOSFAMIDEINJECTABLE;INJECTION
IFOSFAMIDE@ MYLAN LABS LTD
@1GM/20ML (50MG/ML)
3GM/60ML (50MG/ML)A201689 001 Nov 26, 2012 Sep DISC
A201689 002 Nov 26, 2012 Sep DISCILOPERIDONETABLET;ORAL
FANAPT

	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Aug CTEC
	+		2MG	N022192	002	May 06, 2009	Aug CTEC
	+		4MG	N022192	003	May 06, 2009	Aug CTEC
	+		6MG	N022192	004	May 06, 2009	Aug CTEC
	+		8MG	N022192	005	May 06, 2009	Aug CTEC
	+		10MG	N022192	006	May 06, 2009	Aug CTEC
	+		12MG	N022192	007	May 06, 2009	Aug CTEC
		ILOPERIDONE					
	@	INVENTIA	1MG	A207231	001	Nov 28, 2016	Aug CAHN
	@		2MG	A207231	002	Nov 28, 2016	Aug CAHN
	@		4MG	A207231	003	Nov 28, 2016	Aug CAHN
	@		6MG	A207231	004	Nov 28, 2016	Aug CAHN
	@		8MG	A207231	005	Nov 28, 2016	Aug CAHN
	@		10MG	A207231	006	Nov 28, 2016	Aug CAHN
	@		12MG	A207231	007	Nov 28, 2016	Aug CAHN
	@	INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Jul DISC
	@		2MG	A207231	002	Nov 28, 2016	Jul DISC
	@		4MG	A207231	003	Nov 28, 2016	Jul DISC
	@		6MG	A207231	004	Nov 28, 2016	Jul DISC
	@		8MG	A207231	005	Nov 28, 2016	Jul DISC
	@		10MG	A207231	006	Nov 28, 2016	Jul DISC
	@		12MG	A207231	007	Nov 28, 2016	Jul DISC
	@	TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019	Aug DISC
AB			1MG	A207098	001	Jul 22, 2019	Jul NEWA
	@		2MG	A207098	002	Jul 22, 2019	Aug DISC
AB			2MG	A207098	002	Jul 22, 2019	Jul NEWA
	@		4MG	A207098	003	Jul 22, 2019	Aug DISC
AB			4MG	A207098	003	Jul 22, 2019	Jul NEWA
	@		6MG	A207098	004	Jul 22, 2019	Aug DISC
AB			6MG	A207098	004	Jul 22, 2019	Jul NEWA
	@		8MG	A207098	005	Jul 22, 2019	Aug DISC
AB			8MG	A207098	005	Jul 22, 2019	Jul NEWA
	@		10MG	A207098	006	Jul 22, 2019	Aug DISC
AB			10MG	A207098	006	Jul 22, 2019	Jul NEWA
	@		12MG	A207098	007	Jul 22, 2019	Aug DISC
AB			12MG	A207098	007	Jul 22, 2019	Jul NEWA

IMATINIB MESYLATETABLET;ORAL
IMATINIB MESYLATE

	@	AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Aug DISC
AB			EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb NEWA
	@		EQ 400MG BASE	A207495	002	Feb 08, 2019	Aug DISC
AB			EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb NEWA
AB		BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb NEWA
AB			EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb NEWA
AB		NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb NEWA
AB			EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb NEWA
AB		SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan NEWA
AB			EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan NEWA
AB		WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan NEWA

TABLET;ORAL
IMATINIB MESYLATE

AB EQ 400MG BASE A208429 002 Jan 17, 2019 Jan NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

>D>	AB	LUPIN LTD	10MG	A090441	002	Mar 11, 2010	Dec DISC
>A>		@	10MG	A090441	002	Mar 11, 2010	Dec DISC
>D>	AB		25MG	A090441	003	Mar 11, 2010	Dec DISC
>A>		@	25MG	A090441	003	Mar 11, 2010	Dec DISC
>D>	AB		50MG	A090441	001	Mar 11, 2010	Dec DISC
>A>		@	50MG	A090441	001	Mar 11, 2010	Dec DISC
		@ OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar DISC
		@	25MG	A040751	002	Feb 28, 2008	Mar DISC

IMIQUIMOD

CREAM;TOPICAL
ALDARA

AB	+!	BAUSCH	5%	N020723	001	Feb 27, 1997	Aug CAHN
		ZYCLARA					
	+!	BAUSCH	2.5%	N022483	002	Jul 15, 2011	Aug CAHN
	+!		3.75%	N022483	001	Mar 25, 2010	Aug CAHN

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION
INDICLOR

	+	@ GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun DISC
		INDIUM IN 111 CHLORIDE					
	+	!	CURIUM	N019841	001	Sep 27, 1994	Jan CAHN
			5mCi/0.5ML				

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

>D>		@ BWXT ITG	1mCi/ML	A202586	001	Jul 25, 2018	Dec CMFD
>A>	AP		1mCi/ML	A202586	001	Jul 25, 2018	Dec CMFD
>D>		+!	GE HEALTHCARE	N019044	001	Dec 24, 1985	Dec CTEC
>A>	AP	+!		N019044	001	Dec 24, 1985	Dec CTEC

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION
OCTREOSCAN

	+	!	CURIUM	N020314	001	Jun 02, 1994	Jan CAHN
			3mCi/ML				

INDOMETHACIN

CAPSULE;ORAL
INDOCIN

	+	@ EGALET	25MG	N016059	001		Feb CAHN
	+	@	50MG	N016059	002		Feb CAHN

INDOMETHACIN

		@ ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987	May CAHN
		@	50MG	A071149	001	Mar 18, 1987	May CAHN
AB		CADILA	25MG	A090403	001	Nov 15, 2010	May CAHN
AB			50MG	A090403	002	Nov 15, 2010	May CAHN
AB	!	GLENMARK GENERICS	50MG	A091276	002	Dec 22, 2010	Aug CHRS
AB		HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb CAHN
AB			50MG	A070756	001	Feb 12, 1986	Feb CAHN
		@ MYLAN	25MG	N018858	001	Apr 20, 1984	Aug DISC
		@	50MG	A070624	001	Sep 04, 1985	Aug DISC
		@ SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Oct DISC
		@	50MG	A091401	002	Mar 28, 2013	Oct DISC
		TIVORBEX					
	+	EGALET	20MG	N204768	001	Feb 24, 2014	Feb CAHN
	+	!	40MG	N204768	002	Feb 24, 2014	Feb CAHN
	+	GENUS	20MG	N204768	001	Feb 24, 2014	Nov CAHN
	+	!	40MG	N204768	002	Feb 24, 2014	Nov CAHN

CAPSULE, EXTENDED RELEASE;ORAL
INDOCIN SR

	+	@ EGALET	75MG	N018185	001	Feb 23, 1982	Feb CAHN
--	---	----------	------	---------	-----	--------------	----------

SUPPOSITORY;RECTAL
INDOCIN

+ @ EGALET	50MG	N017814	001	Aug 13, 1984	Feb CAHN
------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL
INDOCIN

+! EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb CAHN
-----------	----------	---------	-----	--------------	----------

INDOMETHACIN

@ HIKMA	25MG/5ML	A071412	001	Mar 18, 1987	Sep CAHN
---------	----------	---------	-----	--------------	----------

INSULIN ASPARTSOLUTION;SUBCUTANEOUS
FIASP PENFILL

+! NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	003	Sep 24, 2018	Jun NEWA
---------	------------------------------	---------	-----	--------------	----------

INSULIN ASPART; INSULIN DEGLUDECSOLUTION;SUBCUTANEOUS
RYZODEG 70/30

+ @ NOVO	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313	001	Sep 25, 2015	Jun DISC
----------	--	---------	-----	--------------	----------

INSULIN DEGLUDECSOLUTION;SUBCUTANEOUS
TRESIBA

NOVO	1000 UNITS/10ML (100 UNITS/ML)	N203314	003	Nov 21, 2018	Jun NEWA
------	--------------------------------	---------	-----	--------------	----------

INSULIN HUMANSOLUTION;INTRAVENOUS
MYXREDLIN

+! BAXTER HLTHCARE CORP	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jul CAHN
-------------------------	-----------------------------	---------	-----	--------------	----------

+! CELERITY PHARMS	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jun NEWA
--------------------	-----------------------------	---------	-----	--------------	----------

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

>A>	HUMALOG KWIKPEN				
-----	-----------------	--	--	--	--

>A>	+! LILLY	200UNITS/ML	N020563	004	Nov 15, 2019	Dec NEWA
-----	----------	-------------	---------	-----	--------------	----------

>A>	HUMALOG TEMPO PEN				
-----	-------------------	--	--	--	--

>A>	+! LILLY	100UNITS/ML	N020563	005	Nov 15, 2019	Dec NEWA
-----	----------	-------------	---------	-----	--------------	----------

IOPROMIDEINJECTABLE;INJECTION
ULTRAVIST (PHARMACY BULK)

+ @ BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004	Aug DISC
--------------------	-------	---------	-----	--------------	----------

+!	49.9%	N021425	003	Mar 12, 2004	Apr CMFD
----	-------	---------	-----	--------------	----------

+ @	49.9%	N021425	003	Mar 12, 2004	Feb DISC
-----	-------	---------	-----	--------------	----------

ULTRAVIST 240

+ @ BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995	Aug DISC
--------------------	-------	---------	-----	--------------	----------

+!	49.9%	N020220	003	May 10, 1995	Apr CMFD
----	-------	---------	-----	--------------	----------

+ @	49.9%	N020220	003	May 10, 1995	Feb DISC
-----	-------	---------	-----	--------------	----------

IOTHALAMATE MEGLUMINEINJECTABLE;INJECTION
CONRAY 43

+ @ LIEBEL-FLARSHEIM	43%	N013295	002		Jun DISC
----------------------	-----	---------	-----	--	----------

IPRATROPIUM BROMIDESPRAY, METERED;NASAL
IPRATROPIUM BROMIDE

@ MYLAN SPECIALITY LP	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Mar DISC
-----------------------	---------------	---------	-----	--------------	----------

@	0.042MG/SPRAY	A075553	001	Mar 31, 2003	Mar DISC
---	---------------	---------	-----	--------------	----------

IRINOTECAN HYDROCHLORIDEINJECTABLE;INJECTION
IRINOTECAN HYDROCHLORIDE

AP	@ FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008	Oct DISC
----	----------------------	--------------------	---------	-----	--------------	----------

		40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008	Jan CAHN
--	--	--------------------	---------	-----	--------------	----------

	@	100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008	Oct DISC
--	---	---------------------	---------	-----	--------------	----------

AP		100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008	Jan CAHN
----	--	---------------------	---------	-----	--------------	----------

AP	GLAND PHARMA LTD	40MG/2ML (20MG/ML)	A212993	001	Nov 18, 2019	Nov NEWA
----	------------------	--------------------	---------	-----	--------------	----------

AP		100MG/5ML (20MG/ML)	A212993	002	Nov 18, 2019	Nov NEWA
----	--	---------------------	---------	-----	--------------	----------

AP	ZENNOVA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	Sep CAHN
----	---------	--------------------	---------	-----	--------------	----------

AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	Sep CAHN
----	--	---------------------	---------	-----	--------------	----------

IRON DEXTRANINJECTABLE; INJECTION
DEXFERRUM

@ LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Mar DISC
PROFERDEX					
@ NEW RIVER	EQ 50MG IRON/ML	N017807	001		Mar DISC

IRON SUCROSEINJECTABLE; INTRAVENOUS
VENOFER

+ AM REGENT	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr CAHN
@	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Apr CAHN
@	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005	Apr CAHN
+!	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000	Apr CAHN
+	EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007	Apr CAHN

ISONIAZIDTABLET; ORAL
ISONIAZID

AA ! BARR	100MG	A080936	001		Aug CHRS
AA !	300MG	A080937	002		Aug CHRS
+ @ SANDOZ	100MG	N008678	002		Aug DISC
+ @	300MG	N008678	003		Aug DISC
LANIAZID					
@ LANNETT	300MG	A089776	001	Jun 13, 1988	Oct DISC

ISOPROPYL ALCOHOLSOLUTION; TOPICAL
ZURAGARD

+! ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019	Apr NEWA
-----------------	--------------	---------	-----	--------------	----------

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Jun NEWA
ISUPREL					
AP +! BAUSCH	0.2MG/ML	N010515	001		Mar CAHN

ISOSORBIDE DINITRATETABLET; ORAL
ISORDIL

AB + BAUSCH	5MG	N012093	007	Jul 29, 1988	Mar CAHN
+ @	10MG	N012093	002	Jul 29, 1988	Mar CAHN
+ @	20MG	N012093	006	Jul 29, 1988	Mar CAHN
+ @	30MG	N012093	005	Jul 29, 1988	Mar CAHN
AB +!	40MG	N012093	001	Jul 29, 1988	Nov CTEC
+!	40MG	N012093	001	Jul 29, 1988	Mar CAHN
ISOSORBIDE DINITRATE					
AB ZYDUS	5MG	A213057	001	Nov 20, 2019	Nov NEWA
AB	10MG	A213057	002	Nov 20, 2019	Nov NEWA
AB	20MG	A213057	003	Nov 20, 2019	Nov NEWA
AB	30MG	A213057	004	Nov 20, 2019	Nov NEWA
AB	40MG	A213057	005	Nov 20, 2019	Nov NEWA

ISOSORBIDE MONONITRATETABLET; ORAL
ISOSORBIDE MONONITRATE

>D> AB ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998	Dec DISC
>A> @	20MG	A075147	001	Nov 27, 1998	Dec DISC
TABLET, EXTENDED RELEASE; ORAL					
ISOSORBIDE MONONITRATE					
AB HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Mar CAHN
AB	60MG	A076813	001	Jan 07, 2005	Mar CAHN

ISOSULFAN BLUEINJECTABLE; INJECTION
ISOSULFAN BLUE

AP	ANDA REPOSITORY	1%	A210558	001	Jul 12, 2019	Sep CAHN
	@ BELOTECA INC	1%	A210714	001	Jan 16, 2019	Jul DISC
>D> AP	SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	Dec DISC
>A>	@	1%	A210558	001	Jul 12, 2019	Dec DISC
AP		1%	A210558	001	Jul 12, 2019	Oct CAHN
AP		1%	A210558	001	Jul 12, 2019	Jul NEWA

ISOTRETINOINCAPSULE; ORAL
ABSORICA LD

+	SUN PHARM	8MG	N211913	001	Nov 05, 2019	Nov NEWA
+		16MG	N211913	002	Nov 05, 2019	Nov NEWA
+		20MG	N211913	003	Nov 05, 2019	Nov NEWA
+		24MG	N211913	004	Nov 05, 2019	Nov NEWA
+		28MG	N211913	005	Nov 05, 2019	Nov NEWA
+	!	32MG	N211913	006	Nov 05, 2019	Nov NEWA

ISTRADEFYLLINETABLET; ORAL
NOURIANZ

+	KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019	Aug NEWA
+	!	40MG	N022075	002	Aug 27, 2019	Aug NEWA

ITRACONAZOLECAPSULE; ORAL
ITRACONAZOLE

>D> AB	ANDA REPOSITORY	100MG	A206410	001	Jul 02, 2019	Dec CAHN
AB		100MG	A206410	001	Jul 02, 2019	Aug CAHN
>A> AB	PII	100MG	A206410	001	Jul 02, 2019	Dec CAHN
AB		100MG	A206410	001	Jul 02, 2019	Jun NEWA

SOLUTION; ORAL
ITRACONAZOLE

AA	APOTEX	10MG/ML	A208481	001	Aug 02, 2019	Jul NEWA
----	--------	---------	---------	-----	--------------	----------

IVABRADINESOLUTION; ORAL
CORLANOR

+	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Apr NEWA
---	-----------	------------------	---------	-----	--------------	----------

IVACAFTORGRANULE; ORAL
KALYDECO

+	VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019	May NEWA
---	-------------------	-------------	---------	-----	--------------	----------

TABLET; ORAL
KALYDECO

+	VERTEX PHARMS	75MG	N203188	002	May 20, 2019	May NEWA
---	---------------	------	---------	-----	--------------	----------

IVACAFTOR; IVACAFTOR, TEZACAFTORTABLET, TABLET; ORAL
SYMDEKO (COPACKAGED)

+	VERTEX PHARMS INC	75MG, N/A; 75MG, 50MG	N210491	002	Jun 21, 2019	Nov CHRS
+	!	75MG, N/A; 75MG, 50MG	N210491	002	Jun 21, 2019	Jul NEWA

IVERMECTINCREAM; TOPICAL
IVERMECTIN

AB	TEVA PHARMS USA	1%	A210019	001	Sep 13, 2019	Sep NFTG
	SOOLANTRA					
AB	+! GALDERMA LABS LP	1%	N206255	001	Dec 19, 2014	Sep CFTG

KETOCONAZOLEGEL; TOPICAL
XOLEGEL

+	ALMIRALL	2%	N021946	001	Jul 28, 2006	Feb CAHN
---	----------	----	---------	-----	--------------	----------

SHAMPOO; TOPICAL
KETOCONAZOLE

AB	PERRIGO ISRAEL	2%	A076419	001	Jan 07, 2004	May CAHN
----	----------------	----	---------	-----	--------------	----------

TABLET;ORAL

KETOCONAZOLE

>D>	@ APOTEX	200MG	A075912	001	Jan 10, 2002	Dec CAHN
>A>	@ HAVIX	200MG	A075912	001	Jan 10, 2002	Dec CAHN
	@ HERITAGE PHARMA	200MG	A074971	001	Jun 15, 1999	May CAHN
	@	200MG	A075362	001	Jun 15, 1999	May CAHN
AB	! TARO	200MG	A075319	001	Jun 15, 1999	Apr CHRS
	@ TEVA	200MG	A075273	001	Jun 15, 1999	Apr DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP	WEST-WARD PHARMS INT	15MG/ML	A075772	001	Jul 21, 2004	Feb CMFD
AP		30MG/ML	A075772	002	Jul 21, 2004	Feb CMFD

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

	@ AUROBINDO PHARMA LTD	0.4%	A205191	001	Nov 15, 2018	May DISC
AT	MICRO LABS LTD INDIA	0.5%	A203410	001	Apr 05, 2019	Mar NEWA
	@ SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	May DISC

SPRAY, METERED;NASAL

SPRIX

+!	ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010	Jul CAHN
----	------	---------------	---------	-----	--------------	----------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

AT	LUPIN LTD	EQ 0.3% BASE;EQ 1% BASE	A210183	001	Jul 01, 2019	Jun NFTG
	OMIDRIA					
AT	+! OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Jun CFTG

L-GLUTAMINE

FOR SOLUTION;ORAL

NUTRESTORE

+	@ EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jun DISC
---	----------------	------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

@	MYLAN ASI	5MG/ML	A079134	001	Feb 03, 2010	Sep DISC
---	-----------	--------	---------	-----	--------------	----------

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	CADILA PHARMS LTD	100MG	A211325	001	May 13, 2019	Apr NEWA
AB		200MG	A211325	002	May 13, 2019	Apr NEWA
AB		300MG	A211325	003	May 13, 2019	Apr NEWA
	@ HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Oct DISC
AB		100MG	A074787	001	Aug 03, 1998	Feb CAHN
	@	200MG	A074787	002	Aug 03, 1998	Oct DISC
AB		200MG	A074787	002	Aug 03, 1998	Feb CAHN
	@	300MG	A074787	003	Aug 03, 1998	Oct DISC
AB		300MG	A074787	003	Aug 03, 1998	Feb CAHN
	TRANDATE					
AB	+ CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan CRLD
AB	+	200MG	N018716	002	Aug 01, 1984	Jan CRLD
AB	+	300MG	N018716	003	Aug 01, 1984	Jan CRLD

LACTULOSE

SOLUTION;ORAL

LACTULOSE

>D> AA	ANI PHARMS	10GM/15ML	A078430	001	Nov 28, 2007	Dec DISC
>A>	@	10GM/15ML	A078430	001	Nov 28, 2007	Dec DISC
	@ BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Jan CAHN
	@ TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Nov DISC
AA		10GM/15ML	A207786	001	Jun 11, 2018	Jan CAHN
AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Aug CMFD
	@	10GM/15ML	A075911	001	Feb 21, 2002	Mar CAHN

SOLUTION;ORAL, RECTAL

LACTULOSE

>D> AA	ANI PHARMS	10GM/15ML	A090426	001	Nov 21, 2008	Dec DISC
>A>	@	10GM/15ML	A090426	001	Nov 21, 2008	Dec DISC
	@ BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan CAHN
	@ TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Nov DISC
AA		10GM/15ML	A203762	001	Mar 27, 2015	Jan CAHN

LAMIVUDINETABLET; ORAL
LAMIVUDINE

AB	ANNORA	100MG	A211306	001	Mar 21, 2019	Mar NEWA
AB	MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019	Apr NEWA
AB		300MG	A090198	002	May 01, 2019	Apr NEWA
	@ MYLAN	100MG	A204002	001	Dec 31, 2014	Oct DISC
	@	150MG	A204528	001	Mar 04, 2016	Apr DISC
	@	300MG	A204528	002	Mar 04, 2016	Apr DISC
AB	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb NEWA
AB		300MG	A078545	002	Mar 05, 2019	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	ANDA REPOSITORY	150MG; 300MG	A206375	001	Apr 10, 2018	Sep CAHN
	@ MYLAN	150MG; 300MG	A079079	001	Aug 12, 2019	Aug DISC
AB		150MG; 300MG	A079079	001	Aug 12, 2019	Jul NEWA
	@	150MG; 300MG	A204005	001	Aug 28, 2014	Jan DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

	@ CELLTRION	25MG	A078982	001	Jan 27, 2009	Aug CAHN
	@	100MG	A078982	002	Jan 27, 2009	Aug CAHN
	@	150MG	A078982	003	Jan 27, 2009	Aug CAHN
	@	200MG	A078982	004	Jan 27, 2009	Aug CAHN
AB	RUBICON	25MG	A078625	001	Jan 27, 2009	Jul CAHN
AB		100MG	A078625	002	Jan 27, 2009	Jul CAHN
AB		150MG	A078625	003	Jan 27, 2009	Jul CAHN
AB		200MG	A078625	004	Jan 27, 2009	Jul CAHN
	@ TEVA	25MG	A076388	001	Aug 30, 2006	Nov DISC
	@	100MG	A076388	002	Aug 30, 2006	Nov DISC
	@	150MG	A076388	003	Aug 30, 2006	Nov DISC
	@	200MG	A076388	004	Aug 30, 2006	Nov DISC

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

	@ TEVA	5MG	A076420	001	Jun 21, 2006	Jul DISC
	@	25MG	A076420	002	Jun 21, 2006	Jul DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

	@ RUBICON	25MG	A202887	001	Jun 17, 2013	Mar CAHN
	@	50MG	A202887	002	Jun 17, 2013	Mar CAHN
AB		100MG	A202887	003	Jun 17, 2013	Mar CAHN
AB		200MG	A202887	004	Jun 17, 2013	Mar CAHN

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS; ORAL
LANSOPRAZOLE

	@ AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016	Sep DISC
	@	30MG	A203957	002	Oct 14, 2016	Sep DISC
AB	ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan NEWA
AB		30MG	A207394	002	Jan 18, 2019	Jan NEWA
	@ BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018	May DISC
	@	30MG	A203964	002	Oct 17, 2018	May DISC
AB	INVENTIA	15MG	A205868	001	Aug 30, 2017	Aug CAHN
AB		30MG	A205868	002	Aug 30, 2017	Aug CAHN
	@ KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb DISC
	@	30MG	A091212	002	Sep 16, 2013	Feb DISC
AB	XIROMED	15MG	A203203	001	Jul 25, 2016	Aug CAHN
AB		30MG	A203203	002	Jul 25, 2016	Aug CAHN

LAROTRECTINIB

CAPSULE; ORAL

VITRAKVI

+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
+	!	100MG	N210861	002	Nov 26, 2018	Feb CAHN

SOLUTION; ORAL

VITRAKVI

+	!	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
---	---	------------------	---------	---------	-----	--------------	----------

LAROTRECTINIB SULFATE

CAPSULE; ORAL

VITRAKVI

+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CAIN
+		EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CPOT
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CAIN
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CPOT

SOLUTION; ORAL

VITRAKVI

+	!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CAIN
+	!		EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CPOT

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT		AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Aug NEWA
AT		SOMERSET	0.005%	A201786	001	Mar 22, 2011	Oct CAHN

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS; OPHTHALMIC

ROCKLATAN

+	!	AERIE PHARMS INC	0.005%; EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA
---	---	------------------	-----------------------	---------	-----	--------------	----------

LEDIPASVIR; SOFOSBUVIR

PELLETS; ORAL

HARVONI

+		GILEAD SCIENCES INC	33.75MG; 150MG/PACKET	N212477	001	Aug 28, 2019	Aug NEWA
+	!		45MG; 200MG/PACKET	N212477	002	Aug 28, 2019	Aug NEWA

TABLET; ORAL

HARVONI

+		GILEAD SCIENCES INC	45MG; 200MG	N205834	002	Aug 28, 2019	Aug NEWA
---	--	---------------------	-------------	---------	-----	--------------	----------

LEFAMULIN ACETATE

SOLUTION; INTRAVENOUS

XENLETA

+	!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Aug NEWA
---	---	---------	--------------------------------------	---------	-----	--------------	----------

TABLET; ORAL

XENLETA

+	!	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019	Aug NEWA
---	---	---------	---------------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB		ABHAI LLC	10MG	A212453	001	Jun 03, 2019	May NEWA
AB			20MG	A212453	002	Jun 03, 2019	May NEWA
AB		ZYDUS	10MG	A212308	001	Apr 24, 2019	Apr NEWA
AB			20MG	A212308	002	Apr 24, 2019	Apr NEWA

LESINURAD

TABLET; ORAL

ZURAMPIC

+	@	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Apr DISC
---	---	---------------------	-------	---------	-----	--------------	----------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB		EUGIA PHARMA	2.5MG	A211717	001	Jan 11, 2019	Sep CMFD
	@		2.5MG	A211717	001	Jan 11, 2019	Jul DISC
	@	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011	Oct DISC
AB			2.5MG	A090491	001	Jun 03, 2011	Feb CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

	@	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Oct DISC
AP			EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT

LEUPROLIDE ACETATE

FOR SUSPENSION; INTRAMUSCULAR
LUTRATE DEPOT KIT

+ @ GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun DISC
-----------------	-------------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

@ MYLAN SPECIALITY LP	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Oct DISC
@	EQ 0.021% BASE	A077800	002	Mar 15, 2013	Oct DISC
@	EQ 0.042% BASE	A077800	003	Mar 15, 2013	Oct DISC

>A> LEVAMLODIPINE MALEATE

>A> TABLET; ORAL
>A> CONJUPRI

>A> + CSPC OUYI	EQ 1.25MG BASE	N212895	001	Dec 19, 2019	Dec NEWA
>A> +	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Dec NEWA
>A> +!	EQ 5MG BASE	N212895	003	Dec 19, 2019	Dec NEWA

LEVETIRACETAM

INJECTABLE; INTRAVENOUS
KEPPRA

AP	+! UCB INC	500MG/5ML (100MG/ML)	N021872	001	Jul 31, 2006	Jun CDFR
	LEVETIRACETAM					
	@ AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Aug DISC
AP		500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Jun CDFR
AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jun CDFR
AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	Jun CDFR
AP		500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jun CDFR
AP	HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Jun CDFR
AP	HIKMA FARMACEUTICA	500MG/5ML (100MG/ML)	A090981	001	Oct 13, 2011	Jun CDFR
AP	HOSPIRA INC	500MG/5ML (100MG/ML)	A202869	001	Apr 06, 2012	Jun CDFR
AP	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jun CDFR
AP	MICRO LABS	500MG/5ML (100MG/ML)	A211954	001	Aug 09, 2019	Jul NEWA
AP	MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Jun CDFR
AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun CDFR
AP	SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	Jun CDFR
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jun CDFR
	LEVETIRACETAM IN SODIUM CHLORIDE					
AP	AUROBINDO PHARMA LTD	500MG/100ML (5MG/ML)	A207160	001	Jan 04, 2017	Jun CDFR
AP		1000MG/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Jun CDFR
AP		1500MG/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Jun CDFR
AP	GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A206880	001	Oct 25, 2017	Jun CDFR
AP		1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Jun CDFR
AP		1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Jun CDFR
AP	+! HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011	Jun CDFR
AP	+!	1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Jun CDFR
AP	+!	1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Jun CDFR

SOLUTION; ORAL

LEVETIRACETAM

AA	ANDA REPOSITORY	100MG/ML	A079107	001	Jan 15, 2009	Aug CAHN
	TABLET; ORAL					
	LEVETIRACETAM					
AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Oct CTNA
AB		500MG	A090906	001	Nov 05, 2010	Oct CTNA
AB		750MG	A090906	003	Oct 31, 2016	Oct CTNA
AB		1GM	A090906	004	Oct 31, 2016	Oct CTNA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	ANDA REPOSITORY	500MG	A204511	001	Feb 23, 2016	Sep CAHN
AB		750MG	A204511	002	Feb 23, 2016	Sep CAHN
AB	HISUN PHARM HANGZHOU	500MG	A207175	001	Sep 28, 2017	Sep CAHN
AB		750MG	A207175	002	Sep 28, 2017	Sep CAHN
	@ SUN PHARM INDUSTRIES	500MG	A091285	001	Sep 12, 2011	Oct DISC
	@	750MG	A091285	002	Sep 12, 2011	Oct DISC

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

@ SANDOZ INC 0.5%

A074850 001 Oct 28, 1996 May DISC

LEVOCARNITINE

SOLUTION;ORAL
LEVOCARNITINE

AA NOVITIUM PHARMA 1GM/10ML
LEVOCARNITINE SF

A211676 001 Aug 14, 2019 Jul NEWA

AA NOVITIUM PHARMA 1GM/10ML

A211676 002 Aug 14, 2019 Jul NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE HYDROCHLORIDE

AA HETERO LABS LTD III 2.5MG/5ML

A210914 001 Apr 01, 2019 Mar NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP AKORN EQ 500MG/20ML (EQ 25MG/ML)

A091644 001 Jun 20, 2011 Oct CMFD

AP EQ 750MG/30ML (EQ 25MG/ML)

A091644 002 Jun 20, 2011 Oct CMFD

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

MICRO LABS LTD INDIA 1.5%

A205600 001 Feb 27, 2019 Feb NEWA

TABLET;ORAL

LEVOFLOXACIN

AB CELLTRION 250MG

A090367 001 Jun 20, 2011 Aug CAHN

AB 500MG

A090367 002 Jun 20, 2011 Aug CAHN

AB 750MG

A090367 003 Jun 20, 2011 Aug CAHN

AB HEC PHARM 250MG

A204968 001 Feb 05, 2019 Jan NEWA

AB 500MG

A204968 002 Feb 05, 2019 Jan NEWA

AB 750MG

A204968 003 Feb 05, 2019 Jan NEWA

LEVOLEUCOVORIN

POWDER;INTRAVENOUS

KHAPZORY

+! ACROTECH 175MG/VIAL

N211226 001 Oct 19, 2018 Mar CAHN

+! 300MG/VIAL

N211226 002 Oct 19, 2018 Mar CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

FUSILEV

AP +! ACROTECH EQ 50MG BASE/VIAL

N020140 001 Mar 07, 2008 Mar CAHN

LEVOLEUCOVORIN CALCIUM

+ @ ACTAVIS LLC EQ 175MG BASE/VIAL

N208723 001 Sep 29, 2016 Jun DISC

AP MEITHEAL EQ 50MG BASE/VIAL

A211003 001 Aug 22, 2019 Nov CAHN

AP NANJING KING-FRIEND EQ 50MG BASE/VIAL

A211003 001 Aug 22, 2019 Aug NEWA

SOLUTION;INTRAVENOUS

FUSILEV

+ @ ACROTECH EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

N020140 002 Apr 29, 2011 Mar CAHN

+ @ EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

N020140 003 Apr 29, 2011 Mar CAHN

LEVOLEUCOVORIN CALCIUM

AP MEITHEAL EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

A211002 001 Aug 16, 2019 Nov CAHN

AP EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

A211002 002 Aug 16, 2019 Nov CAHN

@ MYLAN TEORANTA EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

A203576 001 Oct 20, 2015 Aug DISC

@ EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

A203576 002 Oct 20, 2015 Aug DISC

AP NANJING KING-FRIEND EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

A211002 001 Aug 16, 2019 Aug NEWA

AP EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

A211002 002 Aug 16, 2019 Aug NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

	+	ALLERGAN	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jun CTEC
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jun CTEC
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jun CTEC
	+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jun CTEC
AB	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CFTG
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CFTG
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CFTG
AB	+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CFTG

LEVOMILNACIPRAN HYDROCHLORIDE

	@	AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jun DISC
AB			EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan NFTG
	@		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jun DISC
AB			EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan NFTG
	@		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jun DISC
AB			EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan NFTG
	@		EQ 120MG BASE	A210790	004	Feb 04, 2019	Jun DISC
AB			EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan NFTG

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

AB	!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May CAHN
>D> AB		LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Dec DISC
>A>	@		0.75MG	A202684	001	Sep 02, 2016	Dec DISC

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

	@	SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb DISC
	!		3MG	A074278	003	Jun 18, 2018	May CMFD
	@		3MG	A074278	003	Jun 18, 2018	Feb DISC
>A> AB		SPECGX LLC	2MG	A212024	001	Dec 13, 2019	Dec NEWA

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

@ PAR STERILE PRODUCTS 200MCG/VIAL

A205366 001 Dec 07, 2015 Apr DISC

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

+	!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019	Apr NEWA
+	!		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019	Apr NEWA
+	!		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019	Apr NEWA

SOLUTION;ORAL

TIROSINT-SOL

+		INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jan CMFD
+			25MCG/ML	N206977	002	Dec 15, 2016	Jan CMFD
+			50MCG/ML	N206977	003	Dec 15, 2016	Jan CMFD
+			75MCG/ML	N206977	004	Dec 15, 2016	Jan CMFD
+			88MCG/ML	N206977	005	Dec 15, 2016	Jan CMFD
+			100MCG/ML	N206977	006	Dec 15, 2016	Jan CMFD
+			112MCG/ML	N206977	007	Dec 15, 2016	Jan CMFD
+			125MCG/ML	N206977	008	Dec 15, 2016	Jan CMFD
+			137MCG/ML	N206977	009	Dec 15, 2016	Jan CMFD
+			150MCG/ML	N206977	010	Dec 15, 2016	Jan CMFD
+			175MCG/ML	N206977	011	Dec 15, 2016	Jan CMFD
+	!		200MCG/ML	N206977	012	Dec 15, 2016	Jan CMFD

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVO-T

>D> AB1,	+	CEDIPROF INC	0.025MG	N021342	001	Mar 01, 2002	Dec CRLD
AB2,							
AB3							
>A> AB1,			0.025MG	N021342	001	Mar 01, 2002	Dec CRLD
AB2,							
AB3							
>D> AB1,	+		0.05MG	N021342	002	Mar 01, 2002	Dec CRLD

TABLET;ORAL
LEVO-T

AB2, AB3 >A> AB1,	0.05MG	N021342	002	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.075MG	N021342	003	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.075MG	N021342	003	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.088MG	N021342	004	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.088MG	N021342	004	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.1MG	N021342	005	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.1MG	N021342	005	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.112MG	N021342	006	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.112MG	N021342	006	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.125MG	N021342	007	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.125MG	N021342	007	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.137MG	N021342	012	Dec 08, 2003	Dec CRLD
AB2, AB3 >A> AB1,	0.137MG	N021342	012	Dec 08, 2003	Dec CRLD
AB2, AB3 >D> AB1, +	0.15MG	N021342	008	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.15MG	N021342	008	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.175MG	N021342	009	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.175MG	N021342	009	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +	0.2MG	N021342	010	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.2MG	N021342	010	Mar 01, 2002	Dec CRLD
AB2, AB3 >D> AB1, +!	0.3MG	N021342	011	Mar 01, 2002	Dec CRLD
AB2, AB3 >A> AB1,	0.3MG	N021342	011	Mar 01, 2002	Dec CHRS
AB2, AB3 >A> AB1, !	0.3MG	N021342	011	Mar 01, 2002	Dec CRLD
AB2, AB3					
LEVOTHYROXINE SODIUM					
@ AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Jun DISC
AB2	0.025MG	A210831	001	Feb 19, 2019	May CTEC
AB1, AB2	0.025MG	A210831	001	Feb 19, 2019	Feb NEWA
@	0.05MG	A210831	002	Feb 19, 2019	Jun DISC
AB2	0.05MG	A210831	002	Feb 19, 2019	May CTEC
AB1, AB2	0.05MG	A210831	002	Feb 19, 2019	Feb NEWA
@	0.075MG	A210831	003	Feb 19, 2019	Jun DISC
AB2	0.075MG	A210831	003	Feb 19, 2019	May CTEC

TABLET;ORAL							
LEVOTHYROXINE SODIUM							
AB1, AB2		0.075MG	A210831	003	Feb 19, 2019	Feb	NEWA
@		0.088MG	A210831	004	Feb 19, 2019	Jun	DISC
AB2		0.088MG	A210831	004	Feb 19, 2019	May	CTEC
AB1, AB2		0.088MG	A210831	004	Feb 19, 2019	Feb	NEWA
@		0.1MG	A210831	005	Feb 19, 2019	Jun	DISC
AB2		0.1MG	A210831	005	Feb 19, 2019	May	CTEC
AB1, AB2		0.1MG	A210831	005	Feb 19, 2019	Feb	NEWA
@		0.112MG	A210831	006	Feb 19, 2019	Jun	DISC
AB2		0.112MG	A210831	006	Feb 19, 2019	May	CTEC
AB1, AB2		0.112MG	A210831	006	Feb 19, 2019	Feb	NEWA
@		0.125MG	A210831	007	Feb 19, 2019	Jun	DISC
AB2		0.125MG	A210831	007	Feb 19, 2019	May	CTEC
AB1, AB2		0.125MG	A210831	007	Feb 19, 2019	Feb	NEWA
@		0.137MG	A210831	008	Feb 19, 2019	Jun	DISC
AB2		0.137MG	A210831	008	Feb 19, 2019	May	CTEC
AB1, AB2		0.137MG	A210831	008	Feb 19, 2019	Feb	NEWA
@		0.15MG	A210831	009	Feb 19, 2019	Jun	DISC
AB2		0.15MG	A210831	009	Feb 19, 2019	May	CTEC
AB1, AB2		0.15MG	A210831	009	Feb 19, 2019	Feb	NEWA
@		0.175MG	A210831	010	Feb 19, 2019	Jun	DISC
AB2		0.175MG	A210831	010	Feb 19, 2019	May	CTEC
AB1, AB2		0.175MG	A210831	010	Feb 19, 2019	Feb	NEWA
@		0.2MG	A210831	011	Feb 19, 2019	Jun	DISC
AB2		0.2MG	A210831	011	Feb 19, 2019	May	CTEC
AB1, AB2		0.2MG	A210831	011	Feb 19, 2019	Feb	NEWA
@		0.3MG	A210831	012	Feb 19, 2019	Jun	DISC
AB2		0.3MG	A210831	012	Feb 19, 2019	May	CTEC
AB1, AB2		0.3MG	A210831	012	Feb 19, 2019	Feb	NEWA
AB1, AB2, AB3	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Oct	CTEC
AB1, AB2		0.025MG	A209713	001	Jan 18, 2019	Sep	CTEC
AB2		0.025MG	A209713	001	Jan 18, 2019	Jan	NEWA
AB1, AB2, AB3		0.05MG	A209713	002	Jan 18, 2019	Oct	CTEC
AB1, AB2		0.05MG	A209713	002	Jan 18, 2019	Sep	CTEC
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan	NEWA
AB1, AB2, AB3		0.075MG	A209713	003	Jan 18, 2019	Oct	CTEC
AB1, AB2		0.075MG	A209713	003	Jan 18, 2019	Sep	CTEC
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan	NEWA
AB1, AB2, AB3		0.088MG	A209713	004	Jan 18, 2019	Oct	CTEC
AB1, AB2		0.088MG	A209713	004	Jan 18, 2019	Sep	CTEC
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan	NEWA
AB1, AB2, AB3		0.1MG	A209713	005	Jan 18, 2019	Oct	CTEC
AB1, AB2		0.1MG	A209713	005	Jan 18, 2019	Sep	CTEC
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan	NEWA
AB1, AB2, AB3		0.112MG	A209713	006	Jan 18, 2019	Oct	CTEC
AB1, AB2		0.112MG	A209713	006	Jan 18, 2019	Sep	CTEC
AB2		0.112MG	A209713	006	Jan 18, 2019	Jan	NEWA
AB1, AB2, AB3		0.125MG	A209713	007	Jan 18, 2019	Oct	CTEC

TABLET;ORAL						
LEVOTHYROXINE SODIUM						
AB1,		0.125MG	A209713	007	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.125MG	A209713	007	Jan 18, 2019	Jan NEWA
AB1,		0.137MG	A209713	008	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.137MG	A209713	008	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.137MG	A209713	008	Jan 18, 2019	Jan NEWA
AB1,		0.15MG	A209713	009	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.15MG	A209713	009	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.15MG	A209713	009	Jan 18, 2019	Jan NEWA
AB1,		0.175MG	A209713	010	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.175MG	A209713	010	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.175MG	A209713	010	Jan 18, 2019	Jan NEWA
AB1,		0.2MG	A209713	011	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.2MG	A209713	011	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.2MG	A209713	011	Jan 18, 2019	Jan NEWA
AB1,		0.3MG	A209713	012	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.3MG	A209713	012	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan NEWA
THYRO-TABS						
AB2, +	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.088MG	N021116	010	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.1MG	N021116	004	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.112MG	N021116	011	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.125MG	N021116	005	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.137MG	N021116	012	Dec 07, 2004	Mar CAHN
AB4						
AB2, +		0.15MG	N021116	006	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.175MG	N021116	007	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.2MG	N021116	008	Oct 24, 2002	Mar CAHN
AB4						
AB2, +!		0.3MG	N021116	009	Oct 24, 2002	Mar CAHN
AB4						
AB2, +	LLOYD	0.025MG	N021116	001	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.088MG	N021116	010	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.1MG	N021116	004	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.112MG	N021116	011	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.125MG	N021116	005	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.137MG	N021116	012	Dec 07, 2004	Feb CMFD
AB4						
AB2, +		0.15MG	N021116	006	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.175MG	N021116	007	Oct 24, 2002	Feb CMFD
AB4						
AB2, +		0.2MG	N021116	008	Oct 24, 2002	Feb CMFD

TABLET;ORAL							
THYRO-TABS							
AB4							
AB2, +!		0.3MG		N021116	009	Oct 24, 2002	Feb CMFD
AB4							
<u>LIDOCAINE</u>							
OINTMENT;TOPICAL							
LIDOCAINE							
AT	NOVAST LABS	5%		A208604	001	Sep 20, 2017	Sep CAHN
AT	SUNGEN PHARMA	5.0%		A212486	001	Oct 17, 2019	Oct NEWA
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE							
AP	FRESENIUS KABI USA	1%		A080404	002		Jun CTNA
AP		2%		A080404	003		Jun CTNA
AP	! HOSPIRA	1%		A083158	001		Sep CHRS
AP	!	2%		A083158	002		Sep CHRS
	@	20%		A083158	003		Sep DISC
	@ LUITPOLD	1%		A080850	001		Mar DISC
	@	1%		A091564	001	Aug 14, 2015	Feb DISC
XYLOCAINE PRESERVATIVE FREE							
+ @	FRESENIUS KABI USA	1%		N016801	005	Jan 19, 1988	Sep DISC
+ @		2%		N016801	001		Sep DISC
+ @		4%		N016801	002		Sep DISC
+ @		20%		N016801	004		Sep DISC
JELLY;TOPICAL							
ANESTACON							
	@ BIONPHARMA INC	2%		A080429	001		Apr CAHN
SOLUTION;ORAL							
XYLOCAINE VISCOUS							
+ @	FRESENIUS KABI USA	2%		N009470	001		Aug CRLD
SOLUTION;TOPICAL							
LIDOCAINE HYDROCHLORIDE							
AT	LANNETT CO INC	4%		A040710	001	Feb 27, 2007	Sep CMFD
<u>LIDOCAINE; PRILOCAINE</u>							
CREAM;TOPICAL							
EMLA							
AB	+! TEVA BRANDED PHARM	2.5%;2.5%		N019941	001	Dec 30, 1992	Apr CAHN
<u>LIFITEGRAST</u>							
SOLUTION/DROPS;OPHTHALMIC							
XIIDRA							
+!	NOVARTIS	5%		N208073	001	Jul 11, 2016	Sep CAHN
<u>LINEZOLID</u>							
TABLET;ORAL							
LINEZOLID							
AB	CELLTRION	600MG		A210702	001	Apr 25, 2019	Apr NEWA
	@ MYLAN	600MG		A078845	001	Dec 21, 2015	Jun DISC
<u>LIOETHYRONINE SODIUM</u>							
TABLET;ORAL							
CYTOMEL							
AB	+ KING PHARMS	EQ 0.05MG BASE		N010379	003		Jun CHRS
LIOETHYRONINE SODIUM							
	@ MYLAN	EQ 0.005MG BASE		A090326	001	Jul 14, 2009	Mar DISC
	@	EQ 0.025MG BASE		A090326	002	Jul 14, 2009	Mar DISC
	@	EQ 0.05MG BASE		A090326	003	Jul 14, 2009	Mar DISC
AB	! SIGMAPHARM LABS LLC	EQ 0.05MG BASE		A200295	003	Nov 29, 2012	Jun CHRS
	@ SUN PHARM	EQ 0.005MG BASE		A091382	001	Apr 20, 2016	Jun DISC
	@	EQ 0.025MG BASE		A091382	002	Apr 20, 2016	Jun DISC
	@	EQ 0.05MG BASE		A091382	003	Apr 20, 2016	Jun DISC
	@ TEVA PHARMS USA	EQ 0.005MG BASE		A211510	001	Oct 26, 2018	Apr DISC
	@	EQ 0.025MG BASE		A211510	002	Oct 26, 2018	Apr DISC
	@	EQ 0.05MG BASE		A211510	003	Oct 26, 2018	Apr DISC

LISINOPRIL

TABLET;ORAL

LISINOPRIL

	@ HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug DISC
AB		2.5MG	A075752	001	Jul 01, 2002	Feb CAHN
	@	5MG	A075752	002	Jul 01, 2002	Aug DISC
AB		5MG	A075752	002	Jul 01, 2002	Feb CAHN
	@	10MG	A075752	003	Jul 01, 2002	Aug DISC
AB		10MG	A075752	003	Jul 01, 2002	Feb CAHN
	@	20MG	A075752	004	Jul 01, 2002	Aug DISC
AB		20MG	A075752	004	Jul 01, 2002	Feb CAHN
	@	30MG	A075752	005	Jul 01, 2002	Aug DISC
AB		30MG	A075752	005	Jul 01, 2002	Feb CAHN
	@	40MG	A075752	006	Jul 01, 2002	Aug DISC
AB		40MG	A075752	006	Jul 01, 2002	Feb CAHN
>D> AB	HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002	Dec DISC
>A>	@	2.5MG	A076063	001	Jul 01, 2002	Dec DISC
>D> AB		5MG	A076063	002	Jul 01, 2002	Dec DISC
>A>	@	5MG	A076063	002	Jul 01, 2002	Dec DISC
>D> AB		10MG	A076063	003	Jul 01, 2002	Dec DISC
>A>	@	10MG	A076063	003	Jul 01, 2002	Dec DISC
>D> AB		20MG	A076063	004	Jul 01, 2002	Dec DISC
>A>	@	20MG	A076063	004	Jul 01, 2002	Dec DISC
>D> AB		30MG	A076063	006	Jun 27, 2003	Dec DISC
>A>	@	30MG	A076063	006	Jun 27, 2003	Dec DISC
>D> AB		40MG	A076063	005	Jul 01, 2002	Dec DISC
>A>	@	40MG	A076063	005	Jul 01, 2002	Dec DISC
>A>	@ INVATECH	2.5MG	A075903	001	Jul 01, 2002	Dec CAHN
>A>	@	2.5MG	A075999	001	Jul 01, 2002	Dec CAHN
>A>	@	5MG	A075903	002	Jul 01, 2002	Dec CAHN
>A>	@	5MG	A075999	002	Jul 01, 2002	Dec CAHN
>A>	@	10MG	A075903	003	Jul 01, 2002	Dec CAHN
>A>	@	10MG	A075999	003	Jul 01, 2002	Dec CAHN
>A>	@	20MG	A075903	004	Jul 01, 2002	Dec CAHN
>A>	@	20MG	A075999	004	Jul 01, 2002	Dec CAHN
>A>	@	30MG	A075903	005	Jul 01, 2002	Dec CAHN
>A>	@	30MG	A075999	005	Jul 01, 2002	Dec CAHN
>A>	@	40MG	A075903	006	Jul 01, 2002	Dec CAHN
>A>	@	40MG	A075999	006	Jul 01, 2002	Dec CAHN
	@ MYLAN	2.5MG	A076071	001	Jul 01, 2002	Aug DISC
	@	5MG	A076071	002	Jul 01, 2002	Aug DISC
	@	10MG	A076071	003	Jul 01, 2002	Aug DISC
	@	20MG	A076071	004	Jul 01, 2002	Aug DISC
	@	30MG	A076071	005	Jul 01, 2002	Aug DISC
	@	40MG	A076071	006	Jul 01, 2002	Aug DISC
>D>	@ SANDOZ	2.5MG	A075903	001	Jul 01, 2002	Dec CAHN
>D>	@	2.5MG	A075999	001	Jul 01, 2002	Dec CAHN
>D>	@	5MG	A075903	002	Jul 01, 2002	Dec CAHN
>D>	@	5MG	A075999	002	Jul 01, 2002	Dec CAHN
>D>	@	10MG	A075903	003	Jul 01, 2002	Dec CAHN
>D>	@	10MG	A075999	003	Jul 01, 2002	Dec CAHN
>D>	@	20MG	A075903	004	Jul 01, 2002	Dec CAHN
>D>	@	20MG	A075999	004	Jul 01, 2002	Dec CAHN
>D>	@	30MG	A075903	005	Jul 01, 2002	Dec CAHN
>D>	@	30MG	A075999	005	Jul 01, 2002	Dec CAHN
>D>	@	40MG	A075903	006	Jul 01, 2002	Dec CAHN
>D>	@	40MG	A075999	006	Jul 01, 2002	Dec CAHN
	PRINIVIL					
	@ MERCK	10MG	N019558	002	Dec 29, 1987	Oct DISC
	@	20MG	N019558	003	Dec 29, 1987	Oct DISC

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

@ MYLAN 600MG

A078763 001 Apr 15, 2008 Jun DISC

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

@ HERITAGE PHARMA 300MG

A076170 001 Jun 10, 2002 May CAHN

@ 450MG

A076366 001 Aug 21, 2003 May CAHN

LORAZEPAMCONCENTRATE; ORAL
LORAZEPAM

AA	LANNETT CO INC	2MG/ML	A 079244	001	Apr 28, 2009	Jul CAHN
AA	SAPTALIS PHARMS	2MG/ML	A 079244	001	Apr 28, 2009	Feb CAHN

INJECTABLE; INJECTION
ATIVAN

AP	+! HIKMA	2MG/ML	N 018140	001		Mar CAHN
AP	+!	4MG/ML	N 018140	002		Mar CAHN

TABLET; ORAL
ATIVAN

AB	+ BAUSCH	0.5MG	N 017794	001		Feb CAHN
AB	+	1MG	N 017794	002		Feb CAHN
AB	+!	2MG	N 017794	003		Feb CAHN

LORAZEPAM

>D> AB	ANI PHARMS INC	0.5MG	A 077396	001	Dec 13, 2006	Dec DISC
>A>	@	0.5MG	A 077396	001	Dec 13, 2006	Dec DISC
>D> AB		1MG	A 077396	002	Dec 13, 2006	Dec DISC
>A>	@	1MG	A 077396	002	Dec 13, 2006	Dec DISC
>D> AB		2MG	A 077396	003	Dec 13, 2006	Dec DISC
>A>	@	2MG	A 077396	003	Dec 13, 2006	Dec DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

	@ HISUN PHARM HANGZHOU	25MG	A 204795	001	Apr 04, 2019	Oct DISC
AB		25MG	A 204795	001	Apr 04, 2019	Mar NEWA
	@	50MG	A 204795	002	Apr 04, 2019	Oct DISC
AB		50MG	A 204795	002	Apr 04, 2019	Mar NEWA
	@	100MG	A 204795	003	Apr 04, 2019	Oct DISC
AB		100MG	A 204795	003	Apr 04, 2019	Mar NEWA
AB	MICRO LABS	25MG	A 091541	001	Sep 24, 2012	Mar CAHN
AB		50MG	A 091541	002	Sep 24, 2012	Mar CAHN
AB		100MG	A 091541	003	Sep 24, 2012	Mar CAHN
AB	STRIDES PHARMA	25MG	A 090382	001	Oct 06, 2010	Apr CAHN
AB		50MG	A 090382	002	Oct 06, 2010	Apr CAHN
AB		100MG	A 090382	003	Oct 06, 2010	Apr CAHN
	@ TEVA	25MG	A 076958	001	Apr 06, 2010	Jul DISC
	@	50MG	A 076958	002	Apr 06, 2010	Jul DISC
	@	100MG	A 076958	003	Apr 06, 2010	Jul DISC

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX SM

	+! BAUSCH AND LOMB INC	0.38%	N 208219	001	Feb 22, 2019	Feb NEWA
	SUSPENSION/DROPS; OPHTHALMIC					
	LOTEMAX					
AB	+! BAUSCH AND LOMB	0.5%	N 020583	001	Mar 09, 1998	Apr CFTG
	LOTEPREDNOL ETABONATE					
AB	HI TECH	0.5%	A 207609	001	Apr 17, 2019	Apr NFTG

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	BEXIMCO PHARMS USA	10MG	A 075300	001	Dec 17, 2001	Feb CAHN
AB		20MG	A 075300	002	Dec 17, 2001	Feb CAHN
AB		40MG	A 075300	003	Dec 17, 2001	Feb CAHN
	@ MYLAN	10MG	A 075451	001	Dec 17, 2001	Feb DISC
	@	20MG	A 075451	002	Dec 17, 2001	Feb DISC
	@	40MG	A 075451	003	Dec 17, 2001	Feb DISC
	@ SUN PHARM INDUSTRIES	10MG	A 077520	001	Apr 14, 2006	Oct DISC
	@	20MG	A 077520	002	Apr 14, 2006	Oct DISC
	@	40MG	A 077520	003	Apr 14, 2006	Oct DISC

LOXAPINEPOWDER; INHALATION
ADASUVE

+!	ALEXZA PHARMS	10MG	N 022549	001	Dec 21, 2012	Aug CAHN
----	---------------	------	----------	-----	--------------	----------

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

@ TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001		Feb CAHN
----------------------	-----------------	---------	-----	--	----------

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXITANE

+ @ TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001		Feb CAHN
+ @	EQ 10MG BASE	N017525	002		Feb CAHN
+ @	EQ 25MG BASE	N017525	003		Feb CAHN
+ @	EQ 50MG BASE	N017525	004		Feb CAHN

TABLET;ORAL

LOXITANE

+ @ TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006		Feb CAHN
+ @	EQ 25MG BASE	N017525	007		Feb CAHN
+ @	EQ 50MG BASE	N017525	008		Feb CAHN
+ @	EQ 50MG BASE	N017525	008		Feb CAHN

>A> LUMATEPERONE TOSYLATE

>A> CAPSULE;ORAL

>A> CAPLYTA

>A>	+!	INTRA-CELLULAR	EQ 42MG BASE	N209500	001	Dec 20, 2019	Dec NEWA
-----	----	----------------	--------------	---------	-----	--------------	----------

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

	@	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Jun DISC
	@		40MG	A208002	002	Jan 03, 2019	Jun DISC
	@		60MG	A208002	003	Jan 03, 2019	Jun DISC
	@		80MG	A208002	004	Jan 03, 2019	Jun DISC
	@		120MG	A208002	005	Jan 03, 2019	Jun DISC
	@	EMCURE PHARMS LTD	20MG	A208058	001	Sep 04, 2019	Sep DISC
AB			20MG	A208058	001	Sep 04, 2019	Aug NEWA
	@		40MG	A208058	002	Sep 04, 2019	Sep DISC
AB			40MG	A208058	002	Sep 04, 2019	Aug NEWA
	@		60MG	A208058	003	Sep 04, 2019	Sep DISC
AB			60MG	A208058	003	Sep 04, 2019	Aug NEWA
	@		80MG	A208058	004	Sep 04, 2019	Sep DISC
AB			80MG	A208058	004	Sep 04, 2019	Aug NEWA
	@	INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Jul DISC
	@		40MG	A208028	002	Jan 03, 2019	Jul DISC
	@		60MG	A208028	003	Jan 03, 2019	Jul DISC
	@		80MG	A208028	004	Jan 03, 2019	Jul DISC
	@		120MG	A208028	005	Jan 03, 2019	Jul DISC
	@	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Jul DISC
	@		40MG	A208031	002	Jan 03, 2019	Jul DISC
	@		60MG	A208031	003	Jan 03, 2019	Jul DISC
	@		80MG	A208031	004	Jan 03, 2019	Jul DISC
	@		120MG	A208031	005	Jan 03, 2019	Jul DISC
	@	TEVA PHARMS USA	20MG	A208060	001	May 17, 2019	Nov DISC
AB			20MG	A208060	001	May 17, 2019	May NEWA
	@		40MG	A208060	002	May 17, 2019	Nov DISC
AB			40MG	A208060	002	May 17, 2019	May NEWA
	@		60MG	A208060	003	May 17, 2019	Nov DISC
AB			60MG	A208060	003	May 17, 2019	May NEWA
	@		80MG	A208060	004	May 17, 2019	Nov DISC
AB			80MG	A208060	004	May 17, 2019	May NEWA
	@		120MG	A208060	005	May 17, 2019	Nov DISC
AB			120MG	A208060	005	May 17, 2019	May NEWA
	@	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb DISC
	@		40MG	A208055	002	Jan 03, 2019	Feb DISC
	@		80MG	A208055	003	Jan 03, 2019	Feb DISC
	@		120MG	A208055	004	Jan 03, 2019	Feb DISC
	@	ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Aug DISC
AB			20MG	A208052	001	Mar 19, 2019	Mar NEWA
	@		40MG	A208052	002	Mar 19, 2019	Aug DISC
AB			40MG	A208052	002	Mar 19, 2019	Mar NEWA
	@		60MG	A208052	003	Mar 19, 2019	Aug DISC
AB			60MG	A208052	003	Mar 19, 2019	Mar NEWA
	@		80MG	A208052	004	Mar 19, 2019	Aug DISC
AB			80MG	A208052	004	Mar 19, 2019	Mar NEWA

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

	@	120MG	A208052	005	Mar 19, 2019	Aug DISC
AB		120MG	A208052	005	Mar 19, 2019	Mar NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan CTEC
AP		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan CTEC

MALATHION

LOTION;TOPICAL

MALATHION

!	SUVEN LIFE	0.5%	A091559	001	May 23, 2012	Aug CHRS
		0.5%	A091559	001	May 23, 2012	Aug CTEC

OVIDE

+	@	TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	Aug DISC
---	---	---------------------	------	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION

MANNITOL 25%

@	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982	Mar DISC
---	----------	-------------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	12.5MG	N010721	006		Feb CMFD
	+	@	12.5MG	N010721	006		Jan CRLD
AA	+		25MG	N010721	004		Feb CMFD
	+	@	25MG	N010721	004		Jan CRLD
AA	+		50MG	N010721	001	Jan 20, 1982	Feb CMFD
	+	@	50MG	N010721	001	Jan 20, 1982	Jan CRLD
		MECLIZINE HYDROCHLORIDE					
AA	!	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Jan CHRS
AA	!		25MG	A201451	002	Feb 23, 2011	Jan CHRS
	@	ANI PHARMS INC	12.5MG	A084657	002		Sep CMS1
	@		12.5MG	A088732	001	Dec 11, 1985	May CAHN
AA		AUREX	12.5MG	A087127	001		Oct CAHN
AA			25MG	A087128	001		Oct CAHN
AA		INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Feb NEWA
AA			25MG	A205136	002	Feb 22, 2019	Feb NEWA
			50MG	A205136	003	Feb 22, 2019	Feb NEWA
>A> AA		INVATECH	25MG	A084092	003	May 22, 1989	Dec CAHN
>D> AA		SANDOZ	25MG	A084092	003	May 22, 1989	Dec CAHN

TABLET, CHEWABLE;ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	25MG	N010721	005		Feb CMFD
	+	@	25MG	N010721	005		Jan CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

	@	CIPLA	150MG/ML	A210335	001	Jan 25, 2019	Jul DISC
AB			150MG/ML	A210335	001	Jan 25, 2019	Jan NEWA
AB		SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Apr NEWA
AB			150MG/ML	A210761	001	Apr 24, 2019	Apr NEWA

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

@	UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984	Jul CAHN
---	-------------------	------	---------	-----	--------------	----------

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

@	BRECKENRIDGE	250MG	A090359	001	Feb 05, 2013	Feb DISC
---	--------------	-------	---------	-----	--------------	----------

MELOXICAM

CAPSULE;ORAL

VIVLODEX

+	EGALET	5MG	N207233	001	Oct 22, 2015	Feb CAHN
+	!	10MG	N207233	002	Oct 22, 2015	Feb CAHN
+	ZYLA	5MG	N207233	001	Oct 22, 2015	Jul CAHN

CAPSULE; ORAL							
VIVLODEX							
	+!	10MG	N207233	002	Oct 22, 2015	Jul	CAHN
SUSPENSION; ORAL							
MOBIC							
	+ @	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	Jun CAHN
TABLET; ORAL							
MELOXICAM							
	@	HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006	Sep DISC
AB			7.5MG	A077936	001	Jul 19, 2006	Feb CAHN
	@		15MG	A077936	002	Jul 19, 2006	Sep DISC
AB			15MG	A077936	002	Jul 19, 2006	Feb CAHN
<u>MELPHALAN HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
ALKERAN							
AP	+	APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Feb CMFD
MELPHALAN HYDROCHLORIDE							
AP		ALVOGEN INC	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	May NEWA
AP		GLAND PHARMA LTD	EQ 50MG BASE/VIAL	A209826	001	May 28, 2019	May NEWA
AP		NORATECH	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep NEWA
	@	US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Oct DISC
AP			EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Apr NEWA
POWDER; INTRAVENOUS							
EVOMELA							
	+!	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar CAHN
<u>MEMANTINE HYDROCHLORIDE</u>							
SOLUTION; ORAL							
MEMANTINE HYDROCHLORIDE							
AA	!	LANNETT CO INC	2MG/ML	A204033	001	Oct 13, 2015	Nov CHRS
	@	TORRENT	2MG/ML	A205446	001	Dec 07, 2015	Nov DISC
AA	!		2MG/ML	A205446	001	Dec 07, 2015	Jan CAHN
TABLET; ORAL							
MEMANTINE HYDROCHLORIDE							
	@	APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jan DISC
	@		10MG	A090244	002	Jul 11, 2018	Jan DISC
AB		CADILA	5MG	A090961	001	Jul 10, 2017	Feb CAHN
AB			10MG	A090961	002	Jul 10, 2017	Feb CAHN
AB		CELLTRION	5MG	A090073	001	Sep 04, 2015	Aug CAHN
AB			10MG	A090073	002	Sep 04, 2015	Aug CAHN
	@	MYLAN	5MG	A079225	001	Jan 30, 2015	Oct DISC
	@		10MG	A079225	002	Jan 30, 2015	Oct DISC
<u>MEPERIDINE HYDROCHLORIDE</u>							
TABLET; ORAL							
DEMEROL							
	+ @	US PHARM HOLDINGS	50MG	N005010	001		Aug DISC
	+ @		100MG	N005010	004		Aug DISC
MEPERIDINE HYDROCHLORIDE							
	@	SPECGX LLC	50MG	A040352	001	Jun 13, 2000	Aug DISC
	@		100MG	A040352	002	Jun 13, 2000	Aug DISC
	@	SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002	Oct DISC
	@		100MG	A040446	002	Aug 08, 2002	Oct DISC
<u>MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
MEPERGAN							
	@	HIKMA	25MG/ML; 25MG/ML	N011730	001		Jun CAHN
<u>MEQUINOL; TRETINOIN</u>							
SOLUTION; TOPICAL							
SOLAGE							
	@	ALMIRALL	2%; 0.01%	N020922	001	Dec 10, 1999	Feb CAHN
<u>MEROPENEM</u>							
INJECTABLE; INJECTION							
MEROPENEM							
	@	HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010	Sep DISC
	@		1GM/VIAL	A090940	002	Jun 22, 2010	Sep DISC
AP		HQ SPCLT PHARMA	500MG/VIAL	A210773	001	Aug 16, 2019	Aug NEWA
AP			1GM/VIAL	A210773	002	Aug 16, 2019	Aug NEWA

MESALAMINECAPSULE, DELAYED RELEASE;ORAL
DELZICOL

AB	+!	APIL	400MG	N204412	001	Feb 01, 2013	Apr CFTG
----	----	------	-------	---------	-----	--------------	----------

AB		TEVA PHARMS USA	400MG	A207873	001	May 09, 2019	Apr NFTG
----	--	-----------------	-------	---------	-----	--------------	----------

CAPSULE, EXTENDED RELEASE;ORAL
APRISO

AB	+!	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008	Nov CFTG
----	----	---------------------	-------	---------	-----	--------------	----------

AB		MYLAN	375MG	A207271	001	Nov 20, 2019	Nov NFTG
----	--	-------	-------	---------	-----	--------------	----------

SUPPOSITORY;RECTAL
MESALAMINE

>A>	AB		AMNEAL PHARMS LLC	1GM	A210509	001	Jan 02, 2020	Dec NEWA
-----	----	--	-------------------	-----	---------	-----	--------------	----------

AB		AMRING PHARMS	1GM	A208362	001	Jun 21, 2019	Jun NEWA
----	--	---------------	-----	---------	-----	--------------	----------

AB		PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Apr NEWA
----	--	----------------	-----	---------	-----	--------------	----------

AB		SANDOZ INC	1GM	A202065	001	Jun 12, 2019	May NEWA
----	--	------------	-----	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL
MESALAMINE

>D>		@	SUN PHARM	1.2GM	A211858	001	Jan 25, 2019	Dec CMFD
-----	--	---	-----------	-------	---------	-----	--------------	----------

>A>	AB			1.2GM	A211858	001	Jan 25, 2019	Dec CMFD
-----	----	--	--	-------	---------	-----	--------------	----------

		@		1.2GM	A211858	001	Jan 25, 2019	Aug DISC
--	--	---	--	-------	---------	-----	--------------	----------

AB				1.2GM	A211858	001	Jan 25, 2019	Jan NEWA
----	--	--	--	-------	---------	-----	--------------	----------

MESTRANOL; NORETHINDRONE

TABLET;ORAL-28

NORINYL 1+50 28-DAY

		+	@	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001	Jul DISC
--	--	---	---	---------------------	------------	---------	-----	----------

METAPROTERENOL SULFATE

TABLET;ORAL

METAPROTERENOL SULFATE

	@	HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990	May CAHN
--	---	-----------------	------	---------	-----	--------------	----------

	@		20MG	A072520	001	Mar 30, 1990	May CAHN
--	---	--	------	---------	-----	--------------	----------

	@	PAR PHARM	10MG	A072024	001	Jun 28, 1988	Jul DISC
--	---	-----------	------	---------	-----	--------------	----------

	@		20MG	A072025	001	Jun 28, 1988	Jul DISC
--	---	--	------	---------	-----	--------------	----------

METAXALONE

TABLET;ORAL

METAXALONE

AB		APPCO	800MG	A208774	001	Sep 24, 2018	Feb CAHN
----	--	-------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDEFOR SUSPENSION, EXTENDED RELEASE;ORAL
RIOMET ER

		+	!	SUN PHARM	500MG/5ML	N212595	001	Aug 29, 2019	Aug NEWA
--	--	---	---	-----------	-----------	---------	-----	--------------	----------

TABLET;ORAL

GLUCOPHAGE

	+	@	BRISTOL MYERS SQUIBB	500MG	N020357	001	Mar 03, 1995	Jun DISC
--	---	---	----------------------	-------	---------	-----	--------------	----------

	+	@		850MG	N020357	002	Mar 03, 1995	Jun DISC
--	---	---	--	-------	---------	-----	--------------	----------

	+	@		1GM	N020357	005	Nov 05, 1998	Jun DISC
--	---	---	--	-----	---------	-----	--------------	----------

	+	@	EMD SERONO INC	500MG	N020357	001	Mar 03, 1995	Jul CAHN
--	---	---	----------------	-------	---------	-----	--------------	----------

	+	@		625MG	N020357	003	Nov 05, 1998	Jul CAHN
--	---	---	--	-------	---------	-----	--------------	----------

	+	@		750MG	N020357	004	Nov 05, 1998	Jul CAHN
--	---	---	--	-------	---------	-----	--------------	----------

	+	@		850MG	N020357	002	Mar 03, 1995	Jul CAHN
--	---	---	--	-------	---------	-----	--------------	----------

	+	@		1GM	N020357	005	Nov 05, 1998	Jul CAHN
--	---	---	--	-----	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

AB	!	GRANULES INDIA	1GM	A090564	003	Apr 22, 2010	Jun CHRS
----	---	----------------	-----	---------	-----	--------------	----------

AB		HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Feb CAHN
----	--	-----------------	-------	---------	-----	--------------	----------

AB			850MG	A075978	002	Jan 25, 2002	Feb CAHN
----	--	--	-------	---------	-----	--------------	----------

AB			1GM	A075978	003	Nov 05, 2002	Feb CAHN
----	--	--	-----	---------	-----	--------------	----------

	@	SUN PHARM INDUSTRIES	500MG	A076038	001	Feb 21, 2002	Oct DISC
--	---	----------------------	-------	---------	-----	--------------	----------

	@		850MG	A076038	002	Feb 21, 2002	Oct DISC
--	---	--	-------	---------	-----	--------------	----------

	@		1GM	A076038	003	Feb 21, 2002	Oct DISC
--	---	--	-----	---------	-----	--------------	----------

	@	SUNSHINE LAKE	500MG	A208999	001	Oct 12, 2018	Apr DISC
--	---	---------------	-------	---------	-----	--------------	----------

	@		850MG	A208999	002	Oct 12, 2018	Apr DISC
--	---	--	-------	---------	-----	--------------	----------

	@		1GM	A208999	003	Oct 12, 2018	Apr DISC
--	---	--	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

GLUCOPHAGE XR

	+	@	BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000	Jun DISC
--	---	---	----------------------	-------	---------	-----	--------------	----------

	+	@		750MG	N021202	004	Apr 11, 2003	Jun DISC
--	---	---	--	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
GLUCOPHAGE XR

		+ @ EMD SERONO INC	500MG	N021202	001	Oct 13, 2000	Jul CAHN
		+ @	750MG	N021202	004	Apr 11, 2003	Jul CAHN
		METFORMIN HYDROCHLORIDE					
AB	!	AMNEAL PHARMS NY	750MG	A078596	002	Jan 03, 2008	Jun CHRS
AB1		CADILA	500MG	A077060	001	Apr 20, 2005	Feb CAHN
AB			750MG	A077078	001	Apr 21, 2005	Feb CAHN
AB3		GLENMARK PHARMS LTD	500MG	A212969	001	Nov 25, 2019	Nov NEWA
AB3			1GM	A212969	002	Nov 25, 2019	Nov NEWA
AB1		INVENTIA	500MG	A201991	001	Jan 18, 2012	Aug CAHN
AB2	!	LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Apr CHRS
AB1		SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Sep CHRS
AB1	!		500MG	A077336	001	Feb 09, 2006	Jun CHRS
		@ YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Mar DISC
		@	750MG	A211052	002	Sep 24, 2018	Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

		@ MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Jul DISC
		@	850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Jul DISC
		TABLET, EXTENDED RELEASE;ORAL					
		ACTOPLUS MET XR					
		+ @ TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009	Mar DISC
		+ @	1GM;EQ 30MG BASE	N022024	002	May 12, 2009	Mar DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA		PHARM ASSOC	10MG/ML	A207368	001	Aug 22, 2019	Aug NEWA
		SOLUTION;ORAL					
		METHADONE HYDROCHLORIDE					
AA		PHARM ASSOC	5MG/5ML	A207537	001	Oct 02, 2019	Sep NEWA
AA			10MG/5ML	A207537	002	Oct 01, 2019	Sep NEWA

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

>A>		@ INVATECH	25MG	A040102	001	Aug 28, 1996	Dec CAHN
>A>		@	50MG	A040102	002	Aug 28, 1996	Dec CAHN
		@ MICRO LABS	25MG	A207438	001	Oct 05, 2018	Mar DISC
		@	50MG	A207438	002	Oct 05, 2018	Mar DISC
>D>		@ SANDOZ	25MG	A040102	001	Aug 28, 1996	Dec CAHN
>D>		@	50MG	A040102	002	Aug 28, 1996	Dec CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB		MICRO LABS	1GM	A212172	001	Aug 01, 2019	Jul NEWA
----	--	------------	-----	---------	-----	--------------	----------

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

		@ SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007	Oct DISC
		@	10MG	A040870	002	Sep 25, 2007	Oct DISC

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		SLATE	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Feb CAHN
		ROBAXIN					
AP	+	HIKMA	1GM/10ML (100MG/ML)	N011790	001		Feb CAHN
		TABLET;ORAL					
		METHOCARBAMOL					
>D>	AA	ANI PHARMS INC	500MG	A084277	001		Dec DISC
>A>		@	500MG	A084277	001		Dec DISC
	AA		500MG	A084277	001		Sep CAHN
>D>	AA		750MG	A084276	002		Dec DISC
>A>		@	750MG	A084276	002		Dec DISC
AA	!	GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Jul CHRS

TABLET;ORAL
ROBAXIN

+ @ AUXILIUM PHARMS LLC 500MG N011011 004 Jul DISC

METHOTREXATE

SOLUTION;SUBCUTANEOUS
RASUVO

+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr CAHN
+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr CAHN
+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr CAHN
+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr CAHN
+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr CAHN
+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr CAHN
+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr CAHN
+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr CAHN
+ @		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Apr CAHN
+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr CAHN

REDITREX

CUMBERLAND PHARMS

	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Nov NEWA
	10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Nov NEWA
	12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Nov NEWA
	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Nov NEWA
	17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Nov NEWA
	20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Nov NEWA
	22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Nov NEWA
	25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Nov NEWA

METHOXSALLEN

CAPSULE;ORAL
OXSORALEN-ULTRA

AB +! BAUSCH 10MG N019600 001 Oct 30, 1986 Aug CAHN

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

	BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012	Oct CTEC
!		5MG	A200602	002	Sep 24, 2012	Oct CHRS
		5MG	A200602	002	Sep 24, 2012	Oct CTEC
@	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Jun DISC
@		5MG	A040642	002	Dec 06, 2011	Jun DISC
@	VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Oct DISC
@		5MG	A040624	002	Dec 28, 2006	Oct DISC

>D> METHYCLOTHIAZIDE

>D> TABLET;ORAL

>D> METHYCLOTHIAZIDE

>D>	!	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982	Dec DISC
>A>	@		5MG	A087672	001	Aug 17, 1982	Dec DISC

METHYLDOPA

TABLET;ORAL

METHYLDOPA

AB	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Feb CAHN
AB		500MG	A070343	001	Feb 20, 1986	Feb CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

@	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Mar DISC
---	----------	---------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	TEVA PHARMS USA	0.2MG	A211455	001	Mar 20, 2019	Mar NEWA
----	-----------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR

+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Mar CRLD
		25MG	N212038	001	Feb 27, 2019	Feb NEWA
+		35MG	N212038	002	Feb 27, 2019	Feb NEWA
+		45MG	N212038	003	Feb 27, 2019	Feb NEWA

CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR

+	55MG	N212038	004	Feb 27, 2019	Feb NEWA
+	70MG	N212038	005	Feb 27, 2019	Feb NEWA
+	85MG	N212038	006	Feb 27, 2019	Feb NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB1	GRANULES PHARMS	10MG	A211796	001	May 23, 2019	May NEWA
AB1		20MG	A211796	002	May 23, 2019	May NEWA
AB1		30MG	A211796	003	May 23, 2019	May NEWA
AB1		40MG	A211796	004	May 23, 2019	May NEWA
AB1		60MG	A211796	005	May 23, 2019	May NEWA
AB1	! MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	May CTEC

FOR SUSPENSION, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Jan DISC
QUILLIVANT XR					
+! NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012	Feb CAHN
+! NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Jan CTEC

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOVELGENIX THERAPS	5MG/5ML	A210139	001	Oct 03, 2018	Sep CAHN
AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ALKEM LABS LTD	5MG	A211779	001	Oct 04, 2019	Sep NEWA
AB		10MG	A211779	002	Oct 04, 2019	Sep NEWA
AB		20MG	A211779	003	Oct 04, 2019	Sep NEWA
@ AUROLIFE PHARMA LLC	5MG	A209276	001	Oct 25, 2018	Apr DISC	
@	10MG	A209276	002	Oct 25, 2018	Apr DISC	
@	20MG	A209276	003	Oct 25, 2018	Apr DISC	
@ CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Aug DISC	
AB		5MG	A208737	001	Feb 01, 2019	Jan NEWA
@	10MG	A208737	002	Feb 01, 2019	Aug DISC	
AB		10MG	A208737	002	Feb 01, 2019	Jan NEWA
@	20MG	A208737	003	Feb 01, 2019	Aug DISC	
AB		20MG	A208737	003	Feb 01, 2019	Jan NEWA
>D> AB	CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016	Dec DISC
>A>	@	5MG	A206840	001	Sep 15, 2016	Dec DISC
>D> AB		10MG	A206840	002	Sep 15, 2016	Dec DISC
>A>	@	10MG	A206840	002	Sep 15, 2016	Dec DISC
>D> AB		20MG	A206840	003	Sep 15, 2016	Dec DISC
>A>	@	20MG	A206840	003	Sep 15, 2016	Dec DISC
@ LANNETT CO INC	5MG	A086429	001		Jan DISC	
@	10MG	A085799	001		Jan DISC	
@	20MG	A086428	001		Jan DISC	

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

@ LANNETT CO INC	20MG	A089601	001	Jun 01, 1988	Jan DISC
------------------	------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

AB	! ABHAI LLC	20MG	A207488	002	Jun 09, 2015	Jan NEWA
AB	ANDOR PHARMS	18MG	A211918	001	Apr 24, 2019	Apr NEWA
AB		27MG	A211918	002	Apr 24, 2019	Apr NEWA
AB		36MG	A211918	003	Apr 24, 2019	Apr NEWA
AB		54MG	A211918	004	Apr 24, 2019	Apr NEWA
AB	ASCENT PHARMS INC	18MG	A211009	001	Sep 03, 2019	Aug NEWA
AB		27MG	A211009	002	Sep 03, 2019	Aug NEWA
AB		36MG	A211009	003	Sep 03, 2019	Aug NEWA
AB		54MG	A211009	004	Sep 03, 2019	Aug NEWA
@ HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001	May CAHN	
@ PAR PHARM	36MG	A204659	001	Jul 15, 2019	Nov DISC	
AB		36MG	A204659	001	Jul 15, 2019	Jul NEWA
@	54MG	A204659	002	Jul 15, 2019	Nov DISC	
AB		54MG	A204659	002	Jul 15, 2019	Jul NEWA

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	+ PHARMACIA AND UPJOHN	2MG	N011153	002		Mar CFTG
	METHYLPREDNISOLONE					
>A>	@ INVATECH	4MG	A087341	001		Dec CAHN
	@ LUPIN LTD	2MG	A209097	001	Feb 22, 2019	Sep DISC
AB		2MG	A209097	001	Feb 22, 2019	Mar NFTG

TABLET;ORAL

METHYLPREDNISOLONE

AB		2MG	A209097	001	Feb 22, 2019	Feb NEWA
	@	4MG	A209097	002	Feb 22, 2019	Sep DISC
AB		4MG	A209097	002	Feb 22, 2019	Feb NEWA
	@	8MG	A209097	003	Feb 22, 2019	Sep DISC
AB		8MG	A209097	003	Feb 22, 2019	Feb NEWA
	@	16MG	A209097	004	Feb 22, 2019	Sep DISC
AB		16MG	A209097	004	Feb 22, 2019	Feb NEWA
	@	32MG	A209097	005	Feb 22, 2019	Sep DISC
AB		32MG	A209097	005	Feb 22, 2019	Feb NEWA
	@ NOVAST LABS	4MG	A210985	001	Jan 09, 2019	Oct DISC
AB		4MG	A210985	001	Jan 09, 2019	Sep CAHN
>D>	@ SANDOZ	4MG	A087341	001		Dec CAHN
AB		4MG	A212262	001	Jun 27, 2019	Jun NEWA
AB	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL

VIRILON

@ CHARTWELL

10MG

A087750 001 Nov 24, 1982 Jun CAHN

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

@ SANDOZ INC

0.3%

A075720 001 Aug 06, 2001 May DISC

OPTIPRANOLOL

+ @ BAUSCH AND LOMB

0.3%

N019907 001 Dec 29, 1989 Aug DISC

+!

0.3%

N019907 001 Dec 29, 1989 May CTEC

METOLAZONE

TABLET;ORAL

METOLAZONE

@ ANI PHARMS INC

5MG

A076833 001 Mar 01, 2004 Sep CAHN

@

10MG

A075543 003 Dec 24, 2003 Sep CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

TOPROL-XL

AB + TOPROL

EQ 25MG TARTRATE

N019962 004 Feb 05, 2001 Mar CAHN

AB +!

EQ 50MG TARTRATE

N019962 001 Jan 10, 1992 Mar CAHN

AB +

EQ 100MG TARTRATE

N019962 002 Jan 10, 1992 Mar CAHN

AB +!

EQ 200MG TARTRATE

N019962 003 Jan 10, 1992 Mar CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

LOPRESSOR

+ @ NOVARTIS

1MG/ML

N018704 001 Mar 30, 1984 Jun DISC

METOPROLOL TARTRATE

AP ! HOSPIRA

1MG/ML

A078085 001 Apr 29, 2008 Jun CHRS

@ LUITPOLD

1MG/ML

A090386 001 Sep 30, 2009 Mar DISC

@

1MG/ML

A091307 001 Dec 29, 2010 Feb DISC

TABLET;ORAL

METOPROLOL TARTRATE

AB HERITAGE PHARMA

50MG

A074141 001 Jan 31, 1995 Apr CAHN

AB

100MG

A074141 002 Jan 31, 1995 Apr CAHN

AB MYLAN

37.5MG

A076704 004 Mar 18, 2015 Oct CTEC

AB

75MG

A076704 005 Mar 18, 2015 Oct CTEC

AB RUBICON

37.5MG

A200981 004 Aug 21, 2019 Oct NEWA

AB

75MG

A200981 005 Aug 21, 2019 Oct NEWA

@ SUN PHARM INDUSTRIES

25MG

A073654 002 Jul 15, 2009 Oct DISC

@

50MG

A073654 003 Dec 21, 1993 Oct DISC

@

100MG

A073654 001 Dec 21, 1993 Oct DISC

@ WATSON LABS

50MG

A074217 001 May 27, 1994 Oct DISC

@

100MG

A074217 002 May 27, 1994 Oct DISC

METRONIDAZOLE

GEL;VAGINAL

METROGEL-VAGINAL

AB +! BAUSCH

0.75%

N020208 001 Aug 17, 1992 Mar CAHN

METRONIDAZOLE

AB GAGE DEVELOPMENT

0.75%

A211786 001 Jul 02, 2019 Jun NEWA

	GEL;VAGINAL						
	METRONIDAZOLE						
AB	PERRIGO UK FINCO	0.75%	A211786	001	Jul 02, 2019	Jul	CAHN
	INJECTABLE;INJECTION						
	METRONIDAZOLE IN PLASTIC CONTAINER						
AP	INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Feb	NEWA
	TABLET;ORAL						
	METRONIDAZOLE						
AB	CADILA	250MG	A206560	001	Nov 16, 2016	Mar	CAHN
AB		500MG	A206560	002	Nov 16, 2016	Mar	CAHN
AB	STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
AB		500MG	A070039	001	Jan 29, 1985	Apr	CAHN

METYRAPONE

	CAPSULE;ORAL						
	METOPIRONE						
>A>	+! HRA PHARMA	250MG	N012911	002	Aug 09, 1996	Dec	CAHN
>D>	+! LABORATORIE HRA	250MG	N012911	002	Aug 09, 1996	Dec	CAHN
	TABLET;ORAL						
	METOPIRONE						
>A>	@ HRA PHARMA	250MG	N012911	001		Dec	CAHN
>D>	@ LABORATORIE HRA	250MG	N012911	001		Dec	CAHN

METYROSINE

	CAPSULE;ORAL						
	DEMSER						
+!	BAUSCH	250MG	N017871	001		Mar	CAHN

MICAFUNGIN SODIUM

	INJECTABLE;INTRAVENOUS						
	MICAFUNGIN SODIUM						
AP	FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019	May	NFTG
AP		EQ 100MG BASE/VIAL	A207344	002	May 17, 2019	May	NFTG
	MYCAMINE						
AP	+! ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May	CFTG
AP	+!	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May	CDFR

MICONAZOLE

	TABLET;BUCCAL						
	ORAVIG						
+!	FORTOVIA	50MG	N022404	001	Apr 16, 2010	Oct	CAHN

MIDAZOLAM

	SPRAY;NASAL						
	NAYZILAM						
+!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019	May	NEWA

MIDAZOLAM HYDROCHLORIDE

	INJECTABLE;INJECTION						
	MIDOZALAM HYDROCHLORIDE						
	@ MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Sep	DISC
AP		EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	CAHN
	@	EQ 5MG BASE/ML	A090316	002	May 04, 2011	Sep	DISC
AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	CAHN

MIDODRINE HYDROCHLORIDE

	TABLET;ORAL						
	MIDODRINE HYDROCHLORIDE						
	@ CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	May	DISC
	@	5MG	A076514	002	Sep 11, 2003	May	DISC
	@	10MG	A076514	003	Jul 02, 2004	May	DISC
AB	MYLAN PHARMS INC	5MG	A076577	002	Sep 10, 2003	May	CHRS
AB	RUBICON	2.5MG	A212543	001	Aug 19, 2019	Aug	NEWA
AB		5MG	A212543	002	Aug 19, 2019	Aug	NEWA
AB		10MG	A212543	003	Aug 19, 2019	Aug	NEWA
	ORVATEN						
AB	! UPSHER SMITH LABS	5MG	A076725	002	Nov 03, 2004	May	CHRS

MIFEPRISTONE

TABLET;ORAL

MIFEPREX

AB	+	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar CFTG
AB		GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar NFTG

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

AP		WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Oct CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER @ WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Oct CAHN

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+	!	FOAMIX	EQ 4% BASE	N212379	001	Oct 18, 2019	Oct NEWA
---	---	--------	------------	---------	-----	--------------	----------

CAPSULE;ORAL

MINOCIN

AB	+	BAUSCH	EQ 50MG BASE	N050649	001	May 31, 1990	May CAHN
	+	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May CAHN
AB	+		EQ 100MG BASE	N050649	002	May 31, 1990	May CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

SUN PHARM INDS INC

		@	EQ 45MG BASE	N201922	001	Jul 11, 2012	Aug CAHN
		@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Aug CAHN
		@	EQ 90MG BASE	N201922	003	Jul 11, 2012	Aug CAHN
		@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Aug CAHN
		@	EQ 135MG BASE	N201922	005	Jul 11, 2012	Aug CAHN

SUSPENSION;ORAL

MINOCIN

@ BAUSCH

			EQ 50MG BASE/5ML	N050445	001		May CAHN
--	--	--	------------------	---------	-----	--	----------

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

>D>		@	SUN PHARM INDUSTRIES	EQ 50MG BASE	A090217	001	Jan 29, 2016	Dec CMFD
>A>	AB			EQ 50MG BASE	A090217	001	Jan 29, 2016	Dec CMFD
		@		EQ 50MG BASE	A090217	001	Jan 29, 2016	Oct DISC
>D>		@		EQ 75MG BASE	A090217	002	Jan 29, 2016	Dec CMFD
>A>	AB			EQ 75MG BASE	A090217	002	Jan 29, 2016	Dec CMFD
		@		EQ 75MG BASE	A090217	002	Jan 29, 2016	Oct DISC
>D>		@		EQ 100MG BASE	A090217	003	Jan 29, 2016	Dec CMFD
>A>	AB			EQ 100MG BASE	A090217	003	Jan 29, 2016	Dec CMFD
		@		EQ 100MG BASE	A090217	003	Jan 29, 2016	Oct DISC

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB		ALKEM LABS LTD	EQ 55MG BASE	A204453	008	Dec 19, 2019	Dec NEWA
	AB		AUROBINDO PHARMA LTD	EQ 55MG BASE	A202261	008	Aug 21, 2019	Aug NEWA
	AB		BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Jan CMFD
	AB			EQ 105MG BASE	A065485	008	Apr 26, 2017	Jan CMFD
		@	MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019	Aug NEWA
		@	MYLAN LABS LTD	EQ 65MG BASE	A201467	001	Jul 30, 2019	Aug DISC
	AB			EQ 65MG BASE	A201467	001	Jul 30, 2019	Jul NEWA
		@		EQ 115MG BASE	A201467	002	Jul 30, 2019	Aug DISC
	AB			EQ 115MG BASE	A201467	002	Jul 30, 2019	Jul NEWA
	AB		SUN PHARM INDS LTD	EQ 65MG BASE	A091118	003	Dec 03, 2019	Nov NEWA
	AB			EQ 115MG BASE	A091118	007	Dec 03, 2019	Nov NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

>A>	AB		SAWAI USA	25MG	A209446	001	Dec 27, 2019	Dec NFTG
			MYRBETRIQ					
>D>		+	APGDI	25MG	N202611	001	Jun 28, 2012	Dec CFTG
>A>	AB	+		25MG	N202611	001	Jun 28, 2012	Dec CFTG

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

@	WATSON LABS	15MG	A076312	001	Jun 19, 2003	May	DISC
@		30MG	A076312	002	Jun 19, 2003	May	DISC
@		45MG	A076312	003	Jun 19, 2003	May	DISC

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

>D>	AB	ANI PHARMS INC	0.1MG	A076095	001	Jul 10, 2002	Dec	DISC
>A>		@	0.1MG	A076095	001	Jul 10, 2002	Dec	DISC
>D>	AB		0.2MG	A076095	002	Jul 10, 2002	Dec	DISC
>A>		@	0.2MG	A076095	002	Jul 10, 2002	Dec	DISC
>D>	AB	ZYDUS PHARMS	0.1MG	A210201	001	Jul 02, 2019	Dec	DISC
>A>		@	0.1MG	A210201	001	Jul 02, 2019	Dec	DISC
	AB		0.1MG	A210201	001	Jul 02, 2019	Jun	NEWA
>D>	AB		0.2MG	A210201	002	Jul 02, 2019	Dec	DISC
>A>		@	0.2MG	A210201	002	Jul 02, 2019	Dec	DISC
	AB		0.2MG	A210201	002	Jul 02, 2019	Jun	NEWA

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP		WEST-WARD PHARMS INT	20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CMFD
AP			40MG/VIAL	A064117	003	Jun 02, 1999	Jan	CMFD

MITOTANE

TABLET; ORAL

LYSODREN

>A>	+	HRA PHARMA	500MG	N016885	001		Dec	CAHN
>D>	+	LABORATOIRE HRA	500MG	N016885	001		Dec	CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@	MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Mar	DISC
@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Mar	DISC
@	MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Sep	DISC
	NOVANTRONE						
+	@ EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987	Sep	CRLD

MODAFINIL

TABLET; ORAL

MODAFINIL

AB		APPCO	100MG	A207196	001	Aug 16, 2017	Nov	CAHN
AB			200MG	A207196	002	Aug 16, 2017	Nov	CAHN
AB		CADILA	100MG	A209966	001	Sep 14, 2017	Aug	CMFD
		@	100MG	A209966	001	Sep 14, 2017	May	CAHN
AB			200MG	A209966	002	Sep 14, 2017	Aug	CMFD
		@	200MG	A209966	002	Sep 14, 2017	May	CAHN
		@ HIKMA PHARMS	100MG	A090543	001	Sep 26, 2012	Aug	DISC
		@	200MG	A090543	002	Sep 26, 2012	Aug	DISC
		@ ZYDUS PHARMS	100MG	A209966	001	Sep 14, 2017	Apr	DISC
		@	200MG	A209966	002	Sep 14, 2017	Apr	DISC

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

+	MERCK SHARP DOHME	0.05MG/INH	N205641	003	Aug 12, 2019	Aug	NEWA
---	-------------------	------------	---------	-----	--------------	-----	------

CREAM; TOPICAL

ELOCON

+	@ MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Aug	DISC
---	---------------------	------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

AB	!	GLENMARK GENERICS	0.1%	A078541	001	May 28, 2008	Aug	CHRS
----	---	-------------------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

ELOCON

+	@ MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987	Jul	DISC
---	---------------------	------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

AB	!	GLENMARK GENERICS	0.1%	A078571	001	May 28, 2008	Jul	CHRS
----	---	-------------------	------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

GRANULE; ORAL								
MONTELUKAST SODIUM								
AB	@ MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb	DISC	
	TORRENT	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar	CAHN	
TABLET; ORAL								
MONTELUKAST SODIUM								
AB	L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	May	CAHN	
	@ MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012	Jul	DISC	
	@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb	DISC	
TABLET, CHEWABLE; ORAL								
MONTELUKAST SODIUM								
	@ MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Apr	DISC	
	@	EQ 5MG BASE	A079142	002	Aug 03, 2012	Apr	DISC	
	@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb	DISC	
	@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb	DISC	

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL								
MORPHINE SULFATE								
AB	IMPAX LABS INC	40MG	A200411	007	Jul 25, 2018	Nov	NEWA	
INJECTABLE; INJECTION								
ASTRAMORPH PF								
	@ FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986	Mar	DISC	
MITIGO								
AP	PIRAMAL CRITICAL	10MG/ML	A204393	001	Jul 16, 2018	Aug	CAHN	
AP		25MG/ML	A204393	002	Jul 16, 2018	Aug	CAHN	
MORPHINE SULFATE								
	+ @ ICU MEDICAL INC	5MG/ML	N019916	002	Oct 27, 2006	Sep	DISC	
SOLUTION; ORAL								
MORPHINE SULFATE								
	@ LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	Feb	DISC	
	@	20MG/5ML	A202310	001	Oct 30, 2015	Jan	DISC	
	@	100MG/5ML	N201517	001	Jun 23, 2011	Jan	DISC	
TABLET; ORAL								
MORPHINE SULFATE								
AB	UPSHER SMITH LABS	15MG	A210610	001	Jul 22, 2019	Jul	NFTG	
AB		30MG	A210610	002	Jul 22, 2019	Jul	NFTG	
TABLET, EXTENDED RELEASE; ORAL								
ARYMO ER								
	+ @ EGALET	15MG	N208603	001	Jan 09, 2017	Mar	CAHN	
	+ @	30MG	N208603	002	Jan 09, 2017	Mar	CAHN	
	+ @	60MG	N208603	003	Jan 09, 2017	Mar	CAHN	
	+ @ ZYLA	15MG	N208603	001	Jan 09, 2017	Jul	CAHN	
	+ @	30MG	N208603	002	Jan 09, 2017	Jul	CAHN	
	+ @	60MG	N208603	003	Jan 09, 2017	Jul	CAHN	
MORPHINE SULFATE								
	@ MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011	Aug	DISC	
	@	30MG	A200824	002	Oct 18, 2011	Aug	DISC	
	@	60MG	A200824	003	Oct 18, 2011	Aug	DISC	
	@	100MG	A200824	004	Oct 18, 2011	Aug	DISC	
	@	200MG	A200824	005	Oct 18, 2011	Feb	DISC	
	@ SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016	Oct	DISC	
	@	30MG	A205634	002	Aug 25, 2016	Oct	DISC	
	@	60MG	A205634	003	Aug 25, 2016	Oct	DISC	
	@	100MG	A205634	004	Aug 25, 2016	Oct	DISC	
	@	200MG	A205634	005	Aug 25, 2016	Oct	DISC	

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL								
EMBEDA								
	+ @ ALPHARMA PHARMS	20MG; 0.8MG	N022321	001	Aug 13, 2009	Nov	DISC	
	+ @	30MG; 1.2MG	N022321	002	Aug 13, 2009	Nov	DISC	
	+ @	50MG; 2MG	N022321	003	Aug 13, 2009	Nov	DISC	
	+ @	60MG; 2.4MG	N022321	004	Aug 13, 2009	Nov	DISC	
	+ @	80MG; 3.2MG	N022321	005	Aug 13, 2009	Nov	DISC	
	+ @	100MG; 4MG	N022321	006	Aug 13, 2009	Nov	DISC	

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1	ALEMBIC PHARMS LTD	EQ 0.5% BASE	A209469	001	Feb 13, 2019	Jan NEWA
	TABLET;ORAL					
	MOXIFLOXACIN HYDROCHLORIDE					
	@ MYLAN	EQ 400MG BASE	A204635	001	Aug 31, 2015	Oct DISC
	@ SUNSHINE LAKE	EQ 400MG BASE	A206295	001	Sep 28, 2018	Mar DISC

MUPIROCINOINTMENT;TOPICAL
MUPIROCIN

AB	! PERRIGO ISRAEL	2%	A065123	001	Nov 07, 2003	May CAHN
----	------------------	----	---------	-----	--------------	----------

MYCOPHENOLATE MOFETILSUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

AB	VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Jan NEWA
	TABLET;ORAL					
	MYCOPHENOLATE MOFETIL					
	@ OXFORD PHARMS	500MG	A090606	001	Jul 16, 2010	Aug DISC
	@ TEVA PHARMS	500MG	A065457	001	May 04, 2009	Sep DISC

MYCOPHENOLIC ACIDTABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC ACID

>A>	AB	CONCORD BIOTECH LTD	180MG	A211173	001	Dec 13, 2019	Dec NEWA
>A>	AB		360MG	A211173	002	Dec 13, 2019	Dec NEWA

NABUMETONETABLET;ORAL
NABUMETONE

AB	NEXGEN PHARMA INC	500MG	A203166	001	Aug 30, 2019	Aug NEWA
AB		750MG	A203166	002	Aug 30, 2019	Aug NEWA
		1GM	A203166	003	Aug 30, 2019	Aug NEWA
AB	NOSTRUM LABS INC	500MG	A090427	001	Dec 30, 2011	Oct CAHN
AB		750MG	A090427	002	Dec 30, 2011	Oct CAHN
AB	SCIEGEN PHARMS INC	500MG	A078420	001	Sep 24, 2008	Sep CMFD
AB		750MG	A078420	002	Sep 24, 2008	Sep CMFD

NADOLOLTABLET;ORAL
NADOLOL

AB	HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr CAHN
AB		40MG	A074229	002	Aug 30, 1996	Apr CAHN
AB		80MG	A074255	001	Jan 24, 1996	Apr CAHN
	@	120MG	A074255	002	Jan 24, 1996	Apr CAHN
	@	160MG	A074255	003	Jan 24, 1996	Apr CAHN
AB	VGYAAN	20MG	A212856	001	Sep 13, 2019	Sep NEWA
AB		40MG	A212856	002	Sep 13, 2019	Sep NEWA
AB		80MG	A212856	003	Sep 13, 2019	Sep NEWA

NAFCILLIN SODIUMINJECTABLE;INJECTION
NAFCILLIN SODIUM

AP	FRESENIUS	EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019	Nov NEWA
AP		EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019	Nov NEWA
	@ MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Sep DISC
	@	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Sep DISC

NAFTIFINE HYDROCHLORIDEGEL;TOPICAL
NAFTIFINE HYDROCHLORIDE

	@ TARO	2%	A208201	001	Apr 10, 2019	May DISC
AB		2%	A208201	001	Apr 10, 2019	Mar NFTG
AB	TOLMAR	1%	A206165	001	Mar 20, 2019	Mar NFTG
	NAFTIN					
AB	+! SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar CFTG
AB	+!	2%	N204286	001	Jun 27, 2013	Mar CFTG

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION							
NALBUPHINE HYDROCHLORIDE							
	@ DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	May	CAHN
	@	20MG/ML	A074471	002	Mar 19, 1998	May	CAHN
AP	MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan	NEWA
AP		20MG/ML	A206506	002	Feb 06, 2019	Jan	NEWA

NALDEMEDINE TOSYLATE

TABLET; ORAL
SYMPROIC

+! BDSI EQ 0.2MG BASE N208854 001 Mar 23, 2017 Apr CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION							
NALOXONE HYDROCHLORIDE							
AP	AUROBINDO PHARMA LTD	0.4MG/ML	A212455	001	Oct 15, 2019	Sep	NEWA
AP		0.4MG/ML	A212456	001	Nov 04, 2019	Oct	NEWA
	@ VIRTUS PHARMS	0.4MG/ML	A207846	001	Dec 17, 2018	Oct	DISC
AP		0.4MG/ML	A207846	001	Dec 17, 2018	Jul	CAHN
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
EVZIO (AUTOINJECTOR)							
	+! KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb	CTNA
SPRAY, METERED; NASAL							
NALOXONE HYDROCHLORIDE							
	@ TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	May	DISC
AB		4MG/SPRAY	A209522	001	Apr 19, 2019	Apr	NFTG
NARCAN							
	+! ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	May	CTEC
AB	+!	4MG/SPRAY	N208411	001	Nov 18, 2015	Apr	CFTG

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL							
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE							
AB	LUPIN	EQ 0.5MG BASE; EQ 50MG BASE	A075735	001	Jul 11, 2001	Feb	CAHN

NANDROLONE DECANOATE

INJECTABLE; INJECTION							
NANDROLONE DECANOATE							
	@ LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010	Feb	DISC

NAPROXEN

SUSPENSION; ORAL							
NAPROSYN							
AB	+ ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CHRS
TABLET; ORAL							
NAPROXEN							
AB	PERRIGO PHARMS CO	250MG	A077339	001	Apr 27, 2005	Apr	CAHN
AB		375MG	A077339	002	Apr 27, 2005	Apr	CAHN
AB		500MG	A077339	003	Apr 27, 2005	Apr	CAHN
TABLET, DELAYED RELEASE; ORAL							
NAPROXEN							
>D> AB	INVAGEN PHARMS	375MG	A091432	001	Sep 19, 2011	Dec	CAHN
>D> AB		500MG	A091432	002	Sep 19, 2011	Dec	CAHN
>A> AB	SUNRISE PHARM INC	375MG	A091432	001	Sep 19, 2011	Dec	CAHN
>A> AB		500MG	A091432	002	Sep 19, 2011	Dec	CAHN

NAPROXEN SODIUM

TABLET; ORAL							
NAPROXEN SODIUM							
AB	SCIEGEN PHARMS INC	EQ 250MG BASE	A212199	001	Oct 30, 2019	Oct	NEWA
AB		EQ 500MG BASE	A212199	002	Oct 30, 2019	Oct	NEWA

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL							
TREXIMET							
	+ @ CURRAX	60MG; EQ 10MG BASE	N021926	002	May 14, 2015	Apr	CAHN
AB	+!	500MG; EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr	CAHN

NARATRIPTAN HYDROCHLORIDETABLET; ORAL
NARATRIPTAN

>D>	AB	ANI PHARMS INC	EQ 1MG BASE	A078751	001	Jul 07, 2010	Dec DISC
>A>		@	EQ 1MG BASE	A078751	001	Jul 07, 2010	Dec DISC
	AB		EQ 1MG BASE	A078751	001	Jul 07, 2010	Sep CAHN
>D>	AB		EQ 2.5MG BASE	A078751	002	Jul 07, 2010	Dec DISC
>A>		@	EQ 2.5MG BASE	A078751	002	Jul 07, 2010	Dec DISC
	AB		EQ 2.5MG BASE	A078751	002	Jul 07, 2010	Sep CAHN
		@ CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun DISC
		@	EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun DISC
		@ MYLAN PHARMS INC	EQ 1MG BASE	A202431	001	May 31, 2012	Oct DISC
		@	EQ 2.5MG BASE	A202431	002	May 31, 2012	Oct DISC

NATEGLINIDETABLET; ORAL
NATEGLINIDE

	AB	CADILA PHARMS LTD	60MG	A206432	001	Apr 19, 2019	Apr NEWA
	AB		120MG	A206432	002	Apr 19, 2019	Apr NEWA
	AB	! ZYDUS PHARMS	120MG	A205248	002	Jul 06, 2016	Jul CHRS
		STARLIX					
	+	@ NOVARTIS	60MG	N021204	001	Dec 22, 2000	Jul DISC
	+	@	120MG	N021204	002	Dec 22, 2000	Jul DISC

NEBIVOLOL HYDROCHLORIDE; VALSARTANTABLET; ORAL
BYVALSON

	+	@ ALLERGAN	EQ 5MG BASE; 80MG	N206302	001	Jun 03, 2016	Sep DISC
--	---	------------	-------------------	---------	-----	--------------	----------

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

	@	LANNETT CO INC	500MG	A204435	001	Jun 10, 2016	Jun DISC
--	---	----------------	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

	@	WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jul DISC
--	---	-------------	-----------------------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

	AP	AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jan CAHN
	AP		10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jan CAHN
	AP	BE PHARMS	5MG/10ML (0.5MG/ML)	A212512	001	May 13, 2019	Apr NEWA
	AP		10MG/10ML (1MG/ML)	A212512	002	May 13, 2019	Apr NEWA
	AP	GLAND PHARMA LTD	5MG/10ML (0.5MG/ML)	A212968	001	Oct 16, 2019	Sep NEWA
	AP		10MG/10ML (1MG/ML)	A212968	002	Oct 16, 2019	Sep NEWA

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

	+	@ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Aug DISC
--	---	-------------	------------	---------	-----	--------------	----------

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

>D>	AB	CIPLA	400MG	A206448	001	Oct 15, 2015	Dec DISC
>A>		@	400MG	A206448	001	Oct 15, 2015	Dec DISC
		@ MYLAN	100MG	A206271	001	Nov 09, 2015	Oct DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

	AB	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Sep CMFD
		@	500MG	A209156	001	May 14, 2018	Apr DISC
	AB		750MG	A209156	002	May 14, 2018	Sep CMFD
		@	750MG	A209156	002	May 14, 2018	Apr DISC
	AB		1GM	A209156	003	May 14, 2018	Sep CMFD
		@	1GM	A209156	003	May 14, 2018	Apr DISC
>D>	AB	YICHANG HUMANWELL	500MG	A212017	001	Jun 10, 2019	Dec DISC

TABLET, EXTENDED RELEASE;ORAL
 NIACIN

>A>	@	500MG	A212017	001	Jun 10, 2019	Dec	DISC
AB		500MG	A212017	001	Jun 10, 2019	May	NEWA
>D>	AB	750MG	A212017	002	Jun 10, 2019	Dec	DISC
>A>	@	750MG	A212017	002	Jun 10, 2019	Dec	DISC
AB		750MG	A212017	002	Jun 10, 2019	May	NEWA
>D>	AB	1GM	A212017	003	Jun 10, 2019	Dec	DISC
>A>	@	1GM	A212017	003	Jun 10, 2019	Dec	DISC
AB		1GM	A212017	003	Jun 10, 2019	May	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

>D>	AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Dec	DISC
>A>	@		20MG	A074439	001	Dec 10, 1996	Dec	DISC
>D>	AB		20MG	A074540	001	Oct 28, 1996	Dec	DISC
>A>	@		20MG	A074540	001	Oct 28, 1996	Dec	DISC
	@		20MG	A074670	001	Oct 28, 1996	Sep	CAHN
>D>	AB		30MG	A074439	002	Dec 10, 1996	Dec	DISC
>A>	@		30MG	A074439	002	Dec 10, 1996	Dec	DISC
>D>	AB		30MG	A074540	002	Oct 28, 1996	Dec	DISC
>A>	@		30MG	A074540	002	Oct 28, 1996	Dec	DISC
	@		30MG	A074670	002	Oct 28, 1996	Sep	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

	@	MYLAN	30MG	A090649	001	Jun 21, 2010	Nov	DISC
	@		60MG	A090649	002	Jun 21, 2010	Nov	DISC
	@		90MG	A090649	003	Jun 21, 2010	Nov	DISC
AB2		NOVAST LABS	30MG	A210614	001	Mar 12, 2019	Feb	NEWA
AB2			60MG	A210614	002	Mar 12, 2019	Feb	NEWA
AB2			90MG	A210614	003	Mar 12, 2019	Feb	NEWA
AB2		OSMOTICA PHARM US	90MG	A077127	003	Oct 03, 2007	Apr	CMS1
AB2		SPIL	30MG	A210838	001	Apr 16, 2019	Apr	NEWA
AB2			60MG	A210838	002	Apr 16, 2019	Apr	NEWA
AB2			90MG	A210838	003	Apr 16, 2019	Apr	NEWA

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

@	SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007	Oct	DISC
---	--------------------	------	---------	-----	--------------	-----	------

NITISINONE

CAPSULE;ORAL

NITISINONE

AB		NOVITIUM PHARMA	2MG	A211041	001	Aug 26, 2019	Aug	NFTG
AB			5MG	A211041	002	Aug 26, 2019	Aug	NFTG
AB			10MG	A211041	003	Aug 26, 2019	Aug	NFTG
		ORFADIN						
AB	+	SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	Aug	CFTG
AB	+		5MG	N021232	002	Jan 18, 2002	Aug	CFTG
AB	+		10MG	N021232	003	Jan 18, 2002	Aug	CFTG

NITRIC OXIDE

GAS; INHALATION

GENOSYL

>A>	+	VERO BIOTECH	800PPM	N202860	001	Dec 20, 2019	Dec	NEWA
-----	---	--------------	--------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

>A>	@	INVATECH	25MG	A074336	001	Jan 25, 1995	Dec	CAHN
>A>	@		50MG	A074336	002	Jan 25, 1995	Dec	CAHN
>A>	@		100MG	A074336	003	Jan 25, 1995	Dec	CAHN
	@	MYLAN	50MG	A074967	001	Jul 09, 1997	Jul	DISC
	@		100MG	A077025	001	Aug 18, 2004	Jul	DISC
>D>	@	SANDOZ	25MG	A074336	001	Jan 25, 1995	Dec	CAHN
>D>	@		50MG	A074336	002	Jan 25, 1995	Dec	CAHN
>D>	@		100MG	A074336	003	Jan 25, 1995	Dec	CAHN

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL							
NITROMIST							
+!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006	May	CAHN
FILM, EXTENDED RELEASE;TRANSDERMAL							
MINITRAN							
@	MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996	May	DISC
@	VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996	May	DISC
@		0.6MG/HR	A089774	001	Aug 30, 1996	Jun	DISC
@	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	DISC
NITRO-DUR							
+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	May	CTEC
+!		0.2MG/HR	N020145	002	Apr 04, 1995	May	CTEC
+!		0.4MG/HR	N020145	004	Apr 04, 1995	May	CTEC
+!		0.6MG/HR	N020145	005	Apr 04, 1995	Jun	CTEC
NITROGLYCERIN							
AB2	HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Feb	NEWA
AB2	! MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Feb	CTEC
TABLET;SUBLINGUAL							
NITROGLYCERIN							
AB	ALVOGEN	0.3MG	A211604	001	Apr 30, 2019	Apr	NEWA
AB		0.4MG	A211604	002	Apr 30, 2019	Apr	NEWA
AB		0.6MG	A211604	003	Apr 30, 2019	Apr	NEWA

NIZATIDINE

CAPSULE;ORAL							
NIZATIDINE							
>D>	AB	ANI PHARMS INC	150MG	A075668	001	Sep 12, 2002	Dec DISC
>A>	@		150MG	A075668	001	Sep 12, 2002	Dec DISC
>D>	AB		300MG	A075668	002	Sep 12, 2002	Dec DISC
>A>	@		300MG	A075668	002	Sep 12, 2002	Dec DISC

NORETHINDRONE

TABLET;ORAL-28							
MICRONOR							
+	@ JANSSSEN PHARMS	0.35MG	N016954	001		Mar	DISC
NORETHINDRONE							
AB2	! MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013	Mar	CHRS

NORETHINDRONE ACETATE

TABLET;ORAL							
NORETHINDRONE ACETATE							
>A>	AB	NOVAST LABS	5MG	A206490	001	Nov 05, 2018	Dec CAHN
>D>	AB	RISING	5MG	A206490	001	Nov 05, 2018	Dec CAHN
	AB		5MG	A206490	001	Nov 05, 2018	May CAHN

NYSTATIN

CREAM;TOPICAL							
NYSTATIN							
AT	TORRENT	100,000 UNITS/GM	A212557	001	Jul 24, 2019	Jul	NEWA
OINTMENT;TOPICAL							
NYSTATIN							
AT	CADILA	100,000 UNITS/GM	A207767	001	May 25, 2018	Oct	CAHN
AT	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Jan	NEWA
POWDER;TOPICAL							
NYSTATIN							
AT	LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb	CAHN
TABLET;ORAL							
NYSTATIN							
@	UPSHER SMITH LABS	500,000 UNITS	A062524	001	Nov 26, 1985	Jul	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL							
NYSTATIN AND TRIAMCINOLONE ACETONIDE							
@	CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731	001	Dec 26, 2017	Sep	DISC
AT	VITRUVIAS THERAP	100000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	Nov	NEWA
@	ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr CAHN
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr CAHN
	@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar DISC
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan CAHN
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr CAHN
	@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar DISC
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan CAHN
	@ SUN PHARM INDS	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007	Jul DISC
	@	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007	Jul DISC
	@	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007	Jul DISC
	@	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007	Jul DISC
	@	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007	Jul DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT	APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb CMFD
	@ SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar DISC

SOLUTION/DROPS; OTIC

OFLOXACIN

@	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Oct DISC
@	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Mar DISC

TABLET; ORAL

OFLOXACIN

@	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Sep DISC
---	-------------	-------	---------	-----	--------------	----------

OLANZAPINE

TABLET; ORAL

OLANZAPINE

@	SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018	Apr DISC
@		5MG	A206238	002	Nov 19, 2018	Apr DISC
@		7.5MG	A206238	003	Nov 19, 2018	Apr DISC
@		10MG	A206238	004	Nov 19, 2018	Apr DISC
@		15MG	A206238	005	Nov 19, 2018	Apr DISC
@		20MG	A206238	006	Nov 19, 2018	Apr DISC

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

@	HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb DISC
@		10MG	A208146	002	Jul 02, 2018	Feb DISC
@		15MG	A208146	003	Jul 02, 2018	Feb DISC
@		20MG	A208146	004	Jul 02, 2018	Feb DISC

OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

CLINOLIPID 20%

+	!	BAXTER HLTHCARE CORP	16% (160GM/1000ML) ; 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Aug CMFD
+	@		16% (160GM/1000ML) ; 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CDFR

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

AB	MICRO LABS	5MG	A206372	001	Sep 17, 2019	Sep NEWA
AB		20MG	A206372	002	Sep 17, 2019	Sep NEWA
AB		40MG	A206372	003	Sep 17, 2019	Sep NEWA
AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb NEWA
	@ TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Nov DISC
	@	20MG	A091079	002	Apr 24, 2017	Nov DISC
	@	40MG	A091079	003	Apr 24, 2017	Nov DISC
AB	UMEDICA LABS PVT LTD	5MG	A207135	001	Jul 18, 2019	Jul NEWA
AB		20MG	A207135	002	Jul 18, 2019	Jul NEWA
AB		40MG	A207135	003	Jul 18, 2019	Jul NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 0.2% BASE	A209420	001	Apr 29, 2019	Apr NEWA
AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar NEWA
AT	FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019	Sep NEWA
AT	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul NEWA
AT	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Jun CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET;ORAL
TECHNIVIE

	+ @ ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Apr DISC
--	----------------	------------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb NEWA
AB	BIONPHARMA INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Jul NEWA
	@ PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun DISC
>D> AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Dec DISC
>A>	@	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Dec DISC
AB		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Jun NEWA
>A> AB	SUN PHARM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020	Dec NEWA
>D> AB	ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019	Dec DISC
>A>	@	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019	Dec DISC
AB		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019	Jun NEWA

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	HETERO LABS LTD III	10MG	A204012	001	Sep 26, 2019	Sep NEWA
AB		20MG	A204012	002	Sep 26, 2019	Sep NEWA
>D> AB	LUPIN LTD	40MG	A202384	001	Aug 25, 2015	Dec DISC
>A>	@	40MG	A202384	001	Aug 25, 2015	Dec DISC
	@ MYLAN	10MG	A075876	001	May 29, 2003	Jun DISC
	@	40MG	A075876	003	Jan 21, 2009	Sep DISC

OMEPRAZOLE; SODIUM BICARBONATECAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

	@ PAR PHARM	20MG;1.1GM	A078966	001	May 25, 2010	Nov DISC
	@	40MG;1.1GM	A078966	002	May 25, 2010	Nov DISC
	ZEGERID					
AB	+ SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Sep CAHN
AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Sep CAHN
	FOR SUSPENSION;ORAL					
	ZEGERID					
AB	+ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CAHN
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

@ LUITPOLD

EQ 2MG BASE/ML

A079039 001 Nov 18, 2008 Feb DISC

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ HIKMA FARMACEUTICA

EQ 2MG BASE/ML

A076780 001 Dec 26, 2006 Feb DISC

@ LUITPOLD

EQ 2MG BASE/ML

A079032 001 Nov 18, 2008 Feb DISC

@ TEVA

EQ 2MG BASE/ML

A076759 001 Nov 22, 2006 Aug DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ MYLAN

EQ 24MG BASE

A076930 004 Jun 25, 2007 Feb DISC

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

+ @ TELIGENT

30MG/ML

N013055 001 Jan CRLD

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB LUPIN

100MG

A040284 001 Jun 19, 1998 Feb CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB ALEMBIC PHARMS LTD

EQ 30MG BASE

A211823 001 Jun 24, 2019 Jun NEWA

AB

EQ 45MG BASE

A211823 002 Jun 24, 2019 Jun NEWA

AB

EQ 75MG BASE

A211823 003 Jun 24, 2019 Jun NEWA

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB TEVA PHARMS USA

EQ 6MG BASE/ML

A211125 001 Feb 27, 2019 Feb NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

@ HOSPIRA INC

EQ 1GM BASE/VIAL

A203950 001 Dec 11, 2015 Oct DISC

@

EQ 2GM BASE/VIAL

A203950 002 Dec 11, 2015 Oct DISC

AP PIRAMAL CRITICAL

EQ 1GM BASE/VIAL

A206681 001 Sep 11, 2017 Jul CAHN

AP

EQ 2GM BASE/VIAL

A206681 002 Sep 11, 2017 Jul CAHN

AP

EQ 10GM BASE/VIAL

A206760 001 Oct 26, 2017 Jul CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+ @ SANOFI AVENTIS US

50MG/VIAL

N021492 001 Aug 09, 2002 Feb CDFR

AP +!

50MG/10ML (5MG/ML)

N021759 001 Jan 31, 2005 Feb CDFR

+ @

100MG/VIAL

N021492 002 Aug 09, 2002 Feb CDFR

AP +!

100MG/20ML (5MG/ML)

N021759 002 Jan 31, 2005 Feb CDFR

+ @

200MG/40ML (5MG/ML)

N021759 003 Nov 17, 2006 Feb CDFR

OXALIPLATIN

AP ACCORD HLTHCARE

50MG/10ML (5MG/ML)

A207474 001 Mar 21, 2017 Feb CDFR

AP

100MG/20ML (5MG/ML)

A207474 002 Mar 21, 2017 Feb CDFR

AP

200MG/40ML (5MG/ML)

A207474 003 Mar 21, 2017 Feb CDFR

AP ACTAVIS LLC

50MG/10ML (5MG/ML)

A204880 001 Mar 05, 2018 Feb CDFR

AP

100MG/20ML (5MG/ML)

A204880 002 Mar 05, 2018 Feb CDFR

AP ! ACTAVIS TOTOWA

50MG/VIAL

A078803 001 Aug 08, 2012 Jul CHRS

AP

50MG/VIAL

A078803 001 Aug 08, 2012 Feb CDFR

AP !

100MG/VIAL

A078803 002 Aug 08, 2012 Jul CHRS

AP

100MG/VIAL

A078803 002 Aug 08, 2012 Feb CDFR

AP CIPLA

50MG/10ML (5MG/ML)

A208523 001 Feb 10, 2017 Feb CDFR

AP

100MG/20ML (5MG/ML)

A208523 002 Feb 10, 2017 Feb CDFR

AP EUGIA PHARMA

50MG/10ML (5MG/ML)

A205529 001 Sep 06, 2017 Feb CDFR

AP

100MG/20ML (5MG/ML)

A205529 002 Sep 06, 2017 Feb CDFR

AP FRESENIUS KABI USA

50MG/10ML (5MG/ML)

A078811 001 Jun 10, 2010 Feb CDFR

AP

100MG/20ML (5MG/ML)

A078811 002 Jun 10, 2010 Feb CDFR

AP

50MG/VIAL

A078819 001 Jun 02, 2010 Feb CDFR

AP

50MG/10ML (5MG/ML)

A090030 001 Jan 31, 2017 Feb CDFR

AP

100MG/VIAL

A078819 002 Jun 02, 2010 Feb CDFR

AP

100MG/20ML (5MG/ML)

A090030 002 Jan 31, 2017 Feb CDFR

AP

200MG/40ML (5MG/ML)

A090030 003 Jan 31, 2017 Feb CDFR

AP GLAND PHARMA LTD

50MG/10ML (5MG/ML)

A207325 001 Feb 10, 2017 Feb CDFR

AP

50MG/VIAL

A207385 001 May 23, 2017 Feb CDFR

AP

100MG/20ML (5MG/ML)

A207325 002 Feb 10, 2017 Feb CDFR

INJECTABLE; INTRAVENOUS
OXALIPLATIN

AP		100MG/VIAL	A207385	002	May 23, 2017	Feb CDFR
AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Feb CDFR
AP	HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)	A078813	001	Aug 07, 2009	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078813	002	Aug 07, 2009	Feb CDFR
AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Feb CDFR
AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Feb CDFR
AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Feb CDFR
AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Feb CDFR
AP	MYLAN LABS LTD	50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Feb CDFR
	@	50MG/VIAL	A200979	001	Aug 08, 2012	Oct DISC
AP		50MG/VIAL	A200979	001	Aug 08, 2012	Feb CDFR
AP		100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Feb CDFR
	@	100MG/VIAL	A200979	002	Aug 08, 2012	Oct DISC
AP		100MG/VIAL	A200979	002	Aug 08, 2012	Feb CDFR
	@	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Sep DISC
AP		200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Feb CDFR
AP	QILU	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Feb CDFR
AP		50MG/VIAL	A204616	001	May 11, 2016	Feb CDFR
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb CDFR
AP		100MG/VIAL	A204616	002	May 11, 2016	Feb CDFR
AP	!	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb CDFR
AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb CDFR
	@	50MG/VIAL	A090849	001	Apr 28, 2011	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb CDFR
	@	100MG/VIAL	A090849	002	Apr 28, 2011	Feb CDFR
	@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb CDFR
	@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb CDFR
	@ SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009	Jul DISC
	@	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Jul DISC
	@	100MG/VIAL	A078818	002	Aug 07, 2009	Jul DISC
	@	100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Jul DISC
	@	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Jul DISC
AP		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr CDFR
AP	! SUN PHARMA GLOBAL	50MG/VIAL	A078818	001	Aug 07, 2009	Feb CDFR
AP		50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Feb CDFR
AP	!	100MG/VIAL	A078818	002	Aug 07, 2009	Feb CDFR
AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Feb CDFR
AP	+! TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb CDFR
AP	+!	100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb CDFR

INJECTABLE; IV (INFUSION)
OXALIPLATIN

AP	SUN PHARMA GLOBAL	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Feb NEWA
----	-------------------	---------------------	---------	-----	--------------	----------

OXAPROZINTABLET; ORAL
OXAPROZIN

@	BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001	Mar CAHN
@	SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002	Oct DISC

OXCARBAZEPINETABLET; ORAL
OXCARBAZEPINE

>D>	AB	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Dec DISC
>A>	@		150MG	A078005	001	Dec 11, 2007	Dec DISC
>D>	AB		300MG	A078005	002	Dec 11, 2007	Dec DISC
>A>	@		300MG	A078005	002	Dec 11, 2007	Dec DISC
>D>	AB		600MG	A078005	003	Dec 11, 2007	Dec DISC
>A>	@		600MG	A078005	003	Dec 11, 2007	Dec DISC
AB		RUBICON	150MG	A077747	001	Apr 09, 2008	Nov CAHN
AB			300MG	A077747	002	Apr 09, 2008	Nov CAHN
AB			600MG	A077747	003	Apr 09, 2008	Nov CAHN

OXYBUTYNIN CHLORIDEGEL; TRANSDERMAL
GELNIQUE

+!	ALLERGAN	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Nov CTEC
@	PAR PHARM INC	10% (100MG/PACKET)	A207329	001	May 31, 2018	Nov DISC

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

@ LANNETT CO INC

5MG/5ML

A076682 001 Dec 28, 2004 Sep DISC

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB ARISE

5MG

A209025 001 Dec 21, 2017 Sep CAHN

AB EMCURE PHARMS LTD

5MG

A211682 001 May 10, 2019 Apr NEWA

AB NOVAST LABS

5MG

A210611 001 Oct 30, 2019 Oct NEWA

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB ! ACCORD HLTHCARE

15MG

A207138 003 Feb 29, 2016 Aug CHRS

AB AJANTA PHARMA LTD

5MG

A211655 001 Feb 28, 2019 Feb NEWA

AB

10MG

A211655 002 Feb 28, 2019 Feb NEWA

AB

15MG

A211655 003 Feb 28, 2019 Feb NEWA

>A> AB BIONPHARMA INC

5MG

A210717 001 Dec 17, 2019 Dec NEWA

>A> AB

10MG

A210717 002 Dec 17, 2019 Dec NEWA

>A> AB

15MG

A210717 003 Dec 17, 2019 Dec NEWA

>D> AB MYLAN

5MG

A076702 001 Nov 09, 2006 Dec DISC

>A> @

5MG

A076702 001 Nov 09, 2006 Dec DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA ALKEM LABS LTD

5MG/5ML

A211748 001 Feb 07, 2019 Feb NEWA

AA

100MG/5ML

A211749 001 Feb 04, 2019 Jan NEWA

AA EYWA

5MG/5ML

A207511 001 Nov 23, 2016 Sep CAHN

AA

100MG/5ML

A209897 001 Sep 06, 2017 Sep CAHN

@ LANNETT CO INC

100MG/5ML

A204085 001 Sep 09, 2014 Jan DISC

AA PHARM ASSOC

5MG/5ML

A206914 001 Feb 01, 2019 May CPOT

AA

5MG/ML

A206914 001 Feb 01, 2019 Jan NEWA

TABLET;ORAL

OXAYDO

ZYLA

5MG

N202080 001 Jun 17, 2011 Jul CAHN

7.5MG

N202080 002 Jun 17, 2011 Jul CAHN

OXYCODONE HYDROCHLORIDE

AB ! AVANTHI INC

10MG

A091393 002 Aug 31, 2009 Nov CHRS

@ VINTAGE PHARMS

5MG

A077712 003 Mar 02, 2009 Apr DISC

@

10MG

A077712 004 Apr 13, 2015 Apr DISC

@

15MG

A077712 001 Jan 31, 2007 Apr DISC

@

20MG

A077712 005 Apr 13, 2015 Apr DISC

@

30MG

A077712 002 Jan 31, 2007 Apr DISC

ROXYBOND

@ INSPIRION DELIVERY

5MG

N209777 001 Apr 20, 2017 Sep CAHN

@

15MG

N209777 002 Apr 20, 2017 Sep CAHN

@

30MG

N209777 003 Apr 20, 2017 Sep CAHN

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFAD

+! EPI HLTH

1%

N208552 001 Jan 18, 2017 Oct CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OPANA

>D> AB + ENDO PHARMS

5MG

N021611 001 Jun 22, 2006 Dec DISC

>A> + @

5MG

N021611 001 Jun 22, 2006 Dec DISC

>D> AB +!

10MG

N021611 002 Jun 22, 2006 Dec DISC

>A> + @

10MG

N021611 002 Jun 22, 2006 Dec DISC

OXYMORPHONE HYDROCHLORIDE

>D> AB AVANTHI INC

10MG

A203601 002 Jan 30, 2013 Dec CHRS

>A> AB !

10MG

A203601 002 Jan 30, 2013 Dec CHRS

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

@ DR REDDYS

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 May CAHN

@

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008 May CAHN

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

@ ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	Mar DISC
-------------------	--------	---------	-----	--------------	----------

PALBOCICLIBTABLET; ORAL
IBRANCE

+	PFIZER INC	75MG	N212436	001	Nov 01, 2019	Nov NEWA
+		100MG	N212436	002	Nov 01, 2019	Nov NEWA
+	!	125MG	N212436	003	Nov 01, 2019	Nov NEWA

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL
PALIPERIDONE

AB	AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep NEWA
AB		3MG	A204707	002	Sep 23, 2019	Sep NEWA
AB		6MG	A204707	003	Sep 23, 2019	Sep NEWA
AB		9MG	A204707	004	Sep 23, 2019	Sep NEWA
AB	INVENTIA	1.5MG	A204452	001	Jun 12, 2019	Aug CAHN
AB		3MG	A204452	002	Jun 12, 2019	Aug CAHN
AB		6MG	A204452	003	Jun 12, 2019	Aug CAHN
AB		9MG	A204452	004	Jun 12, 2019	Aug CAHN
AB	INVENTIA HLTHCARE	1.5MG	A204452	001	Jun 12, 2019	May NEWA
AB		3MG	A204452	002	Jun 12, 2019	May NEWA
AB		6MG	A204452	003	Jun 12, 2019	May NEWA
AB		9MG	A204452	004	Jun 12, 2019	May NEWA

PALONOSETRON HYDROCHLORIDEINJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

@ DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Mar DISC
----------------------	---	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Jul CAHN
-------	---	---------	-----	--------------	----------

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP	DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May CAHN
AP		60MG/10ML (6MG/ML)	A078156	002	Aug 19, 2008	May CAHN
AP		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May CAHN
	@ LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar DISC
	@	90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar DISC

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)CAPSULE, DELAYED RELEASE; ORAL
ZENPEP

>D>	+	FOREST LABS INC	168,000USP UNITS; 40,000USP UNITS; 126,000USP UNITS	N022210	007	Mar 25, 2014	Dec CAHN
>D>	+		14,000USP UNITS; 3,000USP UNITS; 10,000USP UNITS	N022210	005	Jun 15, 2011	Dec CAHN
>D>	+		24,000USP UNITS; 5,000USP UNITS; 17,000USP UNITS	N022210	001	Aug 27, 2009	Dec CAHN
>D>	+		42,000USP UNITS; 10,000USP UNITS; 32,000USP UNITS	N022210	002	Aug 27, 2009	Dec CAHN
>D>	+		63,000USP UNITS; 15,000USP UNITS; 47,000USP UNITS	N022210	003	Aug 27, 2009	Dec CAHN
>D>	+		84,000USP UNITS; 20,000USP UNITS; 63,000USP UNITS	N022210	004	Aug 27, 2009	Dec CAHN
>D>	+	!	105,000USP UNITS; 25,000USP UNITS; 79,000USP UNITS	N022210	006	Jul 13, 2011	Dec CAHN
>A>	+	ZENPEP	168,000USP UNITS; 40,000USP UNITS; 126,000USP UNITS	N022210	007	Mar 25, 2014	Dec CAHN
>A>	+		14,000USP UNITS; 3,000USP UNITS; 10,000USP UNITS	N022210	005	Jun 15, 2011	Dec CAHN
>A>	+		24,000USP UNITS; 5,000USP UNITS; 17,000USP UNITS	N022210	001	Aug 27, 2009	Dec CAHN
>A>	+		42,000USP UNITS; 10,000USP UNITS; 32,000USP UNITS	N022210	002	Aug 27, 2009	Dec CAHN
>A>	+		63,000USP UNITS; 15,000USP UNITS; 47,000USP UNITS	N022210	003	Aug 27, 2009	Dec CAHN

CAPSULE, DELAYED RELEASE;ORAL
ZENPEP

>A>	+	84,000USP UNITS;20,000USP UNITS;63,000USP UNITS	N022210	004	Aug 27, 2009	Dec CAHN
>A>	+	105,000USP UNITS;25,000USP UNITS;79,000USP UNITS	N022210	006	Jul 13, 2011	Dec CAHN

TABLET;ORAL
VIOKACE

>D>	+	FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Dec CAHN
>D>	+	!	78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Dec CAHN
>A>	+	VIOKACE	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Dec CAHN
>A>	+	!	78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Dec CAHN

PANCURONIUM BROMIDEINJECTABLE;INJECTION
PANCURONIUM BROMIDE

AP	!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
	!		2MG/ML	A072760	001	Jul 31, 1990	May CAHN

PANOBINOSTAT LACTATECAPSULE;ORAL
FARYDAK

+	SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015	Jun CAHN
+		EQ 15MG BASE	N205353	002	Feb 23, 2015	Jun CAHN
+	!	EQ 20MG BASE	N205353	003	Feb 23, 2015	Jun CAHN

PANTOPRAZOLE SODIUMINJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	@	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Oct DISC
		SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Aug NEWA

POWDER;IV (INFUSION)
PANTOPRAZOLE SODIUM

+	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Sep CRLD
!		EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Sep CHRS
		EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul CAHN

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB		INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Feb NEWA
AB		L FERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	May CAHN
AB		RUBICON	EQ 20MG BASE	A090807	001	May 02, 2012	Aug CAHN
AB			EQ 40MG BASE	A090807	002	May 02, 2012	Aug CAHN

PARICALCITOLCAPSULE;ORAL
PARICALCITOL

>D>	AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Dec DISC
>A>		@	1MCG	A206710	001	Feb 24, 2016	Dec DISC
>D>	AB		2MCG	A206710	002	Feb 24, 2016	Dec DISC
>A>		@	2MCG	A206710	002	Feb 24, 2016	Dec DISC
>D>	AB		4MCG	A206710	003	Feb 24, 2016	Dec DISC
>A>		@	4MCG	A206710	003	Feb 24, 2016	Dec DISC

PAROXETINE HYDROCHLORIDETABLET;ORAL
PAROXETINE HYDROCHLORIDE

@	SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Oct DISC
@		EQ 20MG BASE	A078194	002	Jun 29, 2007	Oct DISC
@		EQ 30MG BASE	A078194	003	Jun 29, 2007	Oct DISC
@		EQ 40MG BASE	A078194	004	Jun 29, 2007	Oct DISC

PEGADEMASE BOVINEINJECTABLE;INJECTION
ADAGEN

+	@	LEADIANT BIOSCI INC	250 UNITS/ML	N019818	001	Mar 21, 1990	Oct DISC
---	---	---------------------	--------------	---------	-----	--------------	----------

PENICILLAMINECAPSULE;ORAL
CUPRIMINE

	@ VALEANT PHARMS INTL	125MG	N019853	002		Jan CAHN
AB	+	250MG	N019853	001		Apr CFTG
	+	250MG	N019853	001		Jan CAHN

PENICILLAMINE

AB	AMERIGEN PHARMS LTD	250MG	A209921	001	May 07, 2019	Apr NFTG
>A> AB	PAR PHARM INC	250MG	A211231	001	Dec 23, 2019	Dec NEWA
AB	WATSON LABS INC	250MG	A210976	001	Jun 24, 2019	Jun NEWA

TABLET;ORAL

DEPEN

>D>	+	MYLAN SPECIALITY LP	250MG	N019854	001		Dec CFTG
>A> AB	+		250MG	N019854	001		Dec CFTG
>A>		PENICILLAMINE					
>A> AB		PAR PHARM INC	250MG	A211196	001	Dec 23, 2019	Dec NFTG

PENTAMIDINE ISETHIONATEFOR SOLUTION;INHALATION
NEBUPENT

AN	+	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989	Apr CFTG
		PENTAMIDINE ISETHIONATE					
AN		SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr NFTG

PENTOBARBITAL SODIUMINJECTABLE;INJECTION
PENTOBARBITAL SODIUM

AP		ATHENEX	50MG/ML	A206677	001	Nov 27, 2017	Sep CAHN
----	--	---------	---------	---------	-----	--------------	----------

PENTOSTATININJECTABLE;INJECTION
PENTOSTATIN

	@	MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Mar DISC
--	---	---------------------	-----------	---------	-----	--------------	----------

PENTOXIFYLLINETABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

	@	ANI PHARMS INC	400MG	A074878	001	Jul 09, 1997	May CAHN
	@		400MG	A075107	001	Sep 04, 1998	Sep CAHN
	@	MYLAN	400MG	A074425	001	Jul 08, 1997	Jun DISC

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

>D> AB		ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Dec DISC
>A>	@		2MG	A078138	001	Nov 10, 2009	Dec DISC
>D> AB			4MG	A078138	002	Nov 10, 2009	Dec DISC
>A>	@		4MG	A078138	002	Nov 10, 2009	Dec DISC
>D> AB			8MG	A078138	003	Nov 10, 2009	Dec DISC
>A>	@		8MG	A078138	003	Nov 10, 2009	Dec DISC

PERMETHRINCREAM;TOPICAL
PERMETHRIN

AB		ENCUBE ETHICALS	5%	A211303	001	Apr 03, 2019	Mar NEWA
AB		PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	May CAHN

PEXIDARTINIB HYDROCHLORIDECAPSULE;ORAL
TURALIO

	+	DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019	Aug NEWA
--	---	--------------------	---------------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

	@	UPSHER SMITH LABS	35MG	A084399	001		Jul CAHN
--	---	-------------------	------	---------	-----	--	----------

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE;ORAL
DIBENZYLNE

>D>	AB	+	!	CONCORDIA	10MG	N008708	001		Dec	DISC
>A>		+	@		10MG	N008708	001		Dec	DISC
PHENOXYBENZAMINE HYDROCHLORIDE										
>D>	AB			PAR PHARM INC	10MG	A204522	001	Jan 24, 2017	Dec	CHRS
>A>	AB		!		10MG	A204522	001	Jan 24, 2017	Dec	CHRS

PHENTERMINE HYDROCHLORIDECAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE
@ LANNETT CO INC30MG
A091359 001 Jul 16, 2010 Oct DISC

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE
@ NOVAST LABS 37.5MG
@ SUN PHARM INDS INC 37.5MGA091451 001 Sep 21, 2012 Oct DISC
A040790 001 Aug 21, 2007 Oct DISCPHENYLEPHRINE HYDROCHLORIDESOLUTION;INTRAVENOUS
BIORPHEN

+	!	ETON PHARMS	0.1MG/ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Oct	NEWA
---	---	-------------	---------------------	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

AP2		FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Oct	CTEC
AP			10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Jan	NEWA
AP1			50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Aug	CTEC
AP			50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Jan	NEWA
AP1			100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Aug	CTEC
AP			100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Jan	NEWA
AP2		MEITHEAL	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Aug	CTEC
AP			10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun	CAHN
AP1			50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Aug	CTEC
AP			50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun	CAHN
AP1			100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Aug	CTEC
AP			100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun	CAHN
AP1		PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Aug	CTEC
AP1			50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Aug	CTEC
AP1			100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Aug	CTEC
AP1		SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Aug	CTEC
AP			10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Jan	NEWA
AP1			50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Aug	CTEC
AP			50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Jan	NEWA
AP1			100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Aug	CTEC
AP			100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Jan	NEWA
AP2	+	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Aug	CTEC
AP2	+		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Aug	NEWA
AP2	+		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Aug	NEWA
VAZCULEP								
AP1	+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Oct	CTEC
AP	+		10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Aug	CHRS
AP1	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Oct	CTEC
AP	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Aug	CHRS
AP1	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Aug	CTEC
SOLUTION/DROPS;OPHTHALMIC								
PHENYLEPHRINE HYDROCHLORIDE								
AT	+	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	CTEC
AT	+		10%	N207926	002	Jan 15, 2015	Jan	CTEC
AT	+	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Jan	CTEC
AT	+		10%	N203510	002	Mar 21, 2013	Jan	CTEC

PHENYTOIN SODIUMCAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM

AB		LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019	Sep	NEWA
		@ SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006	Jul	DISC

INJECTABLE;INJECTION
PHENYTOIN SODIUM

@	LUITPOLD	50MG/ML	A040781	001	Dec 04, 2007	Feb	DISC
---	----------	---------	---------	-----	--------------	-----	------

PHYTONADIONEINJECTABLE; INJECTION
PHYTONADIONE

AB	DR REDDYS LABS LTD	10MG/ML	A207719	001	May 22, 2019	May	NEWA
	VITAMIN K1						
AB	! HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	May	CTEC
	TABLET; ORAL						
	MEPHYTON						
AB	+! BAUSCH	5MG	N010104	003		Feb	CAHN
AB	+! VALEANT PHARMS INTL	5MG	N010104	003		Jan	CAHN
	PHYTONADIONE						
AB	ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb	NEWA

PILOCARPINE HYDROCHLORIDESOLUTION; OPHTHALMIC
PILOCARPINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	1%	A210384	001	Nov 25, 2019	Nov	NEWA
AT		2%	A210384	002	Nov 25, 2019	Nov	NEWA
AT		4%	A210384	003	Nov 25, 2019	Nov	NEWA

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Jul	NEWA
AB		7.5MG	A212377	002	Aug 13, 2019	Jul	NEWA
	SALAGEN						
AB	+ CONCORDIA	5MG	N020237	001	Mar 22, 1994	Jul	CAHN
AB	+!	7.5MG	N020237	002	Apr 18, 2003	Jul	CAHN

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

	+ @ ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Jan	DISC
--	-----------------------	--------------	---------	-----	--------------	-----	------

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

AB	+! BAUSCH	1%	N021302	001	Dec 13, 2001	Aug	CAHN
	PIMECROLIMUS						
AB	GLENMARK PHARMS LTD	1%	A211769	001	Aug 29, 2019	Aug	NEWA

PIMOZIDE

TABLET; ORAL

ORAP

	+ @ TEVA	1MG	N017473	003	Aug 27, 1997	Sep	DISC
	+ @	2MG	N017473	001	Jul 31, 1984	Sep	DISC
	PIMOZIDE						
	PAR PHARM	1MG	A204521	001	Sep 28, 2015	Sep	CTEC
	!	2MG	A204521	002	Sep 28, 2015	Sep	CHRS
		2MG	A204521	002	Sep 28, 2015	Sep	CTEC

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	BAYSHORE PHARMS LLC	5MG	A211712	001	Aug 01, 2019	Jul	NEWA
AB		10MG	A211712	002	Aug 01, 2019	Jul	NEWA
	@ ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017	Jun	DISC
	@	10MG	A209866	002	Aug 18, 2017	Jun	DISC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP	ASTRAL	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Dec	DISC
>A>		@	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Dec	DISC
	AP		EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Jul	NEWA
>D>	AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Dec	DISC
>A>		@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Dec	DISC
	AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Jul	NEWA

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Dec DISC
>A>	@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Dec DISC
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Jul NEWA
	@	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Oct DISC
	@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Oct DISC
	@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Oct DISC
	@		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Oct DISC
	AP	QILU	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Nov CAHN
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Nov CAHN
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Nov CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

>D>	AB	BRECKENRIDGE	10MG	A206136	001	Jun 20, 2017	Dec CAHN
	AB		10MG	A206136	001	Jun 20, 2017	Aug CAHN
>D>	AB		20MG	A206136	002	Jun 20, 2017	Dec CAHN
	AB		20MG	A206136	002	Jun 20, 2017	Aug CAHN
	AB	CADILA	10MG	A205585	001	Jul 17, 2018	Feb CAHN
	AB		20MG	A205585	002	Jul 17, 2018	Feb CAHN
>D>	AB	MYLAN IRELAND LTD	10MG	A074116	001	Jun 15, 1993	Dec CAHN
>D>	AB		20MG	A074118	001	Jun 15, 1993	Dec CAHN
>A>	AB	NOSTRUM LABS INC	10MG	A074116	001	Jun 15, 1993	Dec CAHN
>A>	AB		20MG	A074118	001	Jun 15, 1993	Dec CAHN
>A>	AB	PII	10MG	A206136	001	Jun 20, 2017	Dec CAHN
>A>	AB		20MG	A206136	002	Jun 20, 2017	Dec CAHN
	@	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Oct DISC
	@		20MG	A073536	001	Mar 12, 1993	Oct DISC

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

	@	MYLAN	EQ 1MG BASE	A206070	001	Apr 04, 2019	Apr DISC
	@		EQ 2MG BASE	A206070	002	Apr 04, 2019	Apr DISC
	@		EQ 4MG BASE	A206070	003	Apr 04, 2019	Apr DISC
AB		MYLAN PHARMS INC	EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar NEWA
AB			EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar NEWA
AB			EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar NEWA

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

+	@	MEDICURE	EQ 1MG BASE	N208379	001	Jul 14, 2017	Sep DISC
+			EQ 2MG BASE	N208379	002	Jul 14, 2017	Oct CAHN
+	!		EQ 4MG BASE	N208379	003	Jul 14, 2017	Oct CAHN

PITOLISANT HYDROCHLORIDE

TABLET; ORAL

WAKIX

+		BIOPROJET PHARMA	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Aug NEWA
+	!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Aug NEWA
+		HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Sep CAHN
+	!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Sep CAHN

PLAZOMICIN SULFATE

SOLUTION; INTRAVENOUS

ZEMDRI

+	!	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jul CAHN
---	---	-----------	---	---------	-----	--------------	----------

PLECANATIDETABLET; ORAL
TRULANCE

+	!	BAUSCH	3MG	N208745	001	Jan 19, 2017	Mar CAHN
+	!	SALIX	3MG	N208745	001	Jan 19, 2017	Apr CAHN

POLYETHYLENE GLYCOL 3350FOR SOLUTION; ORAL
GLYCOLAX

@	LANNETT CO INC	17GM/SCOOPFUL	A076652	001	Jul 02, 2004	May DISC
@	NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706	001	Sep 27, 2006	May DISC
@	PADDOCK LLC	17GM/SCOOPFUL	A077893	001	May 26, 2006	May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SOLUTION; ORAL
GOLYTELY

>D>	+	!	BRAINTREE	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N019011	002	Jun 02, 1992	Dec DISC
>A>	+	@		227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N019011	002	Jun 02, 1992	Dec DISC

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

AP	!	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Oct CHRS
		@ WEST-WARD PHARMS INT	EQ 500,000 UNITS BASE/VIAL	A060716	001		Oct DISC

PORFIMER SODIUMINJECTABLE; INJECTION
PHOTOFRIN

		PINNACLE BIOLOGICS	75MG/VIAL	N020451	001	Dec 27, 1995	Oct CAHN
--	--	--------------------	-----------	---------	-----	--------------	----------

POSACONAZOLETABLET, DELAYED RELEASE; ORAL
NOXAFIL

AB	+	!	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013	Aug CFTG
AB			SINOTHERAPEUTICS INC	100MG	A212411	001	Aug 21, 2019	Aug NFTG

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

>D>	AB		ANDA REPOSITORY	8MEQ	A205549	001	Dec 08, 2015	Dec CAHN
	AB			8MEQ	A205549	001	Dec 08, 2015	Aug CAHN
>D>	AB			10MEQ	A205549	002	Dec 08, 2015	Dec CAHN
	AB			10MEQ	A205549	002	Dec 08, 2015	Aug CAHN
>A>	AB		PII	8MEQ	A205549	001	Dec 08, 2015	Dec CAHN
>A>	AB			10MEQ	A205549	002	Dec 08, 2015	Dec CAHN
	AB		PRINSTON INC	8MEQ	A209026	001	Jun 11, 2019	May NEWA
	AB			10MEQ	A209026	002	Jun 11, 2019	May NEWA
	AB		ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
	AB			10MEQ	A208445	002	Mar 11, 2019	Feb NEWA

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

AA			AMNEAL PHARMS LLC	20MEQ	A210902	001	May 23, 2019	May NEWA
AA			BELCHER PHARMS LLC	20MEQ	A212183	001	May 06, 2019	Apr NEWA

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA			PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019	Mar NEWA
AA				40MEQ/15ML	A210766	002	Mar 29, 2019	Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

K-TAB

AB3	+	!	ABBVIE	20MEQ	N018279	003	Nov 25, 2013	Sep CTEC
			KLOR-CON M15					
AB1			UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Mar CTEC
			POTASSIUM CHLORIDE					
AB1			ADARE PHARMS INC	10MEQ	A076368	002	Jun 05, 2019	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

>D>	@ ANDA REPOSITORY	8MEQ	A206881	001	Jan 22, 2019	Dec CAHN
	@	8MEQ	A206881	001	Jan 22, 2019	Aug CAHN
>D>	@	10MEQ	A206881	002	Jan 22, 2019	Dec CAHN
	@	10MEQ	A206881	002	Jan 22, 2019	Aug CAHN
>D>	@ BRECKENRIDGE	10MEQ	A206630	001	Mar 29, 2019	Dec CAHN
	@	10MEQ	A206630	001	Mar 29, 2019	Nov DISC
AB1		10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
>D> AB3		10MEQ	A210097	001	Jun 17, 2019	Dec DISC
>A>	@	10MEQ	A210097	001	Jun 17, 2019	Dec DISC
AB3		10MEQ	A210097	001	Jun 17, 2019	Aug CAHN
>D>	@	15MEQ	A206630	002	Mar 29, 2019	Dec CAHN
	@	15MEQ	A206630	002	Mar 29, 2019	Nov DISC
AB1		15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
>D>	@	20MEQ	A206630	003	Mar 29, 2019	Dec CAHN
	@	20MEQ	A206630	003	Mar 29, 2019	Nov DISC
AB1		20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
>D> AB3		20MEQ	A210098	001	Apr 26, 2019	Dec DISC
>A>	@	20MEQ	A210098	001	Apr 26, 2019	Dec DISC
AB3		20MEQ	A210098	001	Apr 26, 2019	Sep CTEC
AB2		20MEQ	A210098	001	Apr 26, 2019	Aug CAHN
>A>	@ PII	8MEQ	A206881	001	Jan 22, 2019	Dec CAHN
	@	8MEQ	A206881	001	Jan 22, 2019	Jul DISC
AB2		8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
>A>	@	10MEQ	A206630	001	Mar 29, 2019	Dec CAHN
AB1		10MEQ	A206630	001	Mar 29, 2019	Mar NEWA
>A>	@	10MEQ	A206881	002	Jan 22, 2019	Dec CAHN
	@	10MEQ	A206881	002	Jan 22, 2019	Jul DISC
AB2		10MEQ	A206881	002	Jan 22, 2019	Jan NEWA
>A>	@	10MEQ	A210097	001	Jun 17, 2019	Dec CAHN
AB3		10MEQ	A210097	001	Jun 17, 2019	Jun NEWA
>A>	@	15MEQ	A206630	002	Mar 29, 2019	Dec CAHN
AB1		15MEQ	A206630	002	Mar 29, 2019	Mar NEWA
>A>	@	20MEQ	A206630	003	Mar 29, 2019	Dec CAHN
AB1		20MEQ	A206630	003	Mar 29, 2019	Mar NEWA
>A>	@	20MEQ	A210098	001	Apr 26, 2019	Dec CAHN
AB2		20MEQ	A210098	001	Apr 26, 2019	Apr NEWA
AB1	PRINSTON INC	10MEQ	A209922	001	Apr 30, 2019	Apr NEWA
AB1		15MEQ	A209922	002	Apr 30, 2019	Apr NEWA
AB1		20MEQ	A209922	003	Apr 30, 2019	Apr NEWA
AB3	VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Sep CTEC
AB3	YICHANG HUMANWELL	10MEQ	A212561	001	Sep 30, 2019	Sep NEWA
AB3		20MEQ	A212561	002	Sep 30, 2019	Sep NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

>A> AB	ANI PHARMS INC	10MEQ	A212779	001	Jan 14, 2020	Dec NEWA
>A> AB		15MEQ	A212779	002	Jan 14, 2020	Dec NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES

+!	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Nov CPOT
+!		4500MG/15ML (300MG/ML);2650MG/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Sep NEWA
+!	FRESENIUS KABI USA	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	N212832	001	Nov 26, 2019	Nov NEWA
+!		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	N212832	002	Nov 26, 2019	Nov NEWA
+!		11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)	N212832	003	Nov 26, 2019	Nov NEWA

PRALATREXATE

SOLUTION;INTRAVENOUS
FOLOTYN

+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar CAHN
+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	May	CAHN
>D>	AB	0.125MG	A090241	001	Oct 08, 2010	Dec	DISC
>A>	@	0.125MG	A090241	001	Oct 08, 2010	Dec	DISC
AB		0.125MG	A090241	001	Oct 08, 2010	Sep	CAHN
	@	0.125MG	A091254	001	Nov 30, 2010	May	CAHN
AB		0.25MG	A077724	002	Feb 19, 2008	May	CAHN
>D>	AB	0.25MG	A090241	002	Oct 08, 2010	Dec	DISC
>A>	@	0.25MG	A090241	002	Oct 08, 2010	Dec	DISC
AB		0.25MG	A090241	002	Oct 08, 2010	Sep	CAHN
	@	0.25MG	A091254	002	Nov 30, 2010	May	CAHN
AB		0.5MG	A077724	003	Feb 19, 2008	May	CAHN
>D>	AB	0.5MG	A090241	003	Oct 08, 2010	Dec	DISC
>A>	@	0.5MG	A090241	003	Oct 08, 2010	Dec	DISC
AB		0.5MG	A090241	003	Oct 08, 2010	Sep	CAHN
	@	0.5MG	A091254	003	Nov 30, 2010	May	CAHN
>D>	AB	0.75MG	A090241	004	Oct 08, 2010	Dec	DISC
>A>	@	0.75MG	A090241	004	Oct 08, 2010	Dec	DISC
AB		0.75MG	A090241	004	Oct 08, 2010	Sep	CAHN
	@	0.75MG	A091254	004	Nov 30, 2010	May	CAHN
AB		1MG	A077724	004	Feb 19, 2008	May	CAHN
>D>	AB	1MG	A090241	005	Oct 08, 2010	Dec	DISC
>A>	@	1MG	A090241	005	Oct 08, 2010	Dec	DISC
AB		1MG	A090241	005	Oct 08, 2010	Sep	CAHN
	@	1MG	A091254	005	Nov 30, 2010	May	CAHN
AB		1.5MG	A077724	005	Feb 19, 2008	May	CAHN
>D>	AB	1.5MG	A090241	006	Oct 08, 2010	Dec	DISC
>A>	@	1.5MG	A090241	006	Oct 08, 2010	Dec	DISC
AB		1.5MG	A090241	006	Oct 08, 2010	Sep	CAHN
	@	1.5MG	A091254	006	Nov 30, 2010	May	CAHN
	@ SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Oct	DISC
	@	0.25MG	A091683	002	Mar 27, 2013	Oct	DISC
	@	0.5MG	A091683	003	Mar 27, 2013	Oct	DISC
	@	0.75MG	A091683	004	Mar 27, 2013	Oct	DISC
	@	1MG	A091683	005	Mar 27, 2013	Oct	DISC
	@	1.5MG	A091683	006	Mar 27, 2013	Oct	DISC

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	APNAR PHARMA LP	10MG	A076397	003	Oct 23, 2006	Jun	CAHN
>A>	AB	10MG	A077491	002	Oct 23, 2006	Dec	CMS1
AB		20MG	A076397	002	Oct 23, 2006	Jun	CAHN
>A>	AB	20MG	A077491	003	Oct 23, 2006	Dec	CMS1
AB		40MG	A076397	001	Oct 23, 2006	Jun	CAHN
>A>	AB	40MG	A077491	004	Oct 23, 2006	Dec	CMS1
AB		80MG	A077491	001	Feb 11, 2008	Jun	CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

ECONOPRED

@	EYEVANCE	0.125%	N017468	001		May	CAHN
---	----------	--------	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	May	CTEC
@	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	May	DISC

PREDNISONE

TABLET;ORAL

PREDNISONE

AB	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Jul	CMFD
	@	1MG	A211496	001	Dec 28, 2018	May	DISC
AB		2.5MG	A211495	001	Dec 07, 2018	Jul	CMFD
	@	2.5MG	A211495	001	Dec 07, 2018	May	DISC
AB		5MG	A211495	002	Dec 07, 2018	Jul	CMFD
	@	5MG	A211495	002	Dec 07, 2018	May	DISC
AB		10MG	A210525	001	Dec 04, 2018	Jul	CMFD
	@	10MG	A210525	001	Dec 04, 2018	May	DISC

TABLET;ORAL
PREDNISONE

AB		20MG	A210525	002	Dec 04, 2018	Jul CMFD
	@	20MG	A210525	002	Dec 04, 2018	May DISC
AB		50MG	A210525	003	Dec 04, 2018	Jul CMFD
	@	50MG	A210525	003	Dec 04, 2018	May DISC
AB	NOVITIUM PHARMA	2.5MG	A211575	001	Nov 15, 2019	Nov NEWA
AB		5MG	A211575	002	Nov 15, 2019	Nov NEWA
AB		10MG	A211575	003	Nov 15, 2019	Nov NEWA
AB		20MG	A211575	004	Nov 15, 2019	Nov NEWA
AB		50MG	A211575	005	Nov 15, 2019	Nov NEWA
AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan CMS1

PREGABALIN

CAPSULE;ORAL
LYRICA

AB	+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Jul CFTG
AB	+		50MG	N021446	002	Dec 30, 2004	Jul CFTG
AB	+		75MG	N021446	003	Dec 30, 2004	Jul CFTG
AB	+		100MG	N021446	004	Dec 30, 2004	Jul CFTG
AB	+		150MG	N021446	005	Dec 30, 2004	Jul CFTG
AB	+		200MG	N021446	006	Dec 30, 2004	Jul CFTG
AB	+		225MG	N021446	007	Dec 30, 2004	Jul CFTG
AB	+		300MG	N021446	008	Dec 30, 2004	Jul CFTG

PREGABALIN

AB		ALEMBIC PHARMS LTD	25MG	A203459	001	Jul 19, 2019	Jul NFTG
AB			50MG	A203459	002	Jul 19, 2019	Jul NFTG
AB			75MG	A203459	003	Jul 19, 2019	Jul NFTG
AB			100MG	A203459	004	Jul 19, 2019	Jul NFTG
AB			150MG	A203459	005	Jul 19, 2019	Jul NFTG
AB			200MG	A203459	006	Jul 19, 2019	Jul NFTG
AB			225MG	A203459	007	Jul 19, 2019	Jul NFTG
AB			300MG	A203459	008	Jul 19, 2019	Jul NFTG
AB		ALKEM LABS LTD	25MG	A211177	001	Sep 30, 2019	Sep NEWA
AB			50MG	A211177	002	Sep 30, 2019	Sep NEWA
AB			75MG	A207799	001	Jul 19, 2019	Jul NFTG
AB			100MG	A207799	002	Jul 19, 2019	Jul NFTG
AB			150MG	A207799	003	Jul 19, 2019	Jul NFTG
AB			200MG	A207799	004	Jul 19, 2019	Jul NFTG
AB			225MG	A207799	005	Jul 19, 2019	Jul NFTG
AB			300MG	A207799	006	Jul 19, 2019	Jul NFTG
AB		AMNEAL PHARMS CO	25MG	A209743	001	Jul 19, 2019	Jul NFTG
AB			50MG	A209743	002	Jul 19, 2019	Jul NFTG
AB			75MG	A209743	003	Jul 19, 2019	Jul NFTG
AB			100MG	A209743	004	Jul 19, 2019	Jul NFTG
AB			150MG	A209743	005	Jul 19, 2019	Jul NFTG
AB			200MG	A209743	006	Jul 19, 2019	Jul NFTG
AB			225MG	A209743	007	Jul 19, 2019	Jul NFTG
AB			300MG	A209743	008	Jul 19, 2019	Jul NFTG
>A>	AB	CIPLA	25MG	A212280	001	Jan 10, 2020	Dec NEWA
>A>	AB		50MG	A212280	002	Jan 10, 2020	Dec NEWA
>A>	AB		75MG	A212280	003	Jan 10, 2020	Dec NEWA
>A>	AB		100MG	A212280	004	Jan 10, 2020	Dec NEWA
>A>	AB		150MG	A212280	005	Jan 10, 2020	Dec NEWA
>A>	AB		200MG	A212280	006	Jan 10, 2020	Dec NEWA
>A>	AB		225MG	A212280	007	Jan 10, 2020	Dec NEWA
>A>	AB		300MG	A212280	008	Jan 10, 2020	Dec NEWA
>A>	AB	CSPC OUYI	50MG	A210585	001	Dec 26, 2019	Dec NEWA
>A>	AB		75MG	A210585	002	Dec 26, 2019	Dec NEWA
>A>	AB		100MG	A210585	003	Dec 26, 2019	Dec NEWA
>A>	AB		150MG	A210585	004	Dec 26, 2019	Dec NEWA
>A>	AB		200MG	A210585	005	Dec 26, 2019	Dec NEWA
>A>	AB		300MG	A210585	006	Dec 26, 2019	Dec NEWA
AB		DR REDDYS	25MG	A209664	001	Jul 19, 2019	Jul NFTG
AB			50MG	A209664	002	Jul 19, 2019	Jul NFTG
AB			75MG	A209664	003	Jul 19, 2019	Jul NFTG
AB			100MG	A209664	004	Jul 19, 2019	Jul NFTG
AB			150MG	A209664	005	Jul 19, 2019	Jul NFTG
AB			200MG	A209664	006	Jul 19, 2019	Jul NFTG
AB			225MG	A209664	007	Jul 19, 2019	Jul NFTG
AB			300MG	A209664	008	Jul 19, 2019	Jul NFTG
AB		HETERO LABS LTD III	25MG	A206912	001	Oct 08, 2019	Sep NEWA
AB			50MG	A206912	002	Oct 08, 2019	Sep NEWA

CAPSULE;ORAL						
PREGABALIN						
AB		75MG	A206912	003	Oct 08, 2019	Sep NEWA
AB		100MG	A206912	004	Oct 08, 2019	Sep NEWA
AB		150MG	A206912	005	Oct 08, 2019	Sep NEWA
AB		200MG	A206912	006	Oct 08, 2019	Sep NEWA
AB		225MG	A206912	007	Oct 08, 2019	Sep NEWA
AB		300MG	A206912	008	Oct 08, 2019	Sep NEWA
AB	INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019	Jul NFTG
AB		50MG	A211384	002	Jul 19, 2019	Jul NFTG
AB		75MG	A211384	003	Jul 19, 2019	Jul NFTG
AB		100MG	A211384	004	Jul 19, 2019	Jul NFTG
AB		150MG	A211384	005	Jul 19, 2019	Jul NFTG
AB		200MG	A211384	006	Jul 19, 2019	Jul NFTG
AB		225MG	A211384	007	Jul 19, 2019	Jul NFTG
AB		300MG	A211384	008	Jul 19, 2019	Jul NFTG
AB	MSN	25MG	A209357	001	Jul 19, 2019	Jul NFTG
AB		50MG	A209357	002	Jul 19, 2019	Jul NFTG
AB		75MG	A209357	003	Jul 19, 2019	Jul NFTG
AB		100MG	A209357	004	Jul 19, 2019	Jul NFTG
AB		150MG	A209357	005	Jul 19, 2019	Jul NFTG
AB		200MG	A209357	006	Jul 19, 2019	Jul NFTG
AB		225MG	A209357	007	Jul 19, 2019	Jul NFTG
AB		300MG	A209357	008	Jul 19, 2019	Jul NFTG
AB	MYLAN	25MG	A091228	001	Sep 20, 2019	Sep NEWA
AB		50MG	A091228	002	Sep 20, 2019	Sep NEWA
AB		75MG	A091228	003	Sep 20, 2019	Sep NEWA
AB		100MG	A091228	004	Sep 20, 2019	Sep NEWA
AB		150MG	A091228	005	Sep 20, 2019	Sep NEWA
AB		200MG	A091228	006	Sep 20, 2019	Sep NEWA
AB		225MG	A091228	007	Sep 20, 2019	Sep NEWA
AB		300MG	A091228	008	Sep 20, 2019	Sep NEWA
AB	RISING	25MG	A210432	001	Jul 19, 2019	Jul NFTG
AB		50MG	A210432	002	Jul 19, 2019	Jul NFTG
AB		75MG	A210432	003	Jul 19, 2019	Jul NFTG
AB		100MG	A210432	004	Jul 19, 2019	Jul NFTG
AB		150MG	A210432	005	Jul 19, 2019	Jul NFTG
AB		200MG	A210432	006	Jul 19, 2019	Jul NFTG
AB		225MG	A210432	007	Jul 19, 2019	Jul NFTG
AB		300MG	A210432	008	Jul 19, 2019	Jul NFTG
AB	SCIEGEN PHARMS INC	25MG	A208677	001	Jul 19, 2019	Jul NFTG
AB		50MG	A208677	002	Jul 19, 2019	Jul NFTG
AB		75MG	A208677	003	Jul 19, 2019	Jul NFTG
AB		100MG	A208677	004	Jul 19, 2019	Jul NFTG
AB		150MG	A208677	005	Jul 19, 2019	Jul NFTG
AB		200MG	A208677	006	Jul 19, 2019	Jul NFTG
AB		225MG	A208677	007	Jul 19, 2019	Jul NFTG
AB		300MG	A208677	008	Jul 19, 2019	Jul NFTG
AB	SHUANGCHENG	75MG	A210891	001	Sep 30, 2019	Sep NEWA
AB		300MG	A210891	002	Sep 30, 2019	Sep NEWA
AB	SUN PHARM	25MG	A091157	001	Nov 29, 2019	Nov NEWA
AB		50MG	A091157	002	Nov 29, 2019	Nov NEWA
AB		75MG	A091157	003	Nov 29, 2019	Nov NEWA
AB		100MG	A091157	004	Nov 29, 2019	Nov NEWA
AB		150MG	A091157	005	Nov 29, 2019	Nov NEWA
AB		200MG	A091157	006	Nov 29, 2019	Nov NEWA
AB		225MG	A091157	007	Nov 29, 2019	Nov NEWA
AB		300MG	A091157	008	Nov 29, 2019	Nov NEWA
AB	TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Jul NFTG
AB		50MG	A091219	002	Jul 19, 2019	Jul NFTG
AB		75MG	A091224	001	Jul 19, 2019	Jul NFTG
AB		100MG	A091224	002	Jul 19, 2019	Jul NFTG
AB		150MG	A091224	003	Jul 19, 2019	Jul NFTG
AB		200MG	A091224	004	Jul 19, 2019	Jul NFTG
AB		225MG	A091224	005	Jul 19, 2019	Jul NFTG
AB		300MG	A091224	006	Jul 19, 2019	Jul NFTG
SOLUTION;ORAL						
LYRICA						
AA	+! PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010	Jul CFTG
PREGABALIN						
AA	ALKEM LABS LTD	20MG/ML	A207623	001	Jul 19, 2019	Jul NFTG

PRETOMANIDTABLET; ORAL
PRETOMANID

+	!	MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019	Oct CAHN
+	!	TB ALLIANCE	200MG	N212862	001	Aug 14, 2019	Aug NEWA

PROBENECIDTABLET; ORAL
PROBENECID

AB		MYLAN	500MG	A084211	002		Sep CHRS
	!	WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	Sep CHRS

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP		NEXUS PHARMS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Feb NEWA
----	--	--------------	----------------	---------	-----	--------------	----------

PROCHLORPERAZINE MALEATETABLET; ORAL
PROCHLORPERAZINE MALEATE

	@	TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996	Jul DISC
	@		EQ 10MG BASE	A040120	002	Jul 11, 1996	Jul DISC

PROGESTERONECAPSULE; ORAL
PROGESTERONE

AB		XIROMED	100MG	A205229	001	Oct 20, 2017	Nov CAHN
AB			200MG	A205229	002	Oct 20, 2017	Nov CAHN

INJECTABLE; INJECTION
PROGESTERONE

	@	LUITPOLD	50MG/ML	A090845	001	Jun 22, 2009	Mar DISC
--	---	----------	---------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDESUPPOSITORY; RECTAL
PROMETHAZINE HYDROCHLORIDE

AB		PERRIGO ISRAEL	12.5MG	A040500	001	Jun 30, 2003	May CAHN
AB			25MG	A040500	002	Jun 30, 2003	May CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

	@	IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008	Mar DISC
	@		25MG	A040791	003	Feb 12, 2008	Mar DISC
>A>	@	INVATECH	12.5MG	A084233	001		Dec CAHN
>A>	@		25MG	A085146	001		Dec CAHN
>A>	@		50MG	A085146	002		Dec CAHN
>D>	@	SANDOZ	12.5MG	A084233	001		Dec CAHN
>D>	@		25MG	A085146	001		Dec CAHN
>D>	@		50MG	A085146	002		Dec CAHN

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
INNOPRAN XL

BX	+	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Jul CRLD
BX	+		120MG	N021438	002	Mar 12, 2003	Jul CHRS
BX	+		120MG	N021438	002	Mar 12, 2003	Jul CRLD

PROPRANOLOL HYDROCHLORIDE

AB		ADARE PHARMS INC	60MG	A078703	001	Jul 15, 2011	Sep CAHN
AB			80MG	A078703	002	Jul 15, 2011	Sep CAHN
AB			120MG	A078703	003	Jul 15, 2011	Sep CAHN
AB			160MG	A078703	004	Jul 15, 2011	Sep CAHN
>A>	AB	AMTA	60MG	A212026	001	Jan 06, 2020	Dec NEWA
>A>	AB		80MG	A212026	002	Jan 06, 2020	Dec NEWA
>A>	AB		120MG	A212026	003	Jan 06, 2020	Dec NEWA
>A>	AB		160MG	A212026	004	Jan 06, 2020	Dec NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	@	ANI PHARMS INC	60MG	A071791	001	Jul 15, 1987	Sep CAHN
AB		INNOGENIX	10MG	A070322	002	Oct 22, 1985	Oct CMFD
	@		10MG	A070322	002	Oct 22, 1985	May CMS1
AB			20MG	A070322	003	Oct 22, 1985	Oct CMFD
	@		20MG	A070322	003	Oct 22, 1985	May CMS1
AB			40MG	A070322	004	Oct 22, 1985	Oct CMFD

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	@	40MG	A070322	004	Oct 22, 1985	May CMS1
AB		60MG	A070322	005	Sep 24, 1986	Oct CMFD
	@	60MG	A070322	005	Sep 24, 1986	May CMS1
AB		80MG	A070322	001	Aug 04, 1986	Oct CMFD
	@	80MG	A070322	001	Aug 04, 1986	Mar CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

	@	QUAGEN	50MG	A080154	001	Nov CAHN
--	---	--------	------	---------	-----	----------

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

VIVACTIL

AB		HERITAGE PHARMA	5MG	A073644	001	Aug 24, 1995	May CAHN
AB	!		10MG	A073645	001	Aug 24, 1995	May CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION

MESTINON

AP	+!	BAUSCH	5MG/ML	N009830	001	Feb CAHN
----	----	--------	--------	---------	-----	----------

SYRUP;ORAL

MESTINON

AA	+!	BAUSCH	60MG/5ML	N015193	001	Feb CFTG
	+!		60MG/5ML	N015193	001	Feb CAHN

PYRIDOSTIGMINE BROMIDE

>A>	AA	AMNEAL PHARMS LLC	60MG/5ML	A212702	001	Jan 10, 2020	Dec NEWA
>A>	AA	INVATECH	60MG/5ML	A208797	001	Jan 09, 2020	Dec NEWA
	AA	NOVITIUM PHARMA	60MG/5ML	A211694	001	Mar 08, 2019	Feb NFTG

TABLET;ORAL

MESTINON

AB	+!	BAUSCH	60MG	N009829	002	Feb CAHN
----	----	--------	------	---------	-----	----------

PYRIDOSTIGMINE BROMIDE

		APNAR PHARMA LP	30MG
		ELYSIUM	30MG

AB			60MG	A211181	002	May 14, 2019	May NEWA
				A211181	002	May 14, 2019	Sep CAHN
				A211181	001	Jul 20, 2018	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

MESTINON

AB	+!	BAUSCH	180MG	N011665	001	Feb CAHN
----	----	--------	-------	---------	-----	----------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

	@	DR REDDYS	100MG/ML	A080572	001	May CAHN
--	---	-----------	----------	---------	-----	----------

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

	@	AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018	Apr DISC
--	---	---------------	---------------	---------	-----	--------------	----------

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

>D>	AB	ANI PHARMS INC	EQ 5MG BASE	A075504	001	Aug 24, 2007	Dec DISC
>A>		@	EQ 5MG BASE	A075504	001	Aug 24, 2007	Dec DISC
>D>	AB		EQ 10MG BASE	A075504	002	Aug 24, 2007	Dec DISC
>A>		@	EQ 10MG BASE	A075504	002	Aug 24, 2007	Dec DISC
>D>	AB		EQ 20MG BASE	A075504	003	Aug 24, 2007	Dec DISC
>A>		@	EQ 20MG BASE	A075504	003	Aug 24, 2007	Dec DISC
>D>	AB		EQ 40MG BASE	A075504	004	Aug 24, 2007	Dec DISC
>A>		@	EQ 40MG BASE	A075504	004	Aug 24, 2007	Dec DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINAGLUTE

+	@	BAYER HLTHCARE	324MG	N016647	001	Sep CRLD
---	---	----------------	-------	---------	-----	----------

QUINIDINE GLUCONATE

!		SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Sep CTEC
---	--	----------------------	-------	---------	-----	--------------	----------

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@ SUN PHARM INDUSTRIES 200MG

A081030 001 Apr 14, 1989 Oct DISC

@ 300MG

A081031 001 Apr 14, 1989 Oct DISC

QUININE SULFATE

CAPSULE; ORAL

QUININE SULFATE

@ MYLAN PHARMS INC 324MG

A202581 001 Dec 14, 2012 Mar DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

+ AYU 5MG

N204736 001 Mar 26, 2013 Nov CAHN

+! 10MG

N204736 002 Mar 26, 2013 Nov CAHN

TABLET, DELAYED RELEASE; ORAL

RABEPRAZOLE SODIUM

@ MYLAN 20MG

A076885 001 Nov 08, 2013 Jul DISC

AB RUBICON 20MG

A204237 001 Nov 18, 2015 Feb CAHN

RAMELTEON

TABLET; ORAL

RAMELTEON

AB ZYDUS PHARMS 8MG

A211567 001 Jul 22, 2019 Jul NEWA

RANITIDINE

CAPSULE; ORAL

RANITIDINE

>D> AB NOVITIUM PHARMA EQ 150MG BASE

A210681 001 Nov 23, 2018 Dec CAIN

>D> AB EQ 300MG BASE

A210681 002 Nov 23, 2018 Dec CAIN

>A> RANITIDINE HYDROCHLORIDE

>A> CAPSULE; ORAL

>A> RANITIDINE

>A> AB NOVITIUM PHARMA EQ 150MG BASE

A210681 001 Nov 23, 2018 Dec CAIN

>A> AB EQ 300MG BASE

A210681 002 Nov 23, 2018 Dec CAIN

RANITIDINE HYDROCHLORIDE

AB APPCO EQ 150MG BASE

A211893 001 Apr 05, 2019 Mar NEWA

AB EQ 300MG BASE

A211893 002 Apr 05, 2019 Mar NEWA

>A> AB NOVITIUM PHARMA EQ 150MG BASE

A210681 001 Nov 23, 2018 Dec CTNA

>A> AB EQ 300MG BASE

A210681 002 Nov 23, 2018 Dec CTNA

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

@ ACTAVIS MID ATLANTIC EQ 15MG BASE/ML

A076124 001 Feb 21, 2007 Nov DISC

@ TORRENT EQ 15MG BASE/ML

A090102 001 May 26, 2009 Jul DISC

AA EQ 15MG BASE/ML

A090102 001 May 26, 2009 Jan CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ ANI PHARMS INC EQ 150MG BASE

A074488 001 Jul 31, 1997 Oct DISC

@ EQ 300MG BASE

A074488 002 Jul 31, 1997 Oct DISC

AB HERITAGE PHARMA EQ 150MG BASE

A075165 001 Sep 30, 1998 Feb CAHN

AB EQ 300MG BASE

A075165 002 Sep 30, 1998 Feb CAHN

AB VKT PHARMA PVT LTD EQ 150MG BASE

A211289 001 Jan 31, 2019 Jan NEWA

AB EQ 300MG BASE

A211289 002 Jan 31, 2019 Jan NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

AB + GILEAD 500MG

N021526 002 Jan 27, 2006 Feb CTEC

AB +! 1GM

N021526 001 Feb 12, 2007 Feb CTEC

RANOLAZINE

AB ACTAVIS ELIZABETH 500MG

A208862 001 May 28, 2019 May NEWA

AB 1GM

A208862 002 May 28, 2019 May NEWA

AB AJANTA PHARMA LTD 500MG

A210054 001 May 28, 2019 May NEWA

AB 1GM

A210054 002 May 28, 2019 May NEWA

AB AMERIGEN PHARMS LTD 500MG

A210482 001 Oct 29, 2019 Oct NEWA

AB 1GM

A210482 002 Oct 29, 2019 Oct NEWA

AB CADILA 500MG

A210188 001 Aug 19, 2019 Aug NEWA

AB 1GM

A210188 002 Aug 19, 2019 Aug NEWA

AB CIPLA 500MG

A211291 001 May 28, 2019 May NEWA

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AB		1GM	A211291	002	May 28, 2019	May NEWA
AB	GLENMARK PHARMS LTD	500MG	A211082	001	Jul 05, 2019	Jun NEWA
AB		1GM	A211082	002	Jul 05, 2019	Jun NEWA
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb CMFD
AB		1GM	A201046	002	Jul 29, 2013	Feb CMFD
AB	SCIEGEN PHARMS INC	500MG	A211829	001	Jun 04, 2019	May NEWA
AB		1GM	A211829	002	Jun 04, 2019	May NEWA
AB	SUN PHARM	500MG	A211707	001	May 28, 2019	May NEWA
AB		1GM	A211707	002	May 28, 2019	May NEWA

RASAGILINE

TABLET;ORAL

>D>	RASAGILINE						
>D>	AB	INDOCO REMEDIES	EQ 0.5MG BASE	A206153	001	Oct 04, 2019	Dec CAIN
	AB		EQ 0.5MG BASE	A206153	001	Oct 04, 2019	Sep NEWA
>D>	AB		EQ 1MG BASE	A206153	002	Oct 04, 2019	Dec CAIN
	AB		EQ 1MG BASE	A206153	002	Oct 04, 2019	Sep NEWA

>A> RASAGILINE MESYLATE

TABLET;ORAL

>A>	RASAGILINE						
>A>	AB	INDOCO REMEDIES	EQ 0.5MG BASE	A206153	001	Oct 04, 2019	Dec CAIN
>A>	AB		EQ 1MG BASE	A206153	002	Oct 04, 2019	Dec CAIN
>A>	RASAGILINE MESYLATE						
>A>	AB	INDOCO REMEDIES	EQ 0.5MG BASE	A206153	001	Oct 04, 2019	Dec CTNA
>A>	AB		EQ 1MG BASE	A206153	002	Oct 04, 2019	Dec CTNA
	AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar NEWA
	AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar NEWA

REPAGLINIDE

TABLET;ORAL

	PRANDIN					
	+ @ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
	+ @	1MG	N020741	002	Dec 22, 1997	Mar DISC
	+ @	2MG	N020741	003	Dec 22, 1997	Mar DISC
	REPAGLINIDE					
AB	! AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar CHRS
	@ MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb DISC
	@	1MG	A090252	002	Jan 22, 2014	Jul DISC
	@	2MG	A090252	003	Jan 22, 2014	Jul DISC

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

+!	ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar CAHN
----	----------	----	---------	-----	--------------	----------

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

@	CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Jun DISC
---	-----------------	-------	---------	-----	--------------	----------

SOLUTION;ORAL

REBETOL

+ @	SCHERING	40MG/ML	N021546	001	Jul 29, 2003	Jun DISC
-----	----------	---------	---------	-----	--------------	----------

TABLET;ORAL

RIBAVIRIN

AB	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb CAHN
AB		400MG	A202546	002	Aug 12, 2014	Feb CAHN
AB		500MG	A202546	003	Aug 12, 2014	Feb CAHN
AB		600MG	A202546	004	Aug 12, 2014	Feb CAHN
	@ HERITAGE PHARMA	200MG	A077053	001	Dec 05, 2005	Oct DISC
AB		200MG	A077053	001	Dec 05, 2005	May CAHN

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE;ORAL

AEMCOLO

>D>	+!	COSMO TECHNOLOGIES	EQ 194MG BASE	N210910	001	Nov 16, 2018	Dec CAHN
	+!		EQ 194MG BASE	N210910	001	Nov 16, 2018	Oct CPOT
	+!		194MG	N210910	001	Nov 16, 2018	Oct CAIN
>A>	+!	REDHILL	EQ 194MG BASE	N210910	001	Nov 16, 2018	Dec CAHN

RILUZOLE

	FILM;ORAL								
	EXSERVAN								
	+! AQUESTIVE THERAP	50MG	N212640	001	Nov 22, 2019	Nov	NEWA		
	TABLET;ORAL								
	RILUZOLE								
	@ DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar	DISC		
AB	STANDARD CHEM PHARM	50MG	A206045	001	Dec 09, 2019	Nov	NEWA		

RIMANTADINE HYDROCHLORIDE

	TABLET;ORAL								
	RIMANTADINE HYDROCHLORIDE								
	@ HERITAGE PHARMA	100MG	A076375	001	Jan 14, 2003	May	CAHN		

RIMEXOLONE

	SUSPENSION/DROPS;OPHTHALMIC								
	VEXOL								
	@ EYEVANCE	1%	N020474	001	Dec 30, 1994	May	CAHN		

RISEDRONATE SODIUM

	TABLET;ORAL								
	RISEDRONATE SODIUM								
	@ HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Aug	DISC		
AB		35MG	A207516	001	Feb 15, 2019	Feb	NEWA		
	@ MYLAN	5MG	A200477	001	Nov 30, 2015	May	DISC		
	@	30MG	A200477	002	Nov 30, 2015	May	DISC		
	@	35MG	A200477	003	Nov 30, 2015	May	DISC		
	@	75MG	A200477	004	Jun 10, 2014	May	DISC		
	@	150MG	A200477	005	Jun 10, 2014	May	DISC		
AB	ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr	NEWA		
AB		35MG	A205280	002	May 13, 2019	Apr	NEWA		
	TABLET, DELAYED RELEASE;ORAL								
	RISEDRONATE SODIUM								
AB	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Jun	NEWA		
	@ ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb	DISC		

RISPERIDONE

	SOLUTION;ORAL								
	RISPERIDONE								
>D> AA	ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Dec	DISC		
>A>	@	1MG/ML	A076440	001	Jan 30, 2009	Dec	DISC		
AA	PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Oct	CAHN		
	@ TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Oct	DISC		
AA		1MG/ML	A078909	001	Jul 29, 2009	Jan	CAHN		
	TABLET;ORAL								
	RISPERIDONE								
AB	CELLTRION	0.25MG	A078871	001	Oct 09, 2008	Aug	CAHN		
AB		0.5MG	A078871	002	Oct 09, 2008	Aug	CAHN		
AB		1MG	A078871	003	Oct 09, 2008	Aug	CAHN		
AB		2MG	A078871	004	Oct 09, 2008	Aug	CAHN		
AB		3MG	A078871	005	Oct 09, 2008	Aug	CAHN		
AB		4MG	A078871	006	Oct 09, 2008	Aug	CAHN		
	@ HERITAGE PHARMA	0.25MG	A076228	001	Jun 30, 2008	Aug	DISC		
AB		0.25MG	A076228	001	Jun 30, 2008	May	CAHN		
>D> AB		0.25MG	A077769	001	Oct 16, 2008	Dec	DISC		
>A>	@	0.25MG	A077769	001	Oct 16, 2008	Dec	DISC		
AB		0.25MG	A077769	001	Oct 16, 2008	May	CAHN		
	@	0.5MG	A076228	002	Jun 30, 2008	Aug	DISC		
AB		0.5MG	A076228	002	Jun 30, 2008	May	CAHN		
>D> AB		0.5MG	A077769	002	Oct 16, 2008	Dec	DISC		
>A>	@	0.5MG	A077769	002	Oct 16, 2008	Dec	DISC		
AB		0.5MG	A077769	002	Oct 16, 2008	May	CAHN		
	@	1MG	A076228	003	Jun 30, 2008	Aug	DISC		
AB		1MG	A076228	003	Jun 30, 2008	May	CAHN		
>D> AB		1MG	A077769	003	Oct 16, 2008	Dec	DISC		
>A>	@	1MG	A077769	003	Oct 16, 2008	Dec	DISC		
AB		1MG	A077769	003	Oct 16, 2008	May	CAHN		
	@	2MG	A076228	004	Jun 30, 2008	Aug	DISC		
AB		2MG	A076228	004	Jun 30, 2008	May	CAHN		
>D> AB		2MG	A077769	004	Oct 16, 2008	Dec	DISC		
>A>	@	2MG	A077769	004	Oct 16, 2008	Dec	DISC		

TABLET;ORAL
RISPERIDONE

AB		2MG	A077769	004	Oct 16, 2008	May CAHN
	@	3MG	A076228	005	Jun 30, 2008	Aug DISC
AB		3MG	A076228	005	Jun 30, 2008	May CAHN
>D> AB		3MG	A077769	005	Oct 16, 2008	Dec DISC
>A>	@	3MG	A077769	005	Oct 16, 2008	Dec DISC
AB		3MG	A077769	005	Oct 16, 2008	May CAHN
	@	4MG	A076228	006	Jun 30, 2008	Aug DISC
AB		4MG	A076228	006	Jun 30, 2008	May CAHN
>D> AB		4MG	A077769	006	Oct 16, 2008	Dec DISC
>A>	@	4MG	A077769	006	Oct 16, 2008	Dec DISC
AB		4MG	A077769	006	Oct 16, 2008	May CAHN
AB	RISING	0.25MG	A078269	001	Oct 08, 2008	Sep CAHN
AB		0.5MG	A078269	002	Oct 08, 2008	Sep CAHN
AB		1MG	A078269	003	Oct 08, 2008	Sep CAHN
AB		2MG	A078269	004	Oct 08, 2008	Sep CAHN
AB		3MG	A078269	005	Oct 08, 2008	Sep CAHN
AB		4MG	A078269	006	Oct 08, 2008	Sep CAHN
	@ SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Oct DISC
	@	0.5MG	A078036	002	Mar 10, 2014	Oct DISC
	@	1MG	A078036	003	Mar 10, 2014	Oct DISC
	@	2MG	A078036	004	Mar 10, 2014	Oct DISC
	@	3MG	A078036	005	Mar 10, 2014	Oct DISC
	@	4MG	A078036	006	Mar 10, 2014	Oct DISC

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	May CAHN
AB		1MG	A076908	002	Mar 12, 2012	May CAHN
AB		2MG	A076908	003	Mar 12, 2012	May CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	BRECKENRIDGE	4.6MG/24HR	A209063	001	Nov 26, 2019	Nov NEWA
AB		9.5MG/24HR	A209063	002	Nov 26, 2019	Nov NEWA
AB		13.3MG/24HR	A209063	003	Nov 26, 2019	Nov NEWA
AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
EXELON

+	@ NOVARTIS	EQ 1.5MG BASE	N020823	003	Apr 21, 2000	Aug DISC
+	@	EQ 3MG BASE	N020823	004	Apr 21, 2000	Aug DISC
+	@	EQ 4.5MG BASE	N020823	005	Apr 21, 2000	Aug DISC
+	@	EQ 6MG BASE	N020823	006	Apr 21, 2000	Aug DISC

RIVASTIGMINE TARTRATE

AB	! DR REDDYS LABS INC	EQ 1.5MG BASE	A077130	001	Oct 31, 2007	Aug CHRS
AB	!	EQ 6MG BASE	A077130	004	Oct 31, 2007	Aug CHRS

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	CAMARGO PHARM	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Jul NEWA
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Jul NEWA
AP	SANOVEL ILAC	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Aug CAHN
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Aug CAHN

ROFLUMILAST

TABLET;ORAL
ROFLUMILAST

AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN
AB	CELLTRION	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jul CAHN
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jul CAHN
AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jul CAHN
AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jul CAHN
AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jul CAHN
AB		EQ 4MG BASE	A079050	006	May 29, 2008	Jul CAHN
AB		EQ 5MG BASE	A079050	007	May 29, 2008	Jul CAHN
AB	LAX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar CAHN
AB	MLV	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Sep CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Sep CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Sep CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Sep CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Sep CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Sep CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

	+ @ GLAXOSMITHKLINE LLC	EQ 4MG BASE	N022008	003	Jun 13, 2008	Nov DISC
	ROPINIROLE HYDROCHLORIDE					
AB	CELLTRION	EQ 2MG BASE	A091395	001	Aug 27, 2012	Aug CAHN
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Aug CAHN
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Aug CAHN
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Aug CAHN
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Aug CAHN

ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE

	@ ANI PHARMS INC	EQ 2MG BASE	A076747	001	Jan 25, 2013	Sep CAHN
	@	EQ 4MG BASE	A076747	002	Jan 25, 2013	Sep CAHN
	@	EQ 8MG BASE	A076747	003	Jan 25, 2013	Sep CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@ AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr DISC
	@	10MG	A208850	002	Oct 16, 2018	Apr DISC
	@	20MG	A208850	003	Oct 16, 2018	Apr DISC
	@	40MG	A208850	004	Oct 16, 2018	Apr DISC
	@ MYLAN	5MG	A079161	001	Jul 19, 2016	Jul DISC
	@	10MG	A079161	002	Jul 19, 2016	Jul DISC
	@	20MG	A079161	003	Jul 19, 2016	Jul DISC
	@	40MG	A079161	004	Jul 19, 2016	Jul DISC
	@ SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24, 2019	Nov DISC
AB	@	5MG	A206381	001	Apr 24, 2019	Apr NEWA
	@	10MG	A206381	002	Apr 24, 2019	Nov DISC
AB	@	10MG	A206381	002	Apr 24, 2019	Apr NEWA
	@	20MG	A206381	003	Apr 24, 2019	Nov DISC
AB	@	20MG	A206381	003	Apr 24, 2019	Apr NEWA
	@	40MG	A206381	004	Apr 24, 2019	Nov DISC
AB	@	40MG	A206381	004	Apr 24, 2019	Apr NEWA
AB	SHANDONG	5MG	A207375	001	May 07, 2019	Apr NEWA
AB		10MG	A207375	002	May 07, 2019	Apr NEWA
AB		20MG	A207375	003	May 07, 2019	Apr NEWA
AB		40MG	A207375	004	May 07, 2019	Apr NEWA
	@ TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul DISC
	@	10MG	A079166	002	Jul 19, 2016	Jul DISC
	@	20MG	A079166	003	Jul 19, 2016	Jul DISC
	@	40MG	A079166	004	Jul 19, 2016	Jul DISC
	@ UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Oct DISC
AB	@	5MG	A207626	001	Apr 09, 2019	Mar NEWA
	@	10MG	A207626	002	Apr 09, 2019	Oct DISC
AB	@	10MG	A207626	002	Apr 09, 2019	Mar NEWA

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@	20MG	A207626	003	Apr 09, 2019	Oct	DISC
AB		20MG	A207626	003	Apr 09, 2019	Mar	NEWA
	@	40MG	A207626	004	Apr 09, 2019	Oct	DISC
AB		40MG	A207626	004	Apr 09, 2019	Mar	NEWA
AB	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Oct	NEWA
AB		10MG	A212059	002	Nov 04, 2019	Oct	NEWA
AB		20MG	A212059	003	Nov 04, 2019	Oct	NEWA
AB		40MG	A212059	004	Nov 04, 2019	Oct	NEWA
	@ ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Aug	DISC
AB		5MG	A206513	001	Mar 01, 2019	Feb	NEWA
	@	10MG	A206513	002	Mar 01, 2019	Aug	DISC
AB		10MG	A206513	002	Mar 01, 2019	Feb	NEWA
	@	20MG	A206513	003	Mar 01, 2019	Aug	DISC
AB		20MG	A206513	003	Mar 01, 2019	Feb	NEWA
	@	40MG	A206513	004	Mar 01, 2019	Aug	DISC
AB		40MG	A206513	004	Mar 01, 2019	Feb	NEWA

RUFINAMIDE

SUSPENSION;ORAL

BANZEL

AB	+! EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Apr	CFTG
	RUFINAMIDE						
AB	BIONPHARMA INC	40MG/ML	A211388	001	Apr 23, 2019	Apr	NFTG
AB	HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Apr	NFTG

TABLET;ORAL

RUFINAMIDE

@ MYLAN

@

200MG

400MG

A205095 001 May 16, 2016 Feb DISC
A205095 002 May 16, 2016 Feb DISC

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

AB	+! BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Aug	CFTG
	+	500MG/PACKET	N205065	002	Oct 27, 2015	Sep	CTEC
AB	+	500MG/PACKET	N205065	002	Oct 27, 2015	Aug	CFTG
	SAPROPTERIN DIHYDROCHLORIDE						
AB	PAR PHARM INC	100MG/PACKET	A207207	001	Aug 20, 2019	Aug	NFTG
	@	500MG/PACKET	A210027	001	Aug 20, 2019	Sep	DISC
AB		500MG/PACKET	A210027	001	Aug 20, 2019	Aug	NFTG

TABLET;ORAL

KUVAN

	+! BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	May	CTEC
AB	+!	100MG	N022181	001	Dec 13, 2007	Apr	CFTG
	SAPROPTERIN DIHYDROCHLORIDE						
	@ PAR PHARM INC	100MG	A207200	001	May 10, 2019	May	DISC
AB		100MG	A207200	001	May 10, 2019	Apr	NFTG

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB	MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019	Jun	NEWA
----	--------------------	----------	---------	-----	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

>A>	@ ALLIED	5MG	A074672	001	Apr 01, 1997	Dec	CAHN
AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Jun	CAHN
AB	KENTON	5MG	A074912	001	Apr 30, 1998	Mar	CAHN
	@ MYLAN	5MG	A074866	001	Nov 26, 1997	Aug	DISC
>D>	@ SIEGFRIED	5MG	A074672	001	Apr 01, 1997	Dec	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

	+! BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar	CAHN
--	-----------	--------	---------	-----	--------------	-----	------

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

	+! AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Apr	NEWA
--	--------------	--	---------	-----	--------------	-----	------

SELINEXORTABLET;ORAL
XPOVIO

+	!	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Jul NEWA
---	---	--------------------	------	---------	-----	--------------	----------

SEMAGLUTIDETABLET;ORAL
RYBELSUS

+		NOVO	3MG	N213051	001	Sep 20, 2019	Sep NEWA
+			7MG	N213051	002	Sep 20, 2019	Sep NEWA
+	!		14MG	N213051	003	Sep 20, 2019	Sep NEWA

SERTACONAZOLE NITRATECREAM;TOPICAL
ERTACZO

+	!	BAUSCH	2%	N021385	001	Dec 10, 2003	Jun CAHN
---	---	--------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

		@ CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Jun DISC
AB			EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
		@	EQ 50MG BASE	A077106	002	Feb 06, 2007	Jun DISC
AB			EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
		@	EQ 100MG BASE	A077106	003	Feb 06, 2007	Jun DISC
AB			EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN
		@ HERITAGE PHARMA	EQ 25MG BASE	A076465	001	Aug 11, 2006	Oct DISC
AB			EQ 25MG BASE	A076465	001	Aug 11, 2006	May CAHN
		@	EQ 25MG BASE	A077299	001	Feb 06, 2007	May CAHN
		@	EQ 25MG BASE	A077345	001	Feb 06, 2007	May CAHN
		@	EQ 50MG BASE	A076465	002	Aug 11, 2006	Oct DISC
AB			EQ 50MG BASE	A076465	002	Aug 11, 2006	May CAHN
		@	EQ 50MG BASE	A077299	002	Feb 06, 2007	May CAHN
		@	EQ 50MG BASE	A077345	002	Feb 06, 2007	May CAHN
		@	EQ 100MG BASE	A076465	003	Aug 11, 2006	Oct DISC
AB			EQ 100MG BASE	A076465	003	Aug 11, 2006	May CAHN
		@	EQ 100MG BASE	A077299	003	Feb 06, 2007	May CAHN
		@	EQ 100MG BASE	A077345	003	Feb 06, 2007	May CAHN
		@ MYLAN PHARMS INC	EQ 25MG BASE	A078626	001	Jan 31, 2008	May DISC
		@	EQ 50MG BASE	A078626	002	Jan 31, 2008	May DISC

SEVELAMER HYDROCHLORIDETABLET;ORAL
RENAGEL

AB	+	GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
AB	+	!	800MG	N021179	002	Jul 12, 2000	Feb CFTG
		SEVELAMER HYDROCHLORIDE					
AB		GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb NFTG
AB			800MG	A204724	002	Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATEFOR SUSPENSION;ORAL
REVATIO

AB	+	!	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	May CFTG
		SILDENAFIL CITRATE						
AB		AJANTA PHARMA LTD	EQ 10MG BASE/ML	A212883	001	Nov 27, 2019	Nov NEWA	
AB		ALKEM LABS LTD	EQ 10MG BASE/ML	A212440	001	Nov 27, 2019	Nov NEWA	
AB		AMNEAL PHARMS	EQ 10MG BASE/ML	A211092	001	Nov 27, 2019	Nov NEWA	
AB		NOVITIUM PHARMA	EQ 10MG BASE/ML	A212260	001	May 31, 2019	May NFTG	

TABLET;ORAL

SILDENAFIL CITRATE

AB		LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar NEWA
AB			EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar NEWA
AB			EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar NEWA
AB		MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar NEWA
AB			EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar NEWA
AB			EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar NEWA

SILODOSINCAPSULE;ORAL
SILODOSIN

AB	ALEMBIC PHARMS LTD	4MG	A211731	001	Nov 22, 2019	Nov	NEWA
AB		8MG	A211731	002	Nov 22, 2019	Nov	NEWA

SIMVASTATINTABLET;ORAL
SIMVASTATIN

AB	MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar	CAHN
AB		10MG	A090383	002	Sep 16, 2011	Mar	CAHN
AB		20MG	A090383	003	Sep 16, 2011	Mar	CAHN
AB		40MG	A090383	004	Sep 16, 2011	Mar	CAHN
AB		80MG	A090383	005	Sep 16, 2011	Mar	CAHN

SIPONIMODTABLET;ORAL
MAYZENT

+	NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Mar	NEWA
+	!	2MG	N209884	002	Mar 26, 2019	Mar	NEWA

SIPONIMOD FUMARIC ACIDTABLET;ORAL
MAYZENT

+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr	CAIN
+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr	CAIN

SIROLIMUSSOLUTION;ORAL
RAPAMUNE

AA	+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan	CFTG
		SIROLIMUS						
AA		AMNEAL PHARMS LLC	1MG/ML	A211212	001	Oct 18, 2019	Oct	NEWA
AA		APOTEX	1MG/ML	A211406	001	Oct 22, 2019	Oct	NEWA
AA		NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan	NFTG

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

AP		EXELA PHARMA SCS LLC	0.5MEQ/ML	A211091	001	Jun 20, 2019	Oct	CTEC
			0.5MEQ/ML	A211091	001	Jun 20, 2019	Jun	NEWA
AP			0.9MEQ/ML	A211091	002	Jun 20, 2019	Jun	NEWA
AP			1MEQ/ML	A211091	003	Jun 20, 2019	Jun	NEWA
AP		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Oct	CMFD

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

>A>	+	B BRAUN	9MG/10ML	N019635	005	Aug 11, 2016	Dec	CPOT
>D>	+		900MG/10ML	N019635	005	Aug 11, 2016	Dec	CPOT
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Sep	CAHN
	+	@ LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Aug	DISC
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb	NEWA

SODIUM CHROMATE CR-51INJECTABLE;INJECTION
SODIUM CHROMATE CR 51
@ CURIUM

100uCi/ML	N016708	001		Jan	CAHN
-----------	---------	-----	--	-----	------

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP		DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Apr	CAHN
----	--	---------	--------------	---------	-----	--------------	-----	------

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

@ CURIUM	0.8-100mCi	N016515	002		Jan CAHN
+ @	0.8-100mCi	N016517	001		Jan CAHN
@	15-100uCi	N016517	002		Jan CAHN

SOLUTION;ORAL

SODIUM IODIDE I 131

+ @ CURIUM	3.5-150mCi/VIAL	N016515	001		Jan CAHN
------------	-----------------	---------	-----	--	----------

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

AP	CAPLIN	25MG/ML	A211016	001	Nov 29, 2019	Nov NEWA
AP	DR REDDYS LABS LTD	25MG/ML	A210114	001	Apr 10, 2019	Mar NEWA
AP	SAGENT PHARMS INC	25MG/ML	A207426	001	Dec 08, 2016	Sep CAHN
	@ SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018	Jul DISC
	@ VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018	Oct DISC
AP		25MG/ML	A209834	001	Jun 26, 2018	Jul CAHN

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+ @ EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Jul DISC
--------------------------	----------------------	---------	-----	--------------	----------

SODIUM PHENYLEBUTYRATE

POWDER;ORAL

BUPHENYL

AB	+! HORIZON THERAP	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Feb CAHN
----	-------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BUPHENYL

AB	+! HORIZON THERAP	500MG	N020572	001	May 13, 1996	Feb CAHN
----	-------------------	-------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	NOVELGENIX THERAPS	454GM/BOT	A206815	001	Feb 18, 2016	Sep CAHN
----	--------------------	-----------	---------	-----	--------------	----------

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP	CUSTOPHARM INC	60MG/2ML (30MG/ML)	A209937	001	Dec 09, 2019	Nov NEWA
	SOTRADECOL					
AP	! MYLAN INSTITUTIONAL	60MG/2ML (30MG/ML)	A040541	002	Nov 12, 2004	Nov CTEC

SOFOSBUVIR

PELLETS;ORAL

SOVALDI

+ GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019	Aug NEWA
+!	200MG/PACKET	N212480	002	Aug 28, 2019	Aug NEWA

TABLET;ORAL

SOVALDI

+ GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019	Aug NEWA
-----------------------	-------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	May NEWA
AB		10MG	A205483	002	May 20, 2019	May NEWA
AB	ALEMBIC PHARMS LTD	5MG	A205575	001	May 20, 2019	May NEWA
AB		10MG	A205575	002	May 20, 2019	May NEWA
AB	ALKEM LABS LTD	5MG	A210224	001	May 20, 2019	May NEWA
AB		10MG	A210224	002	May 20, 2019	May NEWA
AB	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	May NEWA
AB		10MG	A209719	002	May 20, 2019	May NEWA
AB	BRECKENRIDGE	5MG	A209818	001	May 20, 2019	May NEWA
AB		10MG	A209818	002	May 20, 2019	May NEWA
AB	CELLTRION	5MG	A210582	001	May 20, 2019	May NEWA
AB		10MG	A210582	002	May 20, 2019	May NEWA
AB	CIPLA	5MG	A209839	001	May 20, 2019	May NEWA
AB		10MG	A209839	002	May 20, 2019	May NEWA
AB	CSPC OUYI	5MG	A211423	001	Dec 11, 2019	Nov NEWA
AB		10MG	A211423	002	Dec 11, 2019	Nov NEWA

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	GLENMARK PHARMS INC	5MG	A209239	001	May 20, 2019	May NEWA
AB		10MG	A209239	002	May 20, 2019	May NEWA
AB	JIANGXI BOYA SEEHOT	5MG	A210281	001	May 20, 2019	May NEWA
AB		10MG	A210281	002	May 20, 2019	May NEWA
AB	MSN	5MG	A210688	001	May 20, 2019	May NEWA
AB		10MG	A210688	002	May 20, 2019	May NEWA
AB	QILU	5MG	A209333	001	May 20, 2019	May NEWA
AB		10MG	A209333	002	May 20, 2019	May NEWA
AB	SCIEGEN PHARMS INC	5MG	A211657	001	May 20, 2019	May NEWA
AB		10MG	A211657	002	May 20, 2019	May NEWA
AB	STRIDES PHARMA	5MG	A212214	001	Sep 26, 2019	Sep NEWA
AB		10MG	A212214	002	Sep 26, 2019	Sep NEWA
AB	UNICHEM LABS LTD	5MG	A211701	001	Aug 27, 2019	Aug NEWA
AB		10MG	A211701	002	Aug 27, 2019	Aug NEWA
AB	WATSON LABS INC	5MG	A202551	001	May 20, 2019	May NEWA
AB		10MG	A202551	002	May 20, 2019	May NEWA

SOLRIAMFETOL

TABLET;ORAL

SUNOSI

+	JAZZ	75MG	N211230	001	Jun 17, 2019	Jun NEWA
+		150MG	N211230	002	Jun 17, 2019	Jun NEWA

SOMATROPIN

INJECTABLE;INJECTION

GENOTROPIN

>A>	BX	+	PHARMACIA	5.8MG/VIAL	N020280	006	Aug 24, 1995	Dec CAHN
>A>		+		13.8MG/VIAL	N020280	007	Oct 23, 1996	Dec CAHN
>D>	BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995	Dec CAHN
	BX	+		5.8MG/VIAL	N020280	006	Aug 24, 1995	Aug CAIN
>D>		+		13.8MG/VIAL	N020280	007	Oct 23, 1996	Dec CAHN
		+		13.8MG/VIAL	N020280	007	Oct 23, 1996	Aug CAIN
GENOTROPIN PRESERVATIVE FREE								
>A>		+	PHARMACIA	0.2MG/VIAL	N020280	001	Jan 27, 1998	Dec CAHN
>A>		+		0.4MG/VIAL	N020280	002	Jan 27, 1998	Dec CAHN
>A>		+		0.6MG/VIAL	N020280	003	Jan 27, 1998	Dec CAHN
>A>		+		0.8MG/VIAL	N020280	005	Jan 27, 1998	Dec CAHN
>A>		+		1MG/VIAL	N020280	008	Jan 27, 1998	Dec CAHN
>A>		+		1.2MG/VIAL	N020280	009	Jan 27, 1998	Dec CAHN
>A>		+		1.4MG/VIAL	N020280	010	Jan 27, 1998	Dec CAHN
>A>		+	@	1.5MG/VIAL	N020280	004	Aug 24, 1995	Dec CAHN
>A>		+		1.6MG/VIAL	N020280	011	Jan 27, 1998	Dec CAHN
>A>		+		1.8MG/VIAL	N020280	012	Jan 27, 1998	Dec CAHN
>A>		+		2MG/VIAL	N020280	013	Jan 27, 1998	Dec CAHN
>D>		+	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998	Dec CAHN
		+		0.2MG/VIAL	N020280	001	Jan 27, 1998	Aug CAIN
>D>		+		0.4MG/VIAL	N020280	002	Jan 27, 1998	Dec CAHN
		+		0.4MG/VIAL	N020280	002	Jan 27, 1998	Aug CAIN
>D>		+		0.6MG/VIAL	N020280	003	Jan 27, 1998	Dec CAHN
		+		0.6MG/VIAL	N020280	003	Jan 27, 1998	Aug CAIN
>D>		+		0.8MG/VIAL	N020280	005	Jan 27, 1998	Dec CAHN
		+		0.8MG/VIAL	N020280	005	Jan 27, 1998	Aug CAIN
>D>		+		1MG/VIAL	N020280	008	Jan 27, 1998	Dec CAHN
		+		1MG/VIAL	N020280	008	Jan 27, 1998	Aug CAIN
>D>		+		1.2MG/VIAL	N020280	009	Jan 27, 1998	Dec CAHN
		+		1.2MG/VIAL	N020280	009	Jan 27, 1998	Aug CAIN
>D>		+		1.4MG/VIAL	N020280	010	Jan 27, 1998	Dec CAHN
		+		1.4MG/VIAL	N020280	010	Jan 27, 1998	Aug CAIN
>D>		+	@	1.5MG/VIAL	N020280	004	Aug 24, 1995	Dec CAHN
		+	@	1.5MG/VIAL	N020280	004	Aug 24, 1995	Aug CAIN
>D>		+		1.6MG/VIAL	N020280	011	Jan 27, 1998	Dec CAHN
		+		1.6MG/VIAL	N020280	011	Jan 27, 1998	Aug CAIN
>D>		+		1.8MG/VIAL	N020280	012	Jan 27, 1998	Dec CAHN
		+		1.8MG/VIAL	N020280	012	Jan 27, 1998	Aug CAIN
>D>		+		2MG/VIAL	N020280	013	Jan 27, 1998	Dec CAHN
		+		2MG/VIAL	N020280	013	Jan 27, 1998	Aug CAIN

NORDITROPIN

@ NOVO NORDISK INC

@

@

5MG/1.5ML

10MG/1.5ML

15MG/1.5ML

N021148 001 Jun 20, 2000 Aug CAIN

N021148 002 Jun 20, 2000 Aug CAIN

N021148 003 Jun 20, 2000 Aug CAIN

	INJECTABLE; INJECTION							
	NORDITROPIN FLEXPRO							
BX	NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010	Aug	CAIN	
BX		10MG/1.5ML	N021148	009	Mar 01, 2010	Aug	CAIN	
		15MG/1.5ML	N021148	010	Mar 01, 2010	Aug	CAIN	
		30MG/3ML	N021148	011	Jan 23, 2015	Aug	CAIN	
	NORDITROPIN NORDIFLEX							
	@ NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004	Aug	CAIN	
	@	10MG/1.5ML	N021148	005	Oct 01, 2004	Aug	CAIN	
	@	15MG/1.5ML	N021148	006	Oct 01, 2004	Aug	CAIN	
	@	30MG/3ML	N021148	007	Mar 10, 2009	Aug	CAIN	
	NUTROPIN							
	@ GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Aug	CAIN	
	@	10MG/VIAL	N020168	002	Nov 17, 1993	Aug	CAIN	
	NUTROPIN AQ							
	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Aug	CAIN	
	NUTROPIN AQ NUSPIN							
+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Aug	CAIN	
+	!	10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Aug	CAIN	
+	!	20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Aug	CAIN	
	NUTROPIN AQ PEN							
+	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Aug	CAIN	
+	@	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Aug	CAIN	
	OMNITROPE							
BX	SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006	Aug	CAIN	
BX		5MG/1.5ML	N021426	003	Jan 16, 2008	Aug	CAIN	
BX		5.8MG/VIAL	N021426	001	May 30, 2006	Aug	CAIN	
BX		10MG/1.5ML	N021426	004	Aug 25, 2008	Aug	CAIN	
	SAIZEN							
	@ EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007	Aug	CAIN	
BX	+	5MG/VIAL	N019764	002	Oct 08, 1996	Aug	CAIN	
	@	6MG/VIAL	N019764	001	Oct 08, 1996	Aug	CAIN	
	+	!	8.8MG/VIAL	N019764	003	Aug 29, 2000	Aug	CAIN
	SEROSTIM							
	EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997	Aug	CAIN	
BX		5MG/VIAL	N020604	002	Aug 23, 1996	Aug	CAIN	
BX		6MG/VIAL	N020604	001	Aug 23, 1996	Aug	CAIN	
	@	8.8MG/VIAL	N020604	004	Sep 06, 2001	Aug	CAIN	
	INJECTABLE; SUBCUTANEOUS							
	SEROSTIM LQ							
	@ EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005	Aug	CAIN	
	<u>SOTALOL HYDROCHLORIDE</u>							
	TABLET; ORAL							
	BETAPACE							
AB	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May	CTEC
AB	+		120MG	N019865	005	Apr 20, 1994	May	CTEC
AB	+	!	160MG	N019865	002	Oct 30, 1992	May	CTEC
AB	+		240MG	N019865	003	Oct 30, 1992	May	CTEC
	BETAPACE AF							
AB	+	COVIS PHARMA BV	80MG	N021151	001	Feb 22, 2000	May	CTEC
AB	+		120MG	N021151	002	Feb 22, 2000	May	CTEC
AB	+	!	160MG	N021151	003	Feb 22, 2000	May	CTEC
	SORINE							
AB	UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001	May	CTEC	
AB		120MG	A075500	004	Apr 27, 2001	May	CTEC	
AB		160MG	A075500	002	Apr 27, 2001	May	CTEC	
AB		240MG	A075500	003	Apr 27, 2001	May	CTEC	
	SOTALOL HYDROCHLORIDE							
AB	APOTEX	80MG	A076140	001	Sep 26, 2002	May	CTEC	
AB		80MG	A076214	001	Aug 27, 2003	May	CTEC	
AB		120MG	A076140	002	Sep 26, 2002	May	CTEC	
AB		120MG	A076214	002	Aug 27, 2003	May	CTEC	
AB		160MG	A076140	003	Sep 26, 2002	May	CTEC	
AB		160MG	A076214	003	Aug 27, 2003	May	CTEC	
AB		240MG	A076140	004	Sep 26, 2002	May	CTEC	
AB	BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	May	CTEC	
AB		80MG	A207429	001	Nov 02, 2018	May	CTEC	
AB		120MG	A207428	002	Oct 21, 2016	May	CTEC	
AB		120MG	A207429	002	Nov 02, 2018	May	CTEC	
AB		160MG	A207428	003	Oct 21, 2016	May	CTEC	
AB		160MG	A207429	003	Nov 02, 2018	May	CTEC	

TABLET;ORAL

SOTALOL HYDROCHLORIDE

AB	EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	May CTEC
AB		120MG	A077070	002	Nov 04, 2005	May CTEC
AB		160MG	A077070	003	Nov 04, 2005	May CTEC
AB	MYLAN	80MG	A077616	001	Feb 07, 2007	May CTEC
AB		120MG	A077616	002	Feb 07, 2007	May CTEC
AB		160MG	A077616	003	Feb 07, 2007	May CTEC
AB	OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	May CTEC
AB		120MG	A075563	002	Nov 07, 2003	May CTEC
AB		160MG	A075563	003	Nov 07, 2003	May CTEC
AB		240MG	A075563	004	Nov 07, 2003	May CTEC
AB	TEVA	80MG	A075429	001	May 01, 2000	May CTEC
AB		120MG	A075429	002	May 01, 2000	May CTEC
AB		160MG	A075429	003	May 01, 2000	May CTEC
AB		240MG	A075429	004	May 01, 2000	May CTEC

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

@	ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006	Jun DISC
@		50MG	A040353	001	Jul 29, 1999	Jun DISC
@		100MG	A040353	002	Jul 29, 1999	Jun DISC
@	CASI PHARMS INC	25MG	A086809	001		Jun DISC

STAVUDINE

CAPSULE;ORAL

STAVUDINE

@	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008	Nov DISC
@		20MG	A078957	002	Dec 29, 2008	Nov DISC
@		30MG	A078957	003	Dec 29, 2008	Nov DISC
@		40MG	A078957	004	Dec 29, 2008	Nov DISC
@	MYLAN	15MG	A079069	001	Dec 29, 2008	Oct DISC
@		20MG	A079069	002	Dec 29, 2008	Oct DISC
@		30MG	A079069	003	Dec 29, 2008	Oct DISC
@		40MG	A079069	004	Dec 29, 2008	Oct DISC

FOR SOLUTION;ORAL

ZERIT

+	@	BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996	Mar DISC
---	---	----------------------	--------	---------	-----	--------------	----------

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

+	@	HOSPIRA	100% (1ML)	N018801	001	Oct 27, 1982	Nov DISC
AP	+	!	100% (1ML)	N018801	001	Oct 27, 1982	Nov CPOT
AP	+	!	100% (10ML)	N018801	002	Oct 27, 1982	Nov NEWA
	+	!	100% (20ML)	N018801	003	Oct 27, 1982	Nov NEWA
	+	!	100% (50ML)	N018801	004	Oct 27, 1982	Nov NEWA
	+	!	100% (100ML)	N018801	005	Oct 27, 1982	Nov NEWA
		MEDEFIL INC	100% (1ML)	A211188	001	Dec 02, 2019	Nov NEWA
	!		100% (2.5ML)	A211188	002	Dec 02, 2019	Nov NEWA
	!		100% (3ML)	A211188	003	Dec 02, 2019	Nov NEWA
	!		100% (5ML)	A211188	004	Dec 02, 2019	Nov NEWA
AP			100% (10ML)	A211188	005	Dec 02, 2019	Nov NEWA
AP		WEST-WARD PHARMS INT	100% (10ML)	A206369	001	Sep 02, 2015	Nov CPOT
	@		100% (20ML)	A206369	002	Sep 02, 2015	Nov DISC
			100% (20ML)	A206369	002	Sep 02, 2015	Nov NEWA

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER

AT	+	BAXTER HLTHCARE	100%	N017428	001		Oct CRLD
----	---	-----------------	------	---------	-----	--	----------

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	+	!	Q BIOMED	1mCi/ML	N020134	001	Jun 18, 1993	Jan CAHN
			STRONTIUM CHLORIDE SR-89					
AP			Q BIOMED	1mCi/ML	A075941	001	Jan 06, 2003	Oct CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE

AP	AMRING PHARMS	20MG/ML	A210231	001	Jun 04, 2018	Jan CAHN
AP	BRECKENRIDGE	20MG/ML	A212638	001	Oct 09, 2019	Nov CAHN
AP	DR REDDYS	20MG/ML	A210698	001	Aug 02, 2019	Jul NEWA
AP	GPP	20MG/ML	A212638	001	Oct 09, 2019	Sep NEWA
>A> AP	SOMERSET THERAPS LLC	20MG/ML	A211589	001	Jan 15, 2020	Dec NEWA

SUCRALFATE

SUSPENSION;ORAL
CARAFATE

AB	+! ALLERGAN	1GM/10ML	N019183	001	Dec 16, 1993	Nov CFTG
AB	AMNEAL PHARMS LLC	1GM/10ML	A209356	001	Dec 02, 2019	Nov NFTG
	TABLET;ORAL SUCRALFATE					
>D>	@ MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Dec CAHN
>A>	@ NOSTRUM LABS INC	1GM	A074415	001	Jun 08, 1998	Dec CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	ANDA REPOSITORY	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Sep CAHN
AP	! MYLAN LABS LTD	80MG/ML;16MG/ML	A206607	001	Aug 30, 2017	Aug CHRS
AP	SOMERSET	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Oct CAHN
AP	SOMERSET THERAPS LLC	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Jun NEWA
	@ TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Aug DISC

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	ANI PHARMS INC	200MG/5ML;40MG/5ML	A077612	001	Nov 13, 2006	Oct CMFD
	TABLET;ORAL SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH					
	@ HERITAGE PHARMA	800MG;160MG	A070037	001	Jun 02, 1987	Nov DISC
AB		800MG;160MG	A070037	001	Jun 02, 1987	May CAHN
	SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH					
	@ HERITAGE PHARMA	400MG;80MG	A070030	001	Jun 02, 1987	Nov DISC
AB		400MG;80MG	A070030	001	Jun 02, 1987	May CAHN

SUMATRIPTAN

SPRAY;NASAL
TOSYMRA

+!	DR REDDYS LABS LTD	10MG/SPRAY	N210884	001	Jan 25, 2019	Jan NEWA
+!	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019	Sep CAHN
+!		10MG/SPRAY	N210884	001	Jan 25, 2019	Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

	@ MYLAN LABS LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Sep DISC
	@ PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Apr DISC
>D> AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009	Dec DISC
>A>	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009	Dec DISC
	@ ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Apr CAHN

POWDER;NASAL

ONZETRA XSAIL

+!	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Sep CDFR
+!	CURRAX	EQ 11MG BASE	N206099	001	Jan 27, 2016	Sep CAHN

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

+	UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul CAHN
---	-------------------	---------------------------------------	---------	-----	--------------	----------

TACROLIMUSOINTMENT; TOPICAL
TACROLIMUS

AB	ACCORD HLTHCARE	0.03%	A211688	001	Jan 31, 2019	Jan NEWA
AB		0.1%	A211688	002	Jan 31, 2019	Jan NEWA

TADALAFILTABLET; ORAL
ALYQ

AB2	TEVA PHARMS USA	20MG	A209942	001	Feb 05, 2019	Jan NEWA
	TADALAFIL					
AB	ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209167	002	Mar 26, 2019	Mar NEWA
AB1		20MG	A209167	004	Mar 26, 2019	Mar NEWA
AB	AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209654	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209654	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209654	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210392	001	Feb 05, 2019	Jan NEWA
AB	ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Mar NEWA
AB		5MG	A204809	002	Mar 26, 2019	Mar NEWA
AB		10MG	A204809	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A204809	004	Mar 26, 2019	Mar NEWA
AB	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209744	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209744	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209744	004	Mar 26, 2019	Mar NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Mar NEWA
AB		5MG	A206285	002	Mar 26, 2019	Mar NEWA
AB		10MG	A206285	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A206285	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A206286	001	Feb 05, 2019	Jan NEWA
AB	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209539	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209539	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209539	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210255	001	Feb 05, 2019	Jan NEWA
AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210069	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210069	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210069	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210145	001	Feb 05, 2019	Jan NEWA
AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209908	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209908	003	Mar 26, 2019	Mar NEWA
AB2		20MG	A209907	001	Feb 05, 2019	Jan NEWA
AB1		20MG	A209908	004	Mar 26, 2019	Mar NEWA
AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210567	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210567	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210567	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210572	001	Feb 05, 2019	Jan NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Sep NEWA
AB		5MG	A207244	002	Oct 07, 2019	Sep NEWA
AB		10MG	A207244	003	Oct 07, 2019	Sep NEWA
AB1		20MG	A207244	004	Oct 07, 2019	Sep NEWA
AB2		20MG	A207290	001	Oct 16, 2019	Sep NEWA
AB	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Apr NEWA
AB		5MG	A206957	001	Apr 29, 2019	Apr NEWA
AB		10MG	A206956	002	Apr 29, 2019	Apr NEWA
AB1		20MG	A206956	003	Apr 29, 2019	Apr NEWA
AB	QILU	2.5MG	A210420	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210420	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210420	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210420	004	Mar 26, 2019	Mar NEWA
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar NEWA
AB		5MG	A208934	002	Mar 26, 2019	Mar NEWA
AB		10MG	A208934	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A208934	004	Mar 26, 2019	Mar NEWA
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211335	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211335	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211335	004	Mar 26, 2019	Mar NEWA

TABLET;ORAL

TADALAFIL

AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A211839	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A211839	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A211839	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A212062	001	Mar 26, 2019	Mar	NEWA
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209250	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209250	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209250	004	Mar 26, 2019	Mar	NEWA
	@ WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Sep	DISC
AB		2.5MG	A205885	001	Mar 29, 2019	Mar	NEWA
	@	5MG	A205885	002	Mar 29, 2019	Sep	DISC
AB		5MG	A205885	002	Mar 29, 2019	Mar	NEWA
	@	10MG	A205885	003	Mar 29, 2019	Sep	DISC
AB		10MG	A205885	003	Mar 29, 2019	Mar	NEWA
	@	20MG	A205885	004	Mar 29, 2019	Sep	DISC
AB1		20MG	A205885	004	Mar 29, 2019	Mar	NEWA
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A206693	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A206693	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A206693	004	Mar 26, 2019	Mar	NEWA

TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX

+	!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	May	NEWA
---	---	---------------	------	---------	-----	--------------	-----	------

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

+	!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	May	NEWA
---	---	---------------	------	---------	-----	--------------	-----	------

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

AT		MICRO LABS	0.0015%	A209051	001	Aug 19, 2019	Aug	NFTG	
		ZIOPTAN							
AT	+	!	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Aug	CFTG

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

FORTOVIA

EQ 20MG BASE/10ML

N021807 001 Oct 29, 2005 Aug CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB		ANBISON LAB	0.4MG	A211885	001	Oct 17, 2019	Oct	NEWA
	@	MYLAN	0.4MG	A090408	001	Apr 27, 2010	Nov	DISC

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

@ FOUGERA PHARMS INC

0.1%

A211175 001 Jan 28, 2019 Aug DISC

AB 0.1%

A211175 001 Jan 28, 2019 May CPOT

AB 1%

A211175 001 Jan 28, 2019 Jan NEWA

>A> LOTION;TOPICAL

>A> ARAZLO

>A> +! BAUSCH 0.045%

N211882 001 Dec 18, 2019 Dec NEWA

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION

HEPATOLITE

@ PHARMALUCENCE

N/A

N018467 001 Mar 16, 1982 Aug DISC

<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>									
INJECTABLE; INJECTION									
TECHNISCAN MAG3									
AP	+	CURIUM	N/A	N019882	001	Jun 15, 1990	Jul	CFTG	
	+		N/A	N019882	001	Jun 15, 1990	Jan	CAHN	
TECHNETIUM TC99M MERTIATIDE KIT									
AP		PHARMALUCENCE	N/A	A208994	001	Jul 12, 2019	Jul	NFTG	
<u>TECHNETIUM TC-99M OXIDRONATE KIT</u>									
INJECTABLE; INJECTION									
TECHNISCAN									
	+	CURIUM	N/A	N018321	001		Jan	CAHN	
<u>TECHNETIUM TC-99M PENTETATE KIT</u>									
INJECTABLE; INJECTION									
DRAXIMAGE DTPA									
	+	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Sep	CTNA	
<u>TECHNETIUM TC-99M PYROPHOSPHATE KIT</u>									
INJECTABLE; INJECTION									
TECHNISCAN PYP KIT									
AP		CURIUM	N/A	N017538	001		Jan	CAHN	
<u>TECHNETIUM TC-99M RED BLOOD CELL KIT</u>									
INJECTABLE; INJECTION									
ULTRATAG									
	+	CURIUM	N/A	N019981	001	Jun 10, 1991	Jan	CAHN	
<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>									
SOLUTION; INTRAVENOUS									
ULTRA-TECHNEKOW FM									
	+	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan	CAHN	
	@		0.25-3 CI/GENERATOR	N017243	002		Jan	CAHN	
SOLUTION; INTRAVENOUS, ORAL									
TECHNETIUM TC 99M GENERATOR									
	+	@ GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Feb	DISC	
<u>TEGASEROD MALEATE</u>									
TABLET; ORAL									
ZELNORM									
	+	@ ALFASIGMA	EQ 2MG BASE	N021200	001	Jul 24, 2002	Aug	CAHN	
	+		EQ 6MG BASE	N021200	002	Jul 24, 2002	Sep	CMFD	
	+	@	EQ 6MG BASE	N021200	002	Jul 24, 2002	Aug	CAHN	
	+	@ US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jul	CRLD	
	+	@	EQ 6MG BASE	N021200	002	Jul 24, 2002	Jul	CRLD	
<u>TELMISARTAN</u>									
TABLET; ORAL									
TELMISARTAN									
	@	CIPLA	20MG	A078710	001	Jan 08, 2014	Jun	DISC	
AB			20MG	A078710	001	Jan 08, 2014	Feb	CAHN	
	@		40MG	A078710	002	Jan 08, 2014	Feb	CAHN	
	@		80MG	A078710	003	Jan 08, 2014	Feb	CAHN	
	@	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Aug	DISC	
AB			20MG	A207843	001	Feb 19, 2019	Feb	NEWA	
	@		40MG	A207843	002	Feb 19, 2019	Aug	DISC	
AB			40MG	A207843	002	Feb 19, 2019	Feb	NEWA	
	@		80MG	A207843	003	Feb 19, 2019	Aug	DISC	
AB			80MG	A207843	003	Feb 19, 2019	Feb	NEWA	
		INVENTIA	20MG	A205150	001	Oct 30, 2015	Aug	CAHN	
AB			40MG	A205150	002	Oct 30, 2015	Aug	CAHN	
AB			80MG	A205150	003	Oct 30, 2015	Aug	CAHN	
	@	MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar	DISC	
	@		40MG	A207016	002	Oct 03, 2017	Mar	DISC	
	@		80MG	A207016	003	Oct 03, 2017	Mar	DISC	
	@	WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb	DISC	

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

@	APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan	DISC
@		20MG	A204159	002	Jul 05, 2018	Jan	DISC
@		100MG	A204159	003	Jul 05, 2018	Jan	DISC
@		140MG	A204159	004	Jul 05, 2018	Jan	DISC
@		180MG	A204159	005	Jul 05, 2018	Jan	DISC
@		250MG	A204159	006	Jul 05, 2018	Jan	DISC
@	LANNETT CO INC	5MG	A203898	001	Feb 10, 2016	Oct	DISC
@		20MG	A203898	002	Feb 10, 2016	Oct	DISC
@		100MG	A203898	003	Feb 10, 2016	Oct	DISC
@		140MG	A203898	004	Feb 10, 2016	Oct	DISC
@		180MG	A203898	005	Feb 10, 2016	Oct	DISC
@		250MG	A203898	006	Feb 10, 2016	Oct	DISC

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TEMSIROLIMUS

AP	GLAND PHARMA LTD	25MG/ML (25MG/ML)	A207383	001	Aug 16, 2019	Aug	NEWA
----	------------------	-------------------	---------	-----	--------------	-----	------

TENAPANOR HYDROCHLORIDE

TABLET; ORAL

IBSRELA

+	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Sep	NEWA
---	-------------	--------------	---------	-----	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

@	APOTEX	300MG	A206481	001	Jul 26, 2018	Jan	DISC
@	CHARTWELL	300MG	A206481	001	Jul 26, 2018	Nov	CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun	CAHN
AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun	CAHN
AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun	CAHN
AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun	CAHN
	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb	CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb	CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb	CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb	CAHN
AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar	CAHN
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar	CAHN
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar	CAHN
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar	CAHN
AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun	CAHN
AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun	CAHN
AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun	CAHN
AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

	@ CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007	Nov	CAHN
AB	HERITAGE PHARMA	EQ 250MG BASE	A076377	001	Jul 02, 2007	May	CAHN

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@	DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004	May	CAHN
---	-----------	--------	---------	-----	--------------	-----	------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

BX	+	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	May	CAHN
		SUPPOSITORY; VAGINAL						
		TERCONAZOLE						
AB	!	PERRIGO ISRAEL	80MG	A077149	001	Mar 17, 2006	May	CAHN

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB	ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr	NEWA
AB		14MG	A209572	002	Apr 19, 2019	Apr	NEWA
	@ AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb	DISC
	@	14MG	A209613	002	Sep 28, 2018	Feb	DISC
	@ APOTEX	7MG	A209601	001	Nov 02, 2018	Jan	DISC
	@	14MG	A209601	002	Nov 02, 2018	Jan	DISC
	@ AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb	DISC
	@	14MG	A209638	002	Oct 26, 2018	Feb	DISC
	@ MSN	7MG	A209623	001	Apr 24, 2019	Oct	DISC
	@	14MG	A209623	002	Apr 24, 2019	Oct	DISC
AB	MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Apr	NEWA
AB		14MG	A209623	002	Apr 24, 2019	Apr	NEWA
	@ TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar	DISC
	@	14MG	A209700	002	Sep 04, 2018	Mar	DISC
	@ WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb	DISC
	@	14MG	A209549	002	Jul 27, 2018	Feb	DISC
	@ ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	May	DISC
	@	14MG	A209668	002	Nov 30, 2018	May	DISC

TERIPARATIDE RECOMBINANT HUMAN

SOLUTION; SUBCUTANEOUS

BONSITY

	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Nov	CAHN
	PFENEX INC	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Oct	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

TESTOSTERONE

	@ PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Mar	DISC
--	-------------	-------------------	---------	-----	--------------	-----	------

GEL, METERED; NASAL

NATESTO

>A>	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Dec	CAHN
>D>	AYTU	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Dec	CAHN

GEL, METERED; TRANSDERMAL

TESTOSTERONE

AB	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019	Mar	NEWA
AB	AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019	Mar	NEWA
AB	DR REDDYS	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Mar	NEWA
AB	LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019	Mar	NEWA
AB	TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A209390	001	Sep 23, 2019	Sep	NEWA

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

	+ @ AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Jul	DISC
--	-------------------------	------	---------	-----	--------------	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

	@ MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Mar	DISC
AO	WILSHIRE PHARMS INC	200MG/ML	A206368	001	Apr 24, 2019	Apr	NEWA

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL

JATENZO

	+ CLARUS	158MG	N206089	001	Mar 27, 2019	Mar	NEWA
	+	198MG	N206089	002	Mar 27, 2019	Mar	NEWA
	+!	237MG	N206089	003	Mar 27, 2019	Mar	NEWA

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

>D>	@ LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Dec	CMFD
>A> AB		12.5MG	A210544	001	Apr 20, 2018	Dec	CMFD
	@	12.5MG	A210544	001	Apr 20, 2018	Feb	DISC
>D>	@	25MG	A210544	002	Apr 20, 2018	Dec	CMFD
>A> AB		25MG	A210544	002	Apr 20, 2018	Dec	CMFD
	@	25MG	A210544	002	Apr 20, 2018	Feb	DISC
AB	MYLAN	12.5MG	A207682	001	Jan 31, 2017	Jul	CAHN
AB		25MG	A207682	002	Jan 31, 2017	Jul	CAHN

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

BAUSCH 0.5%
VALEANT PHARMS 0.5%N210821 001 Mar 12, 2019 Apr CAHN
N210821 001 Mar 12, 2019 Mar NEWATETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB + AVET 250MG
AB +! 500MGN050278 003 Oct CAHN
N050278 001 Oct CAHNTHALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION

THALLOUS CHLORIDE TL 201

AP +! CURIUM 1mCi/ML

N018150 001 Jan CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB ! HERITAGE PHARMA 100MG
AB ! 200MG
AB 300MG
@ 450MG
>D> AB MYLAN IRELAND LTD 400MG
>D> AB ! 600MG
>A> AB NOSTRUM LABS INC 400MG
>A> AB ! 600MG
>A> AB RHODES PHARMS 400MGA089807 001 Apr 30, 1990 Feb CAHN
A089808 001 Apr 30, 1990 Feb CAHN
A089763 001 Apr 30, 1990 Feb CAHN
A081236 001 Nov 09, 1992 Feb CAHN
A040560 003 Apr 21, 2006 Dec CAHN
A040560 002 Apr 21, 2006 Dec CAHN
A040560 003 Apr 21, 2006 Dec CAHN
A040560 002 Apr 21, 2006 Dec CAHN
A040086 002 Sep 01, 1982 Dec CMS1THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

MYLAN 10MG
25MG
50MG
! 100MG
@ SUN PHARM INDUSTRIES 10MG
@ 25MG
@ 50MG
@ 100MGA088004 002 Mar 15, 1983 Oct CTEC
A088004 003 Mar 15, 1983 Oct CTEC
A088004 004 Mar 15, 1983 Oct CTEC
A088004 001 Nov 18, 1983 Oct CTEC
A089953 004 Aug 01, 1986 Oct DISC
A089953 003 Aug 01, 1986 Oct DISC
A089953 002 Aug 01, 1986 Oct DISC
A089953 001 Oct 07, 1988 Oct DISCTHIOTEPA

INJECTABLE;INJECTION

THIOTEPA

>A> AP STI PHARMA LLC 15MG/VIAL

A208242 001 Jan 10, 2020 Dec NEWA

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB MYLAN 1MG
AB 2MG
AB 5MG
AB ! 5MG
AB 10MG
AB NOVITIUM PHARMA 1MG
AB 2MG
AB ! 5MG
AB 5MG
AB 10MGA071093 002 Jun 23, 1987 Mar CTEC
A071093 003 Jun 23, 1987 Mar CTEC
A071093 004 Jun 23, 1987 Jul CHRS
A071093 004 Jun 23, 1987 Mar CTEC
A071093 001 Jun 23, 1987 Mar CTEC
A211642 001 Apr 05, 2019 Mar NEWA
A211642 002 Apr 05, 2019 Mar NEWA
A211642 003 Apr 05, 2019 Jul CHRS
A211642 003 Apr 05, 2019 Mar NEWA
A211642 004 Apr 05, 2019 Mar NEWATHIOTHIXENE HYDROCHLORIDE

CONCENTRATE;ORAL

THIOTHIXENE HYDROCHLORIDE INTENSOL

@ HIKMA EQ 5MG BASE/ML

A073494 001 Jun 30, 1992 Sep CAHN

TICAGRELOR

TABLET;ORAL							
BRILINTA							
	+ ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jun	CTEC
TICAGRELOR							
	@ AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jun	DISC
AB		90MG	A208531	001	Jan 23, 2019	Jan	NEWA
AB	HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan	NEWA
	@ WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb	DISC
	@	90MG	A208390	002	Sep 04, 2018	Feb	DISC

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL							
TICLOPIDINE HYDROCHLORIDE							
	@ SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002	Oct	DISC

TIGECYCLINE

POWDER;INTRAVENOUS							
TIGECYCLINE							
AP	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Jul	CMFD
	@	50MG/VIAL	N211158	001	Aug 02, 2018	Feb	DISC
AP	AUROBINDO PHARMA LTD	50MG/VIAL	A206335	001	Jun 11, 2019	May	NEWA
AP	XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019	Oct	NEWA

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC							
TIMOLOL MALEATE							
>D> AB	SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Dec	CRLD
>A> AB	+	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Dec	CHRS
>A> AB	+	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Dec	CRLD
>D> AB		EQ 0.5% BASE	N020963	002	Oct 21, 1998	Dec	CRLD
>A> AB	+	EQ 0.5% BASE	N020963	002	Oct 21, 1998	Dec	CHRS
>A> AB	+	EQ 0.5% BASE	N020963	002	Oct 21, 1998	Dec	CRLD
SOLUTION/DROPS;OPHTHALMIC							
TIMOPTIC							
AT	+ VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan	CAHN
AT1	+	EQ 0.5% BASE	N018086	002		Jan	CAHN
TIMOPTIC IN OCUDOSE							
	+! VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan	CAHN
	+!	EQ 0.5% BASE	N019463	002	Nov 05, 1986	Jan	CAHN
TABLET;ORAL							
BLOCADREN							
	+ @ MERCK	5MG	N018017	001		Apr	CRLD
	+ @	10MG	N018017	002		Apr	CRLD
	+ @	20MG	N018017	004		Apr	CRLD
TIMOLOL MALEATE							
	@ ANI PHARMS INC	5MG	A072917	001	Jul 31, 1991	Sep	CAHN
	@	10MG	A072918	001	Jul 31, 1991	Sep	CAHN
	@	20MG	A072919	001	Jul 31, 1991	Sep	CAHN
AB	ELYSIUM	5MG	A207556	001	May 02, 2019	Sep	CAHN
AB		10MG	A207556	002	May 02, 2019	Sep	CAHN
AB		20MG	A207556	003	May 02, 2019	Sep	CAHN
AB	INVATECH PHARMA	5MG	A207556	001	May 02, 2019	Apr	NEWA
AB		10MG	A207556	002	May 02, 2019	Apr	NEWA
AB		20MG	A207556	003	May 02, 2019	Apr	NEWA
AB	MYLAN	5MG	A072668	002	Jun 08, 1990	Apr	CTEC
AB		10MG	A072668	003	Jun 08, 1990	Apr	CTEC
AB	!	20MG	A072668	001	Jun 08, 1990	Apr	CTEC

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL							
THIOLA EC							
	+ MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Jun	NEWA
	+!	300MG	N211843	002	Jun 28, 2019	Jun	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL							
TIZANIDINE HYDROCHLORIDE							
>A> AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A213223	001	Jan 13, 2020	Dec	NEWA
>A> AB		EQ 4MG BASE	A213223	002	Jan 13, 2020	Dec	NEWA
>A> AB		EQ 6MG BASE	A213223	003	Jan 13, 2020	Dec	NEWA

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar NEWA
AB		EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar NEWA
AB		EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar NEWA
AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar NEWA
AB		EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar NEWA
AB		EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar NEWA
AB	NOVAST LABS	EQ 2MG BASE	A210267	001	Mar 12, 2019	Sep CAHN
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Sep CAHN
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Sep CAHN
AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb NEWA
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb NEWA
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan NEWA
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan NEWA
>D> AB	@ ANI PHARMS INC	EQ 2MG BASE	A076283	001	Jul 12, 2002	May CAHN
>A> AB	@	EQ 2MG BASE	A076284	001	Jul 03, 2002	Dec DISC
AB	@	EQ 2MG BASE	A076284	001	Jul 03, 2002	Dec DISC
	@	EQ 2MG BASE	A076284	001	Jul 03, 2002	Sep CAHN
	@	EQ 2MG BASE	A076371	001	Apr 09, 2003	May CAHN
	@	EQ 4MG BASE	A076283	002	Jul 12, 2002	May CAHN
>D> AB	@	EQ 4MG BASE	A076284	002	Jul 03, 2002	Dec DISC
>A> AB	@	EQ 4MG BASE	A076284	002	Jul 03, 2002	Dec DISC
AB	@	EQ 4MG BASE	A076284	002	Jul 03, 2002	Sep CAHN
	@	EQ 4MG BASE	A076371	002	Apr 09, 2003	May CAHN
	@ PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar DISC
	@	EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar DISC

TOBRAMYCIN

SOLUTION;INHALATION

BETHKIS

AN	+! CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Jul CTEC
	+!	300MG/4ML	N201820	001	Oct 12, 2012	Jun CFTG

TOBRAMYCIN

AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar CMFD
>A> AN	@	300MG/5ML	A207080	001	Jul 09, 2018	Jan DISC
	SUN PHARM	300MG/5ML	A207136	001	Dec 26, 2019	Dec NEWA
	@ TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jul DISC
AN		300MG/4ML	A210915	001	Jun 26, 2019	Jun NFTG

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	ALEMBIC PHARMS LTD	0.3%	A211847	001	Apr 19, 2019	Apr NEWA
----	--------------------	------	---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	May CHRS
---	-------------	-------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

XELJANZ XR

>A> +	PFIZER INC	EQ 22MG BASE	N208246	002	Dec 12, 2019	Dec NEWA
-------	------------	--------------	---------	-----	--------------	----------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	COSETTE	100MG	N018894	001	Nov 02, 1984	Jun CAHN
@		250MG	N018894	002	Nov 02, 1984	Jun CAHN
@		500MG	N018894	003	Nov 02, 1984	Jun CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+! BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar CAHN
	@	200MG	N020697	002	Jan 29, 1998	Mar CAHN

TOLCAPONE

AB	KINEDEXE UK	100MG	A210095	001	Aug 01, 2019	Jul NEWA
AB	MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019	Sep CAHN
AB	NOVAST LABS	100MG	A208937	001	Aug 07, 2018	Sep CAHN

TOLMETIN SODIUM

CAPSULE;ORAL

TOLECTIN DS

+ @ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001		Nov	CRLD
TOLMETIN SODIUM						
@ ANI PHARMS INC	EQ 400MG BASE	A073308	001	Jan 24, 1992	May	CAHN
@	EQ 400MG BASE	A073519	001	May 29, 1992	Sep	CAHN

TABLET;ORAL

TOLECTIN

+ @ ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001		Nov	CRLD
TOLECTIN 600						
+ @ ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989	Nov	CRLD
TOLMETIN SODIUM						
@ ANI PHARMS INC	EQ 600MG BASE	A073527	001	Jun 30, 1992	May	CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB	INVENTIA HLTHCARE	2MG	A204562	001	Aug 19, 2019	Aug	NEWA
AB		4MG	A204562	002	Aug 19, 2019	Aug	NEWA

TABLET;ORAL

TOLTERODINE TARTRATE

>A> AB	INVATECH	1MG	A210775	001	Dec 30, 2019	Dec	NEWA
>A> AB		2MG	A210775	002	Dec 30, 2019	Dec	NEWA

TOLVAPTAN

TABLET;ORAL

JYNARQUE

+! OTSUKA PHARM CO LTD	45MG	N204441	003	Apr 23, 2018	Jun	CHRS
+	90MG	N204441	005	Apr 23, 2018	Jun	CHRS

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QUDEXY XR

BC	+ UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb	CTEC
BC	+	50MG	N205122	002	Mar 11, 2014	Feb	CTEC
BC	+	100MG	N205122	003	Mar 11, 2014	Feb	CTEC
BC	+!	200MG	N205122	005	Mar 11, 2014	Feb	CTEC

TROKENDI XR

BC	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Apr	CTEC
----	--------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

TOPIRAMATE

>D> AB	LUPIN	25MG	A078410	001	Sep 11, 2013	Dec	DISC
>A>	@	25MG	A078410	001	Sep 11, 2013	Dec	DISC
>D> AB		50MG	A078410	002	Sep 11, 2013	Dec	DISC
>A>	@	50MG	A078410	002	Sep 11, 2013	Dec	DISC
>D> AB		100MG	A078410	003	Sep 11, 2013	Dec	DISC
>A>	@	100MG	A078410	003	Sep 11, 2013	Dec	DISC
>D> AB		200MG	A078410	004	Sep 11, 2013	Dec	DISC
>A>	@	200MG	A078410	004	Sep 11, 2013	Dec	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

	@ FRESENIUS KABI USA	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010	Oct	CAHN
AP	MEITHEAL	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Nov	CAHN
	@ MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Oct	DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

>D> AB	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Dec	DISC
>A>	@	50MG	A206706	001	Jul 02, 2019	Dec	DISC
AB		50MG	A206706	001	Jul 02, 2019	Jun	NEWA
AB	RUBICON	50MG	A208708	001	Jun 28, 2019	Jun	NEWA
AB		100MG	A208708	002	Jun 28, 2019	Jun	NEWA
	@ SPECGX LLC	50MG	A075983	001	Jun 25, 2002	Nov	DISC
	@ SUN PHARM INDUSTRIES	50MG	A076100	001	Jun 20, 2002	Oct	DISC
AB	UNICHEM LABS LTD	50MG	A211825	001	Aug 09, 2019	Jul	NEWA

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

@	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009	Nov	DISC
@		200MG	A078783	002	Nov 13, 2009	Nov	DISC
@		300MG	A078783	003	Sep 20, 2011	Nov	DISC

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
TARKA

+	@	ABBVIE	1MG;240MG	N020591	003	Oct 22, 1996	Aug	DISC
		TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE						
		GLENMARK GENERICS	1MG;240MG	A079135	004	Aug 30, 2010	Aug	CTEC

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

AP	APOLLO	100MG/ML	A212676	001	Jul 17, 2019	Jul	NEWA	
>A>	AP	APOTEX	100MG/ML	A209860	001	Jan 14, 2020	Dec	NEWA
AP	CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jul	NEWA	
	+!	EXELA PHARMA SCS LLC	10MG/ML	N212020	001	Apr 15, 2019	Apr	NEWA
AP	MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Mar	CAHN	
>D>	AP	VIRTUS PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Dec	DISC
>A>	@	100MG/ML	A202755	001	Feb 25, 2016	Dec	DISC	
	SOLUTION;INTRAVENOUS							
	TRANEXAMIC ACID							
	+!	EXELA PHARMA SCS LLC	1GM/100ML (10MG/ML)	N212020	001	Apr 15, 2019	May	CPOT

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

>A>	AT1		ALEMBIC PHARMS LTD	0.004%	A210458	001	Dec 20, 2019	Dec	NEWA
>D>		!	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Dec	CTEC
>A>	AT1		!	0.004%	A091340	001	Mar 01, 2013	Dec	CTEC

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP		PAR STERILE PRODUCTS	1MG/ML	A209382	001	Sep 24, 2019	Sep	NEWA
AP			2.5MG/ML	A209382	002	Sep 24, 2019	Sep	NEWA
AP			5MG/ML	A209382	003	Sep 24, 2019	Sep	NEWA
AP			10MG/ML	A209382	004	Sep 24, 2019	Sep	NEWA
AP		TEVA PHARMS USA	1MG/ML	A206648	001	Sep 26, 2019	Sep	NEWA
AP			2.5MG/ML	A206648	002	Sep 26, 2019	Sep	NEWA
AP			5MG/ML	A206648	003	Sep 26, 2019	Sep	NEWA
AP			10MG/ML	A206648	004	Sep 26, 2019	Sep	NEWA

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL
ORENITRAM

+	!	UNITED THERAP	EQ 1MG BASE	N203496	003	Dec 20, 2013	Feb	CHRS
+			EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Feb	CHRS

TRETINOIN

CREAM;TOPICAL
TRETINOIN

AB1		TARO PHARMS	0.05%	A211644	001	Jan 25, 2019	Jan	NEWA
AB			0.1%	A211645	001	Jan 22, 2019	Jan	NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

AT		MLV	0.025%	A040671	001	Jun 09, 2006	Sep	CAHN
AT			0.1%	A040671	002	Jun 09, 2006	Sep	CAHN
AT		SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	May	CAHN
AT			0.1%	A040671	002	Jun 09, 2006	May	CAHN
AT		STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Jan	NEWA
AT			0.1%	A210346	002	Feb 11, 2019	Jan	NEWA
AT			0.5%	A210346	003	Feb 11, 2019	Jan	NEWA

INJECTABLE;INJECTION
KENALOG-80

+	!	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019	Apr	NEWA
---	---	-----------	---------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION							
TRIAMCINOLONE ACETONIDE							
AB	TEVA PHARMS USA	40MG/ML	A209852	001	Oct 05, 2018	Jul	CMFD
	@	40MG/ML	A209852	001	Oct 05, 2018	Mar	DISC
LOTION; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	ALLIED	0.1%	A040672	002	Dec 13, 2006	Sep	CAHN
AT	SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	May	CAHN
OINTMENT; TOPICAL							
KENALOG							
>D>							
>D>	+ @ MYLAN	0.025%	N011600	003		Dec	CTNA
>D>	+ @	0.1%	N011600	001		Dec	CTNA
TRIAMCINOLONE ACETONIDE							
AT	ENCUBE	0.05%	A212384	001	Nov 29, 2019	Nov	NEWA
>A>	+ @ MYLAN	0.025%	N011600	003		Dec	CTNA
>A>	+ @	0.1%	N011600	001		Dec	CTNA
TRIAMCINOLONE ACETONIDE IN ABSORBASE							
AT	! CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Nov	CTEC
<u>TRIAMTERENE</u>							
CAPSULE; ORAL							
DYRENIUM							
AB	+ CONCORDIA	50MG	N013174	001		Aug	CFTG
AB	+!	100MG	N013174	002		Aug	CFTG
TRIAMTERENE							
AB	AGNITIO	50MG	A211581	001	Aug 19, 2019	Aug	NFTG
AB		100MG	A211581	002	Aug 19, 2019	Aug	NFTG
<u>TRICLABENDAZOLE</u>							
TABLET; ORAL							
EGATEN							
	+! NOVARTIS	250MG	N208711	001	Feb 13, 2019	Feb	NEWA
<u>TRIENTINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
CLOVIQUE							
AB	KADMON PHARMS LLC	250MG	A209731	001	Oct 21, 2019	Nov	CTNA
AB		250MG	A209731	001	Oct 21, 2019	Oct	NEWA
SYPRINE							
AB	+! BAUSCH	250MG	N019194	001	Nov 08, 1985	Sep	CAHN
TRIENTINE HYDROCHLORIDE							
AB	AMNEAL PHARMS LLC	250MG	A210619	001	Feb 08, 2019	Feb	NEWA
AB	DR REDDYS LABS LTD	250MG	A211076	001	Jul 03, 2019	Jun	NEWA
AB	KADMON PHARMS LLC	250MG	A209415	001	Sep 16, 2019	Sep	NEWA
AB	MSN	250MG	A211134	001	May 22, 2019	May	NEWA
AB	PAR PHARM INC	250MG	A210096	001	Sep 25, 2019	Sep	NEWA
AB	ZYDUS PHARMS	250MG	A211554	001	Apr 26, 2019	Apr	NEWA
<u>TRIFAROTENE</u>							
CREAM; TOPICAL							
AKLIEF							
	+! GALDERMA R AND D	0.005%	N211527	001	Oct 04, 2019	Oct	NEWA
<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>							
TABLET; ORAL							
TRIFLUOPERAZINE HYDROCHLORIDE							
>A>	@ INVATECH	EQ 1MG BASE	A040153	001	Oct 25, 1996	Dec	CAHN
>A>	@	EQ 2MG BASE	A040153	002	Oct 25, 1996	Dec	CAHN
>A>	@	EQ 5MG BASE	A040153	003	Oct 25, 1996	Dec	CAHN
>A>	@	EQ 10MG BASE	A040153	004	Oct 25, 1996	Dec	CAHN
>D>	@ SANDOZ	EQ 1MG BASE	A040153	001	Oct 25, 1996	Dec	CAHN
>D>	@	EQ 2MG BASE	A040153	002	Oct 25, 1996	Dec	CAHN
>D>	@	EQ 5MG BASE	A040153	003	Oct 25, 1996	Dec	CAHN
>D>	@	EQ 10MG BASE	A040153	004	Oct 25, 1996	Dec	CAHN
<u>TRIMETHADIONE</u>							
TABLET; ORAL							
TRIDIONE							
	+ @ ABBVIE	150MG	N005856	009		Jul	DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

	CAPSULE;ORAL						
	TRIMETHOBENZAMIDE HYDROCHLORIDE						
AB	LUPIN	300MG	A076546	001	Aug 20, 2003	Feb	CAHN
	INJECTABLE;INJECTION						
	TIGAN						
	+! PAR STERILE PRODUCTS	100MG/ML	N017530	001		May	CTEC

TRIMIPRAMINE MALEATE

	CAPSULE;ORAL						
	SURMONTIL						
	+ @ ODYSSEY PHARMS	EQ 25MG BASE	N016792	001		Jul	DISC
	+ @	EQ 50MG BASE	N016792	002		Jul	DISC
	+ @	EQ 100MG BASE	N016792	003	Sep 15, 1982	Jul	DISC
	TRIMIPRAMINE MALEATE						
AB	! CROSSMEDIKA SA	EQ 50MG BASE	A208127	002	Apr 15, 2016	Jul	CHRS

TROPICAMIDE

	SOLUTION/DROPS;OPHTHALMIC						
	TROPICAMIDE						
>A> AT	SOMERSET THERAPS LLC	1%	A207524	001	Dec 12, 2019	Dec	NEWA

UBROGEPANT

>A>	TABLET;ORAL						
>A>	UBRELVIY						
>A>	+ ALLERGAN	50MG	N211765	001	Dec 23, 2019	Dec	NEWA
>A>	+!	100MG	N211765	002	Dec 23, 2019	Dec	NEWA

UPADACITINIB

	TABLET, EXTENDED RELEASE;ORAL						
	RINVOQ						
	+! ABBVIE INC	15MG	N211675	001	Aug 16, 2019	Nov	CPOT
	+!	EQ 15MG BASE	N211675	001	Aug 16, 2019	Aug	NEWA

URSODIOL

	CAPSULE;ORAL						
	URSODIOL						
AB	AMNEAL PHARMS CO	300MG	A211301	001	Oct 16, 2018	Jun	CMFD
	@	300MG	A211301	001	Oct 16, 2018	Apr	DISC
AB	EYWA PHARMA	300MG	A212452	001	Oct 30, 2019	Oct	NEWA

VALACYCLOVIR HYDROCHLORIDE

	TABLET;ORAL						
	VALACYCLOVIR HYDROCHLORIDE						
	@ WATSON LABS INC	EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr	DISC
	@	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr	DISC

VALGANCICLOVIR HYDROCHLORIDE

	FOR SOLUTION;ORAL						
	VALGANCICLOVIR HYDROCHLORIDE						
>A> AB	AJANTA PHARMA LTD	50MG/ML	A212890	001	Jan 13, 2020	Dec	NEWA
	TABLET;ORAL						
	VALGANCICLOVIR HYDROCHLORIDE						
>A> AB	AJANTA PHARMA LTD	EQ 450MG BASE	A212234	001	Dec 26, 2019	Dec	NEWA

VALPROATE SODIUM

	INJECTABLE;INJECTION						
	DEPACON						
	+ @ ABBVIE	EQ 100MG BASE/ML	N020593	001	Dec 30, 1996	Apr	DISC
	VALPROATE SODIUM						
AP	! HIKMA FARMACEUTICA	EQ 100MG BASE/ML	A078523	001	Feb 17, 2010	Apr	CHRS

VALPROIC ACID

	CAPSULE;ORAL						
	DEPAKENE						
	+ @ ABBVIE	250MG	N018081	001		Oct	DISC
	VALPROIC ACID						
AB	! BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Oct	CHRS
AB	NOVELGENIX THERAPS	250MG	A207611	001	Aug 05, 2019	Jul	NEWA
	@ UPSHER SMITH LABS	250MG	A070631	001	Jun 11, 1987	Jul	CAHN

		SYRUP; ORAL					
		DEPAKENE					
		+ @ ABBVIE	250MG/5ML	N018082	001		Aug DISC
		VALPROIC ACID					
>D>	AA	ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Dec DISC
>A>		@	250MG/5ML	A073178	001	Aug 25, 1992	Dec DISC
		@ APOTEX	250MG/5ML	A077105	001	Jul 29, 2005	Oct CAHN
		@ PD PARTNERS	250MG/5ML	A077105	001	Jul 29, 2005	May CAHN
AA	!	PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000	Aug CHRS
<u>VALRUBICIN</u>							
		SOLUTION; INTRAVESICAL					
		VALRUBICIN					
AO		CUSTOPHARM INC	40MG/ML	A206430	001	Apr 19, 2019	Apr NFTG
		VALSTAR PRESERVATIVE FREE					
AO	+	ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998	Apr CFTG
<u>VALSARTAN</u>							
		TABLET; ORAL					
		VALSARTAN					
AB		ALKEM LABS LTD	40MG	A205536	001	Mar 12, 2019	Feb NEWA
AB			80MG	A205536	002	Mar 12, 2019	Feb NEWA
AB			160MG	A205536	003	Mar 12, 2019	Feb NEWA
AB			320MG	A205536	004	Mar 12, 2019	Feb NEWA
		@ TORRENT	40MG	A202728	001	Jan 05, 2015	Nov DISC
		@	80MG	A202728	002	Jan 05, 2015	Nov DISC
		@	160MG	A202728	003	Jan 05, 2015	Nov DISC
		@	320MG	A202728	004	Jan 05, 2015	Nov DISC
<u>VANCOMYCIN HYDROCHLORIDE</u>							
		CAPSULE; ORAL					
		VANCOMYCIN HYDROCHLORIDE					
AB		ORIENT PHARMA CO LTD	EQ 125MG BASE	A210729	001	Apr 29, 2019	Apr NEWA
AB			EQ 250MG BASE	A210729	002	Apr 29, 2019	Apr NEWA
		FOR SOLUTION; ORAL					
		VANCOCIN HYDROCHLORIDE					
		ANI PHARMS INC	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Jul CMFD
		INJECTABLE; INJECTION					
		VANCOMYCIN HYDROCHLORIDE					
		@ EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202275	001	Oct 31, 2013	Nov DISC
		@	EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013	Nov DISC
		@	EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013	Nov DISC
		@	EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013	Nov DISC
>D>	AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Dec DISC
>A>		@	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Dec DISC
	AP		EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	May NEWA
>D>	AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Dec DISC
>A>		@	EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Dec DISC
	AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	May NEWA
		SOLUTION; INTRAVENOUS					
		VANCOMYCIN HYDROCHLORIDE					
		+! XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	Feb NEWA
		+!	EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	Feb NEWA
		+!	EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	Feb NEWA
		+!	EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	Feb NEWA
<u>VARDENAFIL HYDROCHLORIDE</u>							
		TABLET; ORAL					
		VARDENAFIL HYDROCHLORIDE					
		@ AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018	Apr DISC
		@	10MG	A210738	002	Oct 31, 2018	Apr DISC
		@	20MG	A210738	003	Oct 31, 2018	Apr DISC
AB		MACLEODS PHARMS LTD	2.5MG	A204632	001	Oct 22, 2019	Oct NEWA
AB			5MG	A204632	002	Oct 22, 2019	Oct NEWA
AB			10MG	A204632	003	Oct 22, 2019	Oct NEWA
AB			20MG	A204632	004	Oct 22, 2019	Oct NEWA

VASOPRESSINSOLUTION; INTRAVENOUS
VASOSTRICT

+	!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Mar CDFR
+	!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Mar CDFR

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

AP		HIKMA	10MG/VIAL	A203725	001	Jul 30, 2019	Jul NEWA
AP			20MG/VIAL	A203725	002	Jul 30, 2019	Jul NEWA

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 37.5MG BASE	A212277	001	Jul 08, 2019	Jun NEWA
AB			EQ 75MG BASE	A212277	002	Jul 08, 2019	Jun NEWA
AB			EQ 150MG BASE	A212277	003	Jul 08, 2019	Jun NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

@	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Oct DISC
@		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Oct DISC
@		EQ 50MG BASE	A090027	003	Aug 04, 2010	Oct DISC
@		EQ 75MG BASE	A090027	004	Aug 04, 2010	Oct DISC
@		EQ 100MG BASE	A090027	005	Aug 04, 2010	Oct DISC

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		CADILA PHARMS LTD	EQ 75MG BASE	A211323	001	Aug 29, 2019	Aug NEWA
AB			EQ 150MG BASE	A211323	002	Aug 29, 2019	Aug NEWA
AB			EQ 225MG BASE	A211323	003	Aug 29, 2019	Aug NEWA
AB		DEXCEL PHARMA	EQ 150MG BASE	A209193	001	Oct 31, 2019	Oct NEWA
AB			EQ 225MG BASE	A209193	002	Oct 31, 2019	Oct NEWA

VERAPAMIL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
VERAPAMIL HYDROCHLORIDE

@	MYLAN	100MG	A078306	001	Aug 09, 2007	Nov DISC
@		200MG	A078306	002	Aug 09, 2007	Nov DISC
@		300MG	A078306	003	Aug 09, 2007	May DISC

VERELAN PM

+		RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Nov CTEC
+			200MG	N020943	002	Nov 25, 1998	Nov CTEC
+	!		300MG	N020943	003	Nov 25, 1998	May CTEC

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		ANDA REPOSITORY	5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Sep CAHN
AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Sep CAHN
AP		SOMERSET	5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Oct CAHN
AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Oct CAHN

TABLET; ORAL

CALAN

+	@	GD SEARLE LLC	80MG	N018817	001	Sep 10, 1984	May DISC
+	@		120MG	N018817	002	Sep 10, 1984	Nov DISC
AB	+		120MG	N018817	002	Sep 10, 1984	May CHRS

VERAPAMIL HYDROCHLORIDE

AB	!	HERITAGE PHARMS INC	120MG	A071881	001	Apr 05, 1988	May CHRS
----	---	---------------------	-------	---------	-----	--------------	----------

VIGABATRIN

FOR SOLUTION; ORAL

VIGABATRIN

AA		INVAGEN PHARMS	500MG/PACKET	A211592	001	Dec 03, 2019	Nov NEWA
----	--	----------------	--------------	---------	-----	--------------	----------

VIGADRON

AA		AUCTA	500MG/PACKET	A210196	001	Jun 21, 2018	Jun CAHN
AA		SHANGHAI	500MG/PACKET	A210196	001	Jun 21, 2018	Mar CAHN

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB	+	ALLERGAN	10MG	N022567	001	Jan 21, 2011	Sep CFTG
AB	+		20MG	N022567	002	Jan 21, 2011	Sep CFTG
AB	+		40MG	N022567	003	Jan 21, 2011	Sep CFTG

VILAZODONE HYDROCHLORIDE

>A>	AB		ALEMBIC PHARMS LTD	10MG	A208202	001	Jan 10, 2020	Dec NEWA
>A>	AB			20MG	A208202	002	Jan 10, 2020	Dec NEWA
>A>	AB			40MG	A208202	003	Jan 10, 2020	Dec NEWA
	AB		TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	Sep NFTG
	AB			20MG	A208212	002	Sep 30, 2019	Sep NFTG
	AB			40MG	A208212	003	Sep 30, 2019	Sep NFTG

VINCRISTINE SULFATE

INJECTABLE;INJECTION

VINCRISTINE SULFATE PFS

!	HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Oct CTEC
@	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Oct DISC

INJECTABLE, LIPOSOMAL;INTRAVENOUS
MARQIBO KIT

+	!	ACROTECH	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Mar CAHN
---	---	----------	------------------	---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

NAVELBINE

+	@	PIERRE FABRE	EQ 10MG BASE/ML	N020388	001	Dec 23, 1994	Jun DISC
---	---	--------------	-----------------	---------	-----	--------------	----------

VINORELBINE TARTRATE

AP		INGENUS PHARMS LLC	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	Jul NEWA
		@ NOVAST LABS	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	Oct DISC
AP			EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	Sep CAHN

VORAPAXAR SULFATE

TABLET;ORAL

ZONTIVITY

+	!	TOPROL	EQ 2.08MG BASE	N204886	001	May 08, 2014	May CAHN
---	---	--------	----------------	---------	-----	--------------	----------

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VFEND

AP	+	!	PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	May CDFR
----	---	---	-------------	------------	---------	-----	--------------	----------

VORICONAZOLE

AP		ALVOGEN	200MG/VIAL	A206398	001	Mar 23, 2016	Sep CAHN
AP		ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	May CDFR
AP		HAINAN POLY PHARM	200MG/VIAL	A211661	001	Nov 30, 2018	May CDFR
AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	May CDFR
AP		ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018	May CDFR

POWDER;INTRAVENOUS

VORICONAZOLE

AP		XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	May CDFR
----	--	-------------------	------------	---------	-----	--------------	----------

POWDER;IV (INFUSION)

VORICONAZOLE

AP		XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb CTEC
----	--	-------------------	------------	---------	-----	--------------	----------

TABLET;ORAL

VORICONAZOLE

AB		APPCO	50MG	A206762	001	May 24, 2016	Feb CAHN
AB			200MG	A206762	002	May 24, 2016	Feb CAHN
AB		CADILA	50MG	A206747	001	May 24, 2016	Apr CAHN
AB			200MG	A206747	002	May 24, 2016	Apr CAHN
		@ TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Nov DISC
		@	200MG	A091658	002	Apr 06, 2012	Nov DISC

VOXELOTOR

TABLET;ORAL

OXBRYTA

+	!	GLOBAL BLOOD THERAPS	500MG	N213137	001	Nov 25, 2019	Nov NEWA
---	---	----------------------	-------	---------	-----	--------------	----------

WARFARIN SODIUMTABLET; ORAL
JANTOVEN

AB	UPSHER SMITH LABS	1MG	A040416	001	Oct 02, 2003	Jul CAHN
AB		2MG	A040416	002	Oct 02, 2003	Jul CAHN
AB		2.5MG	A040416	003	Oct 02, 2003	Jul CAHN
AB		3MG	A040416	004	Oct 02, 2003	Jul CAHN
AB		4MG	A040416	005	Oct 02, 2003	Jul CAHN
AB		5MG	A040416	006	Oct 02, 2003	Jul CAHN
AB		6MG	A040416	007	Oct 02, 2003	Jul CAHN
AB		7.5MG	A040416	008	Oct 02, 2003	Jul CAHN
AB		10MG	A040416	009	Oct 02, 2003	Jul CAHN

XENON XE-133GAS; INHALATION
XENON XE 133
CURIUM

	10mCi/VIAL	N018327	001	Mar 09, 1982	May CAHN
	20mCi/VIAL	N018327	002	Mar 09, 1982	May CAHN

ZANUBRUTINIBCAPSULE; ORAL
BRUKINSA

+!	BEIGENE	80MG	N213217	001	Nov 14, 2019	Nov NEWA
----	---------	------	---------	-----	--------------	----------

ZIDOVUDINEINJECTABLE; INJECTION
ZIDOVUDINE

@	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb DISC
---	----------	---------	---------	-----	--------------	----------

ZILEUTONTABLET, EXTENDED RELEASE; ORAL
ZILEUTON

AB	LUPIN LTD	600MG	A211972	001	Nov 05, 2019	Oct NEWA
>A> AB	PAR PHARM INC	600MG	A212670	001	Dec 16, 2019	Dec NEWA

ZINC SULFATESOLUTION; INTRAVENOUS
ZINC SULFATE

+!	AM REGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Oct CMS1
+!		EQ 25MG BASE/5ML (EQ 5 BASE/ML)	N209377	002	Jul 18, 2019	Jul NEWA
+!		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Jul NEWA

ZIPRASIDONE HYDROCHLORIDECAPSULE; ORAL
ZIPRASIDONE HYDROCHLORIDE

	@ CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Jun DISC
AB		EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb CAHN
	@	EQ 40MG BASE	A208988	002	Aug 22, 2017	Jun DISC
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb CAHN
	@	EQ 60MG BASE	A208988	003	Aug 22, 2017	Jun DISC
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb CAHN
	@	EQ 80MG BASE	A208988	004	Aug 22, 2017	Jun DISC
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb CAHN

ZIPRASIDONE MESYLATEINJECTABLE; INTRAMUSCULAR
GEODON

>D>	+!	PFIZER	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Dec CFTG
>A> AP	+!		EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Dec CFTG
>A>		ZIPRASIDONE MESYLATE					
>A> AP		GLAND PHARMA LTD	EQ 20MG BASE/ML	A211908	001	Dec 26, 2019	Dec NFTG

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
RECLAST

AP	+!	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CDFR
		ZOLEDRONIC					
AP		GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar CDFR
		ZOLEDRONIC ACID					
AP		ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar CDFR
	@	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Jul DISC

INJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

AP		EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar CDFR
AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar CDFR
AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar CDFR
AP	APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar CDFR
AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar CDFR
AP		EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar CDFR
AP	BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar CDFR
AP	BRECKENRIDGE	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar CDFR
AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar CDFR
AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar CDFR
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	May CDFR
	@	EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Oct DISC
AP		EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Mar CDFR
AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar CDFR
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar CDFR
AP		EQ 5MG BASE/100ML	A209578	001	Aug 08, 2019	Jul NEWA
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar CDFR
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar CDFR
AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar CDFR
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar CDFR
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar CDFR
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar CDFR
AP	SAGENT PHARMS INC	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar CDFR
	@ SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Oct DISC
AP		EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Apr NEWA
	@ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar CDFR
	@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar CDFR
AP	USV	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CDFR
	ZOMETA					
	+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar CDFR
AP	+	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar CDFR
AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar CDFR

INJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar CDFR
	SOLUTION; INTRAVENOUS ZOLEDRONIC ACID					
	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar CDFR

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

>D>	AB	ANI PHARMS INC	2.5MG	A090861	001	Mar 04, 2014	Dec DISC
>A>		@	2.5MG	A090861	001	Mar 04, 2014	Dec DISC
>D>	AB		5MG	A090861	002	Mar 04, 2014	Dec DISC
>A>		@	5MG	A090861	002	Mar 04, 2014	Dec DISC
		@ MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Oct DISC
		@	5MG	A203772	002	Sep 30, 2015	Oct DISC
AB		ORCHID HLTHCARE	2.5MG	A203726	001	Oct 21, 2019	Oct NEWA
AB			5MG	A203726	002	Oct 21, 2019	Oct NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

	@ MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015	Oct DISC
	@	5MG	A204336	002	Oct 22, 2015	Oct DISC
AB	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Sep NEWA
AB		5MG	A202855	002	Sep 20, 2019	Sep NEWA

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL							
ZOLPIMIST							
+!	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb CAHN	
TABLET;ORAL							
ZOLPIDEM TARTRATE							
@	MYLAN	5MG	A076578	001	Apr 23, 2007	Nov DISC	
@		10MG	A076578	002	Apr 23, 2007	Nov DISC	
@	STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007	Apr CAHN	
@		10MG	A076062	002	Apr 23, 2007	Apr CAHN	
@	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Oct DISC	
@		10MG	A077359	002	Apr 23, 2007	Oct DISC	
TABLET;SUBLINGUAL							
ZOLPIDEM TARTRATE							
AB	!	NOVEL LABS INC	3.5MG	A204299	002	Jun 03, 2015	Mar CHRS

ZONISAMIDE

CAPSULE;ORAL							
ZONISAMIDE							
AB		BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Apr CAHN
AB			50MG	A077813	002	Aug 16, 2006	Apr CAHN
AB			100MG	A077813	003	Aug 16, 2006	Apr CAHN
AB		CELLTRION	25MG	A077636	003	Jul 27, 2006	Aug CAHN
AB			50MG	A077636	002	Jul 27, 2006	Aug CAHN
AB			100MG	A077636	001	Dec 22, 2005	Aug CAHN
@	MYLAN	25MG	A077637	001	Dec 22, 2005	Nov DISC	
@		50MG	A077637	002	Dec 22, 2005	Nov DISC	
@		100MG	A077637	003	Dec 22, 2005	Nov DISC	

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

ACP NIMBLE	120MG	N018060	001		Feb	CAHN
@	325MG	N018060	003	Dec 18, 1986	Feb	CAHN
@	650MG	N018060	002		Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

GRANULES INDIA LTD	650MG	A211544	001	Apr 16, 2019	Apr	NEWA
HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	Sep	CMFD
@	650MG	A207035	001	May 31, 2018	Mar	DISC

ADAPALENE

GEL;TOPICAL

ADAPALENE

GLENMARK GENERICS	0.1%	A091314	002	Jul 09, 2019	Jul	NEWA
-------------------	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ATHEM	5MG/5ML	A091327	001	Oct 17, 2011	Sep	CAHN
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	NEWA
@ TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Nov	DISC
	5MG/5ML	A090474	002	Mar 30, 2009	Jan	CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ATHEM	5MG/5ML	A091327	002	Oct 17, 2011	Sep	CAHN
@ TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Nov	DISC
	5MG/5ML	A090474	001	Mar 30, 2009	Jan	CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007	May	CAHN
@	10MG	A078615	004	Dec 28, 2007	May	CAHN
@ SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007	Oct	DISC
@	10MG	A077499	002	Dec 27, 2007	Oct	DISC
CETIRIZINE HYDROCHLORIDE HIVES						
@ SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007	Oct	DISC
@	10MG	A077499	004	Dec 27, 2007	Oct	DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	May	DISC
-------------------	-----------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

CHLORHEXIDINE GLUCONATE

BAJAJ	0.75%	N020111	001	Sep 11, 1997	Apr	CTNA
	0.75%	N020111	001	Sep 11, 1997	Jan	CMFD

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

! AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan	CHRS
---------------	------	---------	-----	--------------	-----	------

CLOTTRIMAZOLE

CREAM;VAGINAL

CLOTTRIMAZOLE

! P AND L	1%	A074165	001	Jul 16, 1993	Aug	CAHN
-----------	----	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019	Jan	NEWA
----------------------	--	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

@ ACTAVIS ELIZABETH	25MG;220MG	A207597	001	Jan 25, 2019	Jul	DISC
	25MG;220MG	A207597	001	Jan 25, 2019	Jan	NEWA
APOTEX	25MG;220MG	A211830	001	Aug 22, 2019	Aug	NEWA
@ P AND L	25MG;220MG	A207597	001	Jan 25, 2019	Aug	CAHN
PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019	Apr	NEWA

DOCOSANOL

CREAM; TOPICAL

DOCOSANOL

P AND L	10%	A208754	001	Nov 19, 2018	Aug	CAHN
---------	-----	---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019	May	NEWA
MYLAN	EQ 20MG BASE	A212376	001	Oct 16, 2019	Sep	NEWA

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS ELIZABETH	EQ 20MG BASE	A209202	001	Mar 05, 2019	Apr	DISC
	EQ 20MG BASE	A209202	001	Mar 05, 2019	Feb	NEWA
@ P AND L	EQ 20MG BASE	A209202	001	Mar 05, 2019	Aug	CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

P AND L	10MG	A075512	001	Jul 26, 2001	Aug	CAHN
---------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

P AND L	30MG/5ML	A203330	001	Nov 18, 2014	Aug	CAHN
---------	----------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

! P AND L	30MG/5ML	A203330	002	Nov 18, 2014	Aug	CAHN
-----------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

@ MYLAN	30MG	A077081	004	Jul 21, 2011	Jul	DISC
---------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

@ MYLAN	30MG	A077081	005	Jul 21, 2011	Jul	DISC
---------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

GRANULES INDIA LTD	60MG	A211075	001	Oct 18, 2019	Oct	NEWA
	180MG	A211075	002	Oct 18, 2019	Oct	NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

HI TECH	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Apr	NEWA
---------	--------------	---------	-----	--------------	-----	------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

AUROBINDO PHARMA LTD	600MG	A210453	001	Oct 21, 2019	Oct	NEWA
	1.2GM	A210453	002	Oct 21, 2019	Oct	NEWA
@ OHM LABS INC	600MG	A209254	001	Jul 16, 2018	Mar	DISC
@	1.2GM	A209254	002	Jul 16, 2018	Mar	DISC

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

>D>	STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Dec	DISC
>A>	@	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Dec	DISC

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

@ MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004	Sep	DISC
-----------------------	-----------	---------	-----	--------------	-----	------

IBUPROFEN

@ GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Feb	DISC
P AND L	100MG/5ML	A074916	001	Apr 30, 1999	Aug	CAHN

TABLET;ORAL									
IBUPROFEN									
>A>	!	PERRIGO R AND D	200MG	A 077349	001	Jun 21, 2005	Jun	CHRS	
		ULTRATAB LABS INC	200MG	A 209076	001	Jan 06, 2020	Dec	NEWA	
	IBUPROHM								
	@	OHM LABS	200MG	A 071214	001	Dec 01, 1986	Oct	DISC	
	MOTRIN IB								
	+	J AND J CONSUMER INC	200MG	N 019012	003	Dec 17, 1990	May	CHRS	
<u>ISOPROPYL ALCOHOL</u>									
SOLUTION;TOPICAL									
ZURAGARD									
	+	@ ZUREX PHARMA	70% (10.5ML)	N 210872	001	Apr 26, 2019	Sep	DISC	
	+	!	70% (10.5ML)	N 210872	001	Apr 26, 2019	May	CMS2	
<u>KETOCONAZOLE</u>									
SHAMPOO;TOPICAL									
NIZORAL A-D									
	+	!	KRAMER	1%	N 020310	001	Oct 10, 1997	Jan	CAHN
<u>KETOTIFEN FUMARATE</u>									
SOLUTION/DROPS;OPHTHALMIC									
KETOTIFEN FUMARATE									
		APOTEX INC	EQ 0.025% BASE	A 077354	001	May 09, 2006	Oct	CMFD	
ZADITOR									
	!	ALCON PHARMS LTD	EQ 0.025% BASE	A 077200	001	Sep 02, 2008	Feb	CTNA	
<u>LANSOPRAZOLE</u>									
CAPSULE, DELAYED REL PELLETS;ORAL									
PREVACID 24 HR									
>D>	+	!	GLAXOSMITHKLINE CONS	15MG	N 022327	001	May 18, 2009	Dec	CAHN
>A>	+	!	PERRIGO PHARMA INTL	15MG	N 022327	001	May 18, 2009	Dec	CAHN
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>									
TABLET;ORAL									
LEVOCETIRIZINE DIHYDROCHLORIDE									
	@	PERRIGO R AND D	5MG	A 211983	001	Mar 28, 2019	Nov	DISC	
			5MG	A 211983	001	Mar 28, 2019	Jul	CMS1	
			5MG	A 211983	001	Mar 26, 2019	Mar	NEWA	
<u>LEVONORGESTREL</u>									
TABLET;ORAL									
LEVONORGESTREL									
	@	ACCORD HLTHCARE	1.5MG	A 207660	001	May 02, 2019	Nov	DISC	
			1.5MG	A 207660	001	May 02, 2019	Apr	NEWA	
>D>		ALVOGEN	1.5MG	A 202246	001	Jun 05, 2015	Dec	DISC	
>A>	@		1.5MG	A 202246	001	Jun 05, 2015	Dec	DISC	
			1.5MG	A 202246	001	Jun 05, 2015	Jul	CAHN	
	@	FDN CONSUMER	1.5MG	A 200670	001	Jul 12, 2012	Jun	DISC	
	!	L PERRIGO CO	0.75MG	A 090740	001	Dec 30, 2010	May	CAHN	
>D>		LOTUS PHARM CO LTD	0.75MG	A 202684	001	Sep 02, 2016	Dec	DISC	
>A>	@		0.75MG	A 202684	001	Sep 02, 2016	Dec	DISC	
		NAARI PTE LTD	1.5MG	A 202380	001	May 29, 2015	Sep	CAHN	
<u>LORATADINE</u>									
CAPSULE;ORAL									
LORATADINE									
	@	BIONPHARMA INC	10MG	A 202538	001	Dec 21, 2018	Mar	DISC	
>A>		STRIDES PHARMA	10MG	A 211926	001	Jan 15, 2020	Dec	NEWA	
TABLET;ORAL									
LORATADINE									
>A>		GRANULES INDIA LTD	10MG	A 210722	001	Dec 23, 2019	Dec	NEWA	
		GUARDIAN DRUG	10MG	A 207569	001	Mar 12, 2019	Mar	CAHN	
		NEWGEN PHARMS LLC	10MG	A 207569	001	Mar 12, 2019	Feb	NEWA	
TABLET, CHEWABLE;ORAL									
LORATADINE									
		PERRIGO PHARMA INTL	5MG	A 210033	001	Jun 12, 2019	May	NEWA	
		SUN PHARM	5MG	A 210088	001	Apr 16, 2018	Mar	CAHN	

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

@ HERITAGE PHARMA 5MG;120MG

A076208 001 Jan 28, 2004 May CAHN

P AND L 10MG;240MG

A075706 001 Feb 21, 2003 Aug CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE 7

P AND L 2%

A074164 001 Mar 29, 1996 Aug CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

P AND L 2%,200MG

A074926 001 Apr 16, 1999 Aug CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

P AND L 100MG

A073507 001 Nov 19, 1993 Aug CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

P AND L 5%

A208092 001 Feb 17, 2017 Aug CAHN

MINOXIDIL (FOR WOMEN)

P AND L 5%

A208092 002 Jul 27, 2017 Aug CAHN

TARO 5%

A209074 002 Apr 22, 2019 Apr NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

P AND L 2%

A074588 001 Apr 05, 1996 Aug CAHN

MINOXIDIL EXTRA STRENGTH (FOR MEN)

P AND L 5%

A075518 001 Nov 17, 2000 Aug CAHN

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

CATALENT EQ 200MG BASE

A202807 001 Jan 04, 2019 Nov CMFD

@ EQ 200MG BASE

A202807 001 Jan 04, 2019 Jul DISC

TABLET;ORAL

ALEVE

+! BAYER 220MG

N020204 002 Jan 11, 1994 Sep CPOT

NAPROXEN SODIUM

AMNEAL PHARMS NY 220MG

A079096 001 Dec 16, 2008 Sep CPOT

AUROBINDO PHARMA LTD 220MG

A205497 001 Mar 18, 2016 Sep CPOT

CONTRACT PHARMACAL 220MG

A074635 001 Jan 13, 1997 Sep CPOT

@ 220MG

A074789 001 Feb 27, 1997 Sep CPOT

DR REDDYS LABS INC 220MG

A075168 001 Jul 28, 1998 Sep CPOT

GRANULES INDIA 220MG

A091353 001 Sep 20, 2011 Sep CPOT

LNK INTL INC 220MG

A204872 001 Jan 23, 2017 Sep CPOT

MARKSANS PHARMA 220MG

A090545 001 Mar 16, 2011 Sep CPOT

NOVELGENIX THERAPS 220MG

A207612 001 Nov 16, 2018 Sep CPOT

PERRIGO 220MG

A074661 001 Jan 13, 1997 Sep CPOT

@ PLD ACQUISITIONS LLC 220MG

A074646 001 Jan 13, 1997 Sep CPOT

SUN PHARM INDS LTD 220MG

A091183 001 May 20, 2011 Sep CPOT

YICHANG HUMANWELL EQ 200MG BASE

A212033 001 Aug 30, 2019 Aug NEWA

220MG

A212033 001 Aug 30, 2019 Sep CPOT

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+! BAYER EQ 200MG BASE;120MG

N021076 001 Nov 29, 1999 Mar CPOT

+! 220MG;120MG

N021076 001 Nov 29, 1999 Sep CPOT

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC 220MG;120MG

A077381 001 Sep 27, 2006 Sep CPOT

PERRIGO 220MG;120MG

A076518 001 Mar 17, 2004 Sep CPOT

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

P AND L EQ 2MG BASE

A074507 001 Mar 15, 1999 Aug CAHN

EQ 2MG BASE

A076569 001 Jul 29, 2004 Aug CAHN

EQ 2MG BASE

A078699 001 Dec 29, 2008 Aug CAHN

EQ 2MG BASE

A079044 001 Jul 08, 2009 Aug CAHN

EQ 2MG BASE

A079216 001 Jul 08, 2009 Aug CAHN

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

EQ 2MG BASE	A204794	001	May 10, 2016	Aug CAHN
EQ 4MG BASE	A074707	001	Mar 19, 1999	Aug CAHN
EQ 4MG BASE	A076568	002	Jul 29, 2004	Aug CAHN
EQ 4MG BASE	A078697	001	Dec 29, 2008	Aug CAHN
EQ 4MG BASE	A079038	001	Jul 08, 2009	Aug CAHN
EQ 4MG BASE	A079219	001	Jul 08, 2009	Aug CAHN
EQ 4MG BASE	A204833	001	Feb 26, 2016	Aug CAHN

TROCHE/LOZENGE;ORAL
NICOTINE POLACRILEX

>A> DR REDDYS LABS SA	EQ 2MG BASE	A212796	001	Jan 08, 2020	Dec NEWA
>A>	EQ 4MG BASE	A212796	002	Jan 08, 2020	Dec NEWA
P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019	Oct NEWA
	EQ 2MG BASE	A209206	001	Jun 26, 2018	Nov CMFD
@	EQ 2MG BASE	A209206	001	Jun 26, 2018	Aug CAHN
	EQ 2MG BASE	A209519	001	Jul 02, 2018	Nov CMFD
@	EQ 2MG BASE	A209519	001	Jul 02, 2018	Aug CAHN
	EQ 2MG BASE	A209520	001	Oct 31, 2019	Oct NEWA
	EQ 2MG BASE	A210711	001	Oct 31, 2019	Oct NEWA
	EQ 2MG BASE	A210712	001	Sep 06, 2019	Aug NEWA
	EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul CAHN
	EQ 4MG BASE	A208875	002	Oct 31, 2019	Oct NEWA
	EQ 4MG BASE	A209206	002	Jun 26, 2018	Nov CMFD
@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Aug CAHN
	EQ 4MG BASE	A209519	002	Jul 02, 2018	Nov CMFD
@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Aug CAHN
	EQ 4MG BASE	A209520	002	Oct 31, 2019	Oct NEWA
	EQ 4MG BASE	A210711	002	Oct 31, 2019	Oct NEWA
	EQ 4MG BASE	A210712	002	Sep 06, 2019	Aug NEWA
	EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul CAHN
PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019	Feb NEWA
	EQ 4MG BASE	A207868	002	Feb 07, 2019	Feb NEWA
TEVA PHARMS USA INC	EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul NEWA
	EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul NEWA
@ WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb DISC
@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb DISC
@ WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb DISC
@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb DISC

OMEPRAZOLETABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE

@ APOTEX	20MG	A210070	001	Feb 11, 2019	Aug DISC
APOTEX INC	20MG	A210070	001	Feb 11, 2019	Apr CTEC

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
GLYCOLAX

@ LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jun DISC
@	17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jun DISC
POLYETHYLENE GLYCOL 3350					
NOVELGENIX THERAPS	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep CAHN

RANITIDINE HYDROCHLORIDETABLET;ORAL
RANITIDINE HYDROCHLORIDE

@ ANI PHARMS INC	EQ 75MG BASE	A075296	001	Jan 14, 2000	Oct DISC
@ MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Oct DISC
STRIDES PHARMA	EQ 75MG BASE	A209160	001	Mar 05, 2018	Apr CAHN
	EQ 150MG BASE	A209161	001	Feb 22, 2018	Apr CAHN
UNIQUE PHARM LABS	EQ 75MG BASE	A210250	001	Aug 30, 2019	Aug NEWA
	EQ 150MG BASE	A210228	001	Aug 30, 2019	Aug NEWA

SODIUM FLUORIDE; TRICLOSANPASTE;DENTAL
COLGATE TOTAL

+ @ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997	Mar DISC
-----------------------	------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2019

NO DECEMBER 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327 001					PC	Apr 29, 2019
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579	Y		
	8822438	Aug 24, 2027	U-1580	Y		
	8822438	Aug 24, 2027	U-2235	Y		
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	10292990	May 20, 2034	U-2535			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	>A> 10167291	Jul 01, 2036	DP U-2145		I-817	Nov 21, 2022
	>A> 10167291	Jul 01, 2036	DP U-2666		>A> ODE-274	Nov 21, 2026
	>A> 10167291	Jul 01, 2036	DP U-2667			
	>A> 10167291	Jul 01, 2036	DP U-2668			
	>A> 10167291	Jul 01, 2036	DP U-2669			
	>A> 10167291	Jul 01, 2036	DP U-2670			
	>A> 10167291	Jul 01, 2036	DP U-2671			
	>A> 10239883	Jul 11, 2032	U-2666			
	>A> 10239883	Jul 11, 2032	U-2668			
	>A> 10272083	Jan 21, 2035	U-2519			
	>A> 10272083	Jan 21, 2035	U-2682			
	>A> 10272083	Jan 21, 2035	U-2683			
	>A> 10272083	Jan 21, 2035	U-2684			
	>A> 10272083	Jan 21, 2035	U-2685			
	>A> 10272083	Jan 21, 2035	U-2686			
	>A> 10272083	Jan 21, 2035	U-2687			
	>A> 9796721	Jul 01, 2036	DS DP U-2145			
	>A> 9796721	Jul 01, 2036	DS DP U-2666			
	>A> 9796721	Jul 01, 2036	DS DP U-2667			
	>A> 9796721	Jul 01, 2036	DS DP U-2668			
	>A> 9796721	Jul 01, 2036	DS DP U-2669			
	>A> 9796721	Jul 01, 2036	DS DP U-2670			
	>A> 9796721	Jul 01, 2036	DS DP U-2671			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
N 204767 001	8741959	Apr 19, 2030	DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10034867	Jul 07, 2020	DP U-2513			
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	7078412	Jul 07, 2020	DS DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10034867	Jul 07, 2020	DP U-2513		NC	Mar 29, 2022
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	6681768	Aug 07, 2022	DP			
	7078412	Jul 07, 2020	DS DP U-2513			
	7750023	Jul 07, 2020	DP U-2513			
	8051851	Apr 22, 2027	DP			
	8129405	Jul 07, 2020	DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACYCLOVIR - AVACLYR</u>						
N 202408 001					ODE-235	Mar 29, 2026
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797 001	10076555	Feb 11, 2025	U-2638		NCE	Oct 08, 2024
	8334265	Mar 11, 2029	U-2638		ODE-270	Oct 08, 2026
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003					ODE-230	Jan 12, 2025
<u>AIR POLYMER-TYPE A - EXEM FOAM KIT</u>						
N 212279 001	>A> 9034300	Oct 15, 2030	DP U-2663		NCE	Nov 07, 2024
	>A> 9259494	May 04, 2035	DP U-2663			
	>A> 9849199	Feb 11, 2036	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10124131	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	6329404	Jun 19, 2021	DP U-1334			
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	>A> 10500170	Feb 15, 2038	U-20			
	>A> 10500171	Feb 15, 2038	U-2497			
	>A> 10500172	Feb 15, 2038	U-2497			
	>A> 10512617	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	>A> 10500170	Feb 15, 2038	U-20			
	>A> 10500171	Feb 15, 2038	U-2497			
	>A> 10500172	Feb 15, 2038	U-2497			
	>A> 10512617	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	>A> 10500170	Feb 15, 2038	U-20			
	>A> 10500171	Feb 15, 2038	U-2497			
	>A> 10500172	Feb 15, 2038	U-2497			
	>A> 10512617	Feb 15, 2038	U-2497			
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321 001					ODE-244	May 06, 2026
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214 GAIN	Sep 28, 2025 Sep 28, 2030
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212492 001					CGT	May 30, 2020
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212780 001					CGT	Feb 26, 2020
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-804			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	10238606	Feb 12, 2034	DP			
	9050263	Feb 12, 2034	DP U-2660			
	9498445	Feb 12, 2034	DP U-2660			
	9603806	Feb 12, 2034	DP U-2660			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001				>A> M-248		Sep 13, 2022
				>A> PED		Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002				>A> M-248		Sep 13, 2022
				>A> PED		Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003				>A> M-248		Sep 13, 2022
				>A> PED		Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004				>A> M-248		Sep 13, 2022
				>A> PED		Mar 13, 2023
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10335451	Dec 16, 2029	U-2581			
	>A> 10493124	Dec 18, 2034	U-2679			
	>A> 10500247	Dec 16, 2029	U-2680			
	>A> 10500247	Dec 16, 2029	U-2681			
	9572856	Nov 20, 2030	U-2221			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10335451	Dec 16, 2029	U-2581			
	>A> 10493124	Dec 18, 2034	U-2679			
	>A> 10500247	Dec 16, 2029	U-2680			
	>A> 10500247	Dec 16, 2029	U-2681			
	9572856	Nov 20, 2030	U-2221			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507	Sep 15, 2030	DS DP U-2237		I-808	Sep 17, 2022
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-1504			
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-1504			
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-1504			
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6962940	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
<u>APREPITANT - CINVANTI</u>						
N 209296 001 >A>	10500208	Sep 18, 2035	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	8338429	Jun 30, 2023	U-2577		I-802	Jun 26, 2022
	8765764	Jan 15, 2023	U-2314		ODE-246	Jun 26, 2026
	8765764	Jan 15, 2023	U-2578			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-2508			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-2509			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	10322085	Oct 24, 2023	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9387249	Jul 01, 2031	U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9387249	Jul 01, 2031	U-3			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10392406	Apr 27, 2036	DS		I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10392406	Apr 27, 2036	DS		I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					NPP ODE-251	Aug 09, 2022 Aug 09, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-1761		NPP	Jul 25, 2022
	6753013	Jan 27, 2020	DP U-193		PED	Jan 25, 2023
	6753013	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-88			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10130640	Jun 10, 2031	DP		NPP	Jul 30, 2022
	10130640*PED	Dec 10, 2031			PED	Jan 30, 2023
	6753013	Jan 27, 2020	DP U-1761			
	6753013	Jan 27, 2020	DP U-2627			
	9119781	Jun 10, 2031	DP U-1761			
	9119781	Jun 10, 2031	DP U-2627			
	9119781*PED	Dec 10, 2031				
	9566286	Jun 10, 2031	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10385067	Jun 19, 2035	U-257		NPP	Jun 18, 2022
					ODE-256	Jun 18, 2026
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	7417148	Dec 11, 2025	U-1283			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6579968	Jun 28, 2020	DS DP			
	6794489	Jun 28, 2020	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552			
	10322139	Jan 23, 2033	DP			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	10307368	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10307375	Sep 07, 2031	DP			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001					>A> M-250	Oct 13, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002					>A> M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003					>A> M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004					>A> M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005					>A> M-250	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
<u>CABAZITAXEL - JEV TANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	May 07, 2028	DP U-1280			
	8263580	May 07, 2028	DP U-2662			
	8629128	May 26, 2026	DP U-1280			
	8629128	May 26, 2026	DP U-1767			
	8629128	May 26, 2026	DP U-2662			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-2441		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-2441		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10195159	May 07, 2022	DS			
<u>CAPSAICIN - OUTENZA</u>						
N 022395 001	>A> 10034841	Sep 06, 2025	DP			
	>A> 10463598	Sep 05, 2023	DP			
	>A> 8263059	Sep 05, 2023	U-2705			
	>A> 8821920	Mar 26, 2030	DP			
	>A> 8889113	Sep 05, 2023	U-2705			
	>A> 9226903	Dec 15, 2028	DP			
<u>CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE</u>						
A 211941 001					CGT	Dec 29, 2019
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	>A> 7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142	Sep 17, 2029	DS DP U-2545			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	>A> 7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Sep 17, 2029	DS DP U-2543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142	Sep 17, 2029	DS DP U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	>A> 7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	>A> 7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
<u>CEFIDEROCOL SULFATE TOSYLATE - FETROJA</u>						
N 209445 001	10004750	Sep 03, 2035	DS DP		NCE	Nov 14, 2024
	9238657	Nov 19, 2031	DS DP U-282		GAIN	Nov 14, 2029
	9949982	Sep 03, 2035	DP			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565			
	10028963	Sep 07, 2032	U-2566			
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
	10420841	Mar 14, 2034	U-1672			
	10420841	Mar 14, 2034	U-2631			
	>A> 7129232	May 15, 2028	DS DP U-1676			
	>A> 7129232	May 15, 2028	DS DP U-36			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP			
	7964592	Jan 13, 2027	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - QUZYTIR</u>						
N 211415 001	8263581	Feb 28, 2030	U-2635		NP	Oct 04, 2022
	8314083	Feb 28, 2030	U-2634			
	8513259	Feb 11, 2030	U-2636			
	9119771	Feb 11, 2030	U-2635			
	9180090	Feb 11, 2030	U-2635			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001	8969412	Sep 05, 2026	DP U-2609			
	9504666	Dec 11, 2033	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253 001					CGT	May 25, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253 002					CGT	May 25, 2020
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	9827231	Jun 26, 2034	DP U-2162			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>CLOZAPINE - VERSACLOZ</u>						
N 203479 001	8057811	May 01, 2028	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NPP ODE-260	Aug 22, 2022 Aug 22, 2026
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	>A> 10478400	Jun 29, 2036	DS DP U-1776			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-2479			
	10420760	Feb 07, 2037	U-2478			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	10383876	Mar 29, 2032	DS DP			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744	Jun 02, 2022	DP U-1319			
	9585868	Oct 31, 2031	U-1319			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10441630	Aug 23, 2033	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10328037	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10328037	Aug 16, 2036	U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					M-246	Oct 06, 2022
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					M-246	Oct 06, 2022
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001					PC	Mar 09, 2019
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	8007826	May 26, 2027	U-1030	Y		
	8354437	Dec 22, 2026	U-1030	Y		
	8440703	Apr 08, 2025	U-1030	Y		
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 001					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 002					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 003					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 004					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 005					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 006					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 007					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 008					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 009					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 010					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 011					NPP	May 16, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
	<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>					
N 210874 003	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
	<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>					
N 210874 004	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
	<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>					
N 209091 001	6414126	Oct 04, 2020	DS DP U-493		I-804	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	6936590	Oct 04, 2020	U-493			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
	<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>					
N 209091 002	6414126	Oct 04, 2020	DS DP U-493		NS	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPSONE - ACZONE</u>						
N 207154 001					NPP	Sep 10, 2022
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667 001					CGT	Jan 12, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10383853	Jan 28, 2036	DS			
	8975254	Oct 27, 2030	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
<u>DARUNAVIR - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-225 PED	Dec 21, 2025 Jun 21, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986	005				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	006				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	001				PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	002				PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	003				PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 208697	002				>A> PC	Jun 14, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002	7049328 8703156	Jun 28, 2021 Oct 29, 2029	U-735 DP U-735		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					ODE-252	Jun 07, 2026
<u>DELAFLUXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001					I-815	Oct 24, 2022
<u>DELAFLUXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001					I-815	Oct 24, 2022
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	10307459	May 07, 2023	DP			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	10307459	May 07, 2023	DP			
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	8409606	May 14, 2030	DP		I-800	Jun 20, 2022
	8563027	Feb 12, 2030	U-2487		NP	Nov 30, 2021
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10159683	May 23, 2034	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001					ODE-271	Oct 03, 2026
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 208129 001					PC	Nov 30, 2019
<u>DIAZOXIDE - DIAZOXIDE</u>						
A 211050 001					>A> CGT	Jun 17, 2020
<u>DIGOXIN - DIGOXIN</u>						
A 213000 001					CGT	Apr 01, 2020
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	10080733	Sep 20, 2033	DS DP U-1384			
	8669281	Sep 20, 2033	DS DP			
	9090558	Sep 20, 2033	U-1384			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP		NC	Apr 08, 2022
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	10426780	Jan 24, 2031	DS DP U-257			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394			
	8486975	Oct 07, 2031	DS DP U-2630			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		I-806	Sep 19, 2022
	8486975	Oct 07, 2031	DS DP U-2629			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10238620	May 18, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10179140	Jun 28, 2031	U-2553		NP	May 23, 2022
	9603860	Jun 28, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					NCE	May 05, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-243	Aug 09, 2022
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	>A> 10512640	Jan 03, 2028	U-1969			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-2652		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-2653		>A> ODE-275	Oct 21, 2026
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2645			
	8354427	Jul 06, 2026	U-2646			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2645			
	8598181	May 01, 2027	U-2645			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2648			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2649			
	9670163	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-2650			
	9974781	Apr 09, 2027	DP U-2645			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	6642245	Nov 04, 2020	U-1663		I-812	Oct 03, 2022
	6642245*PED	May 04, 2021				
	7803788	Feb 02, 2022	U-1663			
	8754065	Aug 15, 2032	DS DP U-1259			
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-1259			
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769	Aug 15, 2032	DS DP U-257			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10294215	Jan 07, 2033	DP U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10294215	Jan 07, 2033	DP U-2087			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001					>A> I-808	Dec 16, 2022
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 003	10166344	Jan 21, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 004	10166344	Jan 21, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 001					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 002					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 003					PC	Nov 05, 2019
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 001					CGT	May 09, 2020
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 002					CGT	May 09, 2020
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031	U-2502		NCE*	Mar 05, 2024
	9592207	Mar 20, 2027	U-2502			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
	10471072	Jun 18, 2033	U-2316			
	10471072	Jun 18, 2033	U-2317			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
	10471072	Jun 18, 2033	U-2316			
	10471072	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032	U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	10344765	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
	>A> RE47751	Jun 28, 2025	U-1918			
	>A> RE47751	Jun 28, 2025	U-2664			
	>A> RE47751	Jun 28, 2025	U-2673			
	>A> RE47751	Jun 28, 2025	U-2674			
	>A> RE47769	Jun 28, 2025	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
	>A> RE47751	Jun 28, 2025	U-1918			
	>A> RE47751	Jun 28, 2025	U-2664			
	>A> RE47751	Jun 28, 2025	U-2673			
	>A> RE47751	Jun 28, 2025	U-2674			
	>A> RE47769	Jun 28, 2025	DP			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6414126	Oct 04, 2020	U-2588			
	6515117	Oct 04, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	U-2588			
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2600			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 001					PC	Dec 28, 2019
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 002					PC	Dec 28, 2019
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001 >A>	10391094	Jun 04, 2032	DP U-2607		NCE	Aug 16, 2024
	7528143	Dec 16, 2026	DS		ODE-259	Aug 16, 2026
	7825246	Dec 16, 2026	DS			
	8138199	Jun 30, 2028	U-2607			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	DP U-1432			
	7754702	Feb 15, 2028	DP U-2555			
	7754702	Feb 15, 2028	DP U-2556			
	7754702	Feb 15, 2028	DP U-2557			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030	U-2549		I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP U-1577			
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 02, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 02, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	>A> 8586551	Jul 15, 2023	DS DP			
	>A> 8586551*PED	Jan 15, 2024				
	>A> 8859510	Jul 31, 2027	U-319			
	>A> 8859510*PED	Jan 31, 2028				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	9187405	Jun 25, 2027	U-2613			
	9187405*PED	Dec 25, 2027				
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FLUORODOPA F-18 - FLUORODOPA F18</u>						
N 200655 001					NCE W	Oct 10, 2024 Oct 10, 2024
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
	>A> 10478574	Nov 04, 2033	U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP	U-645		
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-2546			
	8703806	May 28, 2030	U-2546			
	8808713	May 28, 2030	DP U-2546			
	8815258	Mar 17, 2031	U-2546			
	9415009	May 28, 2030	U-2546			
	9463161	May 28, 2030	DP U-2546			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Apr 06, 2025	DS DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Apr 06, 2025	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-801	Jul 12, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBUTROL - GADAVIST</u>						
N 201277	004				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	005				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	006				I-801	Jul 12, 2022
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828	001				NCE W	Aug 21, 2024 Aug 21, 2024
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349	001				NCE	Nov 28, 2023
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194	001	>A> 10119143	Oct 03, 2034	DS DP U-2672	NCE	Nov 20, 2024
		>A> 10125364	Mar 15, 2033	DS DP U-2672	>A> ODE-273	Nov 20, 2026
		>A> 10131907	Aug 24, 2028	DS DP U-2672		
		>A> 10273477	Mar 08, 2024	DS		
		>A> 8106022	Dec 12, 2029	DS DP U-2672		
		>A> 8546143	Jan 09, 2022	DS U-2672		
		>A> 8828956	Dec 04, 2028	DS DP U-2672		
		>A> 9133461	May 14, 2033	DS DP U-2672		
		>A> 9150605	Aug 28, 2025	DS DP		
		>A> 9631193	Mar 15, 2033	U-2672		
		>A> 9708610	Jan 01, 2024	DS DP U-2672		
		>A> 9708615	Mar 08, 2024	DS		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	001	10414748	Apr 13, 2036	DS DP		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	002	10414748	Apr 13, 2036	DS DP		
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394	001	10028937	Jun 10, 2030	U-2141	D-175	Sep 26, 2022
		10028937	Jun 10, 2030	U-2532	NPP	Apr 30, 2022
		10039754	Jun 10, 2030	U-2141	ODE-232	Apr 30, 2026
		10039754	Jun 10, 2030	U-2532	ODE-233	Apr 30, 2026
		10286029	Mar 14, 2034	U-2532		
		8648037	Jan 19, 2032	DS DP U-2141		
		8648037	Jan 19, 2032	DS DP U-2532		
		9586978	Jun 10, 2030	U-2141		
		9586978	Jun 10, 2030	U-2532		
<u>GLUCAGON - BAOSIMI</u>						
N 210134	001	10213487	Feb 16, 2036	DP U-2604	NP	Jul 24, 2022
		6938798	Jan 03, 2022	DP		
<u>GLUCAGON - GVOKE PFS</u>						
N 212097	001				NP	Sep 10, 2022
<u>GLUCAGON - GVOKE PFS</u>						
N 212097	002				NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097	003				NP	Sep 10, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004					NP	Sep 10, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10376661	Sep 14, 2035	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	>A> 10227590	Jun 28, 2025	DS DP		>A> NCE	Dec 12, 2024
	>A> 10266827	Jun 28, 2025	U-2675			
	>A> 10421966	Jun 28, 2025	DS DP			
	>A> 9024007	Jun 28, 2025	DS DP			
	>A> 9416361	May 04, 2021	DS			
	>A> 9994851	Jun 28, 2025	DS DP			
	>A> RE47691	Jun 28, 2025	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	10357570	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	10478502	Nov 02, 2031	DP U-2625			
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
	10426787	Jun 06, 2036	U-2625			
	10478502	Nov 02, 2031	DP U-2625			
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	10369109	Jun 16, 2023	DP			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	10471075	May 02, 2036	U-2236			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10294231	Jun 03, 2033	DP		>A> D-176 M-236	Aug 24, 2021
	10294232	Jun 03, 2033	DP			Jan 25, 2022
	10463668	Oct 24, 2034		U-2654		
	10478439	Jun 03, 2031		U-1456		
	10478439	Jun 03, 2031		U-1650		
	10478439	Jun 03, 2031		U-1684		
	10478439	Jun 03, 2031		U-1946		
	10478439	Jun 03, 2031		U-1947		
	10478439	Jun 03, 2031		U-2241		
	10478439	Jun 03, 2031		U-2242		
	10478439	Jun 03, 2031		U-2665		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10294231	Jun 03, 2033	DP		>A> D-176 M-236	Aug 24, 2021
	10294232	Jun 03, 2033	DP			Jan 25, 2022
	10463668	Oct 24, 2034		U-2654		
	10478439	Jun 03, 2031		U-1456		
	10478439	Jun 03, 2031		U-1650		
	10478439	Jun 03, 2031		U-1684		
	10478439	Jun 03, 2031		U-1946		
	10478439	Jun 03, 2031		U-1947		
	10478439	Jun 03, 2031		U-2241		
	10478439	Jun 03, 2031		U-2242		
	10478439	Jun 03, 2031		U-2665		
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10213386	Mar 03, 2036	DP		>A> D-176 M-236	Aug 24, 2021
	10463668	Oct 24, 2034		U-2654		Jan 25, 2022
	10478439	Jun 03, 2031		U-1456		
	10478439	Jun 03, 2031		U-1650		
	10478439	Jun 03, 2031		U-1684		
	10478439	Jun 03, 2031		U-1946		
	10478439	Jun 03, 2031		U-1947		
	10478439	Jun 03, 2031		U-2241		
	10478439	Jun 03, 2031		U-2242		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10213386	Mar 03, 2036	DP		>A> D-176	Aug 24, 2021
	10463668	Oct 24, 2034	U-2654		M-236	Jan 25, 2022
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10213386	Mar 03, 2036	DP		>A> D-176	Aug 24, 2021
	10463668	Oct 24, 2034	U-2654		M-236	Jan 25, 2022
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP		>A> D-176	Aug 24, 2021
	10463668	Oct 24, 2034	U-2654		M-236	Jan 25, 2022
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002	10238640	May 25, 2024	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-981			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003	8735452	Sep 30, 2029	U-981			
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	>A> 10010517	Apr 29, 2030	U-2690		>A> I-819	Dec 13, 2022
	>A> 10265287	Apr 29, 2030	U-2700			
	>A> 10278935	Jun 28, 2033	U-2701			
	>A> 10278936	Jun 28, 2033	U-2702			
	>A> 10278937	Jun 28, 2033	U-2703			
	>A> 10383840	Jun 28, 2033	U-2704			
	>A> 8410086	Jun 15, 2030	U-2688			
	>A> 8454994	Apr 29, 2030	U-2689			
	>A> 8455472	Jun 15, 2030	U-2690			
	>A> 8617593	Apr 29, 2030	U-1478			
	>A> 8617593	Apr 29, 2030	U-2691			
	>A> 8618166	Apr 29, 2030	U-2689			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	>A> 8623406	Apr 29, 2030	U-1478			
	>A> 8623406	Apr 29, 2030	U-2692			
	>A> 8642077	Apr 29, 2030	U-2693			
	>A> 8669245	Jun 15, 2030	U-2694			
	>A> 8680144	Feb 09, 2030	U-2695			
	>A> 8691871	Apr 29, 2030	U-2689			
	>A> 8703185	Apr 29, 2030	U-2691			
	>A> 8709475	Apr 29, 2030	U-2689			
	>A> 8710041	Jun 15, 2030	U-2690			
	>A> 9198892	Sep 25, 2027	U-2706			
	>A> 9603826	Jun 28, 2033	U-2696			
	>A> 9610272	Jun 28, 2033	U-2697			
	>A> 9623001	Jun 28, 2033	U-2698			
	>A> 9693984	Jun 28, 2033	U-2697			
	>A> 9693985	Jun 28, 2033	U-2696			
	>A> 9693986	Jun 28, 2033	U-2698			
	>A> 9700537	May 31, 2027	U-2707			
	>A> 9918954	Jun 28, 2033	U-2699			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	>A> 10010517	Apr 29, 2030	U-2690		>A> I-819	Dec 13, 2022
	>A> 10265287	Apr 29, 2030	U-2700			
	>A> 10278935	Jun 28, 2033	U-2701			
	>A> 10278936	Jun 28, 2033	U-2702			
	>A> 10278937	Jun 28, 2033	U-2703			
	>A> 10383840	Jun 28, 2033	U-2704			
	>A> 8410086	Jun 15, 2030	U-2688			
	>A> 8454994	Apr 29, 2030	U-2689			
	>A> 8617593	Apr 29, 2030	U-1287			
	>A> 8617593	Apr 29, 2030	U-2691			
	>A> 8623406	Apr 29, 2030	U-1287			
	>A> 8623406	Apr 29, 2030	U-2692			
	>A> 8642077	Apr 29, 2030	U-2693			
	>A> 8669245	Jun 15, 2030	U-2694			
	>A> 8680144	Feb 09, 2030	U-2695			
	>A> 8691871	Apr 29, 2030	U-2689			
	>A> 8703185	Apr 29, 2030	U-2691			
	>A> 8709475	Apr 29, 2030	U-2689			
	>A> 8710041	Jun 15, 2030	U-2690			
	>A> 9198892	Sep 25, 2027	U-2706			
	>A> 9603826	Jun 28, 2033	U-2696			
	>A> 9610272	Jun 28, 2033	U-2697			
	>A> 9623001	Jun 28, 2033	U-2698			
	>A> 9693984	Jun 28, 2033	U-2697			
	>A> 9693985	Jun 28, 2033	U-2696			
	>A> 9693986	Jun 28, 2033	U-2698			
	>A> 9700537	May 31, 2027	U-2707			
	>A> 9918954	Jun 28, 2033	U-2699			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
<u>INSULIN ASPART - FIASP</u>						
N 208751 001					M-247	Oct 21, 2022
				>A> NPP		Dec 19, 2022
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	10220155	Jul 17, 2026	DP		>A> NPP	Dec 19, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	10220155	Jul 17, 2026	DP		>A> NPP	Dec 19, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART - FIASP PENFILL</u>						
N 208751 003					>A> NPP	Dec 19, 2022
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 003	10376652	Jan 20, 2026	DP			
	7615532	Jun 28, 2029	DS DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	10220155	Jul 17, 2026	DP		M-242	Aug 08, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	>A> 10369291	Sep 16, 2035	DP		>A> NPP	Nov 26, 2022
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	>A> 10369291	Sep 16, 2035	DP		>A> NPP	Nov 26, 2022
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	10029011	Nov 11, 2030	DP			
	9011391	Mar 26, 2024	U-1923			
	9011391	Mar 26, 2024	U-2496			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
	>A> 10500159	Nov 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
	>A> 10500159	Nov 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
	>A> 10500159	Nov 02, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10456360	Oct 15, 2036	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001					NP	Apr 26, 2022
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 001	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 002	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 003	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 004	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 005	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 006	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 001	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023		U-2623		
	7727994	Jan 18, 2023		U-2623		
	8318201	Sep 05, 2027	DP			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 002	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023		U-2623		
	7727994	Jan 18, 2023		U-2623		
	8318201	Sep 05, 2027	DP			
<u>ITRACONAZOLE - TOLSURA</u>						
N 208901 001	10463740	Jun 21, 2033	DP U-2453			
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694		NP	Apr 22, 2022
	7867996	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7879842	Feb 22, 2026	DS DP U-1694		PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 203188 002					NPP ODE-186 ODE-187 ODE-189 ODE-190 ODE-199	Jul 31, 2020 Feb 21, 2021 Dec 29, 2021 Jul 31, 2024 May 17, 2024 Aug 15, 2025
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NPP	Jun 21, 2022
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NPP	Jun 21, 2022
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVERMECTIN - IVERMECTIN</u>						
A 210019 001					PC	Apr 11, 2020
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10449184	Mar 13, 2035	DP		I-816	May 02, 2022
	9474779	Aug 19, 2033	DS DP U-2350		ODE-242	May 02, 2026
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	7442830	Nov 20, 2029	DS DP U-2434			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	7442830	Nov 20, 2029	DS DP U-2434			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	7442830	Nov 20, 2029	DS DP U-2434			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035	U-2470			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035	U-2470			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10172861	Nov 16, 2035	DS		NCE	Nov 26, 2023
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028	U-2400			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524		NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP U-1524		NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		>A> D-177	Nov 15, 2022
	10039779	Jan 30, 2034	DS DP U-2370		ODE-136	Apr 07, 2024
	10039779*PED	Jul 30, 2034			PED	Oct 07, 2024
	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		>A> D-177 ODE-136 PED	Nov 15, 2022
	10039779	Jan 30, 2034	DS DP U-2370			Apr 07, 2024
	10039779*PED	Jul 30, 2034				Oct 07, 2024
	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470		>A> D-177	Nov 15, 2022
	10039779*PED	Jul 30, 2034				
	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	10456414	Sep 14, 2032	DP		>A> D-177	Nov 15, 2022
	7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	10456414	Sep 14, 2032	DP		>A> D-177	Nov 15, 2022
	7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	9393256*PED	Mar 14, 2033	U-1470			
	9511056	May 12, 2030				
	9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
	9120727	May 23, 2031	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	9393238	May 15, 2023	U-2550			
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS			
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8962630	Dec 09, 2029	U-2505			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8470367	Oct 31, 2027	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8470367	Oct 31, 2027	DP			
<u>LEVOCARNITINE - LEVOCARNITINE</u>						
A 211676 001					CGT	Apr 13, 2020
<u>LEVOCARNITINE - LEVOCARNITINE SF</u>						
A 211676 002					CGT	Apr 13, 2020
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-249	Oct 07, 2022
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-249	Oct 07, 2022
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-249	Oct 07, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-249	Oct 07, 2022
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 011	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 012	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	10350180	Jan 14, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10201663	Mar 10, 2034	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10201663	Mar 10, 2034	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			
	10463676	Aug 31, 2031	U-2661			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8779187	Jan 23, 2027	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595 001	9962336	May 01, 2035	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	8628799	Jul 13, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	8628799	Jul 13, 2025	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349			
	10231927	Jan 02, 2033	U-1699			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP			
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				

Y

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
>A>	10500162	Oct 30, 2035	U-2357			
>A>	10507186	Oct 30, 2035	DP			
>A>	10512612	Oct 30, 2035	DP			
>A>	10512613	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
>A>	10500162	Oct 30, 2035	U-2357			
>A>	10507186	Oct 30, 2035	DP			
>A>	10512612	Oct 30, 2035	DP			
>A>	10512613	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
>A>	10500162	Oct 30, 2035	U-2357			
>A>	10507186	Oct 30, 2035	DP			
>A>	10512612	Oct 30, 2035	DP			
>A>	10512613	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
>A>	10500162	Oct 30, 2035	U-2357			
>A>	10507186	Oct 30, 2035	DP			
>A>	10512612	Oct 30, 2035	DP			
>A>	10512613	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
>A>	10500162	Oct 30, 2035	U-2357			
>A>	10507186	Oct 30, 2035	DP			
>A>	10512612	Oct 30, 2035	DP			
>A>	10512613	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
>A>	10500162	Oct 30, 2035	U-2357			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	>A> 10507186	Oct 30, 2035	DP			
	>A> 10512612	Oct 30, 2035	DP			
	>A> 10512613	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104*PED	Jul 08, 2021				
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104*PED	Jul 08, 2021				
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
	10495650	Aug 12, 2036	U-1643			
	10500216	Mar 05, 2033	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10251873	May 30, 2038	U-2371			
	10383864	May 16, 2027	U-2371			
	10406143	May 16, 2027	U-2371			
	10471053	May 30, 2038	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10086080	Oct 01, 2030	U-2647			
	10137200	Oct 01, 2030	U-2647			
	10213512	Oct 01, 2030	DP U-2647			
	10265404	Oct 01, 2030	DP			
	10398641	Sep 08, 2037	U-2647			
	8865139	Oct 01, 2030	DP U-2647			
	8945516	Oct 01, 2030	DP			
	8992896	Oct 01, 2030	DP U-2647			
	9675700	Oct 01, 2030	DP U-2647			
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	10232152	Nov 24, 2034	DP U-2272			
	>A> 10357640	Oct 03, 2031	U-2272			
	10406332	Mar 13, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	10314788	Aug 12, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	10314788	Aug 12, 2028	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 001					PC	Oct 01, 2019
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 002					PC	Oct 01, 2019
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	10154990	Dec 20, 2025	U-2620		I-805 ODE-261	Sep 06, 2022 Sep 06, 2026
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10154990	Dec 20, 2025	U-2620		I-805 ODE-261	Sep 06, 2022 Sep 06, 2026
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071579	Aug 12, 2027	U-2655		I-813	Oct 23, 2022
	8143241	Aug 12, 2027	U-2655		I-814	Oct 23, 2022
	8859562	Aug 04, 2031	U-2655		>A> ODE-277	Oct 23, 2026
					>A> ODE-278	Oct 23, 2026
<u>NITISINONE - NITYR</u>						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10266822	Dec 05, 2025	DP U-1942			
	10266822	Dec 05, 2025	DP U-1943			
	10266822	Dec 05, 2025	DP U-1944			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10436802	Sep 11, 2035	U-1941			
	10436802	Sep 11, 2035	U-1942			
	10436802	Sep 11, 2035	U-1943			
	10436802	Sep 11, 2035	U-1944			
	10436802	Sep 11, 2035	U-2093			
	10436802	Sep 11, 2035	U-2094			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		>A> I-818 ODE-226	Dec 27, 2022
	8143241	Aug 12, 2027	U-2103			Dec 19, 2025
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		>A> I-818 ODE-226	Dec 27, 2022
	8143241	Aug 12, 2027	U-2103			Dec 19, 2025
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	>A> 7727984	Jan 19, 2027	DS			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	>A> 7727984	Jan 19, 2027	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
>A>	7960370	Dec 20, 2026	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	10272061	Apr 26, 2020	U-2525			
	10449173	Nov 06, 2029	DP U-2637			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
>A>	10525052	Jul 07, 2023	DP U-1556			
>A>	10525053	Jul 07, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
	>A> 10525052	Jul 07, 2023	DP U-1556			
	>A> 10525053	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
	>A> 10525052	Jul 07, 2023	DP U-1556			
	>A> 10525053	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
	>A> 10525052	Jul 07, 2023	DP U-1556			
	>A> 10525053	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
	>A> 10525052	Jul 07, 2023	DP U-1556			
	>A> 10525053	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	9060976	Aug 06, 2022	DP		Y	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434		ODE-52	Sep 06, 2020
	7758891*PED	Aug 21, 2026			PED	Mar 06, 2021
	7820788	Oct 27, 2024	DP U-1092			
	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	7820788*PED	Apr 27, 2025				
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	7923536*PED	Jun 09, 2024				
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8138229*PED	Jun 09, 2024				
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	8314156*PED	Jun 09, 2024				
	8853260	Oct 10, 2020	DP U-1092			
	8853260	Oct 10, 2020	DP U-1290			
	8853260	Oct 10, 2020	DP U-1434			
	8853260*PED	Apr 10, 2021				
	9101543	Feb 21, 2026	U-1434			
	9101543*PED	Aug 21, 2026				
	9393318	Mar 04, 2032	U-1290			
	9393318*PED	Sep 04, 2032				
	9511046	Jan 12, 2034	U-1434			
	9511046*PED	Jul 12, 2034				
	9597409	Mar 04, 2032	U-1290			
	9597409*PED	Sep 04, 2032				
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	>A> RE47739	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	>A> RE47739	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	>A> RE47739	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-2515			
	RE47739	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-2515			
	RE47739	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-2515			
	RE47739	Jan 16, 2023	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 001					ODE-268	Jun 29, 2025
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 002					ODE-268	Jun 29, 2025
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 003					ODE-268	Jun 29, 2025
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	>A> 10485821	Mar 30, 2024		U-1766		
	>A> 8147873	Jun 20, 2028	DP			
	>A> 8282913	May 29, 2027	DP			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	>A> 10485821	Mar 30, 2024		U-1766		
	>A> 8147873	Jun 20, 2028	DP			
	>A> 8282913	May 29, 2027	DP			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	>A> 10485821	Mar 30, 2024		U-1766		
	>A> 8147873	Jun 20, 2028	DP			
	>A> 8282913	May 29, 2027	DP			
<u>PENICILLAMINE - PENICILLAMINE</u>						
A 210976 001					CGT	Dec 22, 2019
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027		U-2622		
	>A> 6562861	Dec 16, 2023	DS			
	8778997	May 07, 2027		U-1627		
	8778997	May 07, 2027		U-2622		
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10189833	May 05, 2036		U-2606	NCE	Aug 02, 2024
	10435404	Jul 24, 2038	DP		ODE-250	Aug 02, 2026
	7893075	Oct 13, 2028	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028		U-2606		
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033		U-2606		
	9802932	May 05, 2036	DS			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	10028944	Jan 15, 2024		U-1974		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	>A> 10517860	Mar 23, 2037		U-1974	NCE	Apr 29, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10028944	Jan 15, 2024	U-1974			
	10449185	Aug 27, 2038	DP			
	9566271	Jan 15, 2024	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	8383150	Sep 22, 2026	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022	U-1101		ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026	U-1101			
	8486947	Sep 26, 2029	U-1101			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022	U-1101		ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026	U-1101			
	8486947	Sep 26, 2029	U-1101			
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 23, 2022
					PED	Nov 23, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP PED	May 23, 2022 Nov 23, 2022
<u>PRETOMANID - PRETOMANID</u>						
N 212862 001					NCE ODE-253 GAIN	Aug 14, 2024 Aug 14, 2026 Aug 14, 2029
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028		U-1988		
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	RE47301	Feb 02, 2027		DP		
	RE47351	Jun 22, 2019		DS DP	U-869	
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10343995	Mar 10, 2025		U-2440		
	8541451	Aug 25, 2031		DS		
	9765028	Jul 14, 2030		DS		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Oct 02, 2029		U-1481		
	10335397	Oct 02, 2029		U-2579		
	10456384	Feb 26, 2029		U-2643		
	10456384	Feb 26, 2029		U-2644		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7592339	Dec 11, 2020	U-1167		I-810	Oct 11, 2022
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	7592339	Dec 11, 2020	U-2142			
	7592339	Dec 11, 2020	U-2640			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002					I-810	Oct 11, 2022
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003					I-810	Oct 11, 2022
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					I-810	Oct 11, 2022
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 001	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 002	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 003	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 004	10413543	Feb 12, 2036	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10350174	Dec 22, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	10350174	Dec 22, 2030	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10278974	Feb 10, 2031	DP			
	>A> 6495541	Jan 10, 2021	DS DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10278974	Feb 10, 2031	DP			
	>A> 6495541	Jan 10, 2021	DS DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10278974	Feb 10, 2031	DP			
	>A> 6495541	Jan 10, 2021	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	U-2583			
<u>SELENIUS ACID - SELENIUS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	8999996	Sep 15, 2032	DS DP		NCE	Jul 03, 2024
	9079865	Jul 26, 2032	U-2584		ODE-257	Jul 03, 2026
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 212260 001					CGT	Nov 27, 2019
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001	10300041	Apr 26, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002	10300041	Apr 26, 2027	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	10434059	Nov 18, 2022	DP U-172			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-244	Aug 12, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
	7668730	Jun 16, 2024	U-1110	Y		
	7668730*PED	Dec 16, 2024				
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10300087	Oct 14, 2035	DS	U-2312		
	10335432	Feb 10, 2032		U-2312		
	10398730	Feb 10, 2032		U-2312		
	10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10300087	Oct 14, 2035	DS	U-2312		
	10398730	Feb 10, 2032		U-2312		
	10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		NPP	Apr 07, 2020
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		>A> D-177	Nov 15, 2022
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 008	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 009	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 010	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 010	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 011	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001 >A>	10493083	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001 >A>	6174442	Jun 12, 2020	DS U-1468			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
>A>	10507180	Jan 05, 2027	DP U-1351			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP		NPP	Nov 13, 2022
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	10398859	Dec 19, 2027	DP			
	10478574	Nov 04, 2033	U-2404			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
	>A> 8644239	Aug 30, 2028	DP U-2677			
	>A> 8644239	Aug 30, 2028	DP U-2678			
	>A> 8685998	Aug 30, 2028	DP U-1752			
	>A> 8685998	Aug 30, 2028	DP U-2677			
	>A> 8685998	Aug 30, 2028	DP U-2678			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
	>A> 8644239	Aug 30, 2028	DP U-2677			
	>A> 8644239	Aug 30, 2028	DP U-2678			
	>A> 8685998	Aug 30, 2028	DP U-1752			
	>A> 8685998	Aug 30, 2028	DP U-2677			
	>A> 8685998	Aug 30, 2028	DP U-2678			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
	>A> 8644239	Aug 30, 2028	DP U-2677			
	>A> 8644239	Aug 30, 2028	DP U-2678			
	>A> 8685998	Aug 30, 2028	DP U-1752			
	>A> 8685998	Aug 30, 2028	DP U-2677			
	>A> 8685998	Aug 30, 2028	DP U-2678			
<u>TACROLIMUS - PROGRAF</u>						
N 210115 001					ODE-269	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 210115 002					ODE-269	May 24, 2025
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10342791	Dec 02, 2035	U-2582			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10376487	Jul 27, 2035	U-2615			
	10449176	Jan 25, 2033	U-2149			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001					NCE	Jul 07, 2019
					PED	Jan 07, 2020
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001 >A>	6517847	Aug 03, 2020	DP U-2368		>A> NP	Dec 18, 2022
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	10065947	Feb 03, 2030	DP			
	10442829	Feb 03, 2030	DS			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	10065947	Feb 03, 2030	DP			
	10442829	Feb 03, 2030	DS			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020			ODE-37	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320		PED	Jun 21, 2020
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	8541448	Dec 30, 2029	DS DP		NCE	Sep 12, 2024
	8969377	Dec 30, 2029	DS DP			
	9006281	May 02, 2030	U-2626			
	9408840	Dec 30, 2029	U-2626			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 003					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 004					CGT	Oct 02, 2019
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TIOPRONIN - THIOLA</u>						
N 019569 001					ODE-267	Jun 28, 2026
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
	10457666	Jun 17, 2034	DS DP		ODE-229	Feb 22, 2026
	RE46284	Dec 16, 2026	U-1751			
	RE46284	Dec 16, 2026	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
	10457666	Jun 17, 2034	DS DP		ODE-229	Feb 22, 2026
	RE46284	Dec 16, 2026	U-1751			
	RE46284	Dec 16, 2026	U-2503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	10207066	Nov 04, 2030	DP U-909			
	8664187	Jun 20, 2025	U-909			
	8869794	Sep 12, 2028	DP U-909			
	9421166	Dec 19, 2022	DP U-909			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001 >A>	7842699	Dec 08, 2020	U-2322			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002 >A>	6956041	Dec 08, 2020	DP			
	>A> 6965027	Mar 25, 2023	DS			
	>A> 7265221	Dec 08, 2020	DS			
	>A> 7301023	May 23, 2022	DS			
	>A> 7842699	Dec 08, 2020	U-2322			
	>A> RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	10363224	Mar 19, 2033	U-766			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	>A> 9399021	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	>A> 9399021	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	>A> 9399021	Jan 28, 2032	DP			
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 001					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 002					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 003					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 004					PC	Sep 21, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001					>A> I-820	Oct 18, 2022
					>A> ODE-272	Oct 18, 2026
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002					>A> I-820	Oct 18, 2022
					>A> ODE-272	Oct 18, 2026
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003					>A> I-820	Oct 18, 2022
					>A> ODE-272	Oct 18, 2026
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004					>A> I-820	Oct 18, 2022
					>A> ODE-272	Oct 18, 2026
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005					>A> I-820	Oct 18, 2022
					>A> ODE-272	Oct 18, 2026
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP U-2368			
<u>TRIAMCINOLONE ACETONIDE - TRIAMCINOLONE ACETONIDE</u>						
A 212384 001					CGT	May 30, 2020
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	7807708	Oct 01, 2026	DS DP		NCE	Oct 04, 2024
	8227507	Dec 21, 2025	U-818			
	8470871	Dec 21, 2025	U-2639			
	9084778	May 30, 2033	DP U-134			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001					>A> NCE	Dec 23, 2024
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002					>A> NCE	Dec 23, 2024
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681 9844510	Apr 13, 2030 Dec 08, 2028	U-2510 DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	8962629 9951080 9963459 RE47221	Jan 15, 2031 Oct 17, 2036 Oct 17, 2036 Dec 01, 2030	DS U-2616 DS DP DP DS		NCE	Aug 16, 2024
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10493028	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10493028	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-237 PED	Feb 22, 2022 Aug 22, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VORICONAZOLE - VFEND</u>						
N 021266 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021266 002					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630 001					NPP	Jan 29, 2022
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					NCE	Nov 25, 2024
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	9447106	Apr 22, 2034	DS DP U-2145		NCE	Nov 14, 2024
					>A> ODE-276	Nov 14, 2026

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm